<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1910234362
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CAPECITABINE SPC 150 mg Film Coted Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Capecitabine
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        177.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Sudair Pharma Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Sudair Pharma Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2272]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BC06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Capecitabine SPC belongs to the group of medicines called &quot;cytostatic medicines&quot;, which stop the growth of cancer cells.</p><p>&nbsp;</p><p>Capecitabine SPC contains capecitabine, which itself is not a cytostatic medicine. Only after being absorbed by the body is it changed into an active anti-cancer medicine (more in tumor tissue than in normal tissue).</p><p>&nbsp;</p><p>Capecitabine SPC is used in the treatment of colon, rectal, gastric, or breast cancers.</p><p>&nbsp;</p><p>Furthermore, Capecitabine SPC is used to prevent new occurrence of colon cancer after complete removal of the tumor by surgery.</p><p>&nbsp;</p><p>Capecitabine SPC may be used either alone or in combination with other medicines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take Capecitabine SPC:</p><p>&middot;&nbsp;&nbsp; if you are allergic to capecitabine or any of the other ingredients of this medicine (listed in section 6). You must inform your doctor if you know that you have an allergy or over-reaction to this medicine,</p><p>&middot;&nbsp;&nbsp; if you previously have had severe reactions to fluoropyrimidine therapy (a group of anticancer medicines such as fluorouracil),</p><p>&middot;&nbsp;&nbsp; if you are pregnant or breast-feeding,</p><p>&middot;&nbsp;&nbsp; if you have severely low levels of white cells or platelets in the blood (leucopenia, neutropenia or thrombocytopenia),</p><p>&middot;&nbsp;&nbsp; if you have severe liver or kidney problems,</p><p>&middot;&nbsp;&nbsp; if you know that you do not have any activity of the enzyme dihydropyrimidine dehydrogenase (DPD)</p><p>&middot;&nbsp;&nbsp; if you are being treated now or have been treated in the last 4 weeks with brivudine, sorivudine or similar classes of substance as part of herpes zoster (chickenpox or shingles) therapy.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking Capecitabine SPC</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; if you know that you have a partial deficiency in the activity of the enzyme dihydropyrimidine dehydrogenase (DPD)</p><p>&middot;&nbsp;&nbsp; if you have liver or kidney diseases</p><p>&middot;&nbsp;&nbsp; if you have or had heart problems (for example an irregular heartbeat or pains to the chest jaw and back brought on by physical effort and due to problems with the blood flow to the heart)</p><p>&middot;&nbsp;&nbsp; if you have brain diseases (for example. cancer that has spread to the brain, or nervedamage (neuropathy)</p><p>&middot;&nbsp;&nbsp; if you have calcium imbalances (seen in blood tests)</p><p>&middot;&nbsp;&nbsp; if you have diabetes</p><p>&middot;&nbsp;&nbsp; if you cannot keep food or water in your body because of severe nausea and vomiting</p><p>&middot;&nbsp;&nbsp; if you have diarrhea</p><p>&middot;&nbsp;&nbsp; if you are or become dehydrated</p><p>&middot;&nbsp;&nbsp; if you have imbalances of ions in your blood (electrolyte imbalances, seen in tests)</p><p>&middot;&nbsp;&nbsp; if you have a history of eye problems as you may need extra monitoring of your eyes</p><p>&middot;&nbsp;&nbsp; if you have a severe skin reaction.</p><p>&nbsp;</p><p><strong><em>DPD deficiency</em></strong>:</p><p>DPD deficiency is a rare condition present at birth that is not usually associated with health problems unless you receive certain medicines.</p><p>If you have an unrecognized DPD deficiency and take Capecitabine SPC da, you are at an increased risk of acute early-onset of severe forms of the side effects listed under section 4 Possible side effects.</p><p>Contact your doctor immediately if you are concerned about any of the side effects or if you notice any additional side effects not listed in the leaflet.</p><p><strong>Children and adolescents</strong></p><p>Capecitabine SPC is not indicated in children and adolescents. Do not give Capecitabine SPC to children and adolescents.</p><p><strong>Other medicines and Capecitabine SPC</strong></p><p>Before starting treatment, tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is extremely important, as taking more than one medicine at the same time can strengthen or weaken the effect of the medicines.</p><p>&nbsp;</p><p><img alt="" width="867" height="213" src="data:image/png;base64,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" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:487.85pt;height:109.95pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p><strong>You need to be particularly careful if you are taking any of the following:</strong></p><p>&middot;&nbsp;&nbsp; gout medicines (allopurinol),</p><p>&middot;&nbsp;&nbsp; blood-thinning medicines (coumarin, warfarin),</p><p>&middot;&nbsp;&nbsp; certain anti-viral medicines (sorivudine and brivudine),</p><p>&middot;&nbsp;&nbsp; medicines for seizures or tremors (phenytoin),</p><p>&middot;&nbsp;&nbsp; interferon alpha,</p><p>&middot;&nbsp;&nbsp; radiotherapy and certain medicines used to treat cancer (folinic acid, oxaliplatin, bevacizumab, cisplatin, irinotecan),</p><p>&middot;&nbsp;&nbsp; medicines used to treat folic acid deficiency.</p><p>&nbsp;</p><p><strong>Capecitabine SPC with food and drink</strong></p><p>You should take Capecitabine SPC no later than 30 minutes after meals.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>You must not take Capecitabine SPC if you are pregnant or think you might be. You must not breast-feed if you are taking Capecitabine SPC.</p><p><strong>Driving and using machines</strong></p><p>Capecitabine SPC may make you feel dizzy, nauseous or tired. It is therefore possible that Capecitabine SPC could affect your ability to drive a car or operate machines.</p><p><strong>Capecitabine SPC contains anhydrous lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Capecitabine SPC should only be prescribed by a doctor experienced in the use of anticancer medicines.</p><p>&nbsp;</p><p>Your doctor will prescribe a dose and treatment regimen that is right for you. The dose of Capecitabine SPC is based on your body surface area. This is calculated from your height and weight. The usual dose for adults is 1250 mg/m2 of body surface area taken two times daily (morning and evening). Two examples are provided here: A person whose body weight is 64 kg and height are 1.64 m has a body surface area of 1.7 m2 and should take 4 tablets of 500 mg and 1 tablet of 150 mg two times daily. A person whose body weight is 80 kg and height are 1.80 m has a body surface area of 2.00 m2 and should take 5 tablets of 500 mg two times daily</p><p>&nbsp;</p><p>Your doctor may want you to take a combination of 150 mg (light peach color) and 500 mg (peach color) tablets for each dose.</p><p>&nbsp;</p><p>Take the tablets morning and evening as prescribed by your doctor.</p><p>Take the tablets within 30 minutes after the end of a meal (breakfast and dinner) and swallow whole with water. Do not crush or cut tablets. If you cannot swallow Capecitabine SPC tablets whole, tell your healthcare provider.</p><p>&nbsp;</p><p>It is important that you take all your medicine as prescribed by your doctor.</p><p>&nbsp;</p><p>Capecitabine SPC tablets are usually taken for 14-days followed by a 7-day rest period (when no tablets are taken). This 21-day period is one treatment cycle.</p><p>In combination with other medicines the usual dose for adults may be less than 1250 mg/m<sup>2</sup> of body surface area, and you may need to take the tablets over a different time period (e.g. every day, with no rest period).</p><p><strong>If you take more Capecitabine SPC than you should</strong></p><p>If you take more Capecitabine SPC than you should, contact your doctor as soon as possible before taking the next dose.</p><p><strong>You might get the following side effects:</strong></p><p>if you take a lot more capecitabine than you should: feeling or being sick, diarrhea, inflammationor ulceration of the gut or mouth, pain or bleeding from the intestine or stomach, or bone marrow depression (reduction in certain kinds of blood cells). Tell your doctor immediately if you experience any of these symptoms.</p><p><strong>If you forget to take Capecitabine SPC</strong></p><p>Do <u>not</u> take the missed dose at all. Do not take a double dose to make up for a forgotten dose. Instead, continue your regular dosing schedule and check with your doctor.</p><p><strong>If you stop taking Capecitabine SPC</strong></p><p>There are no side effects caused by stopping treatment with capecitabine.</p><p>In case you are using coumarin anticoagulants (containing e.g. phenprocoumon), stopping capecitabine might require that your doctor adjusts your anticoagulant dose.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>STOP taking Capecitabine SPC immediately and contact your doctor if any of these symptoms occur:</strong></p><p>&middot;&nbsp;&nbsp; <strong>Diarrhea</strong>: if you have an increase of 4 or more bowel movements compared to your normal bowel movements each day or any diarrhea at night.</p><p>&middot;&nbsp;&nbsp; <strong>Vomiting</strong>: if you vomit more than once in a 24-hour time period.</p><p>&middot;&nbsp;&nbsp; <strong>Nausea</strong>: if you lose your appetite, and the amount of food you eat each day is much less than usual.</p><p>&middot;&nbsp;&nbsp; <strong>Stomatitis</strong>: if you have pain, redness, swelling or sores in your mouth and/or throat.</p><p>&middot;&nbsp;&nbsp; <strong>Hand-and-foot skin-reaction</strong>: if you have pain, swelling, redness or tingling of hands and/or feet</p><p>&middot;&nbsp;&nbsp; <strong>Fever</strong>: if you have a temperature of 38&deg;C or greater.</p><p>&middot;&nbsp;&nbsp; <strong>Infection</strong>: if you experience signs of infection caused by bacteria or virus, or other organisms.</p><p>&middot;&nbsp;&nbsp; <strong>Chest pain</strong>: if you experience pain localized to the center of the chest, especially if it occurs during exercise.</p><p>&middot;&nbsp;&nbsp; <strong>Steven-Johnson syndrome</strong>: if you experience painful red or purplish rash that spreads and blisters and/or other lesions begin to appear in the mucous membrane (e.g. mouth and lips), in particular if you had before light sensitivity, infections of the respiratory system (e.g. bronchitis) and/or fever.</p><p>&nbsp;</p><p>If caught early, these side effects usually improve within 2 to 3 days after treatment discontinuation.</p><p>&nbsp;</p><p>If these side effects continue, however, contact your doctor immediately. Your doctor may instruct you to restart treatment at a lower dose.</p><p>&nbsp;</p><p>If severe stomatitis (sores in your mouth and/or throat), mucosal inflammation, diarrhoea, neutropenia (increased risk for infections), or neurotoxicity occurs during the first cycle of treatment, a DPD deficiency may be involved (see Section 2: Warning and precautions).</p><p>Hand and foot skin-reaction can lead to loss of fingerprint, which could impact your identification by fingerprint scan.</p><p>&nbsp;</p><p><strong>In addition to the above, when Capecitabine SPC is used alone, very common side effects, which may affect more than 1 in 10 people are:</strong></p><p>&middot;&nbsp;&nbsp; abdominal pain</p><p>&middot;&nbsp;&nbsp; rash, dry or itchy skin</p><p>&middot;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp; loss of appetite (anorexia)</p><p>&nbsp;</p><p>These side effects can become severe; therefore, it is important that you always contact your doctor immediately when you start to experience a side effect. Your doctor may instruct you to decrease the dose and/or temporarily discontinue treatment with Capecitabine SPC. This will help reduce the likelihood that the side effect continues or becomes severe.</p><p>&nbsp;</p><p><strong><em><u>Other side effects are:</u></em></strong></p><p><strong>Common side effects (may affect up to 1 in 10 people) include:</strong></p><p>&middot;&nbsp;&nbsp; decreases in the number of white blood cells or red blood cells (seen in tests)</p><p>&middot;&nbsp;&nbsp; dehydration, weight loss</p><p>&middot;&nbsp;&nbsp; sleeplessness (insomnia), depression</p><p>&middot;&nbsp;&nbsp; headache, sleepiness, dizziness, abnormal sensation in the skin (numbness or tingling sensation), taste changes</p><p>&middot;&nbsp;&nbsp; eye irritation, increased tears, eye redness (conjunctivitis)</p><p>&middot;&nbsp;&nbsp; inflammation of the veins (thrombophlebitis),</p><p>&middot;&nbsp;&nbsp; shortness of breath, nose bleeds, cough, runny nose</p><p>&middot;&nbsp;&nbsp; cold sores or other herpes infections</p><p>&middot;&nbsp;&nbsp; infections of the lungs or respiratory system (e.g. pneumonia or bronchitis)</p><p>&middot;&nbsp;&nbsp; bleeding from the gut, constipation, pain in upper abdomen, indigestion, excess wind, dry mouth</p><p>&middot;&nbsp;&nbsp; skin rash, hair loss (alopecia), skin reddening, dry skin, itching (pruritus), skin discolouration, skin loss, skin inflammation, nail disorder</p><p>&middot;&nbsp;&nbsp; pain in the joints, or in the limbs (extremities), chest orback</p><p>&middot;&nbsp;&nbsp; fever, swelling in the limbs, feeling ill</p><p>&middot;&nbsp;&nbsp; problems with liver function (seen in blood tests) and increased blood bilirubin (excreted by the liver)</p><p>&nbsp;</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people) include:</strong></p><p>&middot;&nbsp;&nbsp; blood infection</p><p>&middot;&nbsp;&nbsp; urinary tract infection</p><p>&middot;&nbsp;&nbsp; infection of the skin</p><p>&middot;&nbsp;&nbsp; infections in the nose and throat</p><p>&middot;&nbsp;&nbsp; fungal infections (including those of the mouth)</p><p>&middot;&nbsp;&nbsp; influenza</p><p>&middot;&nbsp;&nbsp; gastroenteritis</p><p>&middot;&nbsp;&nbsp; tooth abscess</p><p>&middot;&nbsp;&nbsp; lumps under the skin (lipoma)</p><p>&middot;&nbsp;&nbsp; decreases in blood cells including platelets, thinning of blood (seen in tests)</p><p>&middot;&nbsp;&nbsp; allergy</p><p>&middot;&nbsp;&nbsp; diabetes</p><p>&middot;&nbsp;&nbsp; decrease in blood potassium</p><p>&middot;&nbsp;&nbsp; malnutrition</p><p>&middot;&nbsp;&nbsp; increased blood triglycerides</p><p>&middot;&nbsp;&nbsp; confusional state</p><p>&middot;&nbsp;&nbsp; panic attacks</p><p>&middot;&nbsp;&nbsp; depressed mood</p><p>&middot;&nbsp;&nbsp; decreased libido</p><p>&middot;&nbsp;&nbsp; difficulty speaking</p><p>&middot;&nbsp;&nbsp; impaired memory</p><p>&middot;&nbsp;&nbsp; loss of movement coordination</p><p>&middot;&nbsp;&nbsp; balance disorder</p><p>&middot;&nbsp;&nbsp; fainting</p><p>&middot;&nbsp;&nbsp; nerve damage (neuropathy) and problems with sensation</p><p>&middot;&nbsp;&nbsp; blurred or double vision</p><p>&middot;&nbsp;&nbsp; vertigo, ear pain</p><p>&middot;&nbsp;&nbsp; irregular heartbeat and palpitations (arrhythmias)</p><p>&middot;&nbsp;&nbsp; chest pain and heart attack (infarction)</p><p>&middot;&nbsp;&nbsp; blood clots in the deep veins</p><p>&middot;&nbsp;&nbsp; high or low blood pressure</p><p>&middot;&nbsp;&nbsp; hot flushes</p><p>&middot;&nbsp;&nbsp; cold limbs (extremities)</p><p>&middot;&nbsp;&nbsp; purple spots on the skin</p><p>&middot;&nbsp;&nbsp; blood clots in the veins in the lung (pulmonary embolism)</p><p>&middot;&nbsp;&nbsp; collapsed lung</p><p>&middot;&nbsp;&nbsp; coughing up blood</p><p>&middot;&nbsp;&nbsp; asthma, shortness of breath on exertion</p><p>&middot;&nbsp;&nbsp; bowel obstruction, collection of fluid in the abdomen, inflammation of the small or large intestine, the stomach or the esophagus, pain in the lower abdomen, abdominal discomfort, heartburn (reflux of food from the stomach), blood in the stool</p><p>&middot;&nbsp;&nbsp; jaundice (yellowing of skin and eyes)</p><p>&middot;&nbsp;&nbsp; skin ulcer and blister, reaction of the skin with sunlight, reddening of palms, swelling or pain of the face</p><p>&middot;&nbsp;&nbsp; joint swelling or stiffness</p><p>&middot;&nbsp;&nbsp; bone pain</p><p>&middot;&nbsp;&nbsp; muscle weakness or stiffness</p><p>&middot;&nbsp;&nbsp; fluid collection in the kidneys</p><p>&middot;&nbsp;&nbsp; increased frequency of urination during the night, incontinence, blood in the urine, increase in blood creatinine (sign of kidney dysfunction)</p><p>&middot;&nbsp; unusual bleeding from the vagina</p><p>&middot;&nbsp; swelling (oedema)</p><p>&middot;&nbsp; chills and rigors</p><p>&nbsp;</p><p><strong><em><u>Some of these side effects are more common when Capecitabine SPC is used with other medicines </u>&nbsp;<u>for the treatment of cancer. Other side-effects seen in this setting are the following:</u></em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong>Common side effects (may affect up to 1 in 10 people) include:</strong></p><p>&middot;&nbsp;&nbsp; decrease in blood sodium, magnesium or calcium</p><p>&middot;&nbsp;&nbsp; increase in blood sugar</p><p>&middot;&nbsp;&nbsp; nerve pain</p><p>&middot;&nbsp;&nbsp; ringing or buzzing in the ears (tinnitus)</p><p>&middot;&nbsp;&nbsp; loss of hearing</p><p>&middot;&nbsp;&nbsp; vein inflammation</p><p>&middot;&nbsp;&nbsp; hiccups</p><p>&middot;&nbsp;&nbsp; change in voice</p><p>&middot;&nbsp;&nbsp; pain or altered/abnormal sensation in the mouth</p><p>&middot;&nbsp;&nbsp; pain in the jaw</p><p>&middot;&nbsp;&nbsp; sweating or night sweats</p><p>&middot;&nbsp;&nbsp; muscle spasm</p><p>&middot;&nbsp;&nbsp; difficulty in urination</p><p>&middot;&nbsp;&nbsp; blood or protein in the urine</p><p>&middot;&nbsp;&nbsp; bruising or reaction at the injection site (caused by medicines given by injection at the same time)</p><p>&nbsp;</p><p><strong>Rare side effects (may affect up to 1 in 1,000 people) include:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; narrowing or blockage of tear duct (lacrimal duct stenosis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver failure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation leading to dysfunction or obstruction in bile secretion (cholestatic hepatitis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; specific changes in the electrocardiogram (QT prolongation).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain types of arrhythmia (including ventricular fibrillation, torsade de pointes, and bradycardia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye inflammation causing eye pain and possibly eyesight problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the skin causing red scaly patches due to an immune system illness.</p><p>&nbsp;</p><p><strong>Very rare side effects (may affect up to 1 in 10,000 people) include:</strong></p><p>&middot;&nbsp;&nbsp; severe skin reaction such as skin rash, ulceration and blistering which may involve ulcers of the mouth, nose, genitalia, hands, feet and eyes (red and swollen eyes)</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via submitting completed forms to: npc.drug@sfda.gov.sa. By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not store above 30&deg;C.</p><p>Do not use this medicine after the expiry date which is stated on the outer carton and label after EXP.</p><p>The expiry date refers to the last day of that month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Capecitabine SPC tablets are available in two strengths, 150 mg and 500 mg.</p><p>Capecitabine SPC tablets comes in blister packs</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                •	150 mg: Light peach filmcoated tablet of biconvex, oblong shape with the marking “150” on one side and “RDY” on other side.
•	500 mg: Peach, film-coated tablet of biconvex, oblong shape with the marking “500” on one side and “RDY” on the other side.
 
Ingredients Active ingredient
•	Capecitabine
Inactive ingredients
•	lactose
•	croscarmellose sodium
•	hypromellose
•	microcrystalline cellulose
•	magnesium stearate
The tablets have a film-coating which contains:
•	hypromellose
•	purified talc
•	titanium dioxide
•	iron oxide yellow (CI77492)
•	iron oxide red (CI77491)
Capecitabine SPC tablets are gluten free.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>MARKETING AUTHORIZATION HOLDER:</strong></p><p><em>Sudair Pharma Company (SPC)</em></p><p><em>King Fahad road, Building 911- The First Round Riyadh, Saudi Arabia Tel: +966-11-4668193</em></p><p><em>Fax: +966-11-4668195</em></p><p><em>Email: </em><em>info@sudairpharma.com</em></p><p><em>Mailing: P.O. Box 19047 Riyadh, Saudi Arabia</em></p><p><strong>Manufacturer:</strong></p><p><em>Sudair - Exit 12 - Sudair Industrial Area, Stage 1, Almorgan road between street no. 31 &amp; street no.130, Riyadh, 12281, Saudi Arabia, Riyadh,</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                09/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي كابيسيتابين اس بي سي إلى مجموعة الأدوية التي تسمى &quot;أدوية الخلايا&quot; ، والتي توقف نمو الخلايا السرطانية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كابيسيتابين اس بي سي يحتوي على مادة الكابيسيتابين ، وهو في حد ذاته ليس دوا ء تثبيط الخلايا. فقط بعد أ ن يتم امتصاصه من قبل الجسم فإنه ي تحول إلى دواء فعال مضاد للسرطان (أكثر في نسيج الورم منه في الأنسجة الطبيعية).</p><p dir="RTL">يستخدم كابيسيتابين اس بي سي في علاج سرطان القولون أو المستقيم أو المعدة أو سرطان الثدي.</p><p dir="RTL">وعلاوة على ذلك ، يستخدم كابيسيتابين اس بي سي لمنع حدوث سرطان القولون الجدي د بعد الإزالة الكاملة للورم عن طريق الجراحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن استخدام كابيسيتابين اس بي سي إما بمفرده أو مع أدوية أخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تأخذ كابيسيتابين اس بي سي</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية من كابيسيتابين أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6). يجب عليك إبلاغ طبيبك إذا كنت تعرف أن لديك حساسية أو رد فعل مفرط لهذا الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تلقيت ردود أفعال شديدة سابقاً على علاج الفلوروبيريمدين (مجموعة من الأدوية المضادة للسرطان مثل الفلورويوراسيل).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حاملاً أو ترضعي رضاعة طبيعية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مستويات منخفضة جداً من الخلايا البيضاء أو الصفائح الدموية في الدم (قلة الكريات البيضاء أو قلة معدلات أو نقص الصفائح)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل شديدة في الكبد أو الكلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعلم أنه ليس لديك أي نشاط من إنزيم ديهيدروبيريدين ديهيدروجينيز (DPD)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعالج الآن أو عولجت في الأسابيع الأربعة الأخيرة مع البريفيودين او سوريفيودين أو أصناف مماثلة من المادة كجزء من علاج الهربس النطاقي (جدري الماء أو القوباء المنطقية).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل أخذ كابيسيتابين اس بي سي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعلم أن لديك نقصا جزئياً في نشاط إنزيم ديهيدروبيريدين ديهيدروجينيز. (DPD)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أمراض الكبد أو الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في القلب أو تعاني منها وقت الاستخدام (على سبيل المثال عدم انتظام ضربات القلب أو آلام في الفك أو في الصدر عاد ظهورها بسبب مشاكل في تدفق الدم إلى القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أمراض دماغية (مثل السرطان الذي انتشر في الدماغ أو تلف الأعصاب (الالتهاب العصبي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك اختلال توازن الكالسيوم (يظهر في تحليل الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض السكري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت لا تستطيع الاحتفاظ بالطعام أو الماء في جسمك بسبب الغثيان الشديد والقيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الإسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أو أصبحت مصابا بالجفاف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك اختلال في توازن الأيونات في دمك (اختلال توازن الايونات ذات الشحنات الكهربائية، يرى في التحاليل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ من مشاكل في العين حيث قد تحتاج إلى مراقبة إضافية لعينيك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك رد فعل شديد على الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نقص إنزيم ديهيدروبيريدين ديهيدروجينيز (</strong><strong>DPD</strong><strong>)</strong></p><p dir="RTL">نقص إنزيم ديهيدروبيريدين ديهيدروجينيز هو حالة نادرة تحدث عند الولادة لا ترتبط عادة بالمشاكل الصحية إلا إذا كنت تتلقى بعض الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك نقص في إنزيم ديهيدروبيريدين ديهيدروجينيز غير معروف وأخذت دواء كابيسيتابين اس بي سي ، فأنت في خطر متزايد للظهور المبكر للأشكال الحادة من الآثار الجانبية المدرجة تحت القسم 4 من الآثار الجانبية المحتملة.</p><p dir="RTL">اتصل بطبيبك على الفور إذا كنت تشعر بالقلق إزاء أي من الآثار الجانبية أو إذا لاحظت أي آثار جانبية إضافية غير مدرجة في المنشور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يوصى باخذ كابيسيتابين اس بي سي من قبل الأطفال والمراهقين. لا تعطي كابيسيتابين اس بي سي للأطفال والمراهقين.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أدوية أخرى و كابيسيتابين اس بي سي</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت أو ربما تأخذ أي أدوية أخرى قبل البدء بالعلاج.</p><p dir="RTL">هذا أمر مهم للغاية ، حيث إن تناول أكثر من دواء في نفس الوقت يمكن أن يقوي أو يضعف من تأثير الأدوية.</p><p dir="RTL"><strong>&nbsp;</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:1015px"><tbody><tr><td style="width:1014px"><p dir="RTL">يجب أ ن لا تتناول البريفودين (دواء مضاد للفيروسات لعلاج القوباء المنطقية أو جدري الماء) في نفس الوقت مع علاج الكابيسيتابين (بما في ذلك خلال أي فترات راحة عندما لا تتناول أي أقراص كابيسيتابين).</p><p dir="RTL">إذا كنت قد اتخذت بريفودين ، يجب عليك الانتظار لمدة 4 أسابيع على الأقل بعد إيقاف بريفودين قبل البدء في تناول كابيسيتابين . انظر أيضاً القسم &quot;لا تتناول كابيسيتابين اس بي سي&quot;.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب أن تكون حذر ا بشكل خاص إذا كنت تأخذ أ يا مما يلي</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية النقرس (الوبيورينول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تجلط الدم (الكومارين ، الوارفارين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المضادة للفيروسات (البريفيودين او سوريفيودين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية الصرع والتشنجات (الفينيتوئين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانترفيرون ألفا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج الإشعاعي وبعض الأدوية المستخدمة لعلاج السرطان (حمض الفولينيك ، الأكساليبلاتين ، بيفاسيزوماب ، سيسبلاتين ، إرينوتيكان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج نقص حمض الفوليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كابيسيتابين اس بي سي مع الطعام والشراب</strong></p><p dir="RTL">يجب أن تأخذ كابيسيتابين اس بي سي في موعد أقصاه 30 دقيقة بعد الوجبات.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنت حاملًا أو تقومي بالرضاعة طبيعية ، أو أنك قد تكونين حاملاً أو تخططين لإنجاب طفل ، اسأل طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL">يجب ألا تأخذ كابيسيتابين اس بي سي إذا كنت حاملاً أو تعتقدين أنك قد تكونين حاملا.</p><p dir="RTL">يجب عليك عدم القيام بالرضاعة الطبيعية إذا كنت تأخذ كابيسيتابين اس بي سي.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">كابيسيتابين اس بي سي قد يجعلك تشعر بالدوار ، بالغثيان أو التعب، ولذلك فمن الممكن أ ن يؤثر كابيسيتابين اس بي سي على قدرتك على قيادة السيارة أو تشغيل الآلات.</p><p dir="RTL"><strong>كابيسيتابين اس بي سي يحتوي على لاكتوز لا مائي</strong></p><p dir="RTL">إذا أخبرك طبيبك بأن لديك حساسية تجاه بعض السكريات ، فاتصل بطبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم هذا الدواء تماما كما وصفه لك الطبيب أو الصيدلي. استشر طبيبك أو الصيدلي إذا كنت غير متأكد</p><p dir="RTL">&nbsp;</p><p dir="RTL">كابيسيتابين اس بي سي يجب أن يوصف فقط من قبل طبيب من ذوي الخبرة في استخدام الأدوية المضادة للسرطان.</p><p dir="RTL">سيقوم طبيبك بوصف الجرعة ونظام العلاج المناسب لك، حيث تعتمد جرعة كابيسيتابين اس بي سي على مساحة سطح جسمك، بان يتم حساب هذا من الطول والوزن الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة المعتادة للبالغين هي 1250 مجم / م 2 من مساحة سطح الجسم تؤخذ مرتين يومياً (الصباح والمساء)، ويتم تقديم مثالين هنا: الشخص الذي يكون وزن جسمه 64 كجم وطوله 1.64 متر به تكون مساحة سطح الجسم 1.7 م 2 ويجب أن يأخذ 4 أقراص من 500 ملغ و 1 قرص من 150 ملغ مرتين في اليوم .</p><p dir="RTL">الشخص لذي يبلغ وزن جسمه 80 كجم وطوله 1.80 متر تكون مساحة سطح الجسم 2.00 م 2 ويجب أن يأخذ 5 حبة من 500 ملغ مرتين يومياً.</p><p dir="RTL">قد يطلب منك طبيبك تناول 150 ملغ (لون الخوخ الخفيف) و 500 ملغ (لون الخوخ) لكل جرعة.</p><p dir="RTL">خذ أقراص الصباح والمساء على النحو الذي يحدده الطبيب.</p><p dir="RTL">تؤخذ الأقراص في غضون 30 دقيقة بعد نهاية الوجبة )الإفطار والعشاء ( وابتلعها بالكامل بالماء. لا تسحق أو تقطع الأقراص . إذا لم تتمكن من ابتلاع أقراص كابيسيتابين اس بي سي بالكامل ، أخبر مقدم الرعاية الصحية الخاص بك.</p><p dir="RTL">من المهم أن تأخذ كل الأدوية التي وصفها الطبيب.</p><p dir="RTL">عادة ما يتم أخذ أقراص كابيسيتابين اس بي سي لمدة 14 يوم تليها فترة راحة لمدة 7 أيام (لا يتم أخذ أي أقراص)، هذه الفترة ( 21 يوما) هي دورة علاج واحدة .</p><p dir="RTL">بالاقتران مع أدوية أخرى ، قد تكون الجرعة المعتادة للبالغين أقل من 1250 مجم / م 2 من مساحة سطح الجسم ، وقد تحتاج إلى أخذ الأقراص على مدار فترة زمنية مختلفة (على سبيل المثال ، كل يوم ، بدون فترة راحة).</p><p dir="RTL"><strong>إذا كنت تأخذ كابيسيتابين اس بي سي أكثر مما يجب عليك</strong><strong>:</strong></p><p dir="RTL">إذا كنت تأخذ أكثر من كابيسيتابين اس بي سي مما يجب عليك ، اتصل بطبيبك في أقرب وقت ممكن قبل أخذ الجرعة التالية.</p><p dir="RTL"><strong>إذا كنت تأخذ الكثير من كابيسيتابين قد تحصل على الآثار الجانبية التالية</strong><strong>:</strong></p><p dir="RTL">الشعور بالمرض ، الإسهال، الالتهاب أو تقرح في الأمعاء أو الفم، ألم أو نزيف من الأمعاء أو المعدة ، اكتئاب النخاع العظمي (انخفاض في أنواع معينة من خلايا الدم). أخبر طبيبك فورا إذا واجهت أي من هذه الأعراض.</p><p dir="RTL"><strong>إذا نسيت أن تأخذ كابيسيتابين اس بي سي</strong><strong>:</strong></p><p dir="RTL">لا تأخذ الجرعة المنسية على الإطلاق، ولا تأخذ جرعة مضاعفة للتعويض عن الجرعة منسية.</p><p dir="RTL">بدلًا من ذلك ، استمر في جدول الجرعات المعتاد وتأكد من طبيبك.</p><p dir="RTL"><strong>إذا توقفت عن تناول كابيسيتابين اس بي سي</strong><strong>:</strong></p><p dir="RTL">لا توجد أي آثار جانبية الناجمة عن وقف العلاج مع كابيسيتابين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حال كنت تستخدم مضادا ت التخثر الكومارين (التي تحتوي على سبيل المثال phenprocoumon)، فإن التوقف عن تناول كابيسيتابين اس بي سي قد يتطلب الموافقة من طبيبك حيث يتم ضبط الجرعة المضاد للتخثر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء آثارا جانبية، على الرغم من عدم حصول الجميع عليها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقف عن تناول كابيسيتابين اس بي سي على الفور واتصل بطبيبك في حالة حدوث أي من هذه الأعراض</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الإسهال: </strong>إذا كان لديك زيادة في عدد عمليات التبرّز 4 مرات أو أكثر مقارنة بعملية التغوط المعتادة كل يوم، أو في حالة حدوث إسهال بالليل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>القيء: </strong>إذا تقيأت أكثر من مرة خلال 24 ساعة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الغثيان: </strong>إذا فقدت شهيتك ، وكانت كمية الطعام التي تتناولها كل يوم أقل بكثير من المعتاد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التهاب الفم: </strong>إذا كان لديك ألم أو احمرار أو تورم أو تقرحات في الفم و/أو الحلق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تفاعل جلد اليد والقدم: </strong>إذا كان لديك ألم أو تورم أو احمرار أو وخز في اليدين و/أو القدمين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الحمى: </strong>إذا كانت درجة حرارتك 38 درجة مئوية أو أكثر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>العدوى: </strong>إذا كنت تعاني من علامات العدوى التي تسببها البكتيريا أو الفيروسات أو الكائنات الحية الأخرى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ألم في الصدر: </strong>إذا كنت تعاني من ألم موضعي إلى منتصف الصدر، خاصة إذا كان يحدث أثناء التمرين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>متلازمة ستيفن جونسون: </strong>إذا كنت تعاني من طفح أحمر مؤلم أو مستنقعي ينتشر وبثور و/أو آفات أخرى تبدأ بالظهور في الأغشية المخاطية (مثل الفم والشفتين) ، خاصة إذا كان لديك قبل حساسية الضوء، عدوى في الجهاز التنفسي (مثل التهاب الشعب الهوائية) و/أو الحمى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تم اكتشافها مبكرا ، عادة ما تتحسن هذه الآثار الجانبية في غضون يومين إلى 3 أيام بعد التوقف عن العلاج.</p><p dir="RTL">إذا استمرت هذه الآثار الجانبية ، اتصل بطبيبك على الفور. قد يطلب منك الطبيب إعادة العلاج بجرعة أقل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا حدث التهاب شديد بالفم ( تقرحات في فمك و/ أو حلقك)، التهاب في الغشاء المخاطي، إسهال، أو سمية عصبية خلال أول دورة علاجية، فقد يكون ذلك بسبب نقص DPD (انظر القسم الثاني: التحذيرات والاحتياطات) .</p><p dir="RTL">يمكن أن يؤدي تفاعل جلد اليد والقدم إلى فقدان بصمة الإصبع ، مما قد يؤثر على هويتك عن طريق مسح بصمات الأصابع.</p><p dir="RTL"><strong>بالإضافة إلى ما سبق، عند استخدام كابيسيتابين اس بي سي بمفرده فإن الآثار الجانبية الشائعة جدا والتي قد تؤثر على أكثر من 1 من كل 10 أشخاص هي</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بطن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي، جفاف الجلد أو حكة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أ ن تصبح هذه الآثار الجانبية شديدة ؛ لذلك ، من المهم أن تقوم دائماً بالاتصال بطبيبك على الفور عند بداية احساسك بتأثير جانبي.</p><p dir="RTL">وقد يطلب منك الطبيب تقليل الجرعة و/أو التوقف مؤقتاً عن العلاج باستخدام كابيسيتابين اس بي سي. سيساعد هذا على تقليل احتمال استمرار التأثير الجانبي أو يصبح شديدا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><u>الآثار الجانبية الأخرى هي</u></strong><strong><u>:</u></strong></p><p dir="RTL"><strong>الآثار ا لجانبية الشائعة (قد تؤثر على 1 من كل 10 أشخاص) تشمل</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدم البيضاء أو خلايا الدم الحمراء (المشاهدة في اختبارات الدم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجفاف ، وفقدان الوزن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة النوم (الأرق)، الاكتئاب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع ، النعاس ، الدوخة ، الإحساس غير الطبيعي في الجلد (الإحساس بالخدر أو التنميل) ، تغيرات الذوق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيج العين، زيادة الدموع، احمرار العين (التهاب الملتحمة ).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوردة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس ، نزيف الأنف ، السعال ، سيلان الأنف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القروح الباردة أو عدوى الهربس الأخرى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات في الرئتين أو الجهاز التنفسي (مثل الالتهاب الرئوي أو التهاب الشعب الهوائية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف من الأمعاء، الإمساك، الألم في الجزء العلوي من البطن، عسر الهضم، رياح زائدة ، وجفاف الفم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي ، تساقط الشعر، احمرار الجلد ، جفاف الجلد ، حكة ، تغير لون الجلد ، فقدان الجلد ، التهاب الجلد ، اضطراب الأظافر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل ، أو في الأطراف ، الصدر أو الظهر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى ، وتورم في الأطراف ، والشعور بالمرض</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في وظائف الكبد (المشاهدة في اختبارات الدم) وزيادة نسبة البيليروبين في الدم (تفرزها الكبد).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة (قد تؤثر على 1 من كل 100 شخص) تشمل</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المسالك البولية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجلد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات في الأنف والحنجرة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهابات الفطرية (بما في ذلك حالات الفم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإنفلونزا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة والأمعاء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خراج الأسنان.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكتل تحت الجلد (الورم الشحمي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في خلايا الدم بما في ذلك الصفائح الدموية ، ترقق الدم (المشاهدة في اختبارات الدم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء السكري.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في البوتاسيوم في الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوء التغذية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الدهون الثلاثية في الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة ارتباك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات الهلع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مزاج مكتئب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في الرغبة الجنسية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التحدث.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الذاكرة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان التنسيق في الحركة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب التوازن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الأعصاب (الاعتلال العصبي) ومشاكل في الإحساس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيمّ الرؤية (رؤية غير واضحة) أو ازدواج الرؤية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار، ألم بالأذن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب والخفقان (عدم انتظام ضربات القلب).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر ونوبة قلبية (احتشاء).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات الدم في الأوردة العميقة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع أو انخفاض ضغط الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهبات الساخنة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطراف الباردة (الأطراف).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع أرجوانية على الجلد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات الدم في الأوردة في الرئة (انسداد رئوي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رئة منهارة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود دم أثناء السعال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الربو وضيق التنفس عند بذل مجهود.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأمعاء، تجمع سوائل في البطن، التهاب الأمعاء الدقيقة أو الغليظة، التهاب المعدة أو المريء، ألم في أسفل البطن، عدم ارتياح في البطن، حرقة المعدة (ارتجاع الطعام من المعدة) ، دم في البراز.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان (اصفرار الجلد والعيون).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرحة الجلد وبثور، رد فعل من الجلد مع أشعة الشمس، احمرار في الخد، وتورم أو ألم في الوجه.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم أو تصلب المفصل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العظام.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات أو تصلبها.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجمع سوائل في الكلى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة تواتر التبول أثناء الليل، سلس البول، دم في البول، زيادة في الكرياتينين في الدم (علامة على خلل في الكلى).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف غير عادي من المهبل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم (وذمة).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><u>بعض هذه الآثار الجانبية هي أكثر شيوعا عند استخدام كابيسيتابين اس بي سي مع أدوية أخرى لعلاج السرطان. من الآثار الجانبية الأخرى التي تظهر في هذا الإعداد ما يلي</u></strong><strong><u>:</u></strong></p><p dir="RTL"><strong>الآثار ا لجانبية الشائعة (قد تؤثر على 1 من كل 10 أشخاص) تشمل</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض معدل الصوديوم او المغنيسيوم أو الكالسيوم في الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في نسبة السكر في الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام الأعصاب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رنين أو طنين في الأذنين (طنين).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان السمع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الوريد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شهاق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيير في الصوت.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو تغير غير طبيعي في الفم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الفك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرق او تعرق ليلي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج العضلات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التبول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود دم أو بروتين في البول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كدمات أو رد فعل في موقع الحقن (بسبب الأدوية التي تعطى عن طريق الحقن في نفس الوقت).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية النادرة (قد تؤثر على 1 من كل 1000 شخص) تشمل</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضيق أو انسداد القناة الدمعية (تضيق القناة الدمعية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكبد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب يؤدي إلى خلل وظيفي أو عرقلة افراز الصفراء (التهاب الكبد الصفراوي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات محددة في تخطيط كهربية القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أنواع معينة من عدم انتظام ضربات القلب (بما في ذلك الرجفان البطيني، تسرع قلبي بطيني متعدد الأشكال، و بطء القلب).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العين يسبب ألما في العين وربما مشاكل في الرؤية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب من الجلد يسبب بقع قشرية حمراء بسبب مرض جهاز المناعة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية النادرة جدا (قد تؤثر على 1 من 10،000 شخص) تشمل</strong><strong> :</strong></p><p dir="RTL">تفاعل الجلد الشديد مثل الطفح الجلدي، تقرحات أو تقرحات قد تنطوي على قرحة في الفم/، الأنف، الأعضاء التناسلية، اليدين، القدمين والعينين (العين الحمراء والمتورمة)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا حصلت على أي آثار جانبية ، تحدث مع طبيبك أو الصيدلي أو الممرضة. يتضمن ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة. كما يمكنك الإبلاغ عن الآثار الجانبية بشكل مباشر عن طريق ملء النماذج وإرسالها إلى البريد الإلكتروني التالي: npc.drug@sfda.gov.sa</p><p dir="RTL">من خلال إبلاغك عن الآثار الجانبية يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدواء .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ابق هذا الدواء بعيدا عن متناول الأطفال.</p><p dir="RTL">لا يتم خزينه في درجة حرارة فوق 30 درجة مئوية.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على الكرتون الخارجي، حيث يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر .</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. هذه التدابير سوف تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تتوافر أقراص كابيسيتابين اس بي سي بمقيايتين ، 150 مجم و 500 ملغم.</p><p dir="RTL">أقراص كابيسيتابين اس بي سي تأتي في اشرطة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شكل كابيسيتابين اس بي سي</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>150 </strong><strong>ملغ: </strong>أقراص مغلفة مستطيلة الشكل لونها لون الخوخ الفاتح، محفور على أحد جانبيها &quot; 150 &quot; وعلى الجانب الآخر &quot;RDY&quot;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>500 </strong><strong>ملغ: </strong>أقراص مغلفة مستطيلة الشكل لونها لون الخوخ، محفور على أحد جانبيها &quot; 500 &quot; وعلى الجانب الآخر &quot;RDY&quot;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المكونات</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المادة الفعَّالة</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كابيسيتابين</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المكونات غير الفعالة</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لاكتوز</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كروسكارميلوز صوديوم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هيبروميلوز</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيليلوز دقيق التبلور</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستيرات الماغنسيوم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحتوي الأقراص المغلفة على</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هيبروميلوز</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلك نقي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثاني أكسيد التيتانيوم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أكسيد الحديد الأصفر (CI77492)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أكسيد الحديد الأحمر (CI77491)</p><p dir="RTL">كابيسيتابين إس بي سي أقراص خالي من الجلوتين</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التسويق</strong><strong>:</strong></p><p dir="RTL">طريق الملك (SPC) شركة سدير فارما</p><p dir="RTL">فهد، مبنى 911 -الدوار الأول الريا ض -</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">هاتف: 4668193-11-966+</p><p dir="RTL">فاكس: 4668195-11-966+</p><p dir="RTL">البريد الإلكتروني: info@sudairpharma.com عنوان المراسلة: صندوق</p><p dir="RTL">بريد رقم: 19047 ، الرياض -المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جهة التصنيع:</strong></p><p dir="RTL">شركة سدير فارما</p><p dir="RTL">سدير- مخرج 21 - المدينة الصناعية بسدير، المنطقة رقم</p><p dir="RTL">1 طريق المرجان بين شارع رقم 13 وشارع رقم 031</p><p dir="RTL">الرياض, 18221 , المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            09/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capecitabine SPC 150 mg Film Coated Tablets 
Capecitabine SPC 500 mg Film Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 150 mg Capecitabine. 
Excipient with known effect: 15 mg anhydrous lactose. 
Each film-coated tablet contains 500 mg Capecitabine. 
Excipient with known effect: 50 mg anhydrous lactose. For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets
150 mg: Light peach film-coated tablet of biconvex, oblong shape with the marking “150” on one side and “RDY” on other side.
500 mg: Peach, film-coated tablet of biconvex, oblong shape with the marking “500” on one side and “RDY” on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capecitabine is indicated for the treatment of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the adjuvant treatment of patients following surgery of stage III (Dukes&#39; stage C) colon cancer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metastatic colorectal cancer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First-line treatment of advanced gastric cancer in combination with a platinum-basedregimen.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In combination with docetaxel for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included ananthracycline.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Standard Dosage</u></p><p>Capecitabine SPC tablets should be swallowed with water within 30 minutes after the end of a meal.</p><p><em>Monotherapy - Colon, colorectal, breast cancer</em></p><p>The recommended monotherapy starting dose of Capecitabine SPC is 1250 mg/m2 administered twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 2 weeks followed by a 7 day rest period; given as 3 week cycles.</p><p>&nbsp;</p><p><u>Combination therapy - Breast cancer</u></p><p>In combination with docetaxel, the recommended starting dose of Capecitabine SPC is 1250 mg/m2 administered twice daily for 2 weeks followed by a 7 day rest period, combined with docetaxel 75 mg/m2 administered as a 1 hour intravenous infusion every 3 weeks.</p><p>Pre-medication, according to the docetaxel product information, should be started prior to docetaxel administration for patients receiving capecitabine plus docetaxel combination.</p><p><u>Combination therapy - Colorectal cancer</u></p><p>In combination with oxaliplatin with or without bevacizumab the recommended starting dose of Capecitabine SPC is 1000 mg/m2 twice daily for 2 weeks followed by a 7 day rest period. The first dose of Capecitabine SPC is given on the evening of day 1 and the last dose is given on the morning of day 15. Given as a 3-week cycle, on day 1 every 3 weeks bevacizumab is administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes followed by oxaliplatin administered as a 130 mg/m2 intravenous infusion over 2 hours.</p><p><u>Combination therapy &ndash; Adjuvant colon cancer</u></p><p>In combination with oxaliplatin the recommended starting dose of Capecitabine SPC is 1000 mg/m2 twice daily for 2 weeks followed by a 7 day rest period. The first dose of Capecitabine SPC is given on the evening of day 1 and the last dose is given on the morning of day 15. Given as a 3 week cycle, on day 1 oxaliplatin is administered as a 130 mg/m2 intravenous infusion over 2 hours.</p><p>Premedication to maintain adequate anti-emesis according to the oxaliplatin product information should be started prior to oxaliplatin administration for patients receiving the Capecitabine SPC plus oxaliplatin combination.</p><p><u>Combination therapy - Oesophagogastric cancer</u></p><p>In triplet combination with epirubicin and cisplatin/oxaliplatin for oesophagogastric cancer, the recommended starting dose of Capecitabine SPC is 625 mg/m2 twice daily as a continuous regimen. Epirubicin is administered as a 50 mg/m2 intravenous bolus on day 1 of a 3 week cycle. Platinum therapy should consist of either cisplatin administered at a dose of 60 mg/m2 given as a 2 hour intravenous infusion on day 1 of a 3 week cycle; or oxaliplatin administered at a dose of 130 mg/m2 given as a 2 hour intravenous infusion on day 1 of a 3 week cycle.</p><p>In doublet combination with cisplatin for gastric cancer, the recommended starting dose of Capecitabine SPC is 1000 mg/m2 twice daily for 2 weeks followed by a 7-day rest period. The first dose of Capecitabine SPC is given on the evening of day 1 and the last dose is given on the morning of day 15. Cisplatin is administered at a dose of 80 mg/m2 as a 2 hour intravenous infusion on day 1 of a 3-week cycle.</p><p>Pre-medication to maintain adequate hydration and anti-emesis should be started prior to oxaliplatin/cisplatin administration for patients receiving Capecitabine SPC in combination with one of these agents.</p><p>The Capecitabine SPC dose is calculated according to body surface area. The following tables show examples of the standard and reduced dose calculations for a starting dose of Capecitabine SPC of 1250 mg/m2 or 1000 mg/m2.</p><p>&nbsp;</p><p>&nbsp;</p><p>Table: Standard and reduced dose calculations according to body surface area for a starting dose of</p><p>Capecitabine SPC <strong>of 1250 mg/m2</strong></p><p><strong>&nbsp;</strong><img alt="" width="900" height="500" src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAeAB4AAD/2wBDAAMCAgMCAgMDAwMEAwMEBQgFBQQEBQoHBwYIDAoMDAsKCwsNDhIQDQ4RDgsLEBYQERMUFRUVDA8XGBYUGBIUFRT/2wBDAQMEBAUEBQkFBQkUDQsNFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBT/wAARCAJEBBMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD9U6KKKAOK8bfG74dfDXVYtM8XePvC/hXUpoRcx2et6zbWczxFmUSBJHUlSyON2MZUjsa5/wD4ax+CH/RZPh//AOFRY/8Ax2jw5/ydN8Q/+xM8M/8Apdr1eq0AeVf8NY/BD/osnw//APCosf8A47R/w1j8EP8Aosnw/wD/AAqLH/47XqtFAHlX/DWPwQ/6LJ8P/wDwqLH/AOO0f8NY/BD/AKLJ8P8A/wAKix/+O16rRQB5V/w1j8EP+iyfD/8A8Kix/wDjtH/DWPwQ/wCiyfD/AP8ACosf/jteq0UAeVf8NY/BD/osnw//APCosf8A47R/w1j8EP8Aosnw/wD/AAqLH/47XqtFAHlX/DWPwQ/6LJ8P/wDwqLH/AOO0f8NY/BD/AKLJ8P8A/wAKix/+O16rRQB5V/w1j8EP+iyfD/8A8Kix/wDjtH/DWPwQ/wCiyfD/AP8ACosf/jteq0UAeVf8NY/BD/osnw//APCosf8A47R/w1j8EP8Aosnw/wD/AAqLH/47XqtFAHlX/DWPwQ/6LJ8P/wDwqLH/AOO0f8NY/BD/AKLJ8P8A/wAKix/+O16rRQB5V/w1j8EP+iyfD/8A8Kix/wDjtH/DWPwQ/wCiyfD/AP8ACosf/jteq0UAeVf8NY/BD/osnw//APCosf8A47R/w1j8EP8Aosnw/wD/AAqLH/47R8ZP+Si/An/sc7n/ANR7Wa9VoA8q/wCGsfgh/wBFk+H/AP4VFj/8do/4ax+CH/RZPh//AOFRY/8Ax2vVaKAPKv8AhrH4If8ARZPh/wD+FRY//HaP+Gsfgh/0WT4f/wDhUWP/AMdr1WigDyr/AIax+CH/AEWT4f8A/hUWP/x2j/hrH4If9Fk+H/8A4VFj/wDHa9VooA8q/wCGsfgh/wBFk+H/AP4VFj/8do/4ax+CH/RZPh//AOFRY/8Ax2vVaKAPKv8AhrH4If8ARZPh/wD+FRY//HaP+Gsfgh/0WT4f/wDhUWP/AMdr1WigDyr/AIax+CH/AEWT4f8A/hUWP/x2j/hrH4If9Fk+H/8A4VFj/wDHa9VooA8q/wCGsfgh/wBFk+H/AP4VFj/8do/4ax+CH/RZPh//AOFRY/8Ax2vVaKAPKv8AhrH4If8ARZPh/wD+FRY//HaP+Gsfgh/0WT4f/wDhUWP/AMdr1WigDyr/AIax+CH/AEWT4f8A/hUWP/x2j/hrH4If9Fk+H/8A4VFj/wDHa9VooA8q/wCGsfgh/wBFk+H/AP4VFj/8do/4ax+CH/RZPh//AOFRY/8Ax2vVaKAPKv8AhrH4If8ARZPh/wD+FRY//HaP+Gsfgh/0WT4f/wDhUWP/AMdr1WigDyr/AIax+CH/AEWT4f8A/hUWP/x2j/hrH4If9Fk+H/8A4VFj/wDHa9VooA8q/wCGsfgh/wBFk+H/AP4VFj/8do/4ax+CH/RZPh//AOFRY/8Ax2vVaKAPKv8AhrH4If8ARZPh/wD+FRY//HaP+Gsfgh/0WT4f/wDhUWP/AMdr1WigDyr/AIax+CH/AEWT4f8A/hUWP/x2j/hrH4If9Fk+H/8A4VFj/wDHa9VooA8q/wCGsfgh/wBFk+H/AP4VFj/8do/4ax+CH/RZPh//AOFRY/8Ax2vVaKAPKv8AhrH4If8ARZPh/wD+FRY//HaP+Gsfgh/0WT4f/wDhUWP/AMdr1WigDyr/AIax+CH/AEWT4f8A/hUWP/x2j/hrH4If9Fk+H/8A4VFj/wDHa9VooA8q/wCGsfgh/wBFk+H/AP4VFj/8do/4ax+CH/RZPh//AOFRY/8Ax2vVaKAPKv8AhrH4If8ARZPh/wD+FRY//HaP+Gsfgh/0WT4f/wDhUWP/AMdr1WigDyr/AIax+CH/AEWT4f8A/hUWP/x2j/hrH4If9Fk+H/8A4VFj/wDHa9VooA8q/wCGsfgh/wBFk+H/AP4VFj/8do/4ax+CH/RZPh//AOFRY/8Ax2vVaKAPKv8AhrH4If8ARZPh/wD+FRY//HaP+Gsfgh/0WT4f/wDhUWP/AMdr1WigDyr/AIax+CH/AEWT4f8A/hUWP/x2j/hrH4If9Fk+H/8A4VFj/wDHa9VooA8q/wCGsfgh/wBFk+H/AP4VFj/8do/4ax+CH/RZPh//AOFRY/8Ax2vVaKAPKv8AhrH4If8ARZPh/wD+FRY//HaP+Gsfgh/0WT4f/wDhUWP/AMdr1WigDyr/AIax+CH/AEWT4f8A/hUWP/x2j/hrH4If9Fk+H/8A4VFj/wDHa9VooA8q/wCGsfgh/wBFk+H/AP4VFj/8do/4ax+CH/RZPh//AOFRY/8Ax2vVaKAPKv8AhrH4If8ARZPh/wD+FRY//HaP+Gsfgh/0WT4f/wDhUWP/AMdr1WigDyr/AIax+CH/AEWT4f8A/hUWP/x2j/hrH4If9Fk+H/8A4VFj/wDHa9VooA8q/wCGsfgh/wBFk+H/AP4VFj/8do/4ax+CH/RZPh//AOFRY/8Ax2vVaKAPKv8AhrH4If8ARZPh/wD+FRY//HaP+Gsfgh/0WT4f/wDhUWP/AMdr1WigDyr/AIax+CH/AEWT4f8A/hUWP/x2j/hrH4If9Fk+H/8A4VFj/wDHa9VooA8q/wCGsfgh/wBFk+H/AP4VFj/8do/4ax+CH/RZPh//AOFRY/8Ax2vVaKAPKv8AhrH4If8ARZPh/wD+FRY//HaP+Gsfgh/0WT4f/wDhUWP/AMdr1WigDyr/AIax+CH/AEWT4f8A/hUWP/x2j/hrH4If9Fk+H/8A4VFj/wDHa9VooA8q/wCGsfgh/wBFk+H/AP4VFj/8do/4ax+CH/RZPh//AOFRY/8Ax2vVaKAPKv8AhrH4If8ARZPh/wD+FRY//HaP+Gsfgh/0WT4f/wDhUWP/AMdr1WigDyr/AIax+CH/AEWT4f8A/hUWP/x2j/hrH4If9Fk+H/8A4VFj/wDHa9VooA8q/wCGsfgh/wBFk+H/AP4VFj/8do/4ax+CH/RZPh//AOFRY/8Ax2vVaKAPKv8AhrH4If8ARZPh/wD+FRY//HaP+Gsfgh/0WT4f/wDhUWP/AMdr1WigDyr/AIax+CH/AEWT4f8A/hUWP/x2j/hrH4If9Fk+H/8A4VFj/wDHa9VooA8q/wCGsfgh/wBFk+H/AP4VFj/8do/4ax+CH/RZPh//AOFRY/8Ax2vVaKAPKv8AhrH4If8ARZPh/wD+FRY//HaP+Gsfgh/0WT4f/wDhUWP/AMdr1WigDyr/AIax+CH/AEWT4f8A/hUWP/x2j/hrH4If9Fk+H/8A4VFj/wDHa9VooA8q/wCGsfgh/wBFk+H/AP4VFj/8do/4ax+CH/RZPh//AOFRY/8Ax2vVaKAPKv8AhrH4If8ARZPh/wD+FRY//HaP+Gsfgh/0WT4f/wDhUWP/AMdr1WigDyr/AIax+CH/AEWT4f8A/hUWP/x2j/hrH4If9Fk+H/8A4VFj/wDHa9VooA8q/wCGsfgh/wBFk+H/AP4VFj/8do/4ax+CH/RZPh//AOFRY/8Ax2vVaKAPKv8AhrH4If8ARZPh/wD+FRY//HaP+Gsfgh/0WT4f/wDhUWP/AMdr1WigDyr/AIax+CH/AEWT4f8A/hUWP/x2j/hrH4If9Fk+H/8A4VFj/wDHa9VooA8q/wCGsfgh/wBFk+H/AP4VFj/8drtfBPxC8K/ErSpdT8I+JdH8VabDMbaS80S/ivIUlCqxjLxswDBXQ7c5wwPcV0FeVfBv/kovx2/7HO2/9R7RqAPVaKKKACiiigAooooA8q8Of8nTfEP/ALEzwz/6Xa9XqteVeHP+TpviH/2Jnhn/ANLter1WgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyr4yf8lF+BP/Y53P8A6j2s16rXlXxk/wCSi/An/sc7n/1HtZr1WgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACimyIJI2Q7gGGDtJU/gRyK/Nz4NaTqfjH/goZ8Yvhfqnjv4hT+CdD0v7RpunL451hDbSH7L8wkF1vbHmvw7MOenApwTnU9mt7N/+Aq7/wCAErRhzvul95+ktFfFP7Nv7Q/i7w3+1t8R/wBnvx1rUnie00eJtS0HXr0ILoW2yOXybh1ADkRyqd5Gco2ScjHrGl/trfD/AFSbTL3yNYtfBuras2haZ40uIIRpN7fKzL5SESmZQWVwJHiWMlThzxlpcyi468yTXzdvvvpbq9rg7xclLTl3+6/3W19NWe/UV5drv7Q3h/RvHHiDwxBp2razdeHLFL/W7jS4opY9OWRS0SOhkErs6qSPKjcKOXKg0z4iftFeH/AHi6DwnDpureKvFTadJrE2j6DHC89rYIcNcymaWNAueAoYux+6rVHRPv8A1+Sv6a7Ds7tf10/zXzdtz1SisDwH460P4m+DdI8U+G79NT0LVrdbq0uowQHRvUHkEHIIPIIIPSvj/wDZF+IGp6X+0p+1Rp3iPxhrN74S8K3tvJaR6/rFxeQ6bB/pDyFDM7bFwvOOyj0FVa05QlpZNv5NJ/mJe9D2kddUvvPt+ivEvBX7WnhPx1qujWVnpOu2f/CR2VxqHhifUIIIY/EUUIzJ9lzNuVgCCFuBCSDuGVyRj/C39tDQPi54d+Imq6N4H8Y2z+BZGg1TTdQisIbt513b4Y0+1kblCMfnKKcYUk8UNNXv0V/xt+D0fZ6B283Y+haK8c8TftOaJ4a1TStCbw14i1HxheaQddufC9jHavfabYrgPNck3AhXBO3akjsxBCK2K+cP2wfjFJrXiX9lvxl8O/Gut2ug+K/E9rbS/wBk6rc21rf2jSxHZNbq4RjkspDLu6qemKcYuU4w7yUfvdvzTXyfYNLN+Tf3K/5W+9dGfeVFMlDtE4jZUkIO1mXcAexIyMj8RXxp8B/iV8Q9S/4KAfFjwD4q8Zz+I9B0DQoJ7C0S1jtLeFpfszkiNPvMN5AZyzYJ55pQ9+oqfk39yuKXuwdTs0vvaX5s+zqK+Nv2+vBfjvw58M9f+LHhz4weLPDGseGzFPp2g6TOkWlTIZUQRywhN08jFhzIzLk4CYznJ/bW/aP1T4Y/sn+BbfxT4g1jwF428ZQ2kN9qXhiATX2nOsKzXLxRmaD+PbGcSKVEpxnGDHN7jl1TSt67f8Ht8zTl99R6NN39N/z07n2/RX51/s3/ABCg+E/7N/xd+Lml/tB6/wDH2XTtN/0ex8RC7g/sudQ+xXt5riVgZHZPnGAQhwTzjsdD+LWv/Ci8/Zf1++8SavrSfFOOOz8Sxaney3EMt1PaxPDNBE7FLXbI2NkIRSrHKkgEb+z97l/wr5yvZfhv5rpqY8y5eb/E/lFK/wCex9x0VxHxo+K1h8D/AIZ65441XS9S1fS9Gh+0XdvpIha4EWQGcCWWNSFByRuzgcAnivGLz/goR8OtI0f4eazq+h+L9J0Px3bvLo2oTaUsoklUgfZzDDK83mEsoXbGyNuGGI5rJe87LyX37ffZ2NP+D+G/3X18tT6eorxv4VftTeFfil4q8beGH0zWvCHiPwekc2rab4khhieKF0DrMHillQptIzlgR3ArzrUP+CiHgqHT/Dmr6d4K8a654Z8S6u2h6H4gtIdPis9RugxXan2i8ikjG4MA0qIDtOCcU0m2kutvx0X3vReYtk2+n6K/5a+mp9U0V5V408R6nqnxQ8HaJpy6jAmn2Vz4l1aytJkSWZFjMNvaOd4Q75ZXbBbYTbcnHNeR6R/wUk+HmsfCfWfiMnhTxrB4X0PWI9F1W4msbTdZSOUAkYC5IdNzqD5RdxnlcEEpa/158v8A6VoOz6L/AIe17fdqfWNfKX7Tnwk8d2nhnxX8VNO+M/jDw74h8P2txqGlaBpU8Q0PZGpKQTWvlbrhnCgFnYnc/wAoAAFdj4T/AG0PBHi74neFvBcek+JdLl8WWct/4c1fVNOW3s9WijBLGIF/OTgMR50UeQMjIZd3EfFL9q37L8RbrQ7z4IfGTxT4d0W4VorjQvBcs1pqFyjZEm6Voy0cbAFcAhmAbJCrlSi010evys7P5p6Wfo9LjjJa9Vpp3vt8n5fofTXgu+1TUvB+h3euWi2GtXFjBLfWqHKwztGpkQH0DEj8K2ayPCWtXPiTwxperXelXOh3F9bpcNpt7gT224bhHKBwHAIDAZwcjJxmvF/DPxS1H4z/ALQfjXw7pN3dWfhD4ctbw3q2EgSXV9UkBk8lpOCsUSqAUBG9mwx2gqdJ61GrW3fol/SS82jGHu00732Xq/619E2e/wBFfFPwN/bW8W+OvE3xw1jVfhl4pvtF8JX4sItN0ObT55LFLcSCVXWS7jMk7ncx8oOuFChjgbun1L/go54E0v4ReEPiVJ4P8YSeFfE+oSaXZ3CDTN0VwrFQs4N8BHu2uQSeAhLbeMzFc1rdbf8Ak2339DTa6fRtf+A7/d1Pq+ivnn4/fHp9H+HfxWtU8PeN9Ei8P6Ks8/ijQxp0htxNHkSWwa8UtJEpLspCnC5BO5C1b4dftI+G/B37P/whvL3U/EfjTW/FllBa6La3FvF/bWtTBMszoZvKQ4GWd5di5G58nJFqn8l63v8A5fPpsK+qt5v7rf5/LqfR9FeJab+198P7n4W67451CTU9AsdD1N9E1DTtTsyt7DqCsq/ZVRCyyyFmUDy2ZTn73Brq/hn8a9J+JOta5oB0zU/DPirRFhk1Dw/rawi7gimUtDLmGWWN0cA8o7YIIbB4os3t/XX8mn6NML9/66fnp66HoVFedfGL47eHPgrFoMWrRX2qa14gvl03RtD0mNJLzULhv4Iw7oigDku7qo7kV8r/ALN/j3XP+HgHxr8O3mueK4PCemaFBew6B4l1i5u49PlcW7ylVlmkQYZ3wY2K4OFO3FKHvS5elpa/4Vd/h92ncc/dhzen/k0uX8/vs+x920V896f+3F8O9Q1zwdCsOrR+HfGN7Jpvh/xYyW7abqF0jhDCNkxnjbf8o82FASOvSuN8C/ESHx3+2B8bPBlz4j8eW0tpoEMT+Grww22n2KgKPtVncW100ivKsqOCFjddx3HIVUTuunST/wDAVdr1/wCHHpa7fb8Xb+vNW3Praivzu/Y1/av1T4Y/sV6v8RfiEvjb4j21j4mu7W6vreddSu7OALEFaQ3M6N5QY4+UnBbJAGTX2BY/GWHxhp3gQWPhHxNcaf44sWuYr6zmswumwmMPvuJEutyna4IaHzOcAHdgVpKLW2u3/kyuiOazalpZyX/gL5Weo0V4d8GfixqD/Fzx78IfE122oa74ZS31HTdTlVVk1DS51GxpAoA82N90bMAA3ynGSa9xqeiktnr/AF6bPzH1cXuv6/Fa+gUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXlXwb/5KL8dv+xztv/Ue0avVa8q+Df8AyUX47f8AY523/qPaNQB6rRRRQAUUUUAFFFFAHlXhz/k6b4h/9iZ4Z/8AS7Xq9Vr5/wBW+LHgj4X/ALU3jX/hMvGXh/wl9u8GeHfsn9u6pBZfaNl9rm/y/Ndd23emcZxuXPUV1f8Aw1j8EP8Aosnw/wD/AAqLH/47QB6rRXlX/DWPwQ/6LJ8P/wDwqLH/AOO0f8NY/BD/AKLJ8P8A/wAKix/+O0Aeq0V5V/w1j8EP+iyfD/8A8Kix/wDjtH/DWPwQ/wCiyfD/AP8ACosf/jtAHqtFeVf8NY/BD/osnw//APCosf8A47R/w1j8EP8Aosnw/wD/AAqLH/47QB6rRXlX/DWPwQ/6LJ8P/wDwqLH/AOO0f8NY/BD/AKLJ8P8A/wAKix/+O0Aeq0V5V/w1j8EP+iyfD/8A8Kix/wDjtH/DWPwQ/wCiyfD/AP8ACosf/jtAHqtFeVf8NY/BD/osnw//APCosf8A47R/w1j8EP8Aosnw/wD/AAqLH/47QB6rRXlX/DWPwQ/6LJ8P/wDwqLH/AOO0f8NY/BD/AKLJ8P8A/wAKix/+O0Aeq0V5V/w1j8EP+iyfD/8A8Kix/wDjtH/DWPwQ/wCiyfD/AP8ACosf/jtAHqtFeVf8NY/BD/osnw//APCosf8A47R/w1j8EP8Aosnw/wD/AAqLH/47QAfGT/kovwJ/7HO5/wDUe1mvVa+X/ix+038HtS8efBi4tPiv4Hurew8W3FzeSw+I7N1tojoWrRCSQiTCKZJY03HA3SKOrAV6X/w1j8EP+iyfD/8A8Kix/wDjtAHqtFeVf8NY/BD/AKLJ8P8A/wAKix/+O0f8NY/BD/osnw//APCosf8A47QB6rRXlX/DWPwQ/wCiyfD/AP8ACosf/jtH/DWPwQ/6LJ8P/wDwqLH/AOO0Aeq0V5V/w1j8EP8Aosnw/wD/AAqLH/47R/w1j8EP+iyfD/8A8Kix/wDjtAHqtFeVf8NY/BD/AKLJ8P8A/wAKix/+O0f8NY/BD/osnw//APCosf8A47QB6rRXlX/DWPwQ/wCiyfD/AP8ACosf/jtH/DWPwQ/6LJ8P/wDwqLH/AOO0Aeq0V5V/w1j8EP8Aosnw/wD/AAqLH/47R/w1j8EP+iyfD/8A8Kix/wDjtAHqtFeVf8NY/BD/AKLJ8P8A/wAKix/+O0f8NY/BD/osnw//APCosf8A47QB6rRXlX/DWPwQ/wCiyfD/AP8ACosf/jtH/DWPwQ/6LJ8P/wDwqLH/AOO0Aeq0V5V/w1j8EP8Aosnw/wD/AAqLH/47R/w1j8EP+iyfD/8A8Kix/wDjtAHqtFeVf8NY/BD/AKLJ8P8A/wAKix/+O0f8NY/BD/osnw//APCosf8A47QB6rRXlX/DWPwQ/wCiyfD/AP8ACosf/jtH/DWPwQ/6LJ8P/wDwqLH/AOO0Aeq0V5V/w1j8EP8Aosnw/wD/AAqLH/47R/w1j8EP+iyfD/8A8Kix/wDjtAHqtFeVf8NY/BD/AKLJ8P8A/wAKix/+O0f8NY/BD/osnw//APCosf8A47QB6rRXlX/DWPwQ/wCiyfD/AP8ACosf/jtH/DWPwQ/6LJ8P/wDwqLH/AOO0Aeq0V5V/w1j8EP8Aosnw/wD/AAqLH/47R/w1j8EP+iyfD/8A8Kix/wDjtAHqtFeVf8NY/BD/AKLJ8P8A/wAKix/+O0f8NY/BD/osnw//APCosf8A47QB6rRXlX/DWPwQ/wCiyfD/AP8ACosf/jtH/DWPwQ/6LJ8P/wDwqLH/AOO0AepySCONnIYhRk7VLH8AOTX5ufBjVdT8H/8ABRD4v/E7VfAvxCt/BGvaZ9n03U18Daw/2iQfZPl8pbUyLnyn5ZQOOvIr7Q/4ax+CH/RZPh//AOFRY/8Ax2j/AIax+CH/AEWT4f8A/hUWP/x2nBunU9ouzX/gSs/+AErShyPun9x81/Cf9lnxf8Rv2kvjD8bPGOmSeDY/Eem3Gh+HNLunR7tIXgW3+1TKhPlkpGCEJ3fO2cYBPkC/s7+P/EX7Jvw7/Z0PhXW7DxnovjBrzUtSm0+ZdKgsVnnf7Ul6V8iQFZkxGjmTOcqMGvvP/hrH4If9Fk+H/wD4VFj/APHaP+Gsfgh/0WT4f/8AhUWP/wAdpwfs+VLaPL/5I3Jfi3fvfppZyblzX3d//Jo8r/C1vRb63+bf2uvgnqeoePJPiL8MtP8AF/hX406bNbadpmqaNZyXGn+IodkTMt2UBSGNAWQvOUU+WB8+AFyPih8FvEGh/tx2/j7xdoHjDX/AXi3w5Do17feBrvU0k028VFBWZdPdZ/s5MZPIZMyZPIr6p/4ax+CH/RZPh/8A+FRY/wDx2j/hrH4If9Fk+H//AIVFj/8AHamPu20va/4qz++7fr+Ket7aaJfc0191vuuu1ul+Evw58O/CX4f6X4W8KaQ+heHrAP8AZNPkuZbholZ2c5eVmfJLE4JOM47V8EeA/hT4t+I3xD/bQ0SHw34k8P8A/CfWpXw9qes6He2FpeFPOUgTSxKoBMiDBILKxIBAOPtL/hrH4If9Fk+H/wD4VFj/APHaP+Gsfgh/0WT4f/8AhUWP/wAdpS99ycnfmi4v52d/wKjLkioxWzT+4+eP2JvgnoNx4T8A3HjPwD430f4peAFeyDeJNQ1f7Dakq0bTWXmym0aORABsgBA44AANbtj8AvFHhP8Ab48ReIdGtpE+HHjjQ4dR12bY3li/tZkCRBhwGf5WwfvK01e1f8NY/BD/AKLJ8P8A/wAKix/+O0f8NY/BD/osnw//APCosf8A47WzqN1FV66+mq1/HW3dIy5bQdPpp66O6/yv5ny98Yvgtq2h/t6N4+8QaB401/4a+LdBj0aa+8F3epJPptwoUBZ1091m8g+Xk8MmZMnkVk/tcfCGHwFN+zR4b+HXw/8AFEnhjwj4qXWLi20fStR1dbCz+0I7M8oWVtxO9vLLFh0Axivrf/hrH4If9Fk+H/8A4VFj/wDHaP8AhrH4If8ARZPh/wD+FRY//HainJ0/ZpfYafraTkr/ADb+X3mkvelKT6q3/kvLp8vx+49Qe4SO2aciQoqbyFjYvjGfugbifbGa+Cvgdquor/wUY+KPja48FeOtP8JeKNLtNN0rWL/wfqdvBLMi26neXtwYVzG/zyhV45Ir6l/4ax+CH/RZPh//AOFRY/8Ax2j/AIax+CH/AEWT4f8A/hUWP/x2lD3aiqdk196s/wDgEyvKm6fe34NNfij5r/aq/aY8baX8YLLQdI/Zt8d/FLwr4bmjvFubeyvLayutQXlJAVtJRPHFkFeQvmfNg7ENeza9+0P4x8N+Afh1r2ufBfxLq9t4ojJ16w0G3e9uvDyyAGNJbXZ5s2A218KuNjfLkhK67/hrH4If9Fk+H/8A4VFj/wDHaP8AhrH4If8ARZPh/wD+FRY//HaUfdhyvXW/+f36eeiKl70ubbS3+X3avtdvQ8L8QfsYaN44f426p4N00eD9K+IPhaHTbewltJLFJNQDSSm6e2ZVaIbjCpDKrFhKSvOWw9B+E/iH4sah+y9od54d1bRIfhXEt14mbVdPlt4o7uC2ijgit5ZFCXW6RCd8BdAoyWBwD9If8NY/BD/osnw//wDCosf/AI7R/wANY/BD/osnw/8A/Cosf/jtVGXI1y7KzXrHma/9Kf4dFYmXvX5t3dP0aUX+EV+Jg/twWF/rH7KXxJ0vStL1LWtU1HSns7Sw0mwmvLiaVyAoEcSs2M9WxgDkkCviTxJ4X8V/8IL+xNGngLxtNL4NvkuPEEUXhTUWfTkSaAMZFEGQf3bkAAkgZGQQT98/8NY/BD/osnw//wDCosf/AI7R/wANY/BD/osnw/8A/Cosf/jtKm/ZzU+0oy/8Bvb89Ry95W8pL/wJJP8ALQ+Y/g/4d1C8/bz/AGidU1nwb4qi8IeJ9HjsLTULrw/e29rfeVDGkyJM8SrztcKSwD/wk5FfInw8/aO+B+lQ+BPhx43u/HVh4G8E+I5NYsdGuPD1ulxaXfmuwW9vEvC80cbO/wAsdrE/ODnFfqbqn7UHwJ1jTbuwuvjF4Be1uonglVfFdkpKMCpAImBHBPIOa8k07VvgFZeGV8Iz/tNaTqXgBbMaevhG78U6F9jFqAFEJmSFboqAMczkkdSaKTdNxXSKS9bNu781fTR9dupNKfM39p39LxUdPVb6/f09o+HaC+1bx54/ubW5SLU5UtbE/ZZTNJp9pGRGyx7S7B5XuZF2j5lkQgHIz+ZHhn4a+O7X/gnv8ZvBUvw68cJ4q1nxnBeWGlN4V1ATXEDPA4kUeT90CCTJ/hIUHBdQf0wt/wBqn4F2lvHBD8YPh7FDGoRI08T2IVVAwAB5vAAqT/hrH4If9Fk+H/8A4VFj/wDHalxV5W2aS+6Slf1fL+ZpCpKKV+9/waS9Ff8ABHyH4qs9c1X9p/8AZL1628F+M30fw7oIttYvD4V1FY7CWWDylSUmD5SHHzZ+6OWwOa/RGvKv+Gsfgh/0WT4f/wDhUWP/AMdo/wCGsfgh/wBFk+H/AP4VFj/8drWU+ZW85P8A8CdznhBQt5KK/wDAVY9Vr5G/Y48O3Pw//aF/aY8NamjxX154kh8Q2rSDmezulkZJFP8AEoYMnHQqRXsn/DWPwQ/6LJ8P/wDwqLH/AOO1zOufG79nnXPFWk+Jm+MPgWy8Qaapii1Gz8V2McjwMwZ7eT94RJExAJVgcH5l2sAazjpPm7pr72n+aXyuaS96HL2af3XX5N/Ox5f+w34B8TfDX4sftD6X4o8Matpq654tl1WxvJ7N/sV1aSNKyulxjy34ZQUViw3cqMHHnHhj9iPxLd/B39pD4X31uYfDn9s3N14ISSBly7rDdK6N/EgaOCIbejCYc9B9e/8ADWPwQ/6LJ8P/APwqLH/47R/w1j8EP+iyfD//AMKix/8AjtS4+7Zb8qj93LZ+q5S4y5Zc397m+bvdemr+Wh4LrXgzxhpP/BN3xDp/iHS9Y1r4jeI/DRW8sbHS57m9kvJYEhiiaGJGcMkaRIxIwNhLY5rxW1+GvxF8N+Cf2SvihpPgrxJqh+HNvJpniPww2lTw6nbo+EkljtZFWSTC7vuKc/JjIyR9yf8ADWPwQ/6LJ8P/APwqLH/47R/w1j8EP+iyfD//AMKix/8Ajtbuo3VdVb3TXZWurelpNfcYRppU1T6Wa++3+SZ4d/wUB+G/ir9pD9nfSL3wFo2rXd7outWmuR6TcRS6deX0Ko4dVik2SxuvmAgMFfKNgZ259S/Z0+HfgiG5m+Ifh/wv4u0TxDrenxWupz+Nr3VpNQGwgiBo9QkZiEOcOo24xtJBON//AIax+CH/AEWT4f8A/hUWP/x2j/hrH4If9Fk+H/8A4VFj/wDHazjaPNbq7+e1n8mkv60Ll7/LforfjdfNP+tjxj9sj4deJP8AhfHwE+LGlaLqXiTQvB2qTQ6xYaPaSXl3DDPsAuEgjBeQLtO4ICw4ODzjm/ht4N8eaT+3n8Z/iKvw91mfwrrmgRWmm310sVvFPNHb27KjLI4kAcps4RiCcMF2tj6L/wCGsfgh/wBFk+H/AP4VFj/8do/4ax+CH/RZPh//AOFRY/8Ax2pj7qsv71v+31Z/5oqVpXv15b/9uy5l/k/I/PzWvh38UfGXg/4B+K9V+G2uaNe6T8RTeap4a0bw+9raaHZi5Ur5FlCmfLIR5GmKszF+WIK49k+Gqavov/BQ345+Mr3wh4wg8Lan4eW1sdWbwvqJgupbeKDzEjYQfMT5ThcffIATcWXP0/8A8NY/BD/osnw//wDCosf/AI7R/wANY/BD/osnw/8A/Cosf/jtXfSy/vf+TRUX+V/XcHqmn1t+E3P89PQ+bP8Agmz8Mb2T9lPxl8PvH/hHXNCbUNVvlutP8QaPcWXnWtxEihkM0ah+Fb7uSpAzjIz6L+wL8MfGvwy+GeoaD42uEuh4c1S+0HQJABk6dHOSJCcnl34xxhYkGMg50vjD8UP2e/jRoGmaZqfx28K6O+mapbaxZ32jeMNPinhuYH3Rt87OjDrlWUg59cGurt/2l/gZZaIdNtPjX4GtV8pkW5TxTYNMrNnMmWkIL5JbJByeoNVzu7l1so/JJWfr8S9G++ktX0fWTl8222vTZ/Ly18r+H/hy68Sf8FKPib4us/MbRtB8JWWgXUwyIzeSsk/lZ6MVjAJHbcPWvrqvCvBPx2/Z3+HukPp2i/FrwBBHNO91czSeK7OSa6nc5eaWRpizux6sT2A6ACug/wCGsfgh/wBFk+H/AP4VFj/8dqNoRh2X5tt/i3byDeUpd/0SS/Bfeeq0V5V/w1j8EP8Aosnw/wD/AAqLH/47R/w1j8EP+iyfD/8A8Kix/wDjtIZ6rRXlX/DWPwQ/6LJ8P/8AwqLH/wCO0f8ADWPwQ/6LJ8P/APwqLH/47QB6rRXlX/DWPwQ/6LJ8P/8AwqLH/wCO0f8ADWPwQ/6LJ8P/APwqLH/47QB6rRXlX/DWPwQ/6LJ8P/8AwqLH/wCO0f8ADWPwQ/6LJ8P/APwqLH/47QB6rRXlX/DWPwQ/6LJ8P/8AwqLH/wCO0f8ADWPwQ/6LJ8P/APwqLH/47QB6rRXlX/DWPwQ/6LJ8P/8AwqLH/wCO0f8ADWPwQ/6LJ8P/APwqLH/47QB6rRXlX/DWPwQ/6LJ8P/8AwqLH/wCO0f8ADWPwQ/6LJ8P/APwqLH/47QB6rRXlX/DWPwQ/6LJ8P/8AwqLH/wCO0f8ADWPwQ/6LJ8P/APwqLH/47QB6rRXlX/DWPwQ/6LJ8P/8AwqLH/wCO0f8ADWPwQ/6LJ8P/APwqLH/47QB6rRXlX/DWPwQ/6LJ8P/8AwqLH/wCO0f8ADWPwQ/6LJ8P/APwqLH/47QB6rRXlX/DWPwQ/6LJ8P/8AwqLH/wCO0f8ADWPwQ/6LJ8P/APwqLH/47QB6rRXlX/DWPwQ/6LJ8P/8AwqLH/wCO0f8ADWPwQ/6LJ8P/APwqLH/47QB6rRXlX/DWPwQ/6LJ8P/8AwqLH/wCO0f8ADWPwQ/6LJ8P/APwqLH/47QB6rXlXwb/5KL8dv+xztv8A1HtGo/4ax+CH/RZPh/8A+FRY/wDx2sn9nLxZofjjxR8bNb8N6zp/iDRbrxnD5Go6XdJc2823QNHRtkiEq2GVlODwVI6igD2uiiigAooooAKKKKAPKvDn/J03xD/7Ezwz/wCl2vV6rXlXhz/k6b4h/wDYmeGf/S7Xq9VoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8q+Mn/JRfgT/wBjnc/+o9rNeq15V8ZP+Si/An/sc7n/ANR7Wa9VoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPKvjJ/wAlF+BP/Y53P/qPazXqteVfGT/kovwJ/wCxzuf/AFHtZr1WgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPKv2lv8AknWkf9jn4T/9SHTq9Vryr9pb/knWkf8AY5+E/wD1IdOr1WgAooooAKKKKACiiigAorx39rD4h+MfhD8EfEnjnwdc6Gl34ftJL6e01zTpruO6RR/q1MVxCY2yc7jvHGNvevAdb/as+NPgv9lDw/8AH/UB4F8Q6Jc21teah4Zs9HvNPuY45nEYEV217MpKs6k5hGRmlzLVvRKy++9vyf6lKLbUVq3e3ytf80fcFFcb4Z+LHh7xB8KdG+IV3fQ6B4d1LTIdVNzq0yW6W0UkYcea7EKuAeSTjitvTPF+g614bj8Q6frenX+gSRGdNVtbuOS1aMDJcSqSpXHfOKucXTbjLRrfyIi1NJx67GvRXyPq37XWu/8ADX3wz8A+Gta8F+MPhv42trq5i1PSYpJrm38iKXcguY7p4ZD5kfURrgHbjI3H37/hfPwz3a6v/CxPCe7Qf+QuP7bts6diTyz9o+f918/yfPj5uOtK3uqT63/B2f4op6S5fT8djuqKxdD8beHfE3hmPxHo+v6Xq3h6RGkTVrG8jmtGVSQzCVWKEAggnPBBqv4N+I3hP4i6bNqHhTxPo3iewhcxy3WjahFdxIwGSrNGxAPsTRqm12F5nRUVz/hX4heFvHTX6+GvEuj+IW0+Y294ulX8VybaUdY5NjHYw/unBroKQBXlXhz/AJOm+If/AGJnhn/0u16vVa8q8Of8nTfEP/sTPDP/AKXa9QB6rRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5V8G/+Si/Hb/sc7b/ANR7Rq9Vryr4N/8AJRfjt/2Odt/6j2jUAeq0UUUAFFFFABRRRQB5V4c/5Om+If8A2Jnhn/0u16vVa8q8Of8AJ03xD/7Ezwz/AOl2vV6rQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5V8ZP+Si/An/sc7n/1HtZr1WvKvjJ/yUX4E/8AY53P/qPazXqtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5V8ZP+Si/An/sc7n/ANR7Wa9Vryr4yf8AJRfgT/2Odz/6j2s16rQAUUUUAFFFFABRRRQBleKPEtn4P0G81jUEvZLO1XfKunWE99PjIHywwI8j9edqnAyTwCa4r4L/ALSHw4/aF07U734f+Jo/EEWmS+ReRi2nt5oGIyN0UyI+Dzg7cEggHINejzf6p/8AdNfmj8b/AIN+I/2R9V8KftNfByxL6edOtR418MQArBcwtGnmThR0DdWIHyuBJ030otcz53aOiv2bva/lpr2vcrlco+5rLt3XZefbvsff3w/+Lnh74mXWqW+hx64kumOIroat4e1DTAjkZ2A3UEYdsYJCkkBlJwCM9nXyH40/aEl8ZfsY/Ef4w/C7xFeaFMofVbC8W0gkkR44YFeGSOeORDhldGwO2VbvXm0P7SfxUj8Zfsds3jW4lsfiPp6N4j099OsfKuZFWNjIrCAPGW805CMF+VdoXnOkYuU1T2fur5yTf3aMyc0oSqrZKT+UWvx1R+gtFfF+rfFj4mXX/BQ7UvhLZ+Pruw8E3HhZtWW1GmWMktpMVwDBKYN3DAMPN8wcsCDkbfAtL/a6+Puqfsd+Mvi7P4/s4L3wb4hj0aC1t9Ctc6sPPhWRr0shUDbMFUW6wkYJJORjOLUkpdLX+XNyfma8ru0u9vm48y/A/QnxN+0D4E8G/FLw98OtZ1e4sPF/iBS2l2T6ZdmK7xnOy4ERhyMHIL5GRnGRn0Svz6/aQ1i78ZftgfscarDKunXeqWd1dF1j3iIyQxOdqk4yNxxnIzjIPQ9X4d/a98TfC/xr+0f4R8YXj+NYvhnpi63pmrTwQ211dRyRK4t5xBGkeQ0iKHRF4ySKprlg3Pdc9/SD1t8jNS55Lk2ah/5Pt8r2XzPtqiviP9nn9pb4leO/FHwpuriHxR4q0Pxtp9xN4hkfwdcWOl+G5xGHtzaXZtUWWJvmQl5ZgSAwdQdppfs//ET47/GaT49eGNO+I0C6v4P8XJpmjazrGk2bf6PHOwkhlSCFFO6NDltucsNpXBq3Talyvz/CSi/uun5ra47rlUujaX3ptf8ApL8+6tqfdNFcZ8YviNH8IfhL4s8a3Ns18mgaXPqDW8Z2mUxoWCg9skAV8e6X+1X8RfA3hX9n34geI9fXxLpvxT1OLT9T0A2FvBBpYm/1TWTxoJflyNwneXdjjZURXPLlXdL5yukvnb/MG+WPM+zfyWr+6/8AkfVHxQ/aU+G3wb1Iaf4u8Tx6beiBbqWCG1numtoGcRrPOIY38iIuyr5km1MkDOa9CbVrFNLGpNeQJp3lCf7W0gEXlkZD7icYxzmvz48E+AE8Tf8ABVT4saRr2rXXiDSm8LQzXVjqlpZTwXkDfZStpLGbfaYULKV2hZP3a7nb5t36CapomnaxprWF/YWt9Ynbm1uYVki+Ugr8pBHBAI9CBU/8uI1esk39za/QuSUarh0VvxSf6/l5mB8O/i14O+LVpqV34M8R6f4nstOujZXN3pkomgWYIrlVkHyv8rqcqSOeteYfFP8Abv8AgX8FfG954Q8ZeO00nxFZiNriyTS725Me9Q6gvDC65KsDjORkZrxL/gkzbxWXwu+K1vbQxwww+PL+OKGNQqIoihAUAdABxxXjnxQ+Gfxx/Z48U+Ifip8Rfhj8KfjN4Nm1OTU9TMejW11qenWzSM2VuZbaKZvLUoAzeaFCKPlUHFy5Yzhd2i4xbb80n+r+4fK7TSV2m0l6Nr9PxP0X8VfGLwp4Mt9Kk1O+uvO1SE3FnY2Om3V5eTRAKWkFtDG8oRd67mKAJuG4iuk8P+ItM8WaJZaxot/b6ppV7EJra8tJBJFKh6MrDgivjn4e+LZPGv8AwUv1u8BkOkj4YWs+mLKpXbDNPDKSAehJcg4/u47Vs/8ABMLVr7UPgL4ks7j/AI8NN8YataadzkCDzRJgeweR6pRutdHZv7puFvXZ/eYcysmnfWK++HPf9PxPr6ivh6L4wfFHWP29/iZ8J4PiDeWPg/T/AAu+rWUS6XYPPZzNHbspikaDna0px5okBGQQThh4lY/thfHu4/Yrg+OVz46sI77Sdfh0gaVbaHbCLVIhKFle8ZlJDtuAH2fyQADwSQViH7xRe17P75OH/pSN5xcHZ/17vN+R+p1FfKXx4+OnjSH46/BH4aaBfy+DdH8dQz3V/wCJrW2gmuY2jhMi28H2iOSFWJABLI5w4wB1Lf2CviP8QPifa/Ey78b+LtS8WW+i+JrrQ9LvJrGxtrS5ghbAmj+z28ZZz0Yl2XpgA5qoxcr+V/wai/xf67GTdkn3t+KbX4J/8OfT+ta/p3hu0jutTvIrKCS4htUeU4DSyyLHGg9SzsqgeprQr4M/4KMR61N8cP2ZtPsvFesaPYap4rjie1sjB5UU0csGy5VZImDSr5hx5gdBgfJyc9p+0r8UPid8NbrxPp8fiuTw1o2k+EZNT8P65bHTrnU9d1KCNmmjuLN7dz5IAVneGKJUxneAdq5qS9l7R/zSX/gKT/r5Jam3s26ipx6pP75OP9fNvQ97+Kn7QPgT4J6l4dsfGer3GjzeIboWWmuNMu7iGackARmWKJkRjkYDsuQCegJHoM0y28MkrBiqKWIRCzYAzwACSfYc1+YH7TnxY1n47fsv/sp+N9WjtLPXdY8aWbz/AGeNjAJVMse8JuzglN23PfGa+mvDnxs8YeDP25J/gvrmtyeLfD2teHj4g0+7vLW3gudOlDuGgBgjRZIsRtjcC4yMs1aunJNwfxKUl5e7FS/V/cc0akZRVRfDaL8/ek4/nY9n+D/x88DfHiz1m58EaxLq0ej3hsNQWfT7mykt7gDJjZLiONtw78cHjrXoNfmF+zn8cD+zn8E/2tfH0dmt/d6Z48u1tLaTOx55JvKj3452hnBPsDXuHwm+NHxG8aa9ZaFNf+NNX8PeJPCEmp3Hi268HS6QmhapsDeTayy2SRSQlSdhkEpyo/ePnFZOS5eaPSMW/Vw5rfh+S3ZqlrZ9ZNL5SUb/AIr8ex9faXr2n63JfpYXcd21jctZ3PlnIimCqxQn1Adc+mcdQav1+an7EHib4i+Ff2BvHPxB8L6hrPjLxWb+/mt9CuI4LhDN5yGa5TEXnyzFS7FXkZWK4C5PP1Z+yL8etK+Pfhe51TRvG83iu1tbe3hns9Xs4bXWLC6zIZVu0hRIjn5ArRoq/I3Ugk68nTqlFv5r8v8AgLcjm69OaSXyf5/5Poe/0V8g/tzfF34h/Cf4g/A238E+L5dBtPFXiSLRdSsZNPtLqCWNpI/n/eRGQNhyDtkXjpg81Z8C/HrxX4B/a28d/CHxf4hn8ZaFZ+Gh4p0zVryyt4L23RQolt5Ps8cUbr94qfLDdiTWUWnHnei97/yVKT/B3/4Jq4taLXb8Xyr8T61or8+vg/8Atn/Er4oWPgrx1pWneJtft9d8UtpepeEtP8I3Mmk6XpJkeMXS6itr808ZCM5M7JgsPLQjI6jwH8RvjV8Qvj5+0v8ADLRviCsT+G4bY+GdR1TTLM/2fNMhdUYRwL5iZO3c6uQqDhiSTpyS2trZv7rX/wDSl5bq90S7LrpdL721+n3WfU+iP2lv+SdaR/2OfhP/ANSHTq9Vrx74/R3sPwk8NR6lNHc6inizwetzNCmxJJR4g03eyr2BOSBXsNS1Z2FF3SdgooopDCiiigAooooA8G/bwYL+x38WiTgf2FMOfwr4B8TWPjTwT+yV8BPGmt6lefE/4BRW9o/ibwTcJBAtowciNhLbJFJLErYwkzOA6Lv3Bvl/VLxv8M/CHxMs7a08YeFNE8V2ltIZYINc06G8SJyMFlWVWCnHGRVTQPg54B8KeHdT0DRPA/hvR9C1QEX+l6fpNvBa3YK7SJYkQK+V4+YHjipjeLlJb3i1292+/rffdWuitHZPb3k+/vW2+753PiH9tb4qRatqf7LHibwbrelWnwrutdSYalcWbXOmW84EQtTcQJLF8sYMp2b0KlG5G2uc/bO+EPjH4P8A7N/jm4k8ZQ+KNJ8U+OLHWvEMGi6TJp9pYW0oIlVUNxP8jyCBj82eQTndmvvvTfgh8OdF8L3/AIa0/wAAeF7Hw5qD+ZeaPbaNbR2ly+AN0kKoEc4AGSDwBW5Z+CfDum+F18NWmg6Xa+HFhNuNHhs40tBEeDH5IXZt9sYrS6jdx/mvr1V4uz+cVr1XoSunN/LbTTpJXXnaT06M+Efjpq3hfR/+ClX7Nl5Bd6XY2raLPAbkSRxqweGZLZC/AO7eqoued4A6iuZ1Ga30r9rL9tx7547OF/AgcNcEIrA2UYB565JA+pr9DPD/AMOfCfhOOzTQ/C+jaMllF5Fqun6fDAII8sdibFG1csxwOMsfWma78MvB/ijWV1fWfCeh6vqy2z2Qv77TYZpxA4IeLzGUtsYEgrnBycis5rmhyLtUX/gd3+F/mXGXLJSfT2f/AJI0/wAbH5Za/qmt6X/wSS+Etzp8U1z4ej8QKfEcUGfnsRe3JKPj+AyCMH6ivqD9sjw34esf2X/ip8SfhPawR+KvFnh+xkvdU0mdy91pcbxqXVFbaoWBnBZQDtHJO3j6s8M/DDwb4K8P3Wg+HvCWh6Dod07SXGmaZpsNtbTMwCszxIoViQACSOQBU/hP4feFvAOjvpHhjw1pHhzSnJZrHSbCK1gYnqTHGoXJ+la4iXtvadOZ3+9JNPy0/PTUij+5cHvy6Pz95yT9dfyfQ+Wf2T/hpqHia++FHxdh+IOg3mkp4MTQYNB8PeHZbJZYAqttnla9my8MgIJ2KM5GFLV9i1zvhH4c+E/h+L0eF/DGjeGxfSme6/sjT4rX7RIeryeWo3N7nJroqqpP2krrRa/i2366tmVOHs4232/BJL8Egryrw5/ydN8Q/wDsTPDP/pdr1eq15V4c/wCTpviH/wBiZ4Z/9LterI1PVaKKKACiiigAooooAKKKKAPCP24vCOh+Kv2VviU+taNp+rvpug319YtfWyTG1uEt32TRFgdkgycMuCMnmvz/APCem/B/WP8Agn54WsvCkHh+5/aImhC6TH4TEJ8UfbftTkFjB/pAURBixfgIPpX6MftZaV4j8UfAHxn4Y8K+FtQ8Va14g0u60qCCxuLSAQNLC6iWVrmaIeWDgHaWbkYUjJHx5ZfsS+OPHn7IHgvQ7nwre/Dz43/DUNNoOryX9lIl6xnkl8lJreaQhSCv+sCbXxjK7iYVrTvdK8Nt9Oa7Xdq6/pFu96dt/f32+zZS8nZ/0z6Xm+N+s/s9/An4VWnxDgk1/wCKPiD7DoMOnRzqhu9TkUA+bMAVRV6vIA3fAYkA19Y/bf8ADfgfwH8S9X8Z6W+ka/8AD69h07VtF065+2LNPOqtbi2mZIvMWTd1dEK7Wyoxz4r8dvgj8Z/2o/g78N9c8UfDay074neAdUjvLvw5q1/Yz6d4iiwvnLG0csiIHMSZSYKBuYZI5ruPj5+x9Y/Gb9mDXfD/AIH+G+hfCTxNfvaagmlQWdlbPLcQMxEVxJaFo2UhnCtubG7Jxkit6ju5yn/N06JuLuu+nNprrZW01zpRj+7itrde6urPt9nXTra/TyT4vNf6v+3h+yz4k1zwRpXg7xDra3VxeNpl4t41woiURLNP5MTvJGhwQVKruwrMM4+hG/bA10/H74n/AAqTwFYNqXg/QJNftr5vEDiLUIwImSNx9kzCxWXkjzACMfMPmrh/H3wc+LfxY+On7PfxGj8F2fh+LwXby/2vp2t61CsqyPsRwjWwnVhhSy4PIwG2E8T+KvgD8Q9C/bK+IvxG0bw6niPw94x8FyaLbzQ38Fv9ivFjiVVuBI4fYxi4aNZMbhkDGaifuU+SPT2v32bh97St0Y6dpzcp9qf5pSX3N+h0vhH9vjQtW/ZR0z41a54auNIOqX76XY+HbO8F3Nc3XnNFHEkjJGMttLElQFAPXFdtp37R2reGtP8AH938UfAN54Ds/B9hHqc2rWly+o6ZfQuhbbbXBhhLyqQVaPZwcckEGvkfw/8AsQ/FDxZ+wL4e+HF/o/8Awh/xI8H+In1zTY7++tpbe8bzJGAEkEkgUbZiPm2ncnTac19UfEXwL4v/AGov2XfEPg3xR4ak+H/iLWdJEEsF/eQXKx3yFXVla2kkUw70HJIbB+6KrEWiqjpatbenKmmu7ve69FZBS1lBT2e7/wC3nv5ctrfPUj+Hv7XUHiLxJ4S0zxT4cTwjD4y0KbxH4duBqX2szWcSrI63K+UggmEbh9qtKuM/PkYr5K/bk+Mtt+09+xXr/j+y8BWcXhWz1uGz8PeJLy6STUiBdLHNN5BiHkRyFdg2SuzcbkUdPoD9mD9me20n4S2fh7xn8FPDfgjxvpunTaLceLLGz02aXUEaJ4PtME8JMwd0bLeaEPJHOePHbr9kj4wXH7DGp/s8xeGbX+1dN1tZLLxBPqduljf2hvDceagVmlRlyQySIv8AslqKsYc7Ueji15+/q/VRt26u2mhSlJJSe7un5e6/zfr0Vz77+HP/ACT3wx/2C7X/ANFLXRVz3w7sdU0vwH4estbtrW01a1sIYLmCyuGuIUkRApCyMiFhx1Kiuhq6zTqya7sxopxpRT7IK8q+Df8AyUX47f8AY523/qPaNXqteVfBv/kovx2/7HO2/wDUe0asTY9VooooAKKKKACiiigDyrw5/wAnTfEP/sTPDP8A6Xa9XqteVeHP+TpviH/2Jnhn/wBLter1WgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyr4yf8lF+BP8A2Odz/wCo9rNeq15V8ZP+Si/An/sc7n/1HtZr1WgAooooAKKKKACiiigAooooAKK+av2uP2sfEf7Ld34Vmi8A6b4p0TxFqEWkW123iJ7KeK6cE4kh+xyAR4H31cnr8o4z28HxF+Kmm+LNAsPEHw68Mx6NqF0La81HQvF817Lp4ZHMcjwS6fBuVnUJ8rdTnoDRH3tu9vnp/mvvE9NH2v8ALX/Jnr1FFeA/tIftQX37Pfjv4X6J/wAIjBr+meN9Yi0UX/8AaxtpbKV5EXd5PkOJFCvn76kkEYHWmvelGC3k0l6vYfRvsr/ce/UV4D4X/agvta/a68R/A6+8IwWJ0vR/7ag1631Yzi4iLRBVaAwJsY+bz87AbepzmvfqPsxn0eq+9r80wejcXuv8r/kwor57vv2pNU0X9sDR/gdqPg20jh1jTJdWs/EFrrTSt5KLJgSWzWy7XLRMMCRgAQcnoPoSlvFS6P8Azt+aB6ScHurfirr8GFFFFABRRRQB5V8ZP+Si/An/ALHO5/8AUe1mvVa8q+Mn/JRfgT/2Odz/AOo9rNeq0AFFFFABRRRQAUUUUAZniS11a80K9g0K+s9M1aSPbb3d/ZtdwRN6vCssRcYzwJF+tYHw58H6z4e+Hll4b8Xavpviue3txZPdWmlNYxTwBAgV4WmmyxUHcQwBz90V2VFLo13/AK/UO3keI6f+yX4P0f4CeL/hDpsl1p/hLxA96UjtyBJZLcncUjJyCEYkrkdMA5xk+Tr+wV4jW9+BV7/wtKza6+E6tDYo3hg+TexZTaHUXgZX2JtLByDwQq4O77GoqotxkprdW/8AJbpfddiklKLg9nf/AMm3+8+br79lHxBL+1xdfHK18dabBLJo7aLFocvh+SQJDsIVmmF4u5w/zEhACvy4B+avKdP/AOCbviDT/wBmvxf8Gx8V9Pk0rxJrketT6kfCjieJgUZ41H2/bgtFEQT0AcYO4FfueipSSjy9LW+XNzf+lal8zvfzv87cv5aHzX4k/Y9u/FGsfCXxLceNxb+MPhtprWemXlvpAFjczEIvmT27TM5TYgBRJVJJJDjgDb8J/sj6Ba2/xRuvF9+3ivxF8So/I8RahDbmzhMAiMSQ20O9zEiqeNzuxPJY4GPeazvEOvWvhjRL3Vr1Lp7SziM0q2NnNdzbR12Qwq0jn2VSfanOV1Lmejvf/t53f3siEeVxUOlrfLRfd0PJ/wBm34C+IP2f/BMPgu48d/8ACV+F9Mdv7FSfS/s95bRFmIhmmWZlmVc8YjjPHccDB/Zl/Zf8Q/s/+NviLrl/450/xPa+NtSk1m7s7fQHsWt7pnJzHIbuX93hmG0qT907uCD6b8Hfjd4L+PvhN/EvgPWTrmiJcvZtcm0ntsSoAWXZMiNwGHOMc13VaScubmlu1b5Oz/Gyd9+olyuPItr3+auvla7VvkZHi/wppnjvwrq/hzWrZbzSNVtZLO7t26PFIpVh+Rr518M/sQw2bfDXSfEvjA+JfBnw3uje+G9IGli2uPNH+qa8uBKwn8v+EJHCOPm3V9O3FxHaW8s8zrFDEpd3Y4CqBkk/hXMfDH4p+FfjJ4Rt/FHgzWYde0G4kkijvIEdVZkYq4w4DDBB6jnqOCKiN4y5o7qz+69n8tbP7iparlls7r79181ueL+E/wBlTxR4Z/a28RfG6Tx9pV2dctBplzoS+G5Iwlmvl+WqT/bTiUCKPLlCp+bCLkY988VWuuX2g3UHhzUrDSNZcAQXmp2D30EfI3FoUmhZuMgYkXBIPOMHXrj/AAl8XPCHjvxb4p8MaDrlvqWveF5o7fWLKNXDWkjqWQEkANkA8qSAQQeQRSteCpdEvwv/AJv8R3fM6j3dv8l5bI8d/ZF/ZS8S/st2viXTLn4g2Hi3Rtdv5tWnRfDzWN1HeSBFLLKLuRdmE+55eckHcMYOx4F/Z48aaL4e8R+EPGPxXu/iL4H1cyoLbWdLxqsVvIfnt2vhMRIjKWU5iDAN8rJgY96qhpGu6fr0dzJp13HeR21xJaSvEchZYztdM+qnIPoQR2quZtryVvkrflor/INd/O/z1e/3nmHjL4Bm8+JWmfELwXq1n4V8XWmkPoEs15prX1pc2DOriNoVmhYOjLlGD4G4gqwwB0vwV+D+h/An4caX4N8PmaSxsvMka4uSDLcTSOZJJXwAMszE4AAHAHAruaKV2lb+t2/zbfqL+vuVl+GnpofMS/sh+IrP9qbxj8abLx/pkV34g0aTRV0ifw5JIltGYkWJzIL1S7K0UbN8qhhuACZDDzSL/gmzr0X7K9x8Dh8VrA6NNrY1g6p/wir/AGgchjFt+3bfvgHd6ZGO4+2W17T112PRjdx/2rJbNeLa5+fyVZUL47DcwHPXnHQ1z/w++LfhD4qSa+nhTXLfWm0HUJNK1IQK4+z3SfejO4DOPVcg84PBpRVoqMdkvwUr/hJ799GOUnJ80nrf8XG3/pP4anxt+3b4f8d3Vl8MvCFp8QPB3hyC00yaTVdS8d6NbxeGL2VPJRMtdJdIk+clImDHBYhwQM+g/sH6z8Xkj13w5491zwd418J6dZ2suh+J/BEEcenuXMge2jaKGGJwiqp/dx4XcAWOcD63oq4ycea+t7/i/wBOn+WhEop8qWlrfh/n/Wup4f8AtH/syRfHzXPhzr9v4hbw7rvgfWU1ewlks/tdvMQ0bNHLF5kbEHy1wQ4xz1rmPFX7FqeLvjJ458c33jm/kh8XeEm8KXWnSWaM1vGyqrSQS7sIDt3FAmMs5zzx9L1jeJvGGjeD4bSTWNQisjeXC2trE2WluZmyRHFGoLSNgE7VBOAT0BrOyty9Hf8A8mXK/vWn/BNVKSfN2t/5K+Zfc9f+AfMEX/BP+3vvgV8MPhvrPju5nXwDqjatYarpumJbPNIDI0SyRySSjCtJzg/MBj5eteneBf2d7nR/i7q3xW8V+IbbxL8QbrSl0S1ubPTGsbCxtFYvtjt2nlcsznLM0pz0XaK9qorRzlKTk3q7/irP0utNOhjGMYpRS0Vvwd1+Op8i/Df9gOPw/wDD/wCLvgvxl4yt/Fmh/Ea+k1S6+waK2nTWV277/MiZrmYFVbayqV4K8lhxXsnwN+EHiL4WfDmw8G+IfGq+MdP0uA2OnXKaYbK4W1C7ESdvOkEzIvyhgEBxkqTg16tXG/Fj4veFfgf4Nn8V+M7+fS/D9vIkc97DYXF2ISxwpdYI3ZVJwNxAXJAzkjOcmlFxezSX3aL/AC79DRJyatvdv5vV/lc8r/Z8/ZPvv2efhfqPgPRfH94+lNq51LTruHT44ru2Rpo5GilZmdZiRGU3BEG12yp4x03wi/Z7t/hv8SvHXj+9vrG/8T+LTAl02k6adPtEihBCYiMspaQ7svIX+YjgKOK9M8L+JtN8aeGtK8QaNc/bNI1S1ivbO48tk82GRQ6NtYBhlSDggEdxWpWj5oytLdaefRW/BEK0lps3f57/AJ6n5/8A/BULxNpGmfEL9m+3u9etNHuLfxfFfTSyTxq9pbiSIG4YPkBFIPzMNvynPQ19F/Dn9m+Cx+MXin4ueJvEdt4x8SeItNj0q2axsPsdla6cApEcaGaVnZ8AtJvwc8Kor3Wioj7sHHzk/wDwJJNfct/N9C5Pma8kl9zbX4v8j5+/Zx/ZZvv2aG1vQPD/AI2e++HF7ePf2Xh+804/bNOkcgskd4JsGI4+6Yt3+0DkmL4Q/sw+Ifhf+0V8Rvihc+ONO1e38btGbzRo9Ae3aARDbB5c5u35C/eJQ7jkgJ2+hqKpSaalfVK3y0/yRLSaa6N3+e55V+0t/wAk60j/ALHPwn/6kOnV6rXlX7S3/JOtI/7HPwn/AOpDp1eq1IwooooAKKKKACiiigArlPiB460jwfp8VteeLPD/AIV1nVCbXSZPEEyCOa5I+RREZYmm5x8iOpPYjrXV18ReG7i4/wCHpPj9fF7KtmngaP8A4R0XhHlfZcw/aDHu4++Jt3sDnip+KSh3Un90W/xt+vQfwwc+1vxkl+F7npP7DH7R3iz9pHwP4x1PxhaaLa6joXiS40SM6HbzQQyxxRxneVllkO4l2/ixjH1r6Ur4K/4JH6npP/Cv/ixpVjdWYuLfxrdzixhdQ8Vu0caxP5Y5VDscKcYOxgOhr70PtW9SyUH3jF/NxTf4iek5rtKS/F2/A8N/al+Pv/Cpfhz4quvCvinwlF480LTJNaHh7XD9pnuraNSWAt47iKVcnGJPmAwflOeNr4GfGpfG/wCzj4R+JfjS70jw8dS0mPUdQuDL9lsrckHcd0rnYo/2mP1r4L8Dzed+yf8Atqnxn5R8Ztr2pfbl1AAzcRL9l4bnAYN5f0G2nRaxd6t8Gf2FjbXsN54Eg121t9cMUqyW8d8jxiCOfBwGU+aNrdG684qaUea0esvZfLnTv92i832uKq+Vt9Iqp8+S34vX087H6a+HPF2heMNDi1rQda0/W9HmBaPUNNuo7i3cDqRIhKkfQ1D4Y8ceHPG1qLrw74g0vXrYtIgm0u9juU3IwWQbkYjKsQCOxIBr4W8I6GfE37Rn7aOkXutTeHPhrf6bBa32r27bbazvHtFWWUH7u9VLl/oN3aj4e+Kvi94Eg+J/wo8Q6dpviLx/oPw+uL3wt478Pph76xAZLWKZV/5a7lynf5W+9nc2bl7ntLbx5kvk21+F1tdO62saKLc/Z9pcrfq4pP8A8ms+zVnvdfcmj/EPwr4g8Ral4f0vxNo+pa9puDfaXZ38Ut1a56ebErFkz/tAV0NfnT+wz8OdV+LHwn+BPjWD4iaJY23ge/vEfSNP8PyjUZppmdbi3urk3pDFwRISIV4IYg4zX6LVtOHs3yvdf1f5mEJ8+qWn/D6fK39WCvKvDn/J03xD/wCxM8M/+l2vV6rXlXhz/k6b4h/9iZ4Z/wDS7XqyND1WiiigAooooAKKKKACiivDPiR8fraT406f8EtD8LWfjLxDqelSalrFvqt4LWwtNNJ2N5h8mYyu+doi2YIPzMoNLW9lu/8AK/5Ifm9l/wAMe50V+cf/AAT/APiF4c+Bfwx/aX8Va3bjQfDugeMbyR7KBEzAi5VLeNUO3dnbGoU4zgA4r6R8F/tefbvGnw88PeM/Ci+EX+Ili+o+F7i31P7cJkVFfyboeTH5ExR1O1TKmTjzM1ajzNKOt1F/+BR5rfdf7iL2Tb6OS/8AAXZv8vS59F0V4b8M/wBp2L4seLPFGneHtEt77TtB1w6DcvDqYOoQSpKY5J57Mxjy4Mg7HWRy2OVQAkc340/bWsPD+pfEK50fw0de8I/Dq4htfFWsf2gIJoJZCAVtIPLYXBjz8+6SLGMLvPFStUn31+WmvpqtfMu2rXVO3z1083o9PI+lqKy5PEmnx+GW1/zw2lC0+3eeAcGHZv3f98818s/Az4pa547+AHi79oebStR8S+JdTi1F/Dnh+xjkuGtbOGR4re1ggTd88jxh5HALMW5+VFCqV4qba+FXf6L1ev3P5kVzctn8Tsv8/Rfqj66or8ev2N/B3wVk/ai8NSePdC+J3gL4wtevqdppvjOa3ewvrwlzn/jzhlDFsuoIA3LjcxADexTeLpvi58Kf2rvijqag+LvBet39n4V1UqPtOhxWkS+WLV+sJcgl9hG/cd2RxVSXLDnl0Tk7a6Jpad3d+Wgl70+Rd0l87vVdrLfU/SOivg/4v/EW9+J3hz9lnxb4yW3g+EevRm98ZrqAX+zPPezU24uy3yeV5pfaH+Tdtzztrpf2W/G3jrQf2adB0G6+1P4t1zU9Qi8OHWid9no6zHbezBvm8mGNgVDY3FokBAcEVKDi5xe8W19zt8u/+FNu1hXTjCS2kk/S9/ytr5tLW59l0V498EfiF8LNY01PBHgvWo9V8m2kuStzbzIdUjaQie8jklRVu1eVm3zRF1LsQTniuR+FvxDn8B/tSeLfgfd3Vxe6S+jw+KfDj3Ehke0t2fyp7QuxLFFkG9Mk7VYr0VQFy3lyrre3nbf8E38n13L6OXbfyvZL8Wvv7H0fXlXwb/5KL8dv+xztv/Ue0avVa8q+Df8AyUX47f8AY523/qPaNUjPVaKKKACiiigAooooA8q8Of8AJ03xD/7Ezwz/AOl2vV6rXlXhz/k6b4h/9iZ4Z/8AS7Xq9VoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8q+Mn/JRfgT/ANjnc/8AqPazXqteVfGT/kovwJ/7HO5/9R7Wa9VoAKKKKACiiigAooooAKKKKAPgn/grfC9x4K+DcUc8ls7+ObVVmiCl4yY3AZdwK5HXkEccg19V/C34Z654H17xfNr3i7U/HEOrtbSW95rUdsk0SLGyNBst4oo9oPzcRrnzDnJyao/GD9lf4bfHzVLDUPHekalrk1gVe0iXX9RtoLd1ziSOGG4SNZOfvhdxwMngV6VoOi2/h3R7TTLSS7ltrWMRRvfXk13OQO7zTM8kh/2nYn3ojpCUXu238mor/wBtJkr1FJdEl805P9T8fIvCmiw/st/tr2cek2KWmj+NlbToFt0CWZS7MaGIYwmEZlG3GFJHQ169+0B/yTT9gn/sLaJ/6Kta+0PE/wCx/wDCHxhJ4vOq+D0lj8WvHLrdvBf3UEF5Kjb1maKOVUWUNz5qqHOTljk5q6/+xj8JfFGj+DtL1PQtVurHweoXQY/+Em1RTp+GDKyMtyG3KQArEkqFVQQFAF0JezcXLpKk3/3DVn83pYuVpXt/08/8ntb7tTwjwn/yl28af9iDF/6HbV0X/BTTxlrnh34V+BtG029udM0jxN4tsdI1q7tZGjYWb7meMupBUPtAPPIBHevcdN/Zl+Hmk/GCf4p2ulagnjueMwy6s+u37+ZEVC+U0TTmIxgAYQptBUEAEA11vxE+G/hr4teEb7wv4u0iDXNCvgBPaT7gCQQVZWUhkYEAhlIIIyCKlW9nSi1fl37P33K33Ow27zm72urX6r3VG/yaufEOreC9A8A/8FWfhZpPhvS7XRdKi8Ez+XYWKCK3i4uxhIx8qA4yQoGTknkk155f3998Rvhl+158Q/Fkcg8f+D9cuLXw7qjFo7vQ4oMCFbN87oAwALbCPMyd2c1982P7NPwysfFOkeJn8I2epeJNJgit7HWNXklv7yFYixjImnZ3LruPzkluF5+VcN8Wfsz/AA18ceIr3WtZ8Mpc3moNG+oxR3lxBa6k0ePLN3bRyLDdFMDb5yPjHGKUruPLfW0lfqrz5k15pXW/zErKbnbS8Hbvyx5WvR7/AKHx78Rda+Kt14K+DPxzuPDdh8UdJ0vwdb3HibwncERX9jJKnmNqtoOsc21WHmKNyhWCjBJWl8YPixP8Rfi9+y54Q8P6XbeIfhl4j0B9Rg0HxjqD2tpq8whZYor11gn3tHtRgpjdWdx7MPujxl8GfCHj7z/7X0uUvPax2M0thfXFjJLbIzMtuzwSIzQ5dsxk7GzhgRWf8QP2d/h18UPDeh6F4i8LWtzp2hNG+ki1kks5dOaPbsNvNAySRY2L9xh90Vo5Jzbt7vNe3k+a6+TkmtNLWvtaErRt15bX81az/Bp66p33Oe/ZT+H3jr4X/DzUfD3jvUdKvriHV7qbS4NJvpryOwsJGDw2pklhiY+XuZR8uNoXGBwPZ6p6TpNvoenw2VqJfJiUKGnmeaVvd5HJd29WYknuauVMnzP+v69QiuVHlXxk/wCSi/An/sc7n/1HtZr1WvKvjJ/yUX4E/wDY53P/AKj2s16rUlBRRRQAUUUUAFFFFABRRRQAUUUUAFQ3jzR2k7W8ay3CoxjjZtoZscAnsCe9TVS1vTTrOjX+ni5mszdW8kH2i3bbJFuUrvU9mGcg+oqJ35Xy7lRtzK58Ba1+1n8V/AnjP4Qya/rFq2teJPFTeGvFPgm3+xXmmaXulVY/Iu4IvMWcRurmN55CN43KuQK9bsfjV4w+MH7WvxG+HGia8/hTwv4A0qGW4+zWcE8uqXkyhgsrTIxEChsbYvLckffArm9O/wCCb/8AZfw3+GHhmH4jSPeeAfE7eI7LUJtFVkud03mtFLGJwSxIQeZv/hPy84Hrk37MEulftCax8VPCvihfD9z4k0xdN8R6bJpouUvdgAjnhfzV8iVQoGWWRSByuck6SUXHl/x/jGPL8ubm0d+nQV92tNvwm7/Nxtr8tz4y/ZD8XeIvh7/wTE+KHijwvrc2g+IdG1fUL62vre3gl+dBAdpSeORCrcg8ZweCDzXSax+058cNF8IfssaxYeObK+1f4m/8S7UrbVdEtzYCR3iVLjbEqSh1EuSFlVGKj5VGRXtvhb9gr/hA/wBl/wAafBvQfiFeNbeKGZptQ1bS4riO1MgUTGGKN4ny4UY3yuFwODzux9W/YF8S6l4c+BWmR/E/TIJPhPN9osZj4VkcXzrIjJ5q/bhtAWNVIU8nJBGQBrzRlVi5fDenf0San+n5kWtztdfatesneBB8KPjF8RtS+On7Qvwh13xtdazF4W0mG+0fxE2m2MN7bNJbozDYkIhcBnyA8bdMEmvFfDH7RHxJ0T/glofidoXiaHw74s0zWnRZdK0PTYLaWN7wRNG1uLbygP3hbciqxYAknJB+mvDv7Ifizw38dvip8Tbf4i6RJe+O9PbT3sJPC8hjsgqKkDBhfZcqEXcON/ONmeOKtP8Agnhrtp+yDefAJfihYNpVzqa3x1g+F385YhIJjFs+243eYqnfn7uV25O4c+vstfi5YfepO/8A5La/f1L09rf7PM/u5F/7de3YPC/7QPxG0P8Aa3+D3gXVvEv/AAkXh7x14MTV7y1nsLaAWl2IZXLwNFGr7WMQyrs4+Y4xwByfwo+LnxL0v4hftjWmiLb+MPEHhVoZNEhOjWcF1dTbZwvnNawxNcsFRAA5JIQAYzXqtn+xl4rX47fC/wCJl58SdJnufA2jRaHHp8PhaSNLy3EbxyMzm+Yo7CRsEAhTj5WwQdD4Vfsg+Jvht8VPir4zPxMhll+IE8V1cx6boBtZrGSKUvGYZHuZVI2M6kPGwbIPQFW3lytu2l1UX3zvH/yXRdttCIXjBX1f7v8ACNp/jv331MP4I/H2P9oH4KeNJtC+Jmq3GqabociXkN7Y2tn4g0i/Cys5kCQiEpwFRli42Nks3K/Pf7O/ibxz8Pf+CXOv/Efw/wDEPXLLXrZ7u+toprawuYYZFvXEh/e2zSP5u8lzI7HIG0ryD9neDf2Y7TR/iV8QPHeuanZ3/iDxdp66PO2jaZ/Z0Mdqu75mUyymS4bcN0pIB2LhFAwfOtI/YX1Xw9+yZr3wI074iwLo+oTzLb6nc6B5ksFrJN5zRsouVEkuePMBVcf8s881jUbcajjo5Rjbyd3f81+WvXSNuaClqlLXzXKl+d/z0vpt+A9e+OfiH4X+GPiHp2r6R4gF98P0uh4YvbeK2a51t445IpjOoVVRgWDLuVQTwMcr5Z8Pf2pvHdt+058JPBuoeJU8UaX450e4l1ixkjs5INH1GFJWlisru1hRZo1eMxnc82CCN+Qa+hIf2e9SvP2V3+Dmr+L9839h/wBgr4g0mwazcQqgjjbyWmk+bYAG+cBvm4XOB5z4b/YUfwz4y+Bvia38debqHwx0x9J8uTRwIdRgaNkyFWYGFvnc7svkkZ6c9TlT+sya+C7t6Pn/ACbj52tbRa4xUvYWfx2/Fctvvs/xvvp5h8DdK8Qaz/wUu+O1tN498ReXpOnWXlgizk82B1jkFsQ9uwSJGkJURBG4yzMSxPI/Cv8Aa28VfCH9nr9pLxjqbWfiLWfDfjObSdNl/sqzsvPmeQQpNci1ihErZwzMRubGMjjH1r4e/Zfk8H/tNeMvi9onipoG8WafDa6jo91p4m2yxBAjxTCRdqERqGQoxOWw68Y85+Hf/BPyHRfh/wDFrwZ418Y2/i3RPiHqD6vcfYdEOnzWN4zl/MiZrmYEK20qpXIK8kg4rkjdUYw6qFn686enqk9e7NnZ15Tezkn8uS23k+nZadBuh/Hjxv8ADP8AaD+EPgDxP4ik8b6Z8SNElvmurqytrabTLxI/MKw+RGitbkfKFkDyDqZG6V4vB+0V8Z/7F/a2P/Czr13+F92o0Kd9G03zSqyzApLi2COrLGAflDZwQw5B+p/Bv7K01r8UPCfjvxv4qi8X6x4P0ptI8PJa6V9gito2Xa00wM0plnK/KWBRPSMGvLY/2AfFcdl8crf/AIWppJHxYfzNSb/hEpP9DbzHY+T/AMTDptkdfmzztPYg3U1UuTflnb1504/dG6v8hU9Irm7wv6JPn+TdtPmfSH7PXxAv/ir8DPAfjDVY4YtT1vRrW+uktwRGJXjBbaD0Gc8dq8O+Fvi2b4o/t9/Fv+0Sz2Xw70ey0jSLdjlIXuh5tzMB2dtipkfwqBXufwD+Gd98GfhB4X8EX+tW/iGTQbNbCPULexazEsScR5jMsuGC4BIbBIzgdK8tj8AyfBT9rbxH8RDDJJ4Q+IWmW1nqV4iFxpuo22EhaXGdsUsZI3/dV1AYjcK2m4vEtw2fNbybWn4XXq0ZRusO4y392/yav/n6JngXh/8Abh+IXxGtfE/jXwhYeJtbGk+LV0ex8EaL4Qub6xvNLV41mnnvktWKXOx2cKJkC7VBjbIJ9G/ao+N3xN+H958RpbfXIvBGmaL4eXWvCf8AZxsry61uaNC1yl3ayxSypAhKqXQRBeMyEtgei/Bv9lK6+AvxC8Y3/g/xm1v4F8VXjaleeFrvTfNktbtid8ltdCZfLUggbWjfhRgjrWJ4w/Yhg8Y/En4veJ7nxxfLafEXw+ugz2D2ayPp6qgXdDMz/cyqny9o6tzyMc0r+zjGO/L/AOTcqVv/AAJXve2ruraLfT2kn0urenNe/wAo6PTW2mupwviD9sfxVrngH9mzS9OltPDvi74uPEt5q0MCypp0KhBM8EcoZDIxcBBIGUZ5DU39sPQ/iN4d/Yb+Ntj8QfEmn+K1jnjOi6nb26w3clibqAoLtUjji84HIPlKFIAPU4HU6/8AsD23iT4F/DPwZc+NZbPxf8OpFm8P+MNP0wRtC6kFfMt2lfeuVQlRIMlByK9A+O3wB8VfHn4B6t8PNV8dafY6jrCwRX+sQaAxg8uNw58m2+1ZjZmVclpXAGQByMVikpwqxp7uTt/hbja3a1nf573DCydOpRlN6JRv6q9/W91b0PnL4U/Gjx58NfiR+yd4HGvrqfhLxt4KiF5pMtlCkdtJFaho5IZFXzd2AoYO7KcEgDIx9/18i2/7EHiqPx98EPFEvxN0t5fhfpqaXbW6eFpFF/EAY3Lk3x2MYtq8AgMC2CDtH11XTWnGo3Jb80/ucm4/g/XoctOLjZdOWP3pWYUUUVzG4UUUUAeVftLf8k60j/sc/Cf/AKkOnV6rXlX7S3/JOtI/7HPwn/6kOnV6rQAUUUUAFFFFABRRRQAVha94D8M+KtS0zUdb8O6TrGoaXJ51hd39jFPLaSf34ndSUb3Ug1u15h4++MEml/EbQvhx4Zgt9Q8aatbSajILot9n02wjYK11MF5bLkIkYILsT8ygE0LWSS3/AKf4LXyWoPZt7f1/w3nsegaPoOmeHbX7LpWnWmmW2c+TZwLEmf8AdUAVfr4I+NH7S/7YHhDUvGniHwp8JvB8/wALtGluZbXWtZlEc8lnDnM7IdQjYghSwxGMgjAOefSvjd+0t8SPhd8Afh7e2Wn+DpfjJ4rW3xo+sX0enacrFA86p9ouoixXeiBfNLFnHB6Uk7w5/RW667aFOLU+T116ab6/M+hr74X+DdS1+71288JaFda3eW32O51KfTYXuZoM58p5Cu5kyB8pOPatLVPCeia54fm0LUtG0/UNEmjMUum3VqkttIh6q0bAqR7EV8x+D/2hvjV8PP2d/iF8TPj14K8P6Jc6HEJ9J0jw3MH+2R7RhnlW5uFCs7oowQQAxwciuh+BH7SniLxh8Xrn4ceMbLSzq83haz8X2WoaJDLDALachWt5EkkkJeNmA8wEBxk7E6VfLdumtbL805W+5NvtZ9TLm5Up7X/Rpfm4r59j3Xw94J8O+EdBj0PQtA0vRdEjzs03T7OOC2XJycRooUc89KTw54F8N+DrjUZ9A8PaVoc+pTG5vZNNsordrqU9ZJSije3+02TWJ4D8bX/j7WNZ1CzS1Hgy3f7Hp10FYzX8yMRNMrbtvkBvkX5csUds7SucvxJ8WpPAPxU8P+GvElvbwaL4qla10PV4XIxeKm82k6t0Z1VmjdThtrKQpALrVtd3/Vvn/wADfQrZNdF+n+X+fTU6fQvhr4R8L6/qOuaN4V0XSNb1LH23UrHToYLm6x082RVDP/wImukoopeQ/MK8q8Of8nTfEP8A7Ezwz/6Xa9XqteVeHP8Ak6b4h/8AYmeGf/S7XqAPVaKKKACiiigAooooAK+V/E3wT8X+Df25LH4zeHtEk8VeH9c8P/8ACP6ta211bwT6fIGUpcYmkQPFiNAwQlxyQrdK+qKKI+7JTW6v+Kaf4MHrFx7/AKNP80fn94D/AGHfiFq3wW/aG8C+LI9I0QePtbm1vSbu11Frh45vP8yNJUEWAmUTLBycMRtBFdXoH7O3j34kfFD9n3VfFHht/BmmfCTTGgupri+trn+1rsRxRp9lEEjkQ5iD7phG+DjZnkfa1FVCXs2munL/AOSpxT9Un+QpLnTi+vN/5M05L52PjLxt+y/r3iD9pLwN8R/DHhJ/APi221g3HiPxNpOpQ/2bqWlq7jyJYN4le5lUR7v3WwZbMjlVrA+Hn7Gs3w8/aW+Jl14o+Efhz4qeA/GmoPq+m67qFvp9xNo0zs7vFNHdESCNmkIzCHPyKdvJx92UUo+4klsr/jb/ACTVrfi71J8979bfhe35ta9PRGBrfhO31TwHf+GYooLO1uNNk05I7aPy4okaIxgIg+6oB4A6AV8v/sdx+OPBP7GN54K8O2Wly/FXwTcaho7aXrUjLbC6W4eWLzChDbHikR1II3Bgc45r6/rIXwjo8fiiTxFHYRQ63Lbi1lvYso80QOVSTBw4Uk7d2du5sYycrX39fiS+9Xs/xf336Wa0tHT4Xp+TX5fdbqeGt4F179pGx+HOp/Ej4cyfD/xD4T1uHW5VuL+0vSZYVJCW0tvK5MbuV3eZsICY2nhq80179l/xf4X8M/Hf4c+GNFfUdF+KmpTalZeIFubeK20c3CKLhLpGkEpAIYp5Mcm4EBtnWvtSih2d1bR3uujvy3/9JW3b1BNqzvqrW+V7f+lPfv6HN+AvB9p8M/h5oHhfTI5J7PQtNhsLdAQHkWKMIPvHGTt7nHPWuCh+E+p+NPBfji78Ru2meLfGWmT6cR5glGj2rRukNshRsEpv3uynDyFiCVC49hooq/vuZz15r3+e/wB/9dQp/uuXk+za3y2/r/gHxL+zz+zH8QNB+JXwe1LxRpkfh+x+GHhi70GS4S8hnXWppWKq8AjcssIT5j5oR93GzHzV1HhjwfP48/4KL+KvHtkA+g+EPCkHhqe6Byr6jLIZ2iU9ykTru64LqOtfV80K3EMkTFgrqVOxirYIxwQcg+45rO8N+GNJ8H6TFpei6fBpthGWZYbddoLMSzMe7MxJJY5JJJJJrT2jclN9Ob75Xu3/AOBP8O2sciUXGPW33Rtb/wBJRqV5V8G/+Si/Hb/sc7b/ANR7Rq9Vryr4N/8AJRfjt/2Odt/6j2jVmWeq0UUUAFFFFABRRRQB5V4c/wCTpviH/wBiZ4Z/9Lter1WvKvDn/J03xD/7Ezwz/wCl2vV6rQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5V8ZP+Si/An/sc7n/ANR7Wa9Vryr4yf8AJRfgT/2Odz/6j2s16rQAUUUUAFFFFABRRRQAUVX1DULbSbC5vr2eO1s7eNpZp5mCpGijLMSegAFeYfCH9p7wB8dvGHi7w74L1G51W68LNHHqU72ckEKyO0i+WpkCsxBibJC7emCaa952XqD0XM9j1eivnj4zftyeAfgT4mt9N8TaR4uOkNc/Y7nxVZaFLJo1nN/zzkuSQHccgrEJCCpBwQRXVftDftQeDP2a/hbb+PfEpvdR0a6nht7SLR0jlnuWlBZTGJHRSNoLE7hwO9TzLl5+l7fMfK+bk62v8j12ivn/APZ7/bX8B/tGeAfFfjXSbHW/DXhnw0xW+1DxJDBBHxGZHKmKaTIRcE5x94YzXWeA/wBorw9458QaPozabq/h2816xfVNB/tmKFBrFmgQtNB5crlcCRD5cwjkwc7MA4vllfltrv8Aerr8E36JvoyOZW5un9L82l6tdz1SiiipKCiiigAorn/Enjax8Max4b0u4iuLi9169aytY7dA20rDJM8j5IwirGcnk5KjHNdBQAV8wftHftla7+zvdLrF38H9e1n4a210tpqPi+HULeLyXLbQYrQ5kkTdld7+UpOMEggn6fr5c/bG8UfDzx9DafBzxd498M+EtP1CW21LxBJrOtW9lMtjHKJEhiWR1JkmeMDIGFRXJwSgadeaNu69PPz0V3p/wC48tnzbeW/y6b6a6fmd/wDEbW7PxL4p/Z51fT5RPYX/AIrlureUdHjfw3rDKfxBFeyV4l401LRtX1z9nS78O3FvdaDJ4qm+wT2p3QyQDw5rIRoz0ZCAMEcEYIyDXttazspNJaGML8q5twoooqCwooooAKKKKACiiigAoqlrU17b6PfS6bbx3eoxwSNbW8r7EklCkorN2BOBntmvge1/aw+KHhb4wfAzTdd1631C88aalc6L4r8KxLZXOnaPdI8SBbS7to9xkUPueN55iu7a2MinBc9RU1u7fj/Xyur7hL3YOb2Sb+5Xf4ffrY+9PEOvWvhjRL3Vr1Lp7SziM0q2NnNdzbR12Qwq0jn2VSfauW+Dvxu8F/H3wm/iXwHrJ1zREuXs2uTaT22JUALLsmRG4DDnGOa8KsfjV4w+MH7WvxG+HGia8/hTwv4A0qGW4+zWcE8uqXkyhgsrTIxEChsbYvLckffAr5T/AGafH3in4U/8EufiJ4v8Ia9NoHiLR/ElxPBdwW0EwbMltGyMk8ci7SHPQZ4HPXMRkuSVSWyipL5y5fu69y3BuUacd3Llfzi5ffovI/Vuq2palbaPp11f3syW1naxNPNNIcLGigszH2ABNfnvqn7Rnxu03Vv2WLfTfHdndXfxU0ZU1SPVdEt2tIJikLfaY1iWOTzAJT8pk8sso+RQdtdf8NfjX8R9a8RftSfDjW/Glxq03gO1FxoviOTTbFLxFaCR9kkawC3kGUA5i5DN7YutGVONTvHn/wDJGk/zT815kwtKUV35f/Jr2/Jn138NviX4Z+L/AIL07xZ4P1aLW/D2oBjbXsSOgfaxVgVcBlIZSCCAeK6evzE/4aK+JXhP/glx4P8AiZ4b8UReG/E9tqj2jf2XommxWksLXssIjNv9m8tAqgEeWqHI5zk17z4R+Ofj/R/249C+F+r+I/8AhIvDHiDwXHrphuLG3gayugH3eS0SKxRvL+7IzkbuDxW06dqkoLo2vujzfl+JlzcsVJ9f/kuX82fSXhL4ueEPHfi3xT4Y0HXLfUte8LzR2+sWUauGtJHUsgJIAbIB5UkAgg8giuwr87fAfxo+KPh7xp+2JD4fij8Z6/4UuLRtKjj0WyhvJ8tKrPIbaCNrmRIlG0PuJ8sAdSD6Z4T+PkXx0/Zb+Jeu+Evifqd9PpfhqRzJNaW1nr+mXiRTySrciOIRfNhFV4o1GFbadw3Vyyly0farW0YyfzV/u/4a7Z0qm3W9l3lyr10/z/M+ttE1/TvElm93pd5FfWqTzWxmhOV8yKRo5Fz6q6Mp9wa0K/L/AOHPjLx78Hv+CUtr8R/CvxE1qx1u3k+0W9vNZ6dcW8AbUpIZUHmWrOwfzS5LuzblXayrlT9e6HffGy48KDxvYaro/iCC98DQXFh4UuoI7djrZQSb2uAFHlupAYFgM9AorerH2cqi/kdn9zf6W9bephF8yi/5r2+TS/8Abk/S/ofQdUF17T21yTRlu421SO3W7e1By6wsxVXI7AsrAZ67T6GviH4e/tTeO7f9pz4SeDdQ8Sr4n0vxzo9xLrFjJHZyQaPqMKStLFZXdrCizRq8ZjO55sEEb8g1m/su6L4i1r9u79pVJ/iD4lJ0t7OAMwspTPEyS+XG/mWzBFiLEosXljI+bfk5nld0ulpP/wABdvz69hyfLFt7rl/8m/4F/mfaHw1+LnhD4wafql94O1yDXbXTNQm0u7kgV18q5iIDxkMATjIII4IIIJFdfX5q/BH9rnxR8K/2Nfjb4+1NbDXNc0Pxjc6Xpxi0q0sIpJpTCqyzpaxxK53yM7tjc3TPTHtOi/Hbxx8Nf2gPhH8P/E3iSXxppvxJ0OW+a8ubK2tp9LvUi8zEPkRorQEcBZFdx1MjdKajzOKj1UfvcOe33forjn7nNfo5fcpct/x/PQ+waK/Me2/ac+NkHwX/AGlfET/Ey6uNQ+GviddP0iSXRtNDTwrcmJkn224Vgy4JKqrAjIYDiv0I+DvjK6+Inwl8GeKb2KOC81rRrTUZ4oc7EeWFXYLntljipiuaLmtly/8AkyuvwE/ddn3kvnF2f5nQTa/p1vrlro0l5Euq3VvLdQ2mf3jxRsiu4HoDIgz/ALQrQr4C8D2Gv6t/wVc+IVlL458QJa6V4ZguYYx9kdTAz2sjWe14GCQlnPMYSTjPmZyTVvv2w/iJ4m+Efxk+Neh62ulaT4C8Sf2Pp3hCSxt5LO/tkkhSR7qUoZ/NcTEgxSoq7QCrc5UWnTjUel05PySly/5fj0NeSXtHTir6pLzbjzH6AXt5Hp9nPdSiRooY2kcQxNK5AGTtRAWY8cKoJPQA1w/wc+O/gf4/aHqGseBNZfWtP0+8bT7qSSxuLRorhVVmjKTxo2QHXtjnHUGtz4d+MofiJ8PfDfiq3ha2g1vTLfUUhc5aNZYlcKT7bsV+Zf7MviTxl8O/2Sv2gPHfg/xS+hX3hnxrf6ktl9ht7iC/CLDvhn8xGbYynAMTRsDzuPQU17OdSNXTljf0tKMXfy16akQtUhGUPtNL703+h+q9FfEvxG/bc1S6sf2e9M0tb7wzc/E6w/tTU9Q0fS31a90+3WEMyWlusMvmSM5wCYpAqrkoe3tn7KfxL8Z/EXwp4jj8a6LrGn3eja3cafp+p61o02lTaxYrgwXbQSRR7WZThgqKu5ThV+6K9nK8k/s3X3Oz/F/nbREcytF97P702vwX5dz26uP+Jvxc8H/BvR7HVfGeuQaDp99fQ6bbzTq7CS4lJCIAqk84JJPAAJJABNfOPxY+NfjzWf2stT+E2l+J5vhr4d0vwdN4kj1y1s7Wae/nUgbSbuKSMQpklgihv3bfOB0+YfG3x8+LWqfsU/Cr4la/4tvNR1zWvGcVpPZ654e0eeykiV5DFPDG1iChBhVkcMSCzEMfl2zTj7RxfRuP3Obh+af52LmuRO/RN/dDn/L/ACuj9W+vI6UtfG/xy+KXxG+Cv7YPwnh1Hx7fD4P+N7lrB9MXTrAC0vgoVITObfzPKkZoz9/f9/DYAo/aE/aE8W/s6/D3SdSTxPqHiLUPHvi1NN0Wa/0uCb+xtPdz88UNrAjXDeWAyK4djvQfMQd0r3oqXd2+d0rfjftbXsL7XL5X+Vm7/g13vofZFFfFF98cvihH8LPj/HFeeMNPh8HaUur+FfHniDwqNLutRAgMksMsFzZRwvskQoSsKkowxggOeA8PftVfFnRdJ/ZK8Qan4v8A7ej+JV22na7ps2mWkMDgzIizI0cQkSQCTnDBDtHyDnNxi5SUF1cV/wCBXt+TTFJ8qfpJ/wDgKTf4NP8A4Oh+i1FFFQM8q/aW/wCSdaR/2OfhP/1IdOr1WvKv2lv+SdaR/wBjn4T/APUh06vVaACiiigAooooAKKKKACvj34UC8H/AAUw+Nf9pklv+EU0v+zd3/PrlN23POPN35xxnNfYVeaeO/hG2rfETQfiJ4cnt9O8ZaTbSae7XKEwalYyMGe2mK/MuGUOjjJRs/KwJBIe7VjN7ar701+f4XCXvU5Q72/CSf6GP+0L/wAVZeeBvh0nzr4m1iOfUEBH/IOs8XM+4d1d0ghP/XauK/ad+F/7O/xr+I3hHwZ8WpIn8aXVnMfD9tJqV3ZsYy6iTyyjrCXLBcK+WbbwCAcfRcmi6fNq8GrSWFq+qwQvbRXzQqZ44nKs8avjcFYohIBwSqk9BWN42+GPg74mW9tB4w8JaH4rgtXMkEet6bDeLExGCyiVW2nHcUrLRNdW391tH6W/Hvcd3q12t+N9V/Wy7Hy/+y7+zDJ4H0X40fBnX9Su/GPwde4htNGXUpSZUWWEtdQB1wBsYx8pgB8kANmujsvgFpHhLxzJ4a8NaprGteJ9W0q3sNc8T6tcRm70nw/FlYrOEwxxhXlKsitjeQskjOzIufpyzsrfTbWK1tIIrW2iXbHDCgREHoAOAKhstF0/Tby+urSxtrW6v5Fmu54YVR7hwoQNIwGXIVVUE5OFA6Cr5nzXeuiT87Kyv+PyuurIsraaatryu03b7k/VJ9EfnJ8avi9478D6x8a7rQNR1DQdR+G+seHdJ8F+GdOllhsZbO4ZUZGs1IjufNGVBdWK7f3ZUjNevf8ABSqbUJvg78L5rONYtfbx5oz2keMstwfMIC98g+lfVmpeAfDGteJdO8Rah4c0m/8AEGmhlstWubGKS7tQeoilZSyA99pFcj4m+Eb/ABA+KWgeJPE1xb3GieFZWutD0eFCwN4ybDdzsw5ZFLLGijC5LFmJARxlpTUt4yjJv/Dy3+cmr+svVjatz8vWMkv+3k0vlG+nku9kelrnaM9e9LRRUDCvKvDn/J03xD/7Ezwz/wCl2vV6rXlXhz/k6b4h/wDYmeGf/S7XqAPVaKKKACiiigAooooAKKKKACiiigAr54/bi/aE1f8AZ9+ENrceF4Y5/GXiTU4NB0XzlDJFcTZ/elSfm2qpIB43Fc8Zr6Hr5/8A2z/2fdX+Pnw90L/hGLi3t/F3hXW7bxDpK3jlIJ5oScwuwGVDKxw3Ygds1LSbipbXV/S6v+F/PsVG6u1vZ29bO3423076HGfs5t4Cj+IHiDwRfxeJrT47aXp7Pfa541eG61W5gmC7rmzlWWaJICxXEUZULgAp1rzrxR+zrH8Jf27vhJefCS61qyutahvL/wAbLc6tc3yXFnFtVZbgzSMxLs7IoJ27lUqo2mvTvC/wl8Yaz+05rX7QGseErzQprXwkuh6b4RlvrSS+u7gOzyM0kczQIpOFTMvOcsExivMvhjrn7aL/ABea51v4PeD/AA5ofiDVYv7Y8QSX8F1f2mnq/wAsaFb9gfLjLBQsONxLFSWYneD/AHtN7NXv23aS7WatJrbpppbKWlKot0/v2Tb73WqT799b+T/8FI9T0Xxp8dIrf4nfDn4qS/DXwrZrDb+KPCaJb2omlAknb/SLV45R/q13CZMGNhg54+7f2Q9F+Hug/s6+DLT4W38+qeCRbNJZXl2VNxKWkZpDNhVAk3lgw2jBBGOKhk8ZfFq3+L2v+HdZ+F9n4g+Gd3Go0vxBpGpWwkjBjAkivbe4mVmy275olIClRhuSOh/Z9+Ddj8B/hhY+ErARrDFc3V40cGfKieed5jFHkD5E37F4GQoOBms6Xu0XHvr+d7r+vnuXV96on208rWWz/rfpsej0UUUgCiiigAryr4N/8lF+O3/Y523/AKj2jV6rXlXwb/5KL8dv+xztv/Ue0agD1WiiigAooooAKKKKAPKvDn/J03xD/wCxM8M/+l2vV6rXlXhz/k6b4h/9iZ4Z/wDS7Xq9VoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8q+Mn/JRfgT/2Odz/AOo9rNeq15V8ZP8AkovwJ/7HO5/9R7Wa9VoAKKKKACiiigAooooAK+Gv2KP+T1f2t/8AsL2P87ivtrVrObUdLu7W3vrjS55omjjvrRY2mgYjAkQSI6Fh1G9WXI5BHFeFfB39jvSvgr8UPEfjzSviF411XV/Es32jXINWk06S31Fxv2lwlmjJtLkjymTsPu8VVP3ajk9uVr5txf6DnrScVvdP7r/5ifte/D2X49eA4vg9pi+XJ4gura41O+RRt0ywinWWSY9t7lPLjXqxZj0Rsc/+0R+yx4w+Ldr4Dk+F3xguvhhbeD7V7ayh0y2eRblvkQCSWOdPkVYgpQowOWyO1cz8av8Agl38OPj98RtV8a+L/G3j671jUGGUi1CzWG3jHCRRKbQ7UUdBk9ySSST6hr37HvhfUJvh3eaJ4m8WeC9X8C6aukaVqXh+/iSR7RVVfKnjmhkikVtqlsx8kDPAxUQS5EpaO9/wav8ALTTzb8hyfvaapJpfer/f38kj5E+KnxC+NepfsZ/tEfDv4pJDf+NPBa6fG+v6eirFqVhcSo5bhVBIjR8kKpwwyNwJPefFBr0/Hj9hpNNYi6+xXLS7c58j7Db+bnHbbur7OPw30C50HXNJ1GyXV7fXlZNXa+VXe/DRiM+ZgAY2AKAAAAAABXJeAf2c/D/gPXtG1h9U1jxJeaDYyaXoJ1uWFxo9m4QNBB5UUZbIjRfMlMkmFxvwTnWnLlqc8u8X6uMZJ/e2vlzeSecl7lo9pr05+X8kn+Hmzhv+Chms6p4Z/ZE8ea3oes6poGs6bFb3FpqGj6hNZTxv9ojQ/PE6kgq7AqSQc9OBXynq/i74g22ufsbW2lfFDxhpt38QtDW18QXj6m119pUxwNvEM26FZcSOomCeZ0JYsM198fHr4K6X+0J8MdV8Ca5quqaTo2qGMXUujtCk8iI4cJulikABZVJIUHjqOa8quv2EfDN1ffCe8bx341Wf4ZW62/h9lk04bVDA5lH2L5ztWOPt8qD+IsxijaM7z25ov5JSUvvutOppVfNRcY/FaX3vl5fus35HnH7Lvjjxppvx4/ae+H1prur+KdP8KvBP4ctfEWpS6hLDM8Mh8rz5maQoWVOGfAx2ySfn3RfFHxD+JnhP4URx+NfHV/8AG+/8Zyw+N/Cdj4m1GxNppiyuGM9nBNGtlEsYiKuqx7t55Y19zeB/2V9M+EfxE+IvxI0XxL4r13xH4ugkbUNPvLixSGeRQTEIylsjRsudqnfjnLbutfEHhX9m344aPp9u/hb49fF7TPGFrF9otfBeq+G9WbTYJ+v2WTUZZFsJVBODIF2NgkJ2p0Ze9T5tWowv6pu/qnb3vK17dVUV1Pl0vKVvRq3ys3deeuvT76tNIXxh8bNbeRpzpPhLQ10W3kS7kEv2q7Cy3B8wNvDrDHa4fdu/esc85r82PCPxT+IbfsC/Fnx6/wASvGs3ijw142hg0q9m8Q3btBHvtkMbZcmVCsrZjlLpxkKCST+rXg/wO/hvwzfWj6hcHV9Ullvb/Uk8syfapQAzJlNu1AFVAynCogO7nPztYf8ABNvwJpvwZ8TfC+Lxt44/4RXxFqsWsX8bXGn+c06YOFf7FwrFY2I9YlwQCwaLSi5JP7KXz51J/wDt1n5mlOUbK66/hytfK+l133PMLDxd43+Hf7V37NdnJ8QPEviGL4gaBcXPiO31S+Z7O5lMHmK8VoMQ2+07QPJROF5yWYt7v46/4J4/AD4meLtU8UeJ/As2sa9qcxnu72fXtSDSOeOguQAAAAFAAAAAAAqS8/Yr0PUfH3w28YXPj7xnNrHgCzSx0cl9OEZiUbWEqiy+cunysQRwPl2nmvomtpuEkrLVOVvRybX4dDlp88UlJ/Zjf/ElZv8A4J4z8QvD+n+E/E37O+iaRarZaVpviqW0tLZCSsUUfhvWFRQSSThQByc17NXlXxk/5KL8Cf8Asc7n/wBR7Wa9VrNtyd3uaJKKstgooopDCiiigAooooAKKKKAMbxn4c/4TDwhrehfbrnTP7TsprP7bZttmg8xCnmIezLnI9xXybon/BO1tA8OfBGytviHu1L4XarNqFrdSaGPJvo5ZhK8bxLOCrEhR5m9uB92vsuinFuEueO90/uvb82EvejyvbX8VZ/ejwi4/ZhfS/2htZ+KnhPxQPD1x4k0xdN8RaZLpwuUvNgAjnhfzV8mVQoGWWRSB93OSfNNO/4J6jw3+yz4r+C2ifEe9Wx8SXcd3cahqukxXC27BkeTyYo3iYF2jT/WSOABgDqT9hUVHKuTk6Wt8r3t95XM+ZT6p3+aVr+ttD4/vP2FvE11qnwFvl+JmlxyfCW1W2s1/wCEWkK6hgqpaT/TvkzHHGuBn5gzdCFXU8N/sa+K/DfxA+NfiuH4kaTLc/E20e2ngfwvJssDgpGyH7d8+1GYEHG44OVA2n6soq5t1Obm681/+3vi++3y6Ex91prpy/8Akvw/df59T4pvP+CeOu3n7Ien/ARvihYLpdnqhvxrA8Lv5zReYZhFs+243CVmO/PK4XaCNx7bSf2RfFdv+014W+MWofETSbu70XQ4/D76TbeGJIY7i3CMHYSG+co7M7MDhgowMNjJ+oKKrnk5Od9W7/O3L+WhLinHle3/AAeb89T5e+Fv7H/ij4cfFb4n+NR8T4nm8eXlvfXMWm+H/ssto8M/mIscj3MqlGQvG6sh3Bs5GMHqfCv7KWm6frXxW1zXNRtrvWviJZ/2bqMmh6d/ZsEVsI3jGyJpZSZSHJaRmO4gYVRxXvFch4m+LfhDwb428MeENZ1y3sPEniZpV0jT5FcvdGNdz4IBC4BH3iMngZNZ2Uoqn0tyr0tt9y+405mpOpfW/M/XufOd7+wjq8v7H7/AG2+JFvFpP2n5NWm8PGSVbYXLXIj2C6XMu8qDJu2lVwIwTur2HVvgjqfij9mu5+FeteK8Xtxop0V/EGj2LWZ2BdiuIWmkwdgUMPMw3zY2g4HrVFOf7xTU9ebfz0sTH3HFx+ze3ld3f5I+UPDf7Cj+GfGXwN8TW/jrzdQ+GOmPpPlyaOBDqMDRsmQqzAwt87ndl8kjPTntfBf7L9x8Ofj98SPiX4f8WCNPG8EJu9JvtME3kXUSkI6SrKuYueY9u49pFr3qiqlKUndv+b/yZ3l9719dhWVren/ku33HyJ8K/wDgn7a+Ffgx8Svhl4x8Xw+MNA8aag2rNNZ6MdPuLK6baS6M1xMrBWjjZRtGCpyWBwO58H/sq3Ft8TPCvjrxr4rh8Xa34P0l9H8OLbaT9hhto2XaZ5186QzTleCymNPRFPNfQVFHM07rsl9y5V+Gl97Dl72/n+LTf4pM+II/+Cdvilfh78YPCb/FjSmt/iZqq6tqVwvhGQPayCYyssI/tAjaTgDdkgDvmvqz4M+BL74X/Cvwt4Q1HVrfXLjQ7CLThqFtZG0WaOJQkZMRlk2tsC5+cgkEgAHA6bWdWg0HSbzUblLmS3tYmmkSztZbqYqoyQkUStJI3oqKWPQA1xvwc+O/gf4/aHqGseBNZfWtP0+8bT7qSSxuLRorhVVmjKTxo2QHXtjnHUGlG6ThHbS/otF8lewS1tJ93971f32ucVa/svrpH7Vmp/GvSvE8lrPrGkJpOqaPPYrKJFQxFXhl3jy+IVDBkfIJwVOCOI179g+zvNJ8c+ENH8XHRPhn441hdb1zQV0wS3gm3I8iWt35yrDE7RplWhkIAIVlzx9V0UlolHolb5N81vS+pXM7t31dvwVl6WWhQ0LQ7Hwzoen6Pplutpp1hbx2ttAn3Y40UKqj6AAV8q6H+wLJ4Z+HPin4eab8RLiPwV4x1CTUvEkMuko19NI7KZEtLgShbeNgiqQ8UzYzhgTmvrmih+9Jyere/nrfXvqiY+7FRjol/wANofPPxp/Y50b4jWvw2uvCutzeAfEvw7eMeHNUt7YXUUMKhFMEsJdfMQiNf41PXnBIPufh+z1Kz02Iaxfw6lqbIv2i4tbdreBmAwTHE0khRScnBdjz948Vp1yHxE+LfhD4Tx6I/i3XLfRF1rUI9K08zq7efdSZ2RjaDjODycAdyKrmb93u/wAX+rf3smyWvZfgv0X4Hwz+3rpfjXxj8drez0v4i/D/AMD6DpmlWzxw/FnTrEaZLcu8pMlhLd21wskwUASbVQoNoy2Ti/Z/s+/Gj9sT4L2fhX4lePPDemDwr4kjvNO8TaHoJurfW447dfKeLEtsgiUyyKWWIB8DbjaS36DUUqf7tW87ryd73Lk3KXN5WfmrWaPIPj7+zpp37Rnw30Xwx4nv1iu9O1Gy1P8AtGytin72FwZPLQyFoxInmJ98lQ4OWxzD+0x+zFoX7SXw3sfDF1qFz4cvNIu4tQ0bVtPUGSwuYgVRghIDLgkFcj2IIBr1zUtQh0nT7m9uS4t7eNpZDHG0jBQMnCqCzHHYAmodD17TvE+j2mq6RfW+p6bdxiW3u7WQSRSqehVhwRS3Tt3v89LP8NPQS923krfLt+Op5d46+D/jD4i/APXvAeteOdPl1/WdMfSbjxBFoTpB5TgrJILT7V/rWQn5vN2hsELjKnweb/gnz4qk8O/BLSV+K2kqnwqujeaZIfCMhN2/nLIBMP7Q6AIq/LjPJz6fbFFUpOM/aLe6fzV7fddit7vL0s18no/vsIudoycnvgYpaKKkZ5V+0t/yTrSP+xz8J/8AqQ6dXqteVftLf8k60j/sc/Cf/qQ6dXqtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeVeHP8Ak6b4h/8AYmeGf/S7Xq9Vryrw5/ydN8Q/+xM8M/8Apdr1AHqtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXnvxl+NelfBXQV1C90TxH4nu5AzQ6P4V0qTUb2VVALvsThEXIy7sqgkDOSBSclFXY0nJ2R6FRXmX7Pn7RHg39prwCnizwVdXEtksxtrm1vYfJubScKGMUq5I3AMpypZTngmvTauUXF2ZKaewUUUVIwryr4N/8lF+O3/Y523/qPaNXqteVfBv/AJKL8dv+xztv/Ue0agD1WiiigAooooAKKKKAPKvDn/J03xD/AOxM8M/+l2vV6rXlXhz/AJOm+If/AGJnhn/0u16vVaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPKvjJ/wAlF+BP/Y53P/qPazXqteVfGT/kovwJ/wCxzuf/AFHtZr1WgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8q+Mn/JRfgT/2Odz/AOo9rNeq15V8ZP8AkovwJ/7HO5/9R7Wa9VoAKKKKACiiigAooooAKKKKACiiigAr4v1b4sfEy6/4KHal8JbPx9d2Hgm48LNqy2o0yxkltJiuAYJTBu4YBh5vmDlgQcjb9oV83X37KPiCX9ri6+OVr4602CWTR20WLQ5vD8kgSHYQrNMLxdzh/mJCAFflwD81Q78y7Wl/6S7fjb0H9l230/8ASlf8LnyHpf7XXx91T9jvxl8XZ/H9nBe+DfEMejQWtvoVrnVh58KyNelkKgbZgqi3WEjBJJyMfT/xn/aW8RQ+KvgF4D8OXH/CO6t8TgLq81qKCOeSwtlhSRxAkoZPNLOAGkV1AByrZrhtP/4Ju+INP/Zr8X/BsfFfT5NK8Sa5HrU+pHwo4niYFGeNR9v24LRREE9AHGDuBX2jxT+yu/irw/8ACu6l8SW9r8QvhyEOleI4dKP2aXbGI2Sa1MxYxOqruVZlORkMvSt046c214X/APAfe/8AJunrbcmpdyfs9NJ2+/3P/Jev3nkNr+0r46vPDv7T3giXxDND4q+Fdo95pXi23s7UT3cQheWMXELRNAXzHtcpGqsHO1UIBrsv2aNe+Mnxq+EPwl8c6h47t7PT9R0a+HiCBdNtvtVzM25bW5hYRGNHRl3FduzBAKtzWzb/ALHZs/A3xet4vFUD+PfigrprfiafSS1vGjIY/LgtBOCiKjOFDTMQWBYvjFdt+z38GNf+BPwL074ev4q0/XrrSLeS10zVv7Ge2REOSnnQ/aX8wqzEna8e4YHB+Y5v+HL+blj83aSlb7121V97FS+KPLtzS+58vLf7n3avbufBOj/thfHC2/Y08SfFi6+ILX+veHvHK6QlvLo1gkN5afug0UwSEHB3kho9jDnk8Y9++PHxI8S6T+2h+zTZ2uowHRvE0Ny9xp91pdlObZhENzW9w8BniLhwG2yAEKOBznBh/wCCZviGP9nnxB8Ij8W9ObR9Z8QL4gmvv+ESf7QkgA3Rr/p+3aSiHpkYYc5BHqnj39kfxV48+Lnwg8ezfEPSbW8+HlssUdpH4YkaO+kYBZnJN9mMMqjao3bDkkv0raDipQcuko39PZpP/wAnv+aIre8p+z6qVv8AwO8f/Jf8jwy6+PXxg/4S79rjSYviZfJafDfTxqGgyHSNNM0TbJJfLY/ZtroQuw7lLYwQwOSem8YftgfEOT9mn9nvxDYfZtI1r4kapZ6Rq/iKK1WRNMEj7HliSQGMSNgsvmBlG1vlPbqLj9hXxXL4j+OerR/FDSUPxXtDZX0TeE5G+wx8qpiP28biI2dct1YhsADaeH+Pnwg8a/BT9k74c/CfR/iHo0BtdSa1m8Ra7oEcOhNZLHK/l6n57XMcaEnAZlZXYIpVeWGEZKNOHMrtezuu9m+dX89DSS5qsnHb3/xS5dPJpnoP7MXjv4jeIP2pPjN4O8R+Pta8Y+E/Bj21vp1xPp+mwQySSxh3jme3tI2aaPp8rqODlOmPVf2lPG3jLwVp3heXw7NY6R4du9UW18SeIrm9tbefSbNlIE1uLkNHJLvKgKUkJOFCHdkfPH7CN58ZPDXjSPwtrPiv4bfEP4ZyadcXMepfDe3t0s9LuUeMLCXtraCHc+5zs2s3yk5AHPv37RH7NbfHrxN8M9aTxVcaBJ4J1tdZSz+yC6tr1lKkK6F1ww24D84DPxzkayjb2S6e7d+j1bX36J3t1M4yu6j9bLztol/nbR9DwP4MftKfEL4h/Cv9pfT7zxPdLrPw5ub1NF8T/wBm20N9LHGs0kf2i3aAQ7v3IVv3K8MeFYZrz7wz+1t8YNN+Dn7Mnj7UvGf9t3PjbxPJomt6bNpVnFb3MDXLxq+Y4g6SKF4KMqnjKnnP0P4Z/Yr1DwSvx5i0Px5CsHxTaSVv7R0QzvpskokWZtyXMYmBE0m0YTadv3gCDwLf8E6PFC/Cz4U+B4/ixpa2fw71p9b0+6bwjIZLiQy+aiSj+0MbQzPnbgkEdMZJTaUouX/Tq/yv7T7/AMS6msZKPepb0a9z7vwO6uPjZ4s+J37amu/CHw/rsvhPw74O0SPVdSurS0t5rjUbmTyikLGeNwsAWUZ2BXJBw615/wD8EmFlX4YfFVZ3SWcePL8SPGhRWbyockKScDPbJx6mvddU/Zmlh/aIi+MHhrxNH4f12+0oaPr9pJpv2mDUoQVKyR/vVMMq7Fwx8wYUAqecu/Zb/Zbs/wBl7SfEljYeK9U8RRa9qLarPFfQwRxRXDDDvGETf8wCghnYDaMAHJKotQi+bdxafm+dP7uVBPVu214tenI0/nzM4P8Aai/ac1HwH8d/hv8ACbSb7VNCHiO3uNR1TW9C0Z9W1K3t41fy47W2WCcM7vG25jFIFUE7R94eR/F744ftCL+ypqPxJ0rUte8Da14O1yex1K1v/DMNs+u6V5qrFfrDeWpeJ9joTtATiT5RgAfSf7QX7LifGPxx4H8e6D4nl8F+P/B8zPp2rCzF7BJExHmQzwF03ow3Dh1I3tzXqGseC08XeBdV8OeJpotWj1ezks79o4TFC6yR7H8uNmfYuDwCzH3PWsfeVJtfGr/PW6/D3WtOr3syvddWN/gsr/c0/wAdU9ei7o8if4rTW/hfUfi9Z+MtW1bwBovg5NUk0Vray8u+uDbmcSNItuJVk8soWVXCZkXCgAg+M/AH9qb4lfEa/wDhZrhh8T+JNN8azXEWv2MPg64t9J8OR/N9mltb77KFkUEBXMk0ykkkeXjFfSfwn/Z28P8Awy/Z9sfhLK7a3oqabJp19PMhja9EilZWI3HbkMQBk4AAHSsH9mv9nPW/2cfCcngy38eN4i8F2k7zaNaXmmeVe2QZi5ikuFm2zR7iWwI0PJGccV0S5Pazt8PT73dfO6s+iWjRglL2UV9rr9ySfys7rq3rc+O7b9pz42QfBf8AaV8RP8TLq41D4a+J10/SJJdG00NPCtyYmSfbbhWDLgkqqsCMhgOK9B/aw+Nfixvhb+zD42sL61spfFOt6QdQ0ufSrK9tt88SymSM3EDvFIh3BXjZSAx74I2I/wDgnb4pX4e/GDwm/wAWNKa3+Jmqrq2pXC+EZA9rIJjKywj+0CNpOAN2SAO+a6j4n/sQ+JfiV8K/g94Nf4k6Zp5+Hc9vdR3y+GJJPt0tuoSAlPtw8tQgw43NubkFB8tTSajyue6dJ/cvf/H73qVUV1JR6+0+5v3Pu19Njjrz4v8AxUuv2y/jR8Nbf4j31n4X0PwjJrumINK095rOcpA6hHNv8yqZGGJA+V4Jz81ZFp+258SLb/gm1YfGIWVnqvjhrk6bPem1xBGBctD9qeJMKDgDgYXcw4x8tepzfsceMf8AhoDx58VYfiVoseo+LNCk0GXT38KStDbwmNER1P28EuDGhOeDyMDII4nxF8BfGH7Kv7DOo/DnQPHwvr/+0o47DX7fw95UdrFPcq8v2xWmmUQDL+ZLjCxk/I2OcovloqMt7R+b55XV/OLSb/VG7tKspRWl393Iun+JN2/Rmh8N/HfxOT9tiz+HN58UNd8Z+DIvCUHiG5c6ZpMYS4c7RFPJDZKRG4+ZQrI3K/MwBz0X7P3jCXwx+2f8d/hVA+NAVLPxTYWoXC201xHH9rC9gryOsmP7xY9zXgv7JGpfGD4T+PtHtl+IPwb8e/DO8uJv7fh+G1tZImkokDyfapns7S3SPlVX5yxbcAF5yPp/9nf4Y3158Zvil8atXtLnTJPGEltYaPp95EYp49Nto1RJpEPzI0zDeEYBlULkAkgdKVpRa25ZX+bul99rd1F+aObXkknveNvlZN/NKV+zkl1TPouiiisDQKKKKAPKv2lv+SdaR/2OfhP/ANSHTq9Vryr9pb/knWkf9jn4T/8AUh06vVaACiiigAooooAKKKKACiiigAr5n/4KNeNvFvw//ZJ8Yat4NuLqy1MNbwTXtiWWa2tnlVZZFZeVO043DoCTxjNfTFc9461K903w/J9g8LXHjCW4dbdtNgmt4gUfhnkM7ovlgfeA3MR0VulRNXWnl+ez8ns/I0py5ZXPinS9Xs/g5+2R8DNP+G6wWXg/4j+GZpdZ0vTQBa3UkcLSpfbF4M54DSkbmAOSa+UfjAvwy+J37SOt+I/2ivBfxe+HUWsat9l07XMR2+mvbIWjg3Q3FkJI18uNC2x5CSXbCjiv0N+BP7KEPg/4oX3xS13w/wCGPDPiA2LaZovhfwlAsem6LbMxZzvEcfnTyMTvk8tQASoBHJiudI+Kf7QXwt8bfDT4u/C/TtCuNQSWztvEWm6jb3WkyRscJcJE0puUljB3KrJhmQfMmeN2/ehJK7jd2fnK6V+6Vl9+lkZxVlKLdk+VXXlGzduzf5J7s5TxdrGm/Ez9uLwt8HdUsLPWfhvpHgV9ZXRLqFJ7G7neVY4nkjbKyCONRsyMKSWHODXS/sA/E7VPHXgLx5oWq3M96/g3xjqWg2lxcSGSRrRJN0KljyditsGSeFWrfib4Dah8N/j94O+K/hHQrvxXDpnhZvCN/oljPbxXjwqytbzxtcSxRsVIKuGkBxgrkjFdV+yX8Cbr4E+ANat9VeJ/EHiPXr7xDqQgcukUlxJlYg2Bu2IEUkAAkHHFVFxs9ekvm/aXT/8AAOvTYzd7R0t8O3Rclmv/AAL73r5nt1FFFYmgV5V4c/5Om+If/YmeGf8A0u16vVa8q8Of8nTfEP8A7Ezwz/6Xa9QB6rRRRQAUUUUAFFFFABRRRQAUUjLuUqc4IxwcGvyk8H+MPGl98Kv2y7qb4jeOHk8E6rKnh8t4mvWewEU04TZKZDIRtRVKsxVgOQTzUuSipN7RTl8k0n+ZVr8vm1H703+h+rlFfmW3xK+Ifg++/Y78ZT/EbxNrWr/EO8jg8QW95eldPuIJfs4WMWaAQKUWVsSBA5JyWJxjpv2hPiF4o/4Xh8atF8eeMfEXgTS7DwwJPhtb6JrNzpI1S8aMZaHyHQ3s/mlU8pt+M8J3rSpF07rqnJfOCTaXdu+nz7XFT9+3mov/AMCbjr2Sa18vPQ/QLWdWtdA0e+1O+lEFlZQPczyt0SNFLMfwANV/C2vJ4q8M6VrUdpdWEeo2sV2treqqzxK6BgsgVmAYA4IBPPevlj4b6D4tl/ZL+GfgrxkNY/4THxvcwWeuLr2o3N9deQd012XaeR2j32sDKUBCq0uAq5xXF6pfa9qH/BTvUfAi+MfFdl4NuvBzX82h2mvXUdr5xTZujTzP3B4BBh2EEZBGWy5x9nOUHrv/AOSxcn8nsn3X3ZxnzQU/R/JyUV897r+n931i+LfEdp4P0G81i5iknMKbY4LdN01xITiOGMfxOzEKB6tX5M6N8TPifqH7CPxA+J938WPGk3iHwh4oi0rQ9mryRLDELi33mcqQ12XExX/SDIAFAAGTn7v+L/7MejftrfCfwKvjbxT4o0mw+w2+oy6f4fubeCC5uJIVbzJRJBIWK5baAQBuPFRKLcHKP937pR5k/W34mmkKnJP+998XZ/ia37IHwJHwH8Fa1Dqcluvi/wAUarceJdYtbeQOtrJcOSsCEdUjA2bsYZgxHHFe914d+yz+yD4K/ZF0LXNL8G3ms6gmsXKXNzca3PFLLlF2qqmOKMBRknkE5Y817jWk2m1bay+Vlt8tjON9XLdt/nv89/LYKKKKzLCvKvg3/wAlF+O3/Y523/qPaNXqteVfBv8A5KL8dv8Asc7b/wBR7RqAPVaKKKACiiigAooooA8q8Of8nTfEP/sTPDP/AKXa9XqteVeHP+TpviH/ANiZ4Z/9Lter1WgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyr4yf8lF+BP/AGOdz/6j2s16rXlXxk/5KL8Cf+xzuf8A1HtZr1WgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8q+Mn/ACUX4E/9jnc/+o9rNeq15V8ZP+Si/An/ALHO5/8AUe1mvVaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8q/aW/wCSdaR/2OfhP/1IdOr1WvKv2lv+SdaR/wBjn4T/APUh06vVaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8q8Of8nTfEP/sTPDP/AKXa9XqteVeHP+TpviH/ANiZ4Z/9LteoA9VooooAKKKKACiiigAooooARgWUgEqSOo6ivlzSf+CffhHR/DPxQ0OHx142e0+I832jX5JJdO8ySQyNI7RkWQCbt7KQBjDcAHBH1JRSsne/VW+Q7vTyd/mfL+rfsB+GNY0v4W2E3xA8cJF8Nir+Hnjl00NE6urI0mbIiQqEjUZGMIMgksT4j+0l8EfHvi/9oTxZrln8V/iv8I9OuVtLa0Xwroera7aamkcK5mH9msotgrOy+XLyW3sDhsD9DqKptyd5d2/m7Xfrp1v6bWE7Ky7JfJa2/r/M+fv2Wfhb458P+FNIvfij4l1LxV4j0WTULDSr3UEWKWWxkki8ua4jyzeeVh4LOzBXIb5icXr39kvRbv8AaIuvjPH4w8U2niubT20sW8LWJs4rYptCKjWpbg/OGZydw5JX5a9zopyfM032t9+j+/W/qyIrlTXR/wCd/uXT0Pkuz/4JveCLH4L+IfhZH478dHwjr2qR6vewtcacZWnXBOJPsWQrMkbEesa4IBYN9L+BfCa+BPBujeHY9SvdXi0u1js473UfK+0SIg2qX8pEQkKAMhR09ea3aKOZ2a72/BWX3LQbV3zPfX8Xd/e9QoooqRhRRRQAV5V8G/8Akovx2/7HO2/9R7Rq9Vryr4N/8lF+O3/Y523/AKj2jUAeq0UUUAFFFFABRRRQB8/6t8J/BHxQ/am8a/8ACZeDfD/i37D4M8O/ZP7d0uC9+z777XN/l+ajbd2xM4xnauegrq/+GTvgh/0Rv4f/APhL2P8A8ao8Of8AJ03xD/7Ezwz/AOl2vV6rQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB8v/Fj9mX4Pab48+DFvafCfwPa29/4tuLa8ih8OWaLcxDQtWlEcgEeHUSRRvtORujU9VBr0v/hk74If9Eb+H/8A4S9j/wDGqPjJ/wAlF+BP/Y53P/qPazXqtAHlX/DJ3wQ/6I38P/8Awl7H/wCNUf8ADJ3wQ/6I38P/APwl7H/41XqtFAHlX/DJ3wQ/6I38P/8Awl7H/wCNUf8ADJ3wQ/6I38P/APwl7H/41XqtFAHlX/DJ3wQ/6I38P/8Awl7H/wCNUf8ADJ3wQ/6I38P/APwl7H/41XqtFAHlX/DJ3wQ/6I38P/8Awl7H/wCNUf8ADJ3wQ/6I38P/APwl7H/41XqtFAHlX/DJ3wQ/6I38P/8Awl7H/wCNUf8ADJ3wQ/6I38P/APwl7H/41XqtFAHlX/DJ3wQ/6I38P/8Awl7H/wCNUf8ADJ3wQ/6I38P/APwl7H/41XqtFAHlX/DJ3wQ/6I38P/8Awl7H/wCNUf8ADJ3wQ/6I38P/APwl7H/41XqtFAHlX/DJ3wQ/6I38P/8Awl7H/wCNUf8ADJ3wQ/6I38P/APwl7H/41XqtFAHlX/DJ3wQ/6I38P/8Awl7H/wCNUf8ADJ3wQ/6I38P/APwl7H/41XqtFAHlX/DJ3wQ/6I38P/8Awl7H/wCNUf8ADJ3wQ/6I38P/APwl7H/41XqtFAHy/wDFj9mX4Pab48+DFvafCfwPa29/4tuLa8ih8OWaLcxDQtWlEcgEeHUSRRvtORujU9VBr0v/AIZO+CH/AERv4f8A/hL2P/xqj4yf8lF+BP8A2Odz/wCo9rNeq0AeVf8ADJ3wQ/6I38P/APwl7H/41R/wyd8EP+iN/D//AMJex/8AjVeq0UAeVf8ADJ3wQ/6I38P/APwl7H/41R/wyd8EP+iN/D//AMJex/8AjVeq0UAeVf8ADJ3wQ/6I38P/APwl7H/41R/wyd8EP+iN/D//AMJex/8AjVeq0UAeVf8ADJ3wQ/6I38P/APwl7H/41R/wyd8EP+iN/D//AMJex/8AjVeq0UAeVf8ADJ3wQ/6I38P/APwl7H/41R/wyd8EP+iN/D//AMJex/8AjVeq0UAeVf8ADJ3wQ/6I38P/APwl7H/41R/wyd8EP+iN/D//AMJex/8AjVeq0UAeVf8ADJ3wQ/6I38P/APwl7H/41R/wyd8EP+iN/D//AMJex/8AjVeq0UAeVf8ADJ3wQ/6I38P/APwl7H/41R/wyd8EP+iN/D//AMJex/8AjVeq0UAeVf8ADJ3wQ/6I38P/APwl7H/41R/wyd8EP+iN/D//AMJex/8AjVeq0UAeVf8ADJ3wQ/6I38P/APwl7H/41R/wyd8EP+iN/D//AMJex/8AjVeq0UAeVf8ADJ3wQ/6I38P/APwl7H/41R/wyd8EP+iN/D//AMJex/8AjVeq0UAeVf8ADJ3wQ/6I38P/APwl7H/41R/wyd8EP+iN/D//AMJex/8AjVeq0UAeP6b+x38CtJt3gg+D3gd0aaa4JudAtZ23SSNIwDSIxChnIVAdqKFRQqqqi3/wyd8EP+iN/D//AMJex/8AjVeq0UAeVf8ADJ3wQ/6I38P/APwl7H/41R/wyd8EP+iN/D//AMJex/8AjVeq0UAeVf8ADJ3wQ/6I38P/APwl7H/41R/wyd8EP+iN/D//AMJex/8AjVeq0UAeVf8ADJ3wQ/6I38P/APwl7H/41R/wyd8EP+iN/D//AMJex/8AjVeq0UAeVf8ADJ3wQ/6I38P/APwl7H/41R/wyd8EP+iN/D//AMJex/8AjVeq0UAeVf8ADJ3wQ/6I38P/APwl7H/41R/wyd8EP+iN/D//AMJex/8AjVeq0UAeVf8ADJ3wQ/6I38P/APwl7H/41R/wyd8EP+iN/D//AMJex/8AjVeq0UAeVf8ADJ3wQ/6I38P/APwl7H/41R/wyd8EP+iN/D//AMJex/8AjVeq0UAfL/7Qf7Mvwe0XwHpVxp/wn8D2Fw/i3wxbNLbeHLONmil12wiljJWMEq8bujL0ZWYHIJFel/8ADJ3wQ/6I38P/APwl7H/41R+0t/yTrSP+xz8J/wDqQ6dXqtAHlX/DJ3wQ/wCiN/D/AP8ACXsf/jVH/DJ3wQ/6I38P/wDwl7H/AONV6rRQB5V/wyd8EP8Aojfw/wD/AAl7H/41R/wyd8EP+iN/D/8A8Jex/wDjVeq0UAeVf8MnfBD/AKI38P8A/wAJex/+NUf8MnfBD/ojfw//APCXsf8A41XqtFAHlX/DJ3wQ/wCiN/D/AP8ACXsf/jVH/DJ3wQ/6I38P/wDwl7H/AONV6rRQB5V/wyd8EP8Aojfw/wD/AAl7H/41R/wyd8EP+iN/D/8A8Jex/wDjVeq0UAeVf8MnfBD/AKI38P8A/wAJex/+NUf8MnfBD/ojfw//APCXsf8A41XqtFAHlX/DJ3wQ/wCiN/D/AP8ACXsf/jVH/DJ3wQ/6I38P/wDwl7H/AONV6rRQB5V/wyd8EP8Aojfw/wD/AAl7H/41R/wyd8EP+iN/D/8A8Jex/wDjVeq0UAeVf8MnfBD/AKI38P8A/wAJex/+NV5poH7Mvwem/aS8daZJ8J/A76bbeEvD1zBZt4cszDFLJea0skip5eFZ1hiDMBkiNAfujH1BXlXhz/k6b4h/9iZ4Z/8AS7XqAD/hk74If9Eb+H//AIS9j/8AGqP+GTvgh/0Rv4f/APhL2P8A8ar1WigDyr/hk74If9Eb+H//AIS9j/8AGqP+GTvgh/0Rv4f/APhL2P8A8ar1WigDyr/hk74If9Eb+H//AIS9j/8AGqP+GTvgh/0Rv4f/APhL2P8A8ar1WigDyr/hk74If9Eb+H//AIS9j/8AGqP+GTvgh/0Rv4f/APhL2P8A8ar1WigDyr/hk74If9Eb+H//AIS9j/8AGqP+GTvgh/0Rv4f/APhL2P8A8ar1WigDyr/hk74If9Eb+H//AIS9j/8AGqP+GTvgh/0Rv4f/APhL2P8A8ar1WigDyr/hk74If9Eb+H//AIS9j/8AGqP+GTvgh/0Rv4f/APhL2P8A8ar1WigDyr/hk74If9Eb+H//AIS9j/8AGqP+GTvgh/0Rv4f/APhL2P8A8ar1WigDyr/hk74If9Eb+H//AIS9j/8AGqP+GTvgh/0Rv4f/APhL2P8A8ar1WigDyr/hk74If9Eb+H//AIS9j/8AGqP+GTvgh/0Rv4f/APhL2P8A8ar1WigDyr/hk74If9Eb+H//AIS9j/8AGqyf2cvCeh+B/FHxs0Tw3o2n+H9FtfGcPkadpdqltbw7tA0d22RoAq5ZmY4HJYnqa9rryr4N/wDJRfjt/wBjnbf+o9o1AHqtFFFABRRRQAUUUUAeVeHP+TpviH/2Jnhn/wBLter1WvKvDn/J03xD/wCxM8M/+l2vV6rQAUUUUAFFFFABRRRQAUUUUAFFFfFn7W3gv4cWn7VXwR1jxR4E0/XoNUXWF1VYPC7avc3/AJdpGIfNhhgllmCHGMq2wc8AUvtKPf8AyuO2jfY+06K+KfhTqnhhf2ztN0X4RWEngLwvbeHrifxN4bv9On0KK+kdl+zS2umTpE5dCrb5kiC7SAWJIr2XxJ+0ZqtvovifxR4X8Gx+KfBXhe4urbVb9dVEF7K1sP8ASDZWwhdZwjB1PmSwktG20MME07KMZPqm9eiTtf08+zEruTjbZpet1e3r5eR7jVHT9c07Vri8t7LULW8ns3EVzFbzK7QORkK4Bypx2Nec3/x4tNat/CEHgSzt/Fms+LNNbWNLt7m8NlbCyVULXE8ojkaNcyxIAsbsWfG3AYj5r+FPjTxF8FbL9pjxF4U+G2n6nPpPi5bu98M22pixWKIafA8zwNHbyCQ7svt2IWBJ4b5S7OLkp6WTf3SUfzbu+ltQXvKPLrdpfem/0073PuiivLT8VPEd9/wrQaN4e0PWD4qh+130kWvSLHYWwjSRp4W+yZuUG9VG4REs8fADEr6lRKLi2n00+4mMlJJrZ6hRRRUlHlXxk/5KL8Cf+xzuf/Ue1mvVa8q+Mn/JRfgT/wBjnc/+o9rNeq0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHlXxk/5KL8Cf+xzuf8A1HtZr1WvKvjJ/wAlF+BP/Y53P/qPazXqtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeVftLf8k60j/sc/Cf8A6kOnV6rXlX7S3/JOtI/7HPwn/wCpDp1eq0AFFFFABRRRQAUUUUAFcX42+Nnw7+GupQ6f4v8AHvhjwrfzRefFa63rFvZyvHkjeqyOpK5BGQMZBrtK+b/2z/8AWfA//spWkfymoWs4R7yivvaX6j2jOXaMn9yb/G1j2LwV8YPAfxKkmj8I+NvDviqSDHmrourQXhjyCRuEbtjoevpXXV86/t0eAtM1b4B+KPGkUf8AZ3jPwdYS61ofiC0UJeWU8I8wBJOux9pVl6EMcijwL8fPE/xgh8OeHvCcujaP4qk8I6d4m1i+1qxlu4LVrpR5cC20c0LMW2ykkyrsATh93Dj7ydt1b8U3f/yV/d1uJ+7ZvZ3/AAaX/ty/Hax9FUV8yQ/teTQ/DDxbqOt2dj4b8S+E/Eq+F9cuJlkudOsGaRVS/ZVKyG3KOr7SVIJKl1ALjs/EHx3fwH8JJfGOqXekeKrWa4srLSdQ8LpLPb6pJcNFEsiRRGeQDzJG+SMyttX5SxOKLXV1tp87pNfemvv8nY62e+v4Np/k/wCmr+0UV4D8G/jn4u8XfFTUfCut6DqN7oj2B1Cx8UJ4K1fw9bxOHCtZzJfg7pNpDLIjgMARsUjn36i2iff/AIb+vw0F1a7f8P8A1924UUUUhhXlXhz/AJOm+If/AGJnhn/0u16vVa8q8Of8nTfEP/sTPDP/AKXa9QB6rRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5V8G/+Si/Hb/sc7b/ANR7Rq9Vryr4N/8AJRfjt/2Odt/6j2jUAeq0UUUAFFFFABRRRQB5V4c/5Om+If8A2Jnhn/0u16vVa8q8Of8AJ03xD/7Ezwz/AOl2vV6rQAUUUUAFFFFABRRRQAUUUUAFfM/xw0/xzfftKfC7xRonwx8Q+ItA8HrqX2y9sb7SYhc/arZEQQJPexudrAht6p0+XdX0xRRtJS7f5WH0a7nzD4k+HfjT48/tAfC7xlqPg66+HOgeA57u7Mus3lnNqWoyTRBBDGtpNMiQ9SxaTJxjb3qLwH8N/H/wX8M+Ovhtp3hH/hK/D+tahqV7oOvR39tDb2kd5ukaHUEkkEo2SOwDQRy7lxkKa+o6KVk48jWjTT87tN/ktrfmPmd1LqrW8rXt+b37+lvlfR/gB4l/Z58S/DLxB4K0uXx3p/h/wmPB2r6RDdQ2t5LEJElW7tvPdIS3mB9yPImVYYJIwem/Z++H/jjwz8VPjPqPifw7Yaf4Z8WaxHqdhJ/aKz3L4tooWjkhVCoXCHnfnORtIw1fQVcj8UvhP4T+NXhGbwv410dNd0GaaKeSyklkiVnjcOhJjZWwGA4zg9DkVpKcpNt63uvlKXM/x1X3bbZ8qSSWlrf+SrlX4afjueX/ALK/w3m8Fr4oA1VNW8OabqV1o3hULz9k01Jmd4c9ys7SQ5HGy2iHbJ9+qjoeh6f4Z0ey0nSbK303TLKJYLaztYxHFDGowqqo4AA7Cr1KTvZdv6v6vd+bH1b7/wBW+WwUUUVIzyr4yf8AJRfgT/2Odz/6j2s16rXlXxk/5KL8Cf8Asc7n/wBR7Wa9VoAKKKKACiiigAooooAKKKKAPmX4pXXjsftVeCPBulfFPxJoHhzxNpOpahPZ2NjpEn2V7YQBFheexkba3mMW3lzk8FRxUvxA+Injv9mPxR4PuvEviM/ED4a67qcWiXmoalZQW2raVczsRBMzWyRwywlsIVEKsuQct0rl/jJ8ZPAHhn9uT4XnWPHPhvSRo+ga1b6kb7V7eH7FLL9laKObc48tnAJUNgsBkZp37QeuaZ+19N4N+HPw8mXxToY1601nXvFWmky6XY2ltIXMaXS/u5Z5GXYI0ZiOS2AKqlqqVtbvX052n90eoqmntb9Fp68ia/8AJunXY9/8cfHDwZ8OryS11zU7iOWBFkuzY6bdXqWMbZ2yXTwROttGQCd8xRcAnOAa0da+KHhrQ7PSLmS/kv49XVXsF0izn1CS4jO396qW6O3lDehaTGxQwJIBr54+F/jbTPg58SPjX4Y+KmqQaRfeI/EcmsaLcamRHFrNhNbxRRQWpP8ArpYxH5RhXL/dwCGBrh/A/wALp/hf8A/hh/bXxJvfg9430HT76Sw1rVY4jp0FlPdK6WF+swEeMG3ARmRwysEbKkUo6xUn1UX96ba9U9H89L6O5K0nFdG1662T9H+q82vsPUviV4c0rw5b65JqJuNPumZLX7Dby3U12yhiUghiVpJmwjnbGrEhSQMU7wH8RvDvxN0aTU/DmofbraGZradJIZLee2mXG6KaGVVkikGRlHVWGRxXx18WPGWrW3hn4N/Ev4n6Rr2n+E7EatY+JJvA97qGnfZXldRBqeLWRJ/s0ggZypbgTjOTjPvn7Lln8NrzQ9b8UfC621ubQfEVxHdza3rl3qc0uqTqmwyr/aDGUqECL5gwG6DO2qUfiv07dNevqtV8vO2cnZRt1/4O3z/rY6rWP2gvh9onjS/8Hy+I4rzxZYWbX1zoel2819exxKEJ/cwI7lyJFIQDewOQCASNPw/8YPB3ijwQni7Tdchn0BpDB9oZHjdZg/lmBonUSLNvwnlFQ+47dueK8G+IHjjw/wDD/wDb00PVPE2sWeg6X/wrq6R9Q1CUQ20ROoREeZK2EjBxgFiASQByQK8p8deGtWtfDfjH4l2mk+IbzwDc/E2HxFLp3hu6urLULrTEsxaTXkBgZJQDNmYbCC6JuztOaiNnCMm7XT16K1Tk/L3vk+mq1lG0nFdPvfuc2nz0+fc+s4f2lPhsfDeua7e+J4tCsNDaNNUXxBbT6XcWRkOI/NguUjlXefu5T5v4c1t+B/jB4S+JF9JaeHdUe/nTT7XVPmtJ4Va1uAxhkVpEVWDbHBCklSpDAHivkXUPGXwH1H4B/GH4j+ANT1q5ttS8KXWj3ninxVq2sSLcS+W4t7OM6lIfNfe7geVnaTtzl8V9Lfsq+IdL8Sfs4/Di50jUrPVbaLQbK2kmsp0mRJY4EWSMlSQGVgVK9QQQa0jHSd1ty/jzf5J+j9G8ZSty26834cv+bXyv3R6tRRRWZZ5V8ZP+Si/An/sc7n/1HtZr1WvKvjJ/yUX4E/8AY53P/qPazXqtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeVftLf8AJOtI/wCxz8J/+pDp1eq15V+0t/yTrSP+xz8J/wDqQ6dXqtABRRRQAUUUUAFFFFABXgf7Tvwz+InxP1TwCvhDTfDE1h4a8QWfiOWbW9buLOWeSAyD7OscdlMArBwfMLZByNh6175RR1Ul0afzTuvxH0ce6a+TVn+B8/fET4V/Ez9oTRR4V8byeHfBHgi4lQ6tY+GtSuNUvNVhVgxt/tEttbC3RiAGxHIWXIBXNXvEPwV8ReD/AIxR/Ej4aLo0txdaLFoOreG9auZbO1uoYWJtpY7iKGZopIwzLjy2VlIHykZr3Oimna1tP+Gt+X3dLMW+j1/4e/5pfcrnkPg/4Q614J03xNqFnc6Td+J/FWtvrOtLcxP9ilUxCJbVOrBRHHEvmEckM5Tny688X9j+TUfhj460a0bTfhrqniHUrXW9OsfCsr3NhoeoWxRo54S8cO8vJGrOBHGMcAZyx+oaKXppsl5Wta3pZW9Lh1u/N+t73utur+TtseRfBPRfjVC0svxe13wheNa5isYfB9rcxC4GAPOunmbBbGcRogUEk5b5dvrtFFNu4krBRRRSGFeVeHP+TpviH/2Jnhn/ANLter1WvKvDn/J03xD/AOxM8M/+l2vUAeq0UUUAFFFFABRRRQAV84/tb674z8J6p8M7jwr4/wBZ8LQeIPFVh4cvbOxs9OniMMxkLzKbm0lcS/KoB3bMD7hPNfR1fJ37dXxG8J+GdV+C9hrHijRtJv7fx5pWpzWt9qEMMsVmvnBrhlZgREDwXPyg96Fb2lNPrKP3cyv+Fx6+zqNdIy+/ldvxsb/xm1T4nfs2+C7zx/YeM7z4m+HdFxda5oniSwsYbs2YOJZLSezgt1V0Ul9siOG24BXv6rqfxw8H6T4c0TWZr66uYNasl1CwtNL0651C9nt2VD5q21vHJKUUSJuYJhdwyRXiv7SXxq8O/Gv4R+Ivhx8KNSsfiV4p8V2zaOn/AAjlwt7Z6ekw2yXF3cxbo4ERNzAOwZiAFBzWN4Tt7X9lP4/WkPjTVl03wBP4E0vQNG8SalIsVhbT2TMJYJpmwsLyb1ddxAfGASQBVR1upaa6f+Attfeo2821rslLSzWujv8A+BRS/OTfkum59IWvxc8IX/gZPGFnrcN/4edvLS6s0ed3k3+X5KxIpkaXf8nlBS+75dueKs2PxL8N6hoN3rC6j9lsrMot19vgltZbd3VWSOSKVVkSQh0/dsob5lGMkV8ueEvhbp914X+K1/qesa14S8MeJvHx1zwzq2koYp7CRI0JvlDIdsTzRSkllKNH8x+Vi1c7408Q+O/FvwL1e7v77/hbGkeE/E2l6g/ij4fs+n3HiXTY9rTmJraQfv4SQSYHCkphSpDALS2unw79Oblvfzjd3vbRX7pHWy1+L525rW9bab6v5v668C/F3wt8R7/U9P0S+uRqmmbDeaZqenXOnXkCvnY7W9zHHJsba219u1sHBOK6XWtasPDmkXuq6rewadpllC1xc3l1II4oY1BLO7HgKACSTXzf+y3qnwW+JHi698d/Cs+Kdfvv7P8A7M1DxD4h1LW7hY4xIHW0B1CRlkYNub93kJg5I3jd9Nyf6tvoaKnuRv1t/Xye/wDnuKLTk+1/6+f9eR5Rp/7VXwt1bT9E1Ky8UfatH1i7aws9Yi0+6bTzOJDGI5LoReTEzOMJ5jrvyCu4EZ6rx38WPDPw3TOt3V5vEfnPDpumXWozRRZI86SO2jkaOLII8xgFGDzXw78OfFOgeLv2AdY+GFleW2pePdck1ax03w4G/wBMlll1KYRTrFjd5KMys0wGxdjZYFTjpviv4g8J/BX4+6k3xpvfG2meGfEOi6XbaN4k8O6xrNtZNcQRvHNZzR6dKrNKzEyKWViQ7dO7muke+nnpe3r+fqU/dbT6Xv5Wdr+j/Cze231DdftJfDG21fQ9KXxnpt7qmuWJ1LTbLT2a7murby3kEqJEGJUqjYOPmI2jJIFdp4T8VaX448M6X4h0S5+26Rqdul3aXBjePzInAKttcBl4PRgCO4r4n1DXvhl8Mv2g/wBl/wAMaFd23hDRtPg1x7XSNa1GQXVtBdRAWxlF05ljMzk7I5CGydoAIKj7uqpJWuu7/Bta+e3pr30zTd7eS/H+v63ZRRRWZYV5V8G/+Si/Hb/sc7b/ANR7Rq9Vryr4N/8AJRfjt/2Odt/6j2jUAeq0UUUAFFFFABRRRQB5V4c/5Om+If8A2Jnhn/0u16vVa8q8Of8AJ03xD/7Ezwz/AOl2vV6rQAUUUUAFFFFABRRRQAUUUUAfJnxo+K+l+G/2loPDHxY8R614J+Ht9pdtJ4Z1HT9UutJsbrUN8v2lbq8tnjYMqiPbHI4jxkkEkV6F4t+KE/7M3wt13xb4qbxF8QtBg1MSx3+niykuILGVYxEzAyQq0aMdmVy5yGYHLNVj4ha9Z6jfeMvDfxH+H+qeJPh+32c2l1DoT6xBOWiTfD9mt0kn3I/zCTyyo3HDgoQPAf8AhnXxNY/sh/G3wd4Y07WF8N6ndtd+CvDWqs7X1vZqsMjQ7ZW3Rh5El2ROQygjcAzEUU3aLv06/wDbyun2lbbvFMuylUjfq0vT3d15d1tzPqz6b1j48aXoPxg8N/Dy80HXEvfEOnXGpafqyRQPZSLAgaWP5ZTKJFDLx5WDuGCecYHhH9qjSPiFa3E/hTwV4116O31a50WYR6Ulq0F1DB5pWVbmWIwhj+7BkCgOQG2BgT5x4u1nWfE37Q3wF8a6P4E8X3/h7TtK1aHUJpNIezksjMlugMsVwY3XaQSV2lmAPlrJirf7HfiKTR9K+Mt5q3hzxZoqT+MdU8QQRan4X1G3luLKUqY3hR4A0rsEb90gaQcZUZGbUd+bopP5qaS/8l/JsxTfLGW7bj+MW/8A0pL77dUcF8LfEWk/Ebw9rvxS+JPhDxJoGreE/FOo3tv4wgkszMsUF8YU0pfIuJZmj2hY3i2eUxDMHJIc/S3gv4+aT4m8T654b1jRNY8D+IdH09NXuNO8Qm13GxcsouVktp5o9m5GBBcMCOVAIJ+cPhX4y8b6L+zP8R7Twn4T8Y6V40j8SalqkFvqHhm7tLhrC51NpDNa/aYRHLMLd3ZYxubcACvYw6t8G77xl8XvH0HhnQ/E2j6P4y+F39j2fiHV7O6WSS8aeTc1zJPiRJAsi5Wba5AO1SBUttRUYrS348l/xat9/W7NbJynJv7VvlzpflJv/gWR9HaJ+0RpOseKvD2kzeHfEWlWPiXd/YOvX1rCLLUysRmITZK00RMasw8+OLcFO3NReKv2kvD/AIPmt7u/0fWz4Rkv10uXxfFDC2mW90ZvICODKJ9vm4TzVhMYJ5fqRxf7PPx88Y+JF0jwJ4p+DPjjwz4j0u1jtNU1q7s4Y9D3RoFaSG6MuZg23IEaNyQDgZYeJfDH4d6V4I8S3nw18afsqQeMPEy6jdPp3xAj8M2N3pd/bSTPJFc3t7Nho5FDAOvzv8vyryBWnLH2iitV+av/AJene1kzJN8jlLR6X8n/AJXt39dVb77opkSeXEi4UbQB8owPwHYU+silseVfGT/kovwJ/wCxzuf/AFHtZr1WvKvjJ/yUX4E/9jnc/wDqPazXqtAwooooAKKKKACiiigAopskiQxtJIyoigszMcAAdSTXP+D/AIjeE/iHHeSeFfFGi+Jo7KXyLptH1CG7EEn9xzGx2t7HmgDoqK+ffiZ8br2z+O3wt8PeFfGGhXmj6hrdxo/iPSbVI7m7gkWymuEEkgkPk/6sfIUDHruxwfXF+J/g1tS0zTx4t0M3+qSyQWFqNSh827kjJEiRJuy7IQdwUEjBzTSbSfcHo7f11/yZ01Fc9pnjjw74qt9ZXQ/E2k38mlyPa30tjeRXH2CZRkrMFY7GXqVbBql4W8R2Wj+DfDI1vxppuu3l3BFCmuF4baPVZtvMkSK2zLcttQkDtS8/T8f6/HQf9fcddRXC67420fxd8OdV1Xwr8QtF0u1XdCvii3mt721s5EYB9xL+WSMFSGPBNdDrHjLQPDd5ptlq+u6bpl7qTNHZQXl3HDJdsq7mESsQXIUEkLnAGaBHl0vwP8VzftOW/wAVn8Z6T/ZlvpD6Enh8eH5BJ9laQSkm6+2Y83zFHzeVt2jGzPzV7VXm3/DQ/wAP/wDhbR+HJ8VaOnicWa3Zs5L+JJG35KRopOXcoGcquSFwSMMDXRx/E7wdN5+zxZob/Z7aS8m26lCfLgRzG8rfNwiurKWPAYEE5FC0hFdFe33tv8bsHrNt7u35K34WOmorzHxd+0l8OfCfwsvfiD/wmOh6n4YgYwx39hqUM0E8+cLCkiMVLFuMZ45J4BrXXxZp3izUPBuqeHvHuktot887pbWklvdJri+U+FhlDZ/dspcmPOQhB4zTsxXO3orn734heFtN8VWnhi78S6Pa+JbxDJbaNNfxJeTqOrJCW3sPcCugpdLj8jyr4yf8lF+BP/Y53P8A6j2s16rXlXxk/wCSi/An/sc7n/1HtZr1WgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApr7ijBCFbHBYZAP0p1IzBVJJwBySaT2A8V+BPjnxb4i+Jvxg8O+J9XttWi8M6rZ2ti1rYraqkctnHOw27mYndIRlmPAFeL/tAfHTxVf8A7QFr4D0v4sat8AbGN4rGy1LVvAUd/YeIbqRd5EV7cEIm3GwAABm3fM3AHXfsw/E3wf4q/aM/aAttE8V6HrFxe6tYXVrDp+owzvPDHp8EckiBGJZFf5GYcBuDzXXfFvxd8O/j58P/AB98N7HU9N8TeI/IuNOk8O7sXtvdjKxyNCcSRqsm1hMQFwAwbHNPb2crX92Lt30V/Le++l9y7K8ot21td9Nf67abGv4/8aa0/wARvB3ws0PWrjTdV1TTLrVNS8QR28Mlzb2luI4t0SOjQiWSaZMFo2QBX+Q8Yv8Awe+IN/rXiTxx4I1y5a/13wfewQNqDRJE19azwLNBOyIAofl0baApaMkBQdo4PxfoY+E3xy+HnxF8R6lDHoFv4VufC2s65dMY4babfDPFPM5O2KNzFMpdiFDMgJ+YVs/AfQH1j4tfFr4lxqRpHiW5sLHSZtrKLq1s7fYbhc9UeWSUKw4ZUDAkMCdFb10lf157L0vG2nZt+mOtldW+G33a372d9fJHb6p8ePAWkePLjwVN4ktpvF9vZtfy6HZJJdXaQrsOTFErNuIdCqY3MD8oNZDftQfDRfB8fioeIJpNB85re4u49LvH+wOrlG+2IIi1oFZWDNOIwpByRXknjD4jeFbD/gop4N0258R6Xb6hD4Iv7SW2lvI1dJ5LmCWOJgTw7RozhTyVGcYrw7T/AIs+Cb79k39r1bfxdocxufEevPbhNQiPnLcxqLZk+b5hKVYIRkMVIGcGsk/3fP8A3ZS+6fLb5rX/ADOjk99R/vRX/gUHK/yasffHjP4l+HfAOn2V3q97Li+fZZ22n2k19dXbbdxENvAjyy4UFjsU4AJPFV/Afxg8EfE+S7h8KeK9J128swDeWNpdI11ZkkjbPBnzIWyCNsiqQQQRkV8k/Fj4/eBvhr4Y/Z7+KUXiqxZbXSrmxtZ50up9Ju0e1iSaCSe0gnaCYSRptPluRslBXjj0v9h/4neBPiTo3jrUvCfjWw8UavqmvS63q9jp8NzDDpsk6IqxRLcxRSOmIv8AWlFDtvOF+6NvZ+/OO/Lf700l961v026o5lK9OE+srfk7/irfO/Ro+m6KKKyNAooooAKKKKACiiigAooooAKKKKAPKv2lv+SdaR/2OfhP/wBSHTq9Vryr9pb/AJJ1pH/Y5+E//Uh06vVaACiiigAooooAKKKKACiiigDyv9oL45S/AjQNE1UeFL7xLb6lq1rpTyWl1BAlq08qRI0hkYMcs+AEVunzFRzVa3+PFzoPxSfwV450G28LyXmnXOr6PqVtqZvLe9trfb56yZhjMUyKysUG9dpJDtg1xP7fclxF8EtGe1hS4ul8X6CYoZJPLV3/ALQhwpbB2gnvg49DWl4g+F+t/Hj4jWWueJdAvfBmhaLomqaPbWl7c2011eT3qLFJMPs8siLEsafLucOxflE28z73s5Sjq05L7oRa/wDJn/W5Xu8yjLRWi/8AyZp/gjntH/b28G6r468IaUl94WvdG8WXSWOnTaP4rt77VLaeRC0YvbFVHkKxGzcssmGZQwXPHX/DP9ojxJ8U9e16w074a3OnReH/ABN/wj+r/wBpazbrPax/Z1lNyEjDpJguqmNZM4YEMTlRzHwBuv2hPC8Ol/Dvxl4H0NdE0CGO1X4gWWtxkahbRABBHp+wusrIoVi7IoJLDOADf/ZX0Hxr4f8AG3xfu/FXgPVfCdr4m8Sya7p097e6fcI0JhhhEbC3uZWWT92WI27cH7xPFdCUOZpaqzae1/eja66O3Npo7dL6vL3uS8lZ6J21tpK7XdXt38+y+i6KKKxLCiiigAryrw5/ydN8Q/8AsTPDP/pdr1eq15V4c/5Om+If/YmeGf8A0u16gD1WiiigAooooAKKKKACiiua8TfEzwf4L1bTNL8Q+K9D0HU9UbZYWWp6jDbzXbZAxEjsGc5IGFB5Io62DzOlorkviV4xsvCvh6SJ/FGi+F9a1FXtdIn1pkKSXZUlFWJpIzM2efLVgTXC/s3/ABibxn8BPAHiTxprumw+Ide09rqQyvFaiZhvZ/LTI4VEJ4zhVJJ4JoWqb7W/G/8AkD0t5ns9FcjF8XvAk+l6NqUfjXw7Jp2tT/ZdLvF1WAw382SPLgffiV8gjapJ4qxPdPH8QoUbxVaRWq6XIzeGmji852Eif6Xvz5gVQdhGNuXBJzinbW3r+Cv/AF/lqK+mn9a2/r076HTVn6/b6ndaLew6NeWun6rJEy211fWrXUMT44Z4lkjLgf3Q659RWTZ/E7wdqWrafpdp4s0O61PUVleysodShea6WJispjQNlwjKQxUHaQQcYqPw7qBg1DxbPeeL7LWrOC93rbIkMX9jRiCPdBKytljkPLukwQJMdAKlpNNS2t/wP69O5S30OP8A2Y/gtrHwB+GMXg7VfE9n4rjtrq4uLe8ttJbT2AmlaV1dTPKGO92wRt4wMHGT61Xm3jr9oj4f+A/hrdeObrxXo11oEcSvBdWuoRSRXLOSsSo6kg72VgCOPlY9FONtfi94EfRINYHjXw6dJntWvor/APtWDyHt1YK0yyb9pQMQCwOATjNXJuTbfoT19dfx/wAzrqK5n/hZ/g7/AIS+Lwp/wlmh/wDCUyxefHof9pQ/bXjIyHEG7eVwM5xiumqfMYUUUUAFeVfBv/kovx2/7HO2/wDUe0avVa8q+Df/ACUX47f9jnbf+o9o1AHqtFFFABRRRQAUUUUAeVeHP+TpviH/ANiZ4Z/9Lter1WvKvDn/ACdN8Q/+xM8M/wDpdr1eq0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXl/xn/Z38J/tBww6d49S+1jw1CgKaHb6hcWcDzbs+bKYJEMpAC7VbhfmOCTwnfoNW6nqFFeA/sZ+FdY8F+AfEuj3GrX2seFLPxJfQeFptUmaa5XTEYIimRuWQSLKEPdAp6EV79VyS0a2aT+9X18118yVfVPdNr7nY8q+Mn/JRfgT/ANjnc/8AqPazXqteVfGT/kovwJ/7HO5/9R7Wa9VqRhRRRQAUUUUAFFFFAHnf7RHiDR/CvwL8d6r4g0mbXdEttIuGvNNglaJrmIoQ0e9SGQEHlh90ZPavl7xVqHi3QfjJ8TZ9L1i0v/FcnwhE1la6TGsEEE6zzm3iiUlmdlVsqXYk5yAoO0fb95ZwahazWt1BHc20yGOWGZA6OpGCrKeCCOxrD0H4deFPCslg+i+GNG0h7C2ays2sNPigNtbs25oo9qjYhYAlRgE84qXG/wCP4xlH9Uy+ayXk0/ulCX/ttvu7Hyd4+1jwC037Il9BdaJF4eub97eGW4kiETwy6VOhjLMeQ0jKpUnl2AOSa4HTdH0nS/2IrKOzsrO0gtvimqQJBEiLEq+JCihQBhQIyVGOinHSvuCL4M/D+CS8ePwN4bje8mkubll0i3BnldSjyOdnzMykqWPJBIPFY3/DM3wf/sn+y/8AhVHgj+zPP+0/Yv8AhHLPyfN27fM2eXjdt43Yzjiun2vv89vtKX3SUrfg9fPZGKjaChfZW/CSv/5Nt5bnjnjDS9K1T9pn4uaJe2VjeaVc/DCya6sLiBJIZNlxeBN6EYOAeMjjivNdG0PRdT+C/wCxBfXWn2F3frqWm2sdzNAjyiJtOnaSMMRnaWRCVHGUXPQV9cXX7PfwtvtSvNRufhr4QuNQvIfs1zdS6DatLPFtCeW7mPLLtVV2k4wAO1RN+zj8JmtdNtj8L/BhttMdpLGE+H7TZaMzBmaIeXhCWUElcZIB7VFOXJa/eL/8BlN/ipW+Rc258z7pr74Rj/7bc+Ovj7pul6h4T/a7+32tncpp/iHRL61+0Ro4trg2lmpmTI+R8FhuGDgkZr3r47W+uaNres+LPCuoeHvEH2TwwieJfA/iH5FvdMVp3EsE6/6lzmdfnVo32qDsxur0e+/Zp+EOp3F9cXnwq8E3dxfyme7ln8O2btcSEli8hMeXbLE5OTkmt66+FPgm+0/SLC48HaBcWOjtE2m2sulwNFYmMERGFSmIygJ27cYycVn9hR6q3mvhUXp122/Fbl83vt9NfzuvTXr318jxPwhJpHif9pTxMbywjXRdY+G2igafqkYKvDJc3gMUiPw3DhSpz1weteXfB/8A4RLwr+xT4C1S58K6bqt1ca+mmadKU8qOCWXW8QPJJHhhAkkcLsgOH8pFPUV9keIPh/4X8WXQudc8N6RrNyLWWxE2oWMU7i3lAEsOXUny3AG5ejY5BrO0r4N+ANC8J3/hbTfA3hvT/DN+xe80W10i3isrliACZIVQI5IVRyD0HpWnMr381/6U3a++ztfozPXR37fhBRvb1V7fI+K/HTXVlp37V9pqGtxaxdLqPh6eaaGNIIvMEdv5xSNSdoXaAclmAUbmOM17j8YrHR/+Gtf2e9Xit7H+1Zm1qza/VE8+SNLJiIjJ94qrFztzgEtxnNe5L8O/Ciw38K+GNGEOoWiWF5GNPi23NsilUhkG3541UkBDkAEgCszUvgp8PNY1LR9Rv/AXhm+1DRkji0y7udHt5JbFI23RrA5QmMK3ICkYPIqI6ON+n/yPL/X9XTV1Lzv/AF/Xl8vl95F8Vfsf/GG01pY/+FhWGuavJNGMC7h1cXbvprJ/Fv2/ZPJI5K+WF44r7E8Prex6Dpq6k4k1FbaMXLgYDS7BvOP97NZ918PfC174st/FNx4a0efxPbR+TBrUthE17FH/AHFmK71Xk8A4roKfN7tvT8FbT1/yWtrlS1lfzb/8Cd9fTp6t9Tyr4yf8lF+BP/Y53P8A6j2s16rXlXxk/wCSi/An/sc7n/1HtZr1WpAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPP8Ax14F8Wap4ms/EHhLxha6FfQ2ps3sta0g6nYMhbcXEaTwSJISFG4S4IUAqa6Lw74eu7OYajrN5banrz26W813aWf2aEKOSscZeRlUtlsNI5z34reooWisv6/q4PXVhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHlX7S3/JOtI/7HPwn/6kOnV6rXlX7S3/ACTrSP8Asc/Cf/qQ6dXqtABRRRQAUUUUAFFFFABRXO/EDxVdeC/Ct1qtjoV/4kvI3iih03TU3SytJIsYJ67UXduZsHaqscHGK8x8E/tNW154k+IXh3xpY6V4b1fwRp8Wq6pNpGsHVLFbWRXbPnNBC6yL5bbo2jBGVIJzSvv5foOz0t1Oj+Nnwn+HnxYt9EsviDLOYIbxG0+2TxDd6Ykl1vUxkLBPGJZAwXYSGZSflxk59GsbOPT7K3tYmleKCNYkaeZ5pCAMAs7ksx45ZiSepJNfGnx/1nVvG3jj9nbxNrPgSx0OOXxxYtpOom+S51FbeW3mdoZ18pfILFUbZHJKp2DcykAV6Fb/ALWWv6p4O+KGvWHwzmt2+H2ozWmp6fq2uQwzyRQwJPK8ZhSZDIFf5Y9204GZFJwKXuwlfSzd/ko6v/wJJ9gs5Tio63St83LRf+A3Vj6QqhY69pmqahqFhZ6jaXd9pzrHe20E6vLbMyh1WRQcoSpDANjIINeQyftIyW+vfDKSfw0sXg/4gultpWrf2hm8juHt3njE1qItqxsiHDiZmBIBQckcpfftQWnhDR/jh4kg+FGoW2oeB72NdYhhnso7rUVFuHW6kcPtKLD5ZHzPJtIUJkYoknC/N0vfys0nf7196ewo+/bl1va3zvb8n+W59MVQsde0zVNQ1Cws9RtLu+051jvbaCdXltmZQ6rIoOUJUhgGxkEGvKLH9oK9j8ffDzQda8Lx6Xp/juxln0m+h1L7RMlxFAJ5IZ4fKUIpjOVdZHzjDKlW/gz8TLDx548+KGmw+CX8IatoGqw2eoz3BgM+pOYFaOZzCWBHleXtLOzAEAhcYp8rTafS/wCDSf4/p0JUlJKS62/FN/p+m563RRRUlBXlXhz/AJOm+If/AGJnhn/0u16vVa8q8Of8nTfEP/sTPDP/AKXa9QB6rRRRQAUUUUAFFFFABXxf+1prVvrnhn9o6w0xbbw/Jo/hW2XWNQuUMlzqrNDNJbRQhzsiiTLAuqlnZ2A2FNx+0K57V/h54V8QatJqmqeGdH1LU5LOTTnvbywilma1f78BdlLGNu6Z2nuKlpv+v6/r7i4SUZJvo1+Z8/8Awz8Q2usfFz4j2XiaS1mnj8H6SdM+2SK4k08wS/aiA3GPtAcSf7qbjwMeH/s7ReF9cP7HGpWaaRqGqQWWsaddXkAilmjMVq7iCRxlgUZ92wn5S2cAmvu3U/hr4R1r+x/7R8K6Lf8A9jENpn2rToZPsJAwDBuU+XgcfLjisi6+AvwyvdQ0q/uPh14TnvtJSOPT7qXQ7VpbNY2LRrCxjzGFYkgLjBORW/Mudy8//kv/AJLXz1vrYwUbU+S/T9Ev00+62lz5D8Yw2dr+zv8AtlyRR28Rg8R6gYmVVHlt9mtZBj0Pmszf7zE9Sa9OsfD+g3/7Z0f2nS9NnfXvhcx1RZLaM/2gPtcSHzhj96NmF+bPy4HSvYo/2bfhHHp99YJ8LPBSWN9Ik13bL4etBFcOm4o0i+Xh2Xe2Cckbjjqaf/wzj8JvtaXX/Cr/AAZ9qS2+xrN/wj9pvWDyzF5Qby8hPLJTb02nGMcVmvhiv5Y2/wDKbh+buaytLmt1bf8A5PGf6W+Z8ffD+3stK/ZU/Z4l0+K3sx/wsu32SWqqnym/uo+CvYx/L/u8dK9B+GPhHQJbH9qHw5BqNn4J0yXxosaXlrbxLDZyPZ2RV2iwEKmU/MDgNlskZJr3xv2afhC+l2+mN8KvBLabbzPcw2Z8O2fkxSuFDyKnl4DMEQFgMkKvoK1/DHwa8AeCbq/uvDvgbw3oFzf4+2TaXpFvbPc4bePMZEBfDfNznnmr5vj/AL1/x9n/APIfj5ENaxa6W/Bzf/t/4eZ8tfFnxF4jufg/8ZdB8b6Po0PjLSE0Wa917w6ZBZapatdAwSsj8wyqscm9CWwNpDFcY7fxb4X8Nax+3X4Oll0nSr6XUPAmrxXzvbRSNcqtzaxhZTg7wA0iYbOAWHc175pnw48JaL4bvPD2neF9FsNAvPM+06Va6fDHaz+ZnzN8SqFbdk5yOc81n2/wV+Htr4msfEUHgPwzD4gsY0itNWj0e3W7t0RNiLHKE3IFX5QARgcdKUWo1FJ9L/jBx/W/+QWtFpdf0kn+n/DnyL8Sdct9a0nw/qmgm38KaBafGGzsotHjT/TLm7jv/JubiWR2JRW52xRBdqYyxVti/dcciTRpJGyyRuAyspyCD0INczcfCzwXeXmpXdx4Q0Ge71OeG5vp5NMgZ7qWEhoZJWK5dkKgqzZKkDGMV1FKLtSUPO//AJLGP/tvyvYqWtRzX9e9J/8At3z36hRRRUgFeVfBv/kovx2/7HO2/wDUe0avVa8q+Df/ACUX47f9jnbf+o9o1AHqtFFFABRRRQAUUUUAeVeHP+TpviH/ANiZ4Z/9Lter1WvKvDn/ACdN8Q/+xM8M/wDpdr1eq0AFFFFABRRRQAUUUUAFfMP7VfxQ8V+B9W0bxZ4dvpYvCfgLVbO48WWsRIF5b3WYpEYg8iCKRZypBHzxt/DX0B458XQeA/Cuoa5cafqmqpaR7hZaLp819dzMThUjhhVnYkkc4wOpIAJHg2k/Avwd8ZPhNqfiDxZH48iuvEdtcXOt6Y+reINNXzWUiSIaYJIgwQARqog/eBFOH3ZM8zj+8Svy2f8AwPRpO/bTuWkn7r+1df528+3/AAD1j4xfGzw78EfhvdeN9dj1K+0O3QSFtFsJLxypBIY7BtRD/fcqgyMsMiq6fGy0Y3UbeF/EkN358dvplrNaRI+ss8BnBtWMuzaFDBjK0YQqd2OCfjTUPiR4n8SfsCeI/hjrPgT4jXPjyz06TQLFf+EG1fGqQxSBLe5D/Z9qBolUkSMrAhuOmfXf2k/Dd34y8D/Cjx7Y/DST4o6L4bmkk1bwTrGjst3cWstv5Tyx2d1GrGeJlDKjJkgnHUGtZxjHms7q6Sfk+v8Aw+3XYzjdqKa973rrzVvwfTv0Z6zp37TnhW48MeKNU1Cy1jQ9R8M3sGm6toF9bI1/bXM5QW8eIXkjfzPNj2ukjJ83LDBxsfDn41WHxA8Ta74YuNC1jwn4q0WGC5vNF1wWxmEE27yple2mmiZWKOOHyCvIHFeEpd3ek/A3W/FHwh+B1/8ACNr67sIrrT4PDdpYa9PZi4Au5ktIN5LJC0nlqwMm4sQn3d2p8E/B7eGP2r/G2r6b4W8QWHhnW/CukraapqlpcBrqWOS481p5Z/3nnANHlZiJeny4Gaaiuaz/AKajf8enzW6bJb9y6/4dcyX4X6eT2dj1j45ePLrw1D4V8NaTctZ6/wCMtXTRrO7QKWtU8t5ricbuNyQxSbcgjeUyCMiqT/Fzwn8M/iBovwnsdI1+41y6sJ7+0SKxleGdU+aQ/apSFkkLONzb2wXy5XOax/2itJuLPx98F/GQAOm+H/EzQX7HOIory2ltUkOB0EskQJPADZNcv8T9SuYf23vhRdp4e8TXelafomqWV5q1n4fvZ7G3muTB5KvcJEYxny2yd2E43FaiFnaN93K/yjdL77ffYqb5deyT++Vm/u/K51sP7V2h3HgfxJ4ki8JeKnPha6ntfEWlfZrYXekGEBpWlzceXIAhD4gkkZlIKg1mfHT4nfEq+0Pw43wl+F118S9B1m3S9vNSt/Ello6G1ddyRRPKxkDOCpZgnCthWDHK+L6Hq183w8/a2iPhDxtHN4j1K+uNGhk8IaokmoRz2MVtEYkNvubMikEYyo+ZsLzX01+zFeSXX7P/AIAiuNN1TSLyy0W0sbmx1nTp7G5hmiiWORWimRWwGU4bGCOQSOaFHnhzeUH85RbkvRNLz1sypfu5JLvNfc1yv1ab8tNEZXwtbxr8U/Ad/afET4cp8I2t5Eg0vTNN12K+uIFRBtuEuLcKkeCQqoBxsbOQ2K3vgR8RLr4heDbv+1DGfEGh6pd6FqnlDAa4tpTH5gX+ESJslC9hJivRSwUEk4A614V+yX4eks9F+IPiYhltfF3jLU9Zsww4a23rBFID3WRYPMB7hxVJ80pXVla/zvFfinJv08iWuWCtve3ytJ/g0v6Z0Pxk/wCSi/An/sc7n/1HtZr1WvKvjJ/yUX4E/wDY53P/AKj2s16rUDCiiigAooooAKKKKACiiigArjPHnxl8EfDDU9D03xT4lsNF1HXJxbabZ3En766csq/IgBJALrlsbVzkkCuzr5R/bw8feGfCd98ELfW/EGmaROvj/Tb9o727jiZbaISCWchiMRqWUFzwCwyeaI61IR7yivvaX4bg/gnJdIyf3JtffsfQXg34peGvH2ra3pej3sz6posiRX9je2M9nPDvBKP5c6IzRuA22RQUbB2scVm/GD4hT+CdL0ew0sxN4m8SalHo2kLMhdFmcM7yuoxlIokkkIyM7MZGc14h8NviH4W1T/goF8TtOsvEelXd/N4U0q3it4LyN3eWGW5aaNQDyyK6llHIDAmu0/aJsprb4rfATxA8e/StO8UTWt07EBYnubGeCBzn/poyoPeQetUoqXs/71vzt+P6icuV1P7qb/8AJeb8PxsdhD8WPA/gHxJZfD3UPGf9peMvsr3psLh2udQmTljI0canbuJO1AADwqL0FVU/ae+G8ng+58Tprl1JpFnPJbXzJpF60+nPG22T7XAIfNtgh+80yIFHJIHNeS/Fj4heF9J/b6+DemXviHTLTUE0DWLd7aa7RXSWc2/kIwJ4aTY2wHlsHGa8o8P/ABc8D3Hwz/bRki8YaFJHcarqMsLrqMJWVJdPigiZDu+YPKDGpGcsMDmsnP8AdupvaMpfOM1G3zTuawgpVFTvb3or/wACje/3n254q+JnhrwZoljqup6l/ouoMqWKWUEt5PesULhbeGFXkmYorNtjVjgE4wK53TPid4Q+NFjfaV4K8e2kfiO0Tz3trOdRqGnuGwBdWUmJEG75WjlRT24OCPlLxN8bvBPgL4AfszfEn/hJ7VToVslrbzulxcaZJIdOMNxbXUlrFM8EmRtVhG7KwOUIDY9T/Ym+LXgH4q3vxH1rwx4107xD4g1zVk1jVdJ02K6jg03MEcCLEbmGGSVSIQTL5agsfur0rpnTSqVKad+W/wCDVvwd79LW6pnNGo/Z06jVnJL9b/kl8/Jo9t+D/wARD8TPBa6lPbrZ6paXdzpepWqHKw3ltK0MwX/ZLIWXPO1lrt68D/ZI0m4htvitrbuzWGu+PdWu7HcCMxI6W5YexkgkIx1GDXvlZvaL7pP0bSbXyehrtKUVsm18k2l+AUUUVIHlXxk/5KL8Cf8Asc7n/wBR7Wa9Vryr4yf8lF+BP/Y53P8A6j2s16rQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHlX7S3/JOtI/7HPwn/wCpDp1eq15V+0t/yTrSP+xz8J/+pDp1eq0AFFFFABRRRQAUUUUAeXftKeH/ABh4m+FN7ZeCFkuNW+12ks9jBdi0lvrNJ0a5to5iyiN5Ig6AllHzcsucjwrXv2ZfEXjnxd8VLC28LQ+B/CPjLwJY6FpzRXFsF02aFrg+VLDCxwQZEOI90ZXP7zPFfY1FC0TXe/4q3/Ddn6srmejXS34NP9Pu+R8ifEnwz8Z/iR4d+EIj+HFrZeJfBXii01HUftuu2yafepBbyo0tvJGZJRG5YY8yJXUsvyEZYZWg+C/iengL9pqzuvhTrltf+Ob+7u9Et/7U0lzMtxaR2oDMLzahUpvbcfu/d3N8tfaFYHhHxzo3juHU59DvEv7fT7+XTZp4iChniwJFUjrtYlT7qR2ol+8U4v7Sd/R8l/8A0mIRl7Nwkvs2t8uZpf8Ak0v6R8n6/wCD/ifJ4H/Zmt7f4T67c6h4GvrS71y1TVNJUwrBaSWrKjNeBZGYuHXBxt+8Vb5ax/G3hL4ta3pv7S+nWvwX8Rv/AMLGVItFn/tjRQibbFbYtODf5QFk3DaHODyAeK+56zfEfiLTfCOg6hresXkOnaVp8D3N1dTsFSKNASzE+gAp1Z8/PKf2rt/O1/8A0lE0o+zcFD7Nkvle35s+W9e8OfEXU/H37N2qw/C3XhZ+D4pxrjSalpINqZbQ2uABeHzCpAkO3I2MMEtlB2PwC0nxrpfx0+MuqeIfAOqeHNC8S6ja32l6ndX1hMkiwW0duVdILh5EZihdcrjb94qeD7voerweINFsNUtd32a9t47mLzBhtjqGXI7HBFXq1lKXPJyWvvfi0/wa0/G5nFLkjGL0SVvRX/O/+QUUUViaBXlXhz/k6b4h/wDYmeGf/S7Xq9Vryrw5/wAnTfEP/sTPDP8A6Xa9QB6rRRRQAUUUUAFFFFABXjeqftLaPpv7Rdp8KDpWtvevpZv5r6LRL2aFWaWOOIB0iKiPmTdMxEalQpcHIHslfNGsX9v4c/4KA6fd6nMllBqnw/NjYNKcG6nTUAzxxjqzKrBmA6L8xwATRHWrCL2fN+EZP81/WwS0pTkt1a3zlFfk2ejfC3x54G1oePte8PfECTxRpsGqO+p3F1qHnWWkyJBGHggcgJHEqqHIBIDO5J5wNPwr8dPBXjLxIdA0/VLiHV2ha5gtdT026sDeQqQGmtjcRILiMZH7yIuuCDnBFfFF9rkPxe8DftWaL8M9b0/xFrj+MLbWBpek3Uck2o2EUVl9oEQUner+TLHkcM3y55r2fx/4m8P/ALR3jr4Hap8O9ag1C/8ADXiL+1dXltSPN0iyFpKtxBdgjNvI7NHH5T7XJzx8pIuK5lBt6NQ+V4rX0Tuv+3X1CfuuaW6cvm03p6vT71Y9Uj/au+FNzoesazZeLodW0fRrv7FqOoaTaXF7BaPtVi0kkMbKsYDrulJ8tecsMHHq1vcRXdvHPDIssMih0kQ5VlIyCD3BFfnfB8XvA2ofBv8AbWktvGOgzpe6rqL2rJqUJFwsunwwxNH83zh5VKKRkMwwMmvs39nHxFpfin4C/D/UNH1G11SxbQ7OMXFpKsib0hVHXIP3lZWUjqCCDyKIrmhzeUH/AOBRba+TQVPcmorvNf8AgLSX33/AydN+JFv4o8S+L/EF5ro0LwD4IuZLCad5RBDdXUUYa5mmlP8Ayxi3CMLkAushbdhcWLT9qT4YX2m+HdTt/FCzaPr901jp+rJY3JsXnDlBG9z5flRMzKQgkZd/BXcCK4j9mjULT4f/AA/+K1p4ju7fSG0DxhrlxqV1ezLHHHFNKbuOZ3JwqmGeM5J6V8l2fxU8Gx/8EzvBML+KdIS4h8U2cclu15GJUePWRO6lCdwKwkSEY4QhuhzSgk+VPZ+zv/2/u/8AL7hz93na6OaX/bt7flr3vc/RDw78W/C3irxdf+F9P1Cb+3bO3W8e0urG4tjLbscCeBpY1WeLJA8yIsoJAJzWJrn7SHw38M6tdWOseKINKjtZTb3Gq30E0OlQzg4MD37ILZZgf+WRlD/7NeJa78VvBd3/AMFBPh9FB4t0S4kufA95bQiHUIn8yWe4t5YIxhuWkjBdB1ZeRkGvnzxN+0X8LfD9n4p+C2tfECy8N+H/APhMZ9SnvtU07Vf7asWGpC7aIQpZtC+6RWKTmddqOpMZIOSKUuS7s5X/AAnyv8NbfLtdS93mfa33OPN+eh9ya98QF8I+KPCOuWusrrfgjxldxackkc6TQWtxLGWtriCUHmKUoIyoLDc8bLjLZ9Xr55/auWP4ifDf4d2Xh+8ivH13xfoU+n3ED7klijuFumlUjqohid8jsK+hqdvcd9LSa+SUX+ba+VuhN/eVusU/xkv0QUUUVBQV5V8G/wDkovx2/wCxztv/AFHtGr1WvKvg3/yUX47f9jnbf+o9o1AHqtFFFABRRRQAUUUUAeVeHP8Ak6b4h/8AYmeGf/S7Xq9Vryrw5/ydN8Q/+xM8M/8Apdr1eq0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAU9Y0ex8QaVd6ZqVpDfafdxNDPbXCB45UYYKsD1BFQ+HtETw5o9tpsV1d3kNuCkcl9MZpQmTtUueW2jCgsSxAGSTknSooAKKKKAMrxN4dg8VaTJpt3Pcw2cxAnS1lMRmTvGzD5grdDtIJHGcE1fs7ODTrOC0tYI7a1gRYooYVCpGijAVQOAAABgVNRQB5V8ZP+Si/An/sc7n/ANR7Wa9Vryr4yf8AJRfgT/2Odz/6j2s16rQAUUUUAFFFFABRRRQAUUUUAFFFFABWT4q8L6d408P3mjatCZ7G6UBgrlHVgQyujDBV1YBlYEEEAjkVrUUD2M3w9p97pOj21pqGpPrFzCChvpYljklUE7S4X5d23GSoAJyQq5wNKiim9dRHBeP/AAN4n1vX9M13wr4uh0DUrG3lthaarpf9o6fKsjIS7QpNBIJAE2hllGAzAg5qWTwLrWq6ckmq+IoB4he3+xz6ppOnfZQkLEGVbdHklaIuVXlnkxtGOea7iil0sHW5n+H9BsPC2h2Oj6VbJZ6dYwrBbwR5wiKMAc8n6nk1oUUU223diWmiCiiikM8q+Mn/ACUX4E/9jnc/+o9rNeq15V8ZP+Si/An/ALHO5/8AUe1mvVaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiqmpatY6LbpcaheW9hbvNDbLLcyrGrSyyLFFGCxALPI6Iq9WZlAySBVugAooooAKKKKACiqmm6tY61bvcafeW9/bpNNbNLbSrIqyxSNFLGSpIDJIjoy9VZWBwQRVugAooooAKKKKACiiigAooooAKKKKACiiigAooooA8q/aW/5J1pH/Y5+E/8A1IdOr1WvKv2lv+SdaR/2OfhP/wBSHTq9VoAKKKKACiiigAooooAKa33WwdvH3vSnUhG4EHpSeqsB8k/DGO8+G3xE0Lwx8RPAtm1zr17Mun/Ejw/Ok1r4klaCfampIQJBMYNxG/fHkYRlAxXjnhn4YeFdK/Yf/aG1bStEtdB1a11jxII9Q0QHT7jy7a5lNvC0kBRniTAxExKYGNuK+5dC+DfhHw3rVrqmn6bNHPZoEs7eS/uJbSz+UqWt7Z5DDC5VmBeNFZgxyTk1z2vfsu/DbxLoXiTRb7RLwaT4ju5L3U7K11q+top5JDmXCxTqESRgGdE2o7AMwJGaJLmi0t3Fr8U1+T2t6dTRSSmpdFJP8JX/ADXf12R5b4q8E+A/Dvws8FyzaJc3Wt+NptDsJNNtLzyYtduIrdmjgvTJuQ2/liTzflLMiBcOQq14hr3haHTvhJ+2d4Ov9J0WHQ9Bt4L3TdC020C6bpkz6aJi1tEwxGQ4D7lC5fLAKTX2rqHwD8E6t4A0rwZfaffXuh6TPHc6e1zrF7JeWksbExyRXjTG4RlyQpEgIX5RheKW3+APgC2uvFFwvhyF38UWy2usrLNLIl6ixtFl0Zyu8ozK0gAdgfmY1dV8/tbfavb58tvus/wt1MqK9mqSf2bX+V7/AIP/AD6Wk+BPhPQ/Bvwj8KWHh/RtP0OxfTre4a2021S3jaV4lZ3KoACzHknqT1rvaxPB/g7SvAfh+10XRoZobC2RUjFzdS3UpAUKN0srNI5CqoBZicKB0Arbq6slOcpLqZ0ounTjF7pBRRRWRqFeVeHP+TpviH/2Jnhn/wBLter1WvKvDn/J03xD/wCxM8M/+l2vUAeq0UUUAFFFFABRRRQAUUUUAFFFFABRRRQBzE3geKPxsvifTryTT7yeJbfUYFUPDfxJu8vep+7IhY7ZAc4JUhhjHT0UUdLB1uNkUyRsoZkLAjcvUe4ry7wV8OfiB4PWHSJPiBpureF4IzGhuvDzf2w2Ry8l2LryXctuYsbXknkHqfU6KA6WOO0f4aWOm+IrPVJJTPHpdt9j0axVAkGnxFVVyqg/NI23Bc9F+VQuW3djRRTuAUUUUgCvKvg3/wAlF+O3/Y523/qPaNXqteVfBv8A5KL8dv8Asc7b/wBR7RqAPVaKKKACiiigAooooA+f9W+E/gj4oftTeNf+Ey8G+H/Fv2HwZ4d+yf27pcF79n332ub/AC/NRtu7YmcYztXPQV1f/DJ3wQ/6I38P/wDwl7H/AONUeHP+TpviH/2Jnhn/ANLter1WgDyr/hk74If9Eb+H/wD4S9j/APGqP+GTvgh/0Rv4f/8AhL2P/wAar1WigDyr/hk74If9Eb+H/wD4S9j/APGqP+GTvgh/0Rv4f/8AhL2P/wAar1WigDyr/hk74If9Eb+H/wD4S9j/APGqP+GTvgh/0Rv4f/8AhL2P/wAar1WigDyr/hk74If9Eb+H/wD4S9j/APGqP+GTvgh/0Rv4f/8AhL2P/wAar1WqWsa3p/h3T5b/AFS+t9Osohl7i6lWONfqzECgDzf/AIZO+CH/AERv4f8A/hL2P/xqj/hk74If9Eb+H/8A4S9j/wDGq2v+E413xQxj8J6BIlrnB1rxAj2lvjkExQEedMQQDyIkYMCshruV3BBuIZsckDAJoA8s/wCGTvgh/wBEb+H/AP4S9j/8ao/4ZO+CH/RG/h//AOEvY/8Axqq3wq+Kvifxb8X/AIleDvEOm6TYReF0017VtMmlmaUXMUkjb3dVzjaqjCDoT3wvpviDUp9H0S9vLSwm1S7hjLQ2UBw88nRUBPC5OBuPAHJ4FD0V/mC1fKed/wDDJ3wQ/wCiN/D/AP8ACXsf/jVH/DJ3wQ/6I38P/wDwl7H/AONV5to3xt+NngH4xeFPDvxa8KeD18MeNLyWw0fUPBt7dTy6fcLE8qw3fnqvmbkRvnjVVBUk16h41+Kmqf8ACdReA/BGm2useKhbLfahdX8rJY6RbMxVHm2As8jlW2QrgsFYlkAyXZ2TXX+n935a7Bpdp9Py2/PTvfTcg/4ZO+CH/RG/h/8A+EvY/wDxqj/hk74If9Eb+H//AIS9j/8AGq9D8NwaxbaHaRa/e2Oo6wqYubrTbN7S3kbPVInllZBjHBkb69q0qHuJaq55V/wyd8EP+iN/D/8A8Jex/wDjVH/DJ3wQ/wCiN/D/AP8ACXsf/jVeq0Uhny/8WP2Zfg9pvjz4MW9p8J/A9rb3/i24tryKHw5ZotzENC1aURyAR4dRJFG+05G6NT1UGvS/+GTvgh/0Rv4f/wDhL2P/AMao+Mn/ACUX4E/9jnc/+o9rNeq0AeVf8MnfBD/ojfw//wDCXsf/AI1R/wAMnfBD/ojfw/8A/CXsf/jVeq0UAeVf8MnfBD/ojfw//wDCXsf/AI1R/wAMnfBD/ojfw/8A/CXsf/jVeq0UAeVf8MnfBD/ojfw//wDCXsf/AI1R/wAMnfBD/ojfw/8A/CXsf/jVeq0UAeVf8MnfBD/ojfw//wDCXsf/AI1R/wAMnfBD/ojfw/8A/CXsf/jVeq0UAeVf8MnfBD/ojfw//wDCXsf/AI1R/wAMnfBD/ojfw/8A/CXsf/jVeq0UAeVf8MnfBD/ojfw//wDCXsf/AI1R/wAMnfBD/ojfw/8A/CXsf/jVeq0UAeVf8MnfBD/ojfw//wDCXsf/AI1R/wAMnfBD/ojfw/8A/CXsf/jVeq0UAeVf8MnfBD/ojfw//wDCXsf/AI1R/wAMnfBD/ojfw/8A/CXsf/jVeq0UAeVf8MnfBD/ojfw//wDCXsf/AI1R/wAMnfBD/ojfw/8A/CXsf/jVeq0UAeVf8MnfBD/ojfw//wDCXsf/AI1R/wAMnfBD/ojfw/8A/CXsf/jVeq0UAfL/AMWP2Zfg9pvjz4MW9p8J/A9rb3/i24tryKHw5ZotzENC1aURyAR4dRJFG+05G6NT1UGvS/8Ahk74If8ARG/h/wD+EvY//GqPjJ/yUX4E/wDY53P/AKj2s16rQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB5V/wAMnfBD/ojfw/8A/CXsf/jVH/DJ3wQ/6I38P/8Awl7H/wCNV6rRQB8v/tB/sy/B7RfAelXGn/CfwPYXD+LfDFs0tt4cs42aKXXbCKWMlYwSrxu6MvRlZgcgkV6X/wAMnfBD/ojfw/8A/CXsf/jVH7S3/JOtI/7HPwn/AOpDp1eq0AeVf8MnfBD/AKI38P8A/wAJex/+NUf8MnfBD/ojfw//APCXsf8A41XqtFAHlX/DJ3wQ/wCiN/D/AP8ACXsf/jVH/DJ3wQ/6I38P/wDwl7H/AONV6rRQB5V/wyd8EP8Aojfw/wD/AAl7H/41R/wyd8EP+iN/D/8A8Jex/wDjVeq0UAeVf8MnfBD/AKI38P8A/wAJex/+NUf8MnfBD/ojfw//APCXsf8A41XqtFAHlX/DJ3wQ/wCiN/D/AP8ACXsf/jVH/DJ3wQ/6I38P/wDwl7H/AONV6rRQB5V/wyd8EP8Aojfw/wD/AAl7H/41R/wyd8EP+iN/D/8A8Jex/wDjVeq0UAeVf8MnfBD/AKI38P8A/wAJex/+NUf8MnfBD/ojfw//APCXsf8A41XqtFAHlX/DJ3wQ/wCiN/D/AP8ACXsf/jVH/DJ3wQ/6I38P/wDwl7H/AONV6rRQB5V/wyd8EP8Aojfw/wD/AAl7H/41Xmmgfsy/B6b9pLx1pknwn8Dvptt4S8PXMFm3hyzMMUsl5rSySKnl4VnWGIMwGSI0B+6MfUFeVeHP+TpviH/2Jnhn/wBLteoAP+GTvgh/0Rv4f/8AhL2P/wAao/4ZO+CH/RG/h/8A+EvY/wDxqvVaKAPKv+GTvgh/0Rv4f/8AhL2P/wAao/4ZO+CH/RG/h/8A+EvY/wDxqvVaKAPKv+GTvgh/0Rv4f/8AhL2P/wAao/4ZO+CH/RG/h/8A+EvY/wDxqvVaKAPKv+GTvgh/0Rv4f/8AhL2P/wAao/4ZO+CH/RG/h/8A+EvY/wDxqvVaKAPKv+GTvgh/0Rv4f/8AhL2P/wAao/4ZO+CH/RG/h/8A+EvY/wDxqvVaKAPKv+GTvgh/0Rv4f/8AhL2P/wAao/4ZO+CH/RG/h/8A+EvY/wDxqvVaKAPKv+GTvgh/0Rv4f/8AhL2P/wAao/4ZO+CH/RG/h/8A+EvY/wDxqvVaKAPKv+GTvgh/0Rv4f/8AhL2P/wAao/4ZO+CH/RG/h/8A+EvY/wDxqvVaKAPKv+GTvgh/0Rv4f/8AhL2P/wAao/4ZO+CH/RG/h/8A+EvY/wDxqvVaKAPKv+GTvgh/0Rv4f/8AhL2P/wAao/4ZO+CH/RG/h/8A+EvY/wDxqvVaKAPKv+GTvgh/0Rv4f/8AhL2P/wAarJ/Zy8J6H4H8UfGzRPDejaf4f0W18Zw+Rp2l2qW1vDu0DR3bZGgCrlmZjgcliepr2uvKvg3/AMlF+O3/AGOdt/6j2jUAeq0UUUAFFFFABRRRQB5V4c/5Om+If/YmeGf/AEu16vVa8q8Of8nTfEP/ALEzwz/6Xa9XqtABRRRQAUUUUAFFFFABWJ4r8F6P42s7e21izFyLWdbq1mR2imtplBCyxSIQ0bgMw3KQcEjua26wPGfgnT/HmlJp2pXGr21usomD6LrN5pc24AjBltZY3K8n5S2DxkcCkxow/sPjfwixazu4fG2lg5+y6gUtNRjXknZMqiKb+FVV0jPBLSsTXdKxZQSpUkZ2nqPavLF/Zr8JIwYav4/yDnn4jeISPy+3V6kqhVCjJAGOSSfzNV0J6ngXwi/5O0+Pn/Xv4f8A/Saaval8VaI11qtsNYsDc6SiyajCLlN9mrKXVplzmMFQWBbGQM1z/hv4JfDvwb4kl8Q6B4B8MaHr8u/zNV03Rra3un3nL5lRAx3Hrzz3rW1P4f8AhbWotai1Hw1pF/HriJHqqXVhFIL9UGEWcMp80KOAHzgdKl35Ulul+I18Tb2ueLaB8ePhD8U/iNoetD4j+EdQubGR7Tw5olrrNtcXss82I3uDAjmTey5RE25VGdm+9hOP8G/DHwf4t+Kn7Q+lfFHStL1K/m1i31e1k1VULxaX9ijjt7mFm/1fltHMvmJgqytzXuvhz9nT4UeD9atdY0D4YeDdD1e1Yvb6hpvh+0t7iFiCCUkSMMpwSOD3rovFXw78KeOp9Pn8SeGNG8QzadKJ7KTVdPiuWtZByHjLqdje64NNpWt3TX3tO/rdfdpoO7u/k/uureln9+up55+x/deJr39nHwXN4tuLi81VraTy7q8cvPPa+a4tZJGPJdoPKYk8nOTzXslIOOBwKWrnLnk5dyIrlVgoooqCjyr4yf8AJRfgT/2Odz/6j2s16rXlXxk/5KL8Cf8Asc7n/wBR7Wa9VoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPKvjJ/yUX4E/9jnc/wDqPazXqteVfGT/AJKL8Cf+xzuf/Ue1mvVaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8q/aW/5J1pH/AGOfhP8A9SHTq9Vryr9pb/knWkf9jn4T/wDUh06vVaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8q8Of8nTfEP8A7Ezwz/6Xa9XqteVeHP8Ak6b4h/8AYmeGf/S7XqAPVaKKKACiiigAooooAKKKKACiiigDI8XWmp6h4U1m10S6Wx1maymjsrphkQzlCI3PB6Ng9O1fIHwGvvC/jHxd4R0fw3oK+BPi/wCGLlJfHwuU8m+u4Y4pIZBLNndqKTS4ZXLSBQu4lGChvrrxxo+peIPBevaXo+pHRtWvbCe3tNRVdxtZnjZUlA77WIP4V86+G/hT4n8SWPwn07VfAEnhHxP8P57Tf4wa/tZ4J4Y023MdqYpjPItwAQy3EcYG/cdzKMul/Ed/7v5vX0X2l9pW7WZU/h6f3vyWnq/sv7LT7j/A2h6b+0U3xc8T6/Al5faV4hv9B8OXUgPm6KlnEIhLbN1hlaUyuZEwxBUEkKBXN+Cfi7c/tHx/s+eHNfWO407xL4evvEHiOzK/uNRe1WO38iRCMNE00rSFDwdig5GQfSrfwT4w+Fmp/EPSvCXh19d07xnqE+r2GoC9ggg0i7nhVJhdK7iTyzInmK0KSsTIylVwGMKfs/zfCjTfhLqfhCzm8QX/AMPdNm0eWwSaOGfU7OaJRNsaRljEvmxxyAOyqfmBZc5p07KMefa0P/AlCSb/APA+Vt9d9bBO/M+XvK3+FyVl/wCA3S7fMt/BnVo/CPx2+JPwssIY7Xw5pNjpmtaPYwrtisYrhZI5beNQMJGHg3qo4HmEAAcV7xXlfwp8A6jbePPGnxE16xbStZ8UCztodLklSWSxsraNhHHI0bMhkLyTO2xmUbgAzYyfVKHsr72/r8PxF1dtv6v+N2FFFFSMKKKKACvKvg3/AMlF+O3/AGOdt/6j2jV6rXlXwb/5KL8dv+xztv8A1HtGoA9VooooAKKKKACiiigDyrw5/wAnTfEP/sTPDP8A6Xa9XqteVeHP+TpviH/2Jnhn/wBLter1WgAooooAKKKKACiiigAooooA8x0/4zXF38e5/hpc+F7rTtmiSa3Fq1xdxMs8a3CwALGhYjJJbLEEDbxkkL6TdXMVnbS3E7rFDEhkeRjgKoGST+FeCz/8n4Wf/ZO5f/Tile/0LWlCXV834Tkl+CQPSrOPRcv4wi/zbPmXVv2wPEvg7xtpS+Mfgzr/AIW+GusX8Omaf40uNRtpm86ZgkLXFnGTJbRuxwGdsjK5UE4HRfFv41fF7wv40n0j4d/Aaf4k6RbQxmfWZPFNpo6CdgWMSJOhMgVShLqcZYr1U11HxA0Ww+LWoWOl3hiPhPw/qUWqapdSsBFNcWzeZFbgk4wkgWSRjwPLCckts6X4meIZ9A8C6ldac6nUrhUs9PPVTczssUHTtvdSfYGl9hW3u7ea0tfzvfa3T519uz2a+53d7fK3fr8s74H+P9e+J3w30/xF4l8KL4L1a5lnjk0ZdSTUPJEcrxg+eiKr7tm4FQRgjBNd5WZ4Z0G28K+HdL0ayXbaafbR2sQPXaihRn34ryPxV8WPjNpPxZXQNF+A/wDb/gg3VvEfGH/CYWVtiFwnmzfY2TzP3e5/lzltnHUVpK0qnLHr9347fNmcb8nM/wCv8/ke30UUVBQUUUUAeVfGT/kovwJ/7HO5/wDUe1mvVa8q+Mn/ACUX4E/9jnc/+o9rNeq0AFFFFABRRRQAUUUUAFFFeBWOoa5pv7ar6JL4m1fUNCuvBU2prpV1Kn2aCf7ciBkREUZCYUFtxwDzlmJcfemod7/hFy/QUvdg59rfi0v1PfaK+V/23tX8bJaaJY6dovxHi8AxLJe674j+F+q29rq9u6kCONY23SvEF8x3CKM4T5uGBkj8dWPhn4L/AAd8PfD/AMca94og8eaxBp9p4t16/a91NrVhLc3MrSSAYlEcTxgbRsJHy/LilH31dd0vvdte36rVDl7r17N/JK79Xb/Lc+pKK+fYfHEfwJ+L954KudR1PUfC914UuvE1k2salNf3NvLaSgXMf2i4d5WRkljYB2O0qwGBwOHk8da/4W/Zz8PftBX2s6rPrd2tjq2qaXJqMp00abdXCbrZLXd5KtFDMNsqqJGaMbnYEiqiuazWzt+LcV+MX8lftcd02uv56J/k183buz66opsciyxq6nKsMg+xp1SLfVBRRRQMKKKKACiiigDyr4yf8lF+BP8A2Odz/wCo9rNeq15V8ZP+Si/An/sc7n/1HtZr1WgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPKv2lv+SdaR/2OfhP/ANSHTq9Vryr9pb/knWkf9jn4T/8AUh06vVaACiiigAooooAKKKKACiiigAorwL9ozUtc8O/Ej4LXGmeJdWsLLVPF0GmXul28qJbXEJtrmQhwF3tlo04LY46cmu8+Pyaivwd8X3ela5qHh+/sdKuryG80xo1l3xwOyjLo2BuCnjB+UDOCQYnLkpSqvpf8En+ppGDlUjT/AJkn97a/Q9Borzf4M67ql5+zv4J1iRLrxBrMnhmzumSScGe8nNsjYMkjAbnb+Jj1OSa+Y/2a7q/1b9obHxO8QfF/wf8AFCSGfUk8E6/4hSXwveqRtkNikCiOSOLcMRliV4J3kFq6JU+WtKi+l/wvt3217dTnjUUqMay62/Hv23Xr0PuSivmDRdY1v4z+E/iP8Q7HxBq2mX2g6pqlj4WtbPUJYLKJbIGItcW6OI7nzZo5CfOVtqlQm0jJ9w+EPxAg+K/ws8JeMreLyItd0u31Dyc58syRhiv4EkfhWaV483o//Ak2vyd+xpL3ZcvqvnF2f56dzr6KKKQBXlXhz/k6b4h/9iZ4Z/8AS7Xq9Vryrw5/ydN8Q/8AsTPDP/pdr1AHqtFFFABRRRQAUUUUAFFFFABRRRQAUVkeLtWu9B8Kazqen2LanfWdlNcW9kpINxIiFljBAP3iAOnevn/4cfEzxHr9l8MPFWkePZPHtv4yuEj1LQ/sNpHbadEIHa4kg8mNZofJlCIwuJJuWCcMymiPvNpdLfje35PyXUH7qv6/hq/669D6XorwODxt4w+Kmo/ETU/CniF9B03wbqM2k6fZR2cE0Wr3cEIef7S0iM4i8xxGFhaNgY2JY5AEEf7QU/xV0/4R6Z4PuZNBvviFp02rzXwjSafS7OGFTMY1kVozL5skcYLqyjLEq2MFxTkk15P5NNp/cm/K2oPR2fn96dmvvdvU+g6K8q+E/jzUZvHXjT4da9fyavrPhdbO5h1WaKOKW/s7mNjHJIsarGJBJHMjbFVTtBCrnFeq0NbC8gooopDCiiigAryr4N/8lF+O3/Y523/qPaNXqteVfBv/AJKL8dv+xztv/Ue0agD1WiiigAooooAKKKKAPKvDn/J03xD/AOxM8M/+l2vV6rXlXhz/AJOm+If/AGJnhn/0u16vVaACiiigAooooAKKKKACiiigDzr/AIUD4O/4WgPiGY9cPiwIYhdnxJqXkiIncYfs/wBo8nytwDeVs2Z5255roG+HPh9vF2qeKRZSR6/qenR6TdX0V1MjtbIzsiKFcBCGkc71AbnrwMdJXmXw2+M1x4++JHjvwhd+F7rw9c+FlsWaS7u4pmuBco7qQsRZVwqD+I8k9gCwldci2Sf3dfzBu15Prb/gfl+R5pZ/8E2f2c7HxFBrqfDxpdWhulvRc3Ou6lOWmD797h7khyW5O4EHvmvorVNDsdZksJLyHzmsbgXduN7KFlCsoYgEBsBjgNkA4PUAibUrw6fYz3At5rpo1LLBbrukkPZVHqT64A7kDmvOND+LOvRfFi38C+K/Ctro1xqVjc6lpF/peqm/huIYHiSRZg0ELQyjzoztAdDkgOSOXG7tBeq+Wv5L8AtvL5P+u2p6hRXkGsfG3XbjVvFQ8JeErPxDo/hK4a11u5vNZ+xXPmrAk7x2sPkSLKwSRf8AWyQqSQAxGSPSfCfiax8a+FtH8QaYzvp2q2cN9bNIu1jHIgdcjscMOKFquZbafjt9/TuJtJ8vXX8N/u69jWooopDCiiigDyr4yf8AJRfgT/2Odz/6j2s16rXlXxk/5KL8Cf8Asc7n/wBR7Wa9VoAKKKKACiiigAooooAK+a5PEBf9ua2vBoXij+zE8JSaE2qf8IzqP2EXhvFlCfafI8rbsBPmb9nbdnivpSiiPuzjPtf8U4/k38xS96Dh3t+DT/NL5HFa58VLPQfGQ8N3Ph/xRPcTQLNbX1lodxdWE5O7MZuYlaOJxt584xj5hgmvG9X/AGfb/wAJ+AvAmoaTZtd6t4R8YXHiz+ybXYT5F1NcG4tYRgKSkV020DG4xgDqK+maKabjZre6f3O6/wCCU9U4vZ/qmvybsfP0PgZPjr8XrvxtdabqWneFrfwpc+GrFdY0+WwubmS7kDXMn2edFlRVWKNQXVdxZiARgnhpfAuv+Kv2dPD/AOz9d6Lq0Ws2QsNI1bVJtOkTTv7Otp0L3MdyR5MhlihAWNGaRWlXeigEj66opxfLZLZW/BuS/GT+Tt2snd69f+Al+SXzV+6GxxrFGqKMKowB7CnUUVIttEFFFFAwooooAKKKKAPKvjJ/yUX4E/8AY53P/qPazXqteVfGT/kovwJ/7HO5/wDUe1mvVaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8q/aW/5J1pH/Y5+E//AFIdOr1WvKv2lv8AknWkf9jn4T/9SHTq9VoAKKKKACiiigAooooAKKKKAPmz9rDXWtvHXwaSHQvE2rLo3iqHWb+bRfDWoajFb2otrmIu0lvA67t7qNgO/DA7cc16Z+0FrC2fwQ8YbLHVtRm1DSbmztrXStKur64eWWF1jXyYI3kAyQCxUBf4iK9HoqJx56UqT63/ABSX5I0jPlqRqL7KS+5t/m38jx34F+KH0L9mPwney+H/ABE93oegW1tdaPJo9xa6g00ECLJHHb3Cxs5yCARw2PlJp9zY2fxw8VfDzxRY6dq+l2nhi+n1L7RrOkz6Zcs720tv9nENzGkuD5u9jtCny1wWzx6/RXROo6lSVR7t3+Zz04ezpqmuit8rWPmHRdH1v4NeE/iN8OtO8Patquoa7qWqah4YubTT5JbGRb3MpWe5VfKt/KlkkB85k3KBs3nivb/hD8P4PhR8LPCXg23l8+LQtLt9P87GPMMcYUt+JBP4119FZp2jb0X/AICml+bv3NJe9Lm82/8AwJpv8tOwUUUUgCvKvDn/ACdN8Q/+xM8M/wDpdr1eq15V4c/5Om+If/YmeGf/AEu16gD1WiiigAooooAKKKKACiiigAooooAw/HGpato/gvXr/QNPGra5a2E81hYM20XE6xsY4ycjG5gB+NfG/wAKYfDdv4t8EeNvhlrsR+JuvT2cPxF8J2YVWuRIC1zPe2nWylgdpGVyF3Y2fMXBr7kopw92fP6fhe69JdfRCn70OT1/HZ+sd0+l2fLngbXNM/Z1f4t+FdeuEttS1bxBqGv+HLE5M+tR3cSy+Xap1mkWUSIyJllAViAGBPN+CfhHP+zdD+z94k8Qyw2mm+GPDt9oHiO8d/3GnvdLHOJnfOFiWaJoy5+Ub1JIHI+x6KItwStukl8oxcfxTdxy95u/Vt/NtS/NaHhHwb0dfFnx4+JXxRsnWfw7qtlpui6PeR8x30VuskktxG3R4y8+1XHDeWSCQQT7vRRRfRJdBdW31/4b8gooopDCiiigAryr4N/8lF+O3/Y523/qPaNXqteVfBv/AJKL8dv+xztv/Ue0agD1WiiigAooooAKKKKAPKvDn/J03xD/AOxM8M/+l2vV6rXlXhz/AJOm+If/AGJnhn/0u16vVaACiiigAooooAKKKKACiiigArwD4Rf8nafHz/r38P8A/pNNXv8AXnXg/wCAPg7wL461XxhpEeuL4g1QAX1xeeJNSvI7gAEKHhmuHjOwEhPl+QHC4FEdJXfZ/oKWsbLyPRa+b30Hxj8L/wBqjwxdP4ovvHPh7xrDe2U1trFtbC40PyYzOjWzwxR4gYgIysCSfKJZm5r1bU/gh4J1iy8a2l5ognt/Gbq+uobqYfa2WJYlIIfMZCIgBj28jPXmr3gn4W+Hfh7HGNIt7yWaOH7PHd6tqd1qVykOd3lLPcySSBMgHYG28DjgU46SUvL81r/wH+QS1i4r+rPQ+X/GnhTW/iF8Rvip4q+El7/Z02iX0ej+K/CuoS7LHxfJFbRvIpYfNaOI5EjE68vtIcbBk/Ufwt8Yad8QPhv4Y8S6RatY6XqumwXdtasoUwxvGCqYHA2g4444rH8QfAXwT4m8UXHiG7027t9Vugq3r6bqt5YxagFAVRdxQSpHcgKNoEyuMcdOK7uzs4NPtILW1gjtrWBFiihhQKkaAYCqBwAAMACiLtT5Xvp+Cd/k3ql9nZDl70+b1/S3zXfr16WmooopAFFFFAHlXxk/5KL8Cf8Asc7n/wBR7Wa9Vryr4yf8lF+BP/Y53P8A6j2s16rQAUUUUAFFFFABRRRQAV4jYeNvGFr+1vJ4Lv8AWrW78LTeE5dZgsbfT1haKYXiRLukLMz4T02glmOPuhfbq+XJviZ4Pb/goJa6YPFehnUl8EyaWbMajD5wvDfJJ9m2bs+bsBby8bsc4xTp61oR783/AKRL9bfMVTSjN9uX/wBLjf8AC/yO3+O3x8h8AeINM8IabrOg6Brd9atqF7rniW4WLT9FsVcR/aJQzoJHeQiOOPeu47iThSC/x5461f4R/s/6v4m07Vte+KupyR+bYXml6TBfyt5pAR44LOONXgjBL8nJVSGkOc1yWr3ek/B39rDxZ4y8d6hZ6P4V8T+G7Cz07XdVdYrO2mtpJhNavO/yRM4mR1Ukb/mAyVNVvgFr+g/s+/D3xNqni7Vrfwf4G13xpqE3hr+0le2trSzlbMYZnAWCOR0lkTeVXEiAYLAVKjzQd3unr/29bl8nbbro32Ll7s00tmtP+3eZvzSej6bdU7t/ZC8eat4k8H+KPGOu/Hx/i7pNmGiks5fCdtoM2jSw7mmWeJP3m8gDAbAwCRnOQ6H4zeLdJ+D+gfHPVdYnbw7qklpcXPhP7JAttZ6ZdXCpHMsgj88zxxyxu5aQxttYCNcgjp7T4W6V45+InxG8TaEYItA8XeGIdGub21H7rUrj9+BcKwOHCRSovmLw27GTt48i1CMeNv2SfDvwDSWE/EcW+m+HdV0Nd3n2MME8az3cifeWDyoHdJThHygUksAdovmlqrO8LL5yUvlpF33Se9yLJdfd1u/kmrffJW2bR9qKwZQQcg8ilpkMSwQxxL91FCj6AYp9ZAr21CiiigYUUUUAFFFFAHlXxk/5KL8Cf+xzuf8A1HtZr1WvKvjJ/wAlF+BP/Y53P/qPazXqtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVDXJNSh0m4fSIbW41ED90l7K0UOcjJZlVjwMnAHOMZGchN8quxrV2L9FeYfs1/FDVvjN8G9E8Xa3Z2en6nfS3SS22nlzDH5VzLEoUv8x4QZJxk5OB0Hp9XKLi7MlO6uFFFFSMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyr9pb/knWkf9jn4T/8AUh06vVa8q/aW/wCSdaR/2OfhP/1IdOr1WgAooooAKKKKACiiigAooooA8S+PHjjxd4H+IXwmi0jWLW20LxD4mh0e/sTYB5pI2gnlYiZmO0ZiUYCA8n5vT0vxnpuqatp7wWXiKbwpa+U7z6rZJA91ERjaU+0RyQgY3El0boMDuPn79sX4leEfCfxA+BVprninRdGurXxlBqM8GoajDA8Vr9lu0891dgVj3kLvPy5OM5r1L4yfET4Safb6b4S+KOo+H00zxJGz21r4miQ6feeWyHBklXydwLIyqzBj1UHBISXNT035mvwj/wAEuVo1I325U3/4FLX7rfgct4b+M2t+Bf2dfF3jrxrMviCPw61+9jqcEKwNrdnCxFtPsT5FaXgZQBGyGUBWApreNPGHwr1L4d6j4w8Qya/Z+M7+DSL+x+xwQ2+kXk0DPEbUxoshiMiGMiZ5GJdSGXBU+b2P7Ouo6v8As2/HHwB4aE0PhXVr+5k8E6feM6rBEIonEab+Vga6SXYOm0gj5SK6PxtrumftHS/CPw94duEvLvSfENjr/iK2UMJdGW0iaTyblesMrStEgjkwxBZgCFJG0bOUfPkv5RfxP1te9tmtLGUrqD/7ifevhXpfbv1vY10+InjP4iaP4/8AG/hbXZNN0rwlqF/YaXoaWsEkGtNZrtnN08kbSqGmWRE8l49oUM2/O0e0/DzxtY/EnwH4e8V6Zu/s/WrCDUIA3UJKgcA+4zj8K+bfB+r2fwH+H/xO+HGpSx/8JXdatrN74b0fJ+063FeM08P2ZOsu1pTG+3OzYS20c17t8Bfh7L8J/gr4H8HXEiy3OiaPbWU8i9GkSMByPbdmojbkv5Qt6tPm/G11020Kn8dl3n9ya5fwvZ9fM72iiipAK8q8Of8AJ03xD/7Ezwz/AOl2vV6rXlXhz/k6b4h/9iZ4Z/8AS7XqAPVaKKKACiiigAooooAKKKKACiiigDgfj58QL34U/BTxv4x060F9f6JpFxfQW7AlWdIyV3Y/hB5PsDXjPibVL/4K6H8MPH9j4q1vXv8AhI9X0rS9fh1XVJry1vo70CMTwwsxitnSR0cfZ1jQruBU8EfSXiSextvD+pS6nayX2mrbyG5tYrOS8eWPadyCCNWeUkZGxVYtnABzXzn4I+BWleJvFXha40XwzrHhL4a+Gb7+2bHT9duroy3l5sxCILK4djY20W9m8rbExkVf3aquWqnpO72vG/om+Zf9vLTza8ron/D07S+9pcr+T+69/Xz/APa/8Qa+3xRt/wDhNJvi58N/hNp6RQW/jP4b65BBbNNJkzTahHGskyRKRGiswAGHOPmBr2fx74gkn8ffC74SaRrWox6brGnXeo6jqkOoSfbp7C1ijRVW6DCQPLJNGWlVg+FbDAnI6PxR46tfHlr4w8Bp4T8Qvqj289h5eq6FcR6ZdI6bBIt4UNu8ZD5I3l8BvkJGK47xF8K5/hb4i+EPjCxi1DX7TwTo0/hzVFs7Zrq8ls5IYgLhIo1LysslvGSkYLEO21SRilTsopS+G9/W6la/pLlv0s2ujCpfmvHezXpZx266q9vNJrc3/hB4sudJ+LHj74W3d7d6jB4et7DU9KutQuXubn7Hco6+VJNIxeUpLDJ87ksVdckkZr2avGvhF4Ru9T+LXj/4o3tjdabD4hgsNM0q1v4Gt7n7HbI7ebJE4DxF5ZpMI4DBUXcFJwPZabvZX3tr/Xe2/W97i6u239X/ABvbyCiiipGFFFFABXlXwb/5KL8dv+xztv8A1HtGr1WvKvg3/wAlF+O3/Y523/qPaNQB6rRRRQAUUUUAFFFFAHlXhz/k6b4h/wDYmeGf/S7Xq9Vryrw5/wAnTfEP/sTPDP8A6Xa9XqtABRRRQAUUUUAFFFFABRRRQB5jp/xmuLv49z/DS58L3WnbNEk1uLVri7iZZ41uFgAWNCxGSS2WIIG3jJIX01jtUn09BmvAZ/8Ak/Cz/wCydy/+nFK9/prWlCXV834TkvySE/4s49Fy/jCL/Ns8o134weIPCnjDwxbaz4Njt/CniO+TS7PVLfUzJfQXLozRi5szCoRGCEbklkKnG5QMkT+Ifi5q9x401jwt4F8OWfirVdBign1n7fqx0+K3Eys0cMbCGUyTlV3bGCIAy5kGa89/aI0Lxh4I8feDfiVo3im+12wg12x0ybwVqNtbPaLFdypbPNaMkSyJOvmF97s52mRQQpIrR17wnrPwK+KXjz4o6dqHh9/BviS3trnxBb65dy2kthNbRGNbiB0ilE29Nq+Swj+YAh+cVK+DmemrXzSTSfye68l0bKlfmsuy/N3t/k/O26R6v8MfiPpPxY8FWHiXRvNS1uTJHJb3ChZraaN2jlhkAJAdHVlOCRleCRzXVV4r+yH4J1bwX8GoZNdhls9V17VL/wAQzWMy7WtBeXLzpCVydpVHXcMnDFhmovFXxY+M2k/FldA0X4D/ANv+CDdW8R8Yf8JhZW2IXCebN9jZPM/d7n+XOW2cdRWso++obN/cn1V/J9yI6xck7pfiuj+a10Pb6KKKzKCiiigDyr4yf8lF+BP/AGOdz/6j2s16rXlXxk/5KL8Cf+xzuf8A1HtZr1WgAooooAKKKKACiiigAoorxGw8beMLX9reTwXf61a3fhabwnLrMFjb6esLRTC8SJd0hZmfCem0Esxx90K4+9JQ73/BN/kmEvdi59rfi0vzaPbqK8M+IHjrVNX+O1v8Nl8ZXfw5tpNDXV7DUdPgtHudVlErpNCjXcMsQWFFjZlVC580HcoXnJPx08V2/wALfBq3EVqnjDxZ4lfw5pV81uRDNbiebbqPlZPDWsJmC52ksv8ACaIpySa6u348v5/1uOXutp9NX93N+X+W9j6JorxbQ/iJf/DX4nX3gLxZ4guvEkB8PSeJLDXNQgt4rlo4Zdl1DILeKKI7N8LKVRThiDkjJ4mH4zeLdJ+D+gfHPVdYnbw7qklpcXPhP7JAttZ6ZdXCpHMsgj88zxxyxu5aQxttYCNcghxjzWa2dtfVtL8U18n0E9Lp7/8AAT/Jr711Pp+ikVgygg5B5FLUgFFFFABRRRQAUUUUAeVfGT/kovwJ/wCxzuf/AFHtZr1WvKvjJ/yUX4E/9jnc/wDqPazXqtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHiPgf/ho//haUn/CY/wDCrf8AhXHnXGz+w/7S/tfyvm8jPm/ud33N/b72O1e2Sf6tvoadWfr/AIe0rxZo13pGt6ZZ6xpN4nlXNhqECTwTJ/deNwVYexFTLWHKuwfabPEv2Ff+TY/C/wD186j/AOl9xXvtc14I+Gfg/wCGdnc2vg/wpofhS1uXEs8Gh6dDZpK4GAzLEqhjjjJrpa1nLmldExVgoooqCgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPKv2lv8AknWkf9jn4T/9SHTq9Vryr9pb/knWkf8AY5+E/wD1IdOr1WgAooooAKKKKACiiigAooooAKK8S+PHjjxd4H+IXwmi0jWLW20LxD4mh0e/sTYB5pI2gnlYiZmO0ZiUYCA8n5vT1bxV4kg8K6NLfTRvcSZEVvaw48y5mY4SJAf4mbA54HU4AJo+zzedvy/zQ3pJR8r/ACu1+jNeivnv9lP4yeKfiF8M/HfiHxp/p2paN4o1ewW00m13+XBbPtSCJUUNKRggEgsxP4V5r+zD8W/GPxq+Mt9c6r8ZtR0prMSXl78HNW8EQaVe2MTgrGv2mQtNLGjFcyLgsQM7A22nFczS7pS+TV1/S0XVkt2TfZtfNO39dT7Oor51T4ieM/iJo/j/AMb+Ftdk03SvCWoX9hpehpawSQa01mu2c3TyRtKoaZZETyXj2hQzb87R7T8PPG1j8SfAfh7xXpm7+z9asINQgDdQkqBwD7jOPwoSbjzej/8AAldffZ/qOXuvlfmvnF2f3X/yOhooopAFeVeHP+TpviH/ANiZ4Z/9Lter1WvKvDn/ACdN8Q/+xM8M/wDpdr1AHqtFFFABRRRQAUUUUAFFFFABRRRQAUV4F+1PqGueH9Q+Fuo6R4m1fSorrxrpOmXWn2cqRwXMEkrGRZMJvIbCgjfjC4xgtu2fjZ40vj8Q/hr8N9Nvp9Mk8WXV3NqF3ZymK4SwtIPMlSJwdyM7tEm9cMFZypBwQRXNG67tfck7+ln+AO0ZWfbm/Fq3roeyUV8y6n8aj+z/AK18W/DV7c3us6Z4T8KQ+LtIOqX0l3cmJhNHJbPNKxkkAlhUhpGZv3xBPApmratrfwV8K/Df4gan4h1bV9R1/U9L07xRDeahLLZSC9xGHt7ZnMVt5U0kZHkqu5VO/eeaqMeZq3WyXrJtJfemn2FL3U+bdXfySUn+DTXc+naK+b/D99qvx4ufih4gtvEWr6OvhnWbrQ/Dcel6hJbwRzWsQEk88SMEuC07ONkwdAsa4UEkn1L4CfE3/hcnwZ8HeNTCltNrOnRXM8MZysc2MSKD6Bww/ClFc0ebyi/lJXX4LXsN6O3m184uz/r1O+ooopAFFFFABXlXwb/5KL8dv+xztv8A1HtGr1WvKvg3/wAlF+O3/Y523/qPaNQB6rRRRQAUUUUAFFFFAHlXhz/k6b4h/wDYmeGf/S7Xq9Vryrw5/wAnTfEP/sTPDP8A6Xa9XqtABRRRQAUUUUAFFFFABRRRQB51/wAKB8Hf8LQHxDMeuHxYEMQuz4k1LyRETuMP2f7R5PlbgG8rZszztzzXRL8PPDy+MtS8V/2cDr2o6fHpV1dNLIRLaxs7pHsLbBhpHOQoJzyeldFXmXw2+M1x4++JHjvwhd+F7rw9c+FlsWaS7u4pmuBco7qQsRZVwqD+I8k9gCwldci2Sf3dfzBu15Prb/gfl+Ra+HvwA8D/AAujtYvD2mXkVvZvvsrW/wBWvL+CxO0r/o0dxLItv8rMv7oLwSOlbF/8LfDWreLo/Euo2U2p6nEUeBb+9nuLW2dBhZIbZ3MMMn+2iKx7k11E88drDJNNIsUUal3kc4VVAyST2FeAfCf9orx98X/HUX9k/Ce1X4VXEkptvHq+MLKfz4VUmNxZRK0is5x8jMCoPzYI2003KXmv63/Lv0B6Rb6H0HRXzh8YP2rPFnwvv7/VrL4L694l+GmjmQav4vttTtYmhWPiSSCyJMs8aHILnYPlYjIGT9AaBrll4n0LTtY02dbnTtQt47q2mXpJG6hlYfUEUl70eZbf1+fTuEvdlyv+v+G69upfooooAKKKKAPKvjJ/yUX4E/8AY53P/qPazXqteVfGT/kovwJ/7HO5/wDUe1mvVaACiiigAooooAKKKKACvlyb4meD2/4KCWumDxXoZ1JfBMmlmzGow+cLw3ySfZtm7Pm7AW8vG7HOMV9R0UR92pGfa/4xcf1FL3oSh3t+ElL9D5R/aYHgnxt8VU8GfGw2Hh74aroqX2h65qNytjG+rmV1kKXpI8qaKNUKR7huEjkhwo25s2h+L9U+Hvwv8YeILm88Rv8AD7xpLOdWmszHc6lo2JrUXrQrzuEcqyEgfMsZcDDCvsCinFuCVt07/NO+v/pO+3orVL3736q3yceV2/P117nzLqHhvTP2kPjdc+JtA1K21bwZYeCb7w/HrdhKJrW6ur6Rd6xSqdsgijhG4qSA0gGcggcJqEY8bfsk+HfgGksJ+I4t9N8O6roa7vPsYYJ41nu5E+8sHlQO6SnCPlApJYA/atFOL5UorbT8JSl+cn8vQTbb5uvTy0S/9tT9RkMSwQxxL91FCj6AYp9FFSJJJWQUUUUDCiiigAooooA8q+Mn/JRfgT/2Odz/AOo9rNeq15V8ZP8AkovwJ/7HO5/9R7Wa9VoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBsjCNGYgkKM4UZP4Cvl/xd8dPjd8NPF+i6/wCKvBHhZfhRrGq2ukpb6dfXEmv6ebmZYoZrgMohb5nXdHHuK7vvnGT9RV88+Kv2gPg94v8AG1tYav8AEzwdb2HhjUfObTJ9atftN5qUWQiiEvvKxMcgBdzShcfc+Zw/iR66rTyvr+Gi8wl8Evz87afjv5L1PoaikVtygjoeaWkAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeVftLf8k60j/sc/Cf8A6kOnV6rXlX7S3/JOtI/7HPwn/wCpDp1eq0AFFFFABRRRQAUUUUAFFFFAHy5+2L8SvCPhP4gfAq01zxToujXVr4yg1GeDUNRhgeK1+y3aee6uwKx7yF3n5cnGc16x498F+NvE3ivR9d8K+LPDemWVjbN5FrrXh2fUwJnyGnR4r+3AJjOwZViAXwfnIr0uihaRt5t/ekv0HJ8zTXZL7m3+v3Hxp+wrrOp+B/hn8Wtf8W69pbeHbDxnrktz9h0eeOWOZLjM024Ty5iPVYwm5e7vXq2p23hf45fEz4XeOfA2raZrn/CPXV1Nc+INJlW4iazktpYmtDMjbSWlaJthyV8okgd/daKpO3L/AHUl9yt+Pb5E2+K32nJ/e7/h3767nyZ4P1ez+A/w/wDid8ONSlj/AOErutW1m98N6Pk/adbivGaeH7MnWXa0pjfbnZsJbaOa92+Avw9l+E/wV8D+DriRZbnRNHtrKeRejSJGA5HtuzXe0Uk2o27qK/8AAU0vzd/0HL3pc3nJ/wDgTTf5afqFFFFIAryrw5/ydN8Q/wDsTPDP/pdr1eq15V4c/wCTpviH/wBiZ4Z/9LteoA9VooooAKKKKACiiigAooooAKKKKAPnD9sbV3j/AOFZWltoniTWJrLxhpus3J0Pw7f6kkNpDI3mu728LqCMj5Cdx7A10vxk8L3Nx43+GPxR0uwvNRHhaa6W+sre0d7x9Pu7fZIyQ48xnR1hcxgbyFcBS2FPtVFEbxjZb3b+9JW+5fn8iVpSu+3L+Ld/W7f4fP5m1T4KP8ftb+LfiS/tbzRdM8WeFIfCWjjU7N7W58kCaV7l4ZAJIwZZlASRVf8AcklRkUzV9H1r42eFfhz4B1Dw9q+k3vh/VdMv/FFxfafJBZxiyxKEt53UR3PmyxxgGFnCqTv2H5a+nKKqL5WrdLNesW2n97bfcUvevzbu6+TSi/wSS7Hzf4fsdV+A938T/Dtp4d1jWj4n1i817w3JpenST28ktzEplgnmUeXbFZ1c7p2RCrrtZiCB6l8BPhn/AMKb+DPg7wUZkuZtG06K2nmjGFkmxmRgPQuWP4131FKL5Y8vlFfKKaX4PXuN6y5vNv5yd3/XqFFFFIAooooAK8q+Df8AyUX47f8AY523/qPaNXqteVfBv/kovx2/7HO2/wDUe0agD1WiiigAooooAKKKKAPKvDn/ACdN8Q/+xM8M/wDpdr1eq15V4c/5Om+If/YmeGf/AEu16vVaACiiigAooooAKKKKACiiigArwD4Rf8nafHz/AK9/D/8A6TTV7/XnXg/4A+DvAvjrVfGGkR64viDVABfXF54k1K8juAAQoeGa4eM7ASE+X5AcLgUR0ld9n+gpaxsvI73UNPtdWsbiyvraG9srmNoZ7e4jEkcqMMMrKeGBBIIPBzXzZ/wz9oXwL/aD8CeIfhZpa+GLPxHcXOm+JfD2l4i0+4tltpZY7ryAQkbxSpGoZFGRNjvz7RN8HfCFxH4ySTRw6+MHWTXAbiX/AEthEsIP3/3eERR+729M9eaveC/h3ongGzS30pL6UonlLcatqd1qVyEznZ59zJJJsB6LuwOwpx92XN1/4Gq9P+H0Y5arl3X9Wfr/AFqYPxY04fEfRNT+HtpIy/2xbG31a6jP/HnZSfLJz2kkTcqDtkseFwe00G20+x0WytNJEK6ZbRLb2625BjREGwKuOMDbj8K8A8b/APBO/wCAHxI8V6n4l8T+B7jWtd1KYz3V9deIdTLyMf8At5wABgBQAAAAAAAK988N+HdO8I+H9N0PR7RLHSdNto7S0tYySsUSKFRRkk8AAcnNKPwa7/1+XT1ewS+JW2X/AAPz6+iNKiiigAooooA8q+Mn/JRfgT/2Odz/AOo9rNeq15V8ZP8AkovwJ/7HO5/9R7Wa9VoAKKKKACiiigAooooAiupHhtpZIomnkVCyxKQC5A4UEkAZ9zivk34kax+0J8F/Eeg+OtT8caF4t8LaprdlpV74Bs9AW2+xR3UyQq1rd72lnkQsCfM2qRuO0cAfWN3dwafazXV1NHb20KNJLNKwVEUDJZieAABnJr45f/goN+z342+IlnDd+ODfS6VqBg0TRrTSL6Y3t6cxLPvWExtncViG7aN+9jkrsdP+LG2rutO6vqreey69rahL+HK+is9fO2mvlv8Anc9o8QeL9c8ffGjVfh14d8QXXhS20DSLfVNU1awtrea5ea4lcW8CfaI5I1XZDKz5QsQ6BSvJrkY/2lNW1DwPpWlwR20PxAvfGUngV3aEmCK4hdzNdiPP3fs0ZmVCcZZVJxzVuS40z4J/tNeMvF/ijULXQfDXjXRNNSDVNQkEUCX1o0sbW7yE7Fd0miKKTlyHC5INeW2Hwl1bSdH0X4rXGnXMLJ8T7rxpc2LQSCeLS7hHsxIYvvhlhMczKRuA3AjIIp0+VuPN8Ol3586Vr9Fy83bRX8wqbScd+np7Nv5+/bvr7vkvcND+Il/8NfidfeAvFniC68SQHw9J4ksNc1CC3iuWjhl2XUMgt4oojs3wspVFOGIOSMniYfjN4t0n4P6B8c9V1idvDuqSWlxc+E/skC21npl1cKkcyyCPzzPHHLG7lpDG21gI1yCJdQ8N6Z+0h8brnxNoGpW2reDLDwTfeH49bsJRNa3V1fSLvWKVTtkEUcI3FSQGkAzkEDhNQjHjb9knw78A0lhPxHFvpvh3VdDXd59jDBPGs93In3lg8qB3SU4R8oFJLAGqeqjzfFdaeXPNP/yVQ17O/UJWu/5er7e7F6fNy07q3Sx9qKwZQQcg8ilpkMSwQxxL91FCj6AYp9ZiV7ahRRRQMKKKKACiiigDyr4yf8lF+BP/AGOdz/6j2s16rXlXxk/5KL8Cf+xzuf8A1HtZr1WgAooooAKKKKACiiigAooooAKKKKACiiigAooqhrkmpQ6TcPpENrcaiB+6S9laKHORksyqx4GTgDnGMjOQm+VXY1q7F+ivMP2a/ihq3xm+DeieLtbs7PT9TvpbpJbbTy5hj8q5liUKX+Y8IMk4ycnA6D0+rlFxdmSndXCiiipGFFFFABRRRQAyWJJ43jkRZI3BVkYZDA9QR3FeaWH7L/wa0u/t76y+EngWzvbeRZobm38N2SSRSKcq6sIshgQCCOQRXp1FC0d1uG6swooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPKv2lv+SdaR/2OfhP/wBSHTq9Vryr9pb/AJJ1pH/Y5+E//Uh06vVaACiiigAooooAKKKKACiiigDxL48eOPF3gf4hfCaLSNYtbbQvEPiaHR7+xNgHmkjaCeViJmY7RmJRgIDyfm9F/a2+K+s/Cn4X+foEeuW2p6lcpZDXNE8Ovrf9ixnJe8ltwQrKgGAGOCWHDY2niP2xfiV4R8J/ED4FWmueKdF0a6tfGUGozwahqMMDxWv2W7Tz3V2BWPeQu8/Lk4zmvcfGnxi8EfDm90a28U+J9N8PHWdwsJ9SnEFvcMu0lBM2I95DDClgzc7QcHC5eanp/M/yi7d++3nYuXuVE7fZT/Gevba34XPFfhL8XbrwX+y74l+Kuv8AxeHxz02G2m1K01K20O30cIiRgC18mIZEhk4O/wCYFgMDHPQN408YfCvUvh3qPjDxDJr9n4zv4NIv7H7HBDb6ReTQM8RtTGiyGIyIYyJnkYl1IZcFTynjL9neTxl8J/2gdM8MWsdhZ+OJvt+kWWwxRy3cdvFunwT8ommiHYAgbuQ2TN4213TP2jpfhH4e8O3CXl3pPiGx1/xFbKGEujLaRNJ5NyvWGVpWiQRyYYgswBCkjZNSmnbdwuu0X8XbZXu7X0TdmzKS5abs+k/m0vd/Hpez1WqWmunxE8Z/ETR/H/jfwtrsmm6V4S1C/sNL0NLWCSDWms12zm6eSNpVDTLIieS8e0KGbfnaPafh542sfiT4D8PeK9M3f2frVhBqEAbqElQOAfcZx+FfNvg/V7P4D/D/AOJ3w41KWP8A4Su61bWb3w3o+T9p1uK8Zp4fsydZdrSmN9udmwlto5r3b4C/D2X4T/BXwP4OuJFludE0e2sp5F6NIkYDke27NRG3Jfyhb1afN+NrrptoVP47LvP7k1y/hez6+Z3tFFFSAV5V4c/5Om+If/YmeGf/AEu16vVa8q8Of8nTfEP/ALEzwz/6Xa9QB6rRRRQAUUUUAFFFFABRRRQAUUUUAeBftT6hrnh/UPhbqOkeJtX0qK68a6Tpl1p9nKkcFzBJKxkWTCbyGwoI34wuMYLbtn42eNL4/EP4a/DfTb6fTJPFl1dzahd2cpiuEsLSDzJUicHcjO7RJvXDBWcqQcEcp+2Nq7x/8KytLbRPEmsTWXjDTdZuTofh2/1JIbSGRvNd3t4XUEZHyE7j2BrpfjJ4Xubjxv8ADH4o6XYXmojwtNdLfWVvaO94+n3dvskZIceYzo6wuYwN5CuApbCl07cnvbc7/wDSYW+XNe/TfzFO/tNN+Rffee3na1uu3kcfqfxqP7P+tfFvw1e3N7rOmeE/CkPi7SDql9Jd3JiYTRyWzzSsZJAJYVIaRmb98QTwKZq2ra38FfCvw3+IGp+IdW1fUdf1PS9O8UQ3moSy2UgvcRh7e2ZzFbeVNJGR5KruVTv3nmpNU+Cj/H7W/i34kv7W80XTPFnhSHwlo41Oze1ufJAmle5eGQCSMGWZQEkVX/cklRkUzV9H1r42eFfhz4B1Dw9q+k3vh/VdMv8AxRcX2nyQWcYssShLed1Edz5sscYBhZwqk79h+Wrp/FHn3vC/+HmfN/5Lbm63t1FPaXJtaX38sbf+Tc3L/wAMXPD99qvx4ufih4gtvEWr6OvhnWbrQ/Dcel6hJbwRzWsQEk88SMEuC07ONkwdAsa4UEkn1L4CfE3/AIXJ8GfB3jUwpbTazp0VzPDGcrHNjEig+gcMPwry3w/Y6r8B7v4n+HbTw7rGtHxPrF5r3huTS9Oknt5JbmJTLBPMo8u2Kzq53TsiFXXazEED1L4CfDP/AIU38GfB3gozJczaNp0VtPNGMLJNjMjAehcsfxqYW9nr2h9/K+f8bX+Q5/H852/w3XL+G3z6nfUUUVIwooooAK8q+Df/ACUX47f9jnbf+o9o1eq15V8G/wDkovx2/wCxztv/AFHtGoA9VooooAKKKKACiiigDyrw5/ydN8Q/+xM8M/8Apdr1eq15V4c/5Om+If8A2Jnhn/0u16vVaACiiigAooooAKKKKACiiigDzHT/AIzXF38e5/hpc+F7rTtmiSa3Fq1xdxMs8a3CwALGhYjJJbLEEDbxkkL6dXgE/wDyfhZ/9k7l/wDTile/0460oS6vm/Ccl+SQn/FnHorfjCL/ADbPnnUv2kfHOufFm68M/Dn4V2fjzwxpt/HpureKR4ysrMWE4YCcNaFXmIiDDPALEEAdCfSPiV428V+FdPvb7w14QtvEcGmp596L7Vjp7PGELsLb9xIssgAHDmJMnG/IbHjfxy/Zr8K+CtW0f4o/DfRLfwf8RLDWbMGTQYltk1iK4uo47i2uYlKpIJFZmLEbgRuz1r1f4+fDHXPip4FutK0Hx1qnge7EbsJbGC2mguTjiO5WWNmaLjBVGTcCQSRxWcm40U/tK9/uT+7Xbfpro3qknV/uv/g/j57emqOw8EeLbPx94N0LxNpyTR2GsWMN/brcJskWOVA6hl7HDDNbdec/s6+MtV+IHwP8F+INb0+DS9VvtNje4trRdsAYfLujHaNtoZR/dYVy3ir4sfGbSfiyugaL8B/7f8EG6t4j4w/4TCytsQuE82b7GyeZ+73P8ucts46iuipFe1cI99P+H/zsYU+b2alLdLX/AIb/ACPb6KKKyLCiiigDyr4yf8lF+BP/AGOdz/6j2s16rXlXxk/5KL8Cf+xzuf8A1HtZr1WgAooooAKKKKACiiigAoqK6keG2lkiiaeRULLEpALkDhQSQBn3OK+TfiRrH7QnwX8R6D461PxxoXi3wtqmt2WlXvgGz0Bbb7FHdTJCrWt3vaWeRCwJ8zapG47RwA4+9NQ7tL5vRfe/u62B6Rcu1392r/r7j63orxL9rPxx4u+Gvw1g8ReFdYtdMeHVNPtLiOawFw8qT3kMDbWZtqYWRuqNzjpXU/H74i6h8K/hNr3iHSNG1bXtVgiEdraaLpj6hOJHIUS+ShBZEzvbJUYUjcM5qG7Qc/O3z0/zRSjeSj3PRKK+Xv2QvHmreJPB/ijxjrvx8f4u6TZhopLOXwnbaDNo0sO5plniT95vIAwGwMAkZzkOh+M3i3Sfg/oHxz1XWJ28O6pJaXFz4T+yQLbWemXVwqRzLII/PM8ccsbuWkMbbWAjXII15Hzcvp8ubb77enmZ811defztv9333Pp+ikVgygg5B5FLUFBRRRQAUUUUAFFFFAHlXxk/5KL8Cf8Asc7n/wBR7Wa9Vryr4yf8lF+BP/Y53P8A6j2s16rQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4j4H/4aP/4WlJ/wmP8Awq3/AIVx51xs/sP+0v7X8r5vIz5v7nd9zf2+9jtXtkn+rb6GnVn6/wCHtK8WaNd6RremWesaTeJ5VzYahAk8Eyf3XjcFWHsRUy1hyrsH2mzxL9hX/k2Pwv8A9fOo/wDpfcV77XNeCPhn4P8AhnZ3Nr4P8KaH4UtblxLPBoenQ2aSuBgMyxKoY44ya6WtZy5pXRMVYKKKKgoKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyr9pb/AJJ1pH/Y5+E//Uh06vVa8q/aW/5J1pH/AGOfhP8A9SHTq9VoAKKKKACiiigAooooAKKKKACivEvjx448XeB/iF8JotI1i1ttC8Q+JodHv7E2AeaSNoJ5WImZjtGYlGAgPJ+b06D47fGaH4Q6HpaW8drdeI9du/7P0m1vrgW9v5m0vJNPKfuQxRq0jt1wuBywpfZ5vO3z0/zQ7NS5fK/y1/yZ6bRXl3wr1yabwZqHi6f4jp8U7WaDzQfDdtayWETxIfMSyW3V5XLMD8sk0rZAAxznwL9mH4t+MfjV8Zb651X4zajpTWYkvL34Oat4Ig0q9sYnBWNftMhaaWNGK5kXBYgZ2BttXy3nydlf+uv4W7kt2hz+dj7Oor51T4ieM/iJo/j/AMb+Ftdk03SvCWoX9hpehpawSQa01mu2c3TyRtKoaZZETyXj2hQzb87R7T8PPG1j8SfAfh7xXpm7+z9asINQgDdQkqBwD7jOPwpJNx5vR/8AgSuvvs/1HL3XyvzXzi7P7r/5HQ0UUUgCvKvDn/J03xD/AOxM8M/+l2vV6rXlXhz/AJOm+If/AGJnhn/0u16gD1WiiigAooooAKKKKACiiigAooooAKK8C/an1DXPD+ofC3UdI8TavpUV1410nTLrT7OVI4LmCSVjIsmE3kNhQRvxhcYwW3ep/FCzu7zwBrv2HWL7Q7qKzmmjvNOMYmVljYjBdGA5wenb61EpKNKVXs2vuSf6lRjzVFT7pP721+h1VFeSfsveItV8Qfsv/DjXNSnutd1m68N2l1PNPNvnupjCGJZ3PLMe7Hvya+cPgfqGqa5+01bH4raz8Yfh98Qbx7jUbDwbqXiOOXwnqKKHHlWot12P5SbXMZfORuJfknolTcK8qL6X/Dt32/zM1JSpe1X9f5H3VRXzf4fvtV+PFz8UPEFt4i1fR18M6zdaH4bj0vUJLeCOa1iAknniRglwWnZxsmDoFjXCgkk+pfAT4m/8Lk+DPg7xqYUtptZ06K5nhjOVjmxiRQfQOGH4VnFc0ebyi/lJXX4LXsU9Hbza+cXZ/wBep31FFFIAooooAK8q+Df/ACUX47f9jnbf+o9o1eq15V8G/wDkovx2/wCxztv/AFHtGoA9VooooAKKKKACiiigDyrw5/ydN8Q/+xM8M/8Apdr1eq15V4c/5Om+If8A2Jnhn/0u16vVaACiiigAooooAKKKKACiiigDzr/hQPg7/haA+IZj1w+LAhiF2fEmpeSIidxh+z/aPJ8rcA3lbNmeduea6SH4f6BB421DxclhjxDf2EWmXN550h8y2jd3SPYW2DDSOchQTnk8CugrzL4bfGa48ffEjx34Qu/C914eufCy2LNJd3cUzXAuUd1IWIsq4VB/EeSewBYW3Kuif/B/MG95Pra/6fl+RreA/gv4T+GoC6DZ30UMbl7e3vtWu76GzyCCLeOeV1t1wSNsQUYOMYqnqnwB8Eav441DxbcadfLrOpRrDfi31i9gtL5FTy1FxapMIJvk+X95G3AHoK9DJCgknAFeYeF/jDqXxI1xW8F+GV1TwfDdtbXPijUr/wCxwThSVkayjWKR7jaw27m8pGIO1yBmnvLzDZN/13PTIII7WGOGGNYYY1CJHGoVVUDAAA6ACpK878dfF4eH/FNt4Q8O6LceLfGlxbG8/sy3mWCCzt+Qs93OwIhjZxtXCu7HO1GCsR22hzalcaPaSaxaWthqjRg3NtY3TXMEcndUlaONnA/vFFJ9BRq1zf1/X6hbl0L1FFFIAooooA8q+Mn/ACUX4E/9jnc/+o9rNeq15V8ZP+Si/An/ALHO5/8AUe1mvVaACiiigAooooAKKKKAIbu7g0+1murqaO3toUaSWaVgqIoGSzE8AADOTXxy/wDwUG/Z78bfESzhu/HBvpdK1AwaJo1ppF9Mb29OYln3rCY2zuKxDdtG/exyV2fZlFEdJJvb+v628wfwtLf+v63PmX/goB428P8Ahv4ERWms65puj3l9rWky21rf3kUMsyxajbPKUVmBYIvzMRkKOTxXsvib40eBfBvhbSPE2s+K9LsfDOqyRx2euPcA2EnmKWRjcDMaowHDswUkgZyQD2tFNaRcfO/4JfoPt6W/M8HtPhbpXjn4ifEbxNoRgi0Dxd4Yh0a5vbUfutSuP34FwrA4cJFKi+YvDbsZO3jyLUIx42/ZJ8O/ANJYT8Rxb6b4d1XQ13efYwwTxrPdyJ95YPKgd0lOEfKBSSwB+1aKcXy6LbT/AMlba+XvP5aK1gbbfN9r/gJf+2r7vMZDEsEMcS/dRQo+gGKfRRUkpJKyCiiigYUUUUAFFFFAHlXxk/5KL8Cf+xzuf/Ue1mvVa8q+Mn/JRfgT/wBjnc/+o9rNeq0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA2RhGjMQSFGcKMn8BXy/4u+Onxu+Gni/Rdf8VeCPCy/CjWNVtdJS306+uJNf083MyxQzXAZRC3zOu6OPcV3ffOMn6ir558VftAfB7xf42trDV/iZ4Ot7DwxqPnNpk+tWv2m81KLIRRCX3lYmOQAu5pQuPufM4fxI9dVp5X1/DReYS+CX5+dtPx38l6n0NRSK25QR0PNLSAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPKv2lv+SdaR/wBjn4T/APUh06vVa8q/aW/5J1pH/Y5+E/8A1IdOr1WgAooooAKKKKACiiigAooooA+XP2xfiV4R8J/ED4FWmueKdF0a6tfGUGozwahqMMDxWv2W7Tz3V2BWPeQu8/Lk4zmtv47Wsfh347fCP4m6q6N4H0e31Ow1G+cboNNe5jjaG8lbokWYShlOAu9SSBkj6IopxfKl3Tb+9KP5de45e8/LlS+5t3+9nzN8Lr/RdB+L3xl+Kml30EXwqvtP06ZtQsI3ltb29iSQ3N5D5akSqI2hUyR5DFSMkoa6TU7bwv8AHL4mfC7xz4G1bTNc/wCEeurqa58QaTKtxE1nJbSxNaGZG2ktK0TbDkr5RJA7+60U72tbpt/X9aaE66+e/wB1v6ffXc+TPB+r2fwH+H/xO+HGpSx/8JXdatrN74b0fJ+063FeM08P2ZOsu1pTG+3OzYS20c17t8Bfh7L8J/gr4H8HXEiy3OiaPbWU8i9GkSMByPbdmu9opJtRt3UV/wCAppfm7/oOXvS5vOT/APAmm/y0/UKKKKQBXlXhz/k6b4h/9iZ4Z/8AS7Xq9Vryrw5/ydN8Q/8AsTPDP/pdr1AHqtFFFABRRRQAUUUUAFFFFABRRRQB84ftjau8f/CsrS20TxJrE1l4w03Wbk6H4dv9SSG0hkbzXd7eF1BGR8hO49ga9c+J/iS30z4X61qLWmq3cdxYPHFb6fpN1eXbNKhVB9nhjaXOWGfk+XktjBrs6KiUealKk+rb+9Jfkl8ylLlqxqLokvubf5t/geD/ALKmtXPh39kvwYl14d8RRar4d0CC0vNFutHuLK+a4hgXfFFFcrH5hJ4VgdjHo3Wta+Wy+PmoeAtXsNJ1rS7bw9rA1iS417RrjTLmJlglj8hI7mNJCWMo3Mo2bVb5jkA+xUV0VKjqVXVe7d/ne/5/0zKMeWCguzXyat+R83+H7HVfgPd/E/w7aeHdY1o+J9YvNe8NyaXp0k9vJLcxKZYJ5lHl2xWdXO6dkQq67WYggepfAT4Z/wDCm/gz4O8FGZLmbRtOitp5oxhZJsZkYD0Llj+Nd9RWcXyx5fKK+UU0vwevct6y5vNv5yd3/XqFFFFIAooooAK8q+Df/JRfjt/2Odt/6j2jV6rXlXwb/wCSi/Hb/sc7b/1HtGoA9VooooAKKKKACiiigDyrw5/ydN8Q/wDsTPDP/pdr1eq15V4c/wCTpviH/wBiZ4Z/9Lter1WgAooooAKKKKACiiigAooooAK8A+EX/J2nx8/69/D/AP6TTV7/AF514P8AgD4O8C+OtV8YaRHri+INUAF9cXniTUryO4ABCh4Zrh4zsBIT5fkBwuBRHSV32f6ClrGy8jH/AGutQ1zSv2Y/ibdeHBL/AGxHoV0YTACZFBQh2XHO4IWIx3FeV+ItDn+Ctn8Dtc+HOta1cWWqappfh+60GXU5rvT73T5oCC8cDsY4GiRPM3wqmQrbsgk19H6F8P8Aw/4b1nxJqunaesF/4juEutVkaV5BcyJEsSkqzFV+RFXCgA4yRnmsTwj8C/BPgXWI9S0XSJLea3BWzt5r+5ntdPBBDCzt5JGitQQSCIETIODVQtGV33i/uvdeju1fzbsOfvR5V2kv/ArWfqrX/VHz78M/h7J8SNU/aE1DWNf8QeGfF8HjC4ihvNF1eeye0ggtIvsLlI3Cyx+W4fy5Q8bbjleTXt37L/jjX/iV+z74D8T+KIvK17U9LinuiE2CVjkCUL2DgB8Dj5uK1vFvwR8GeNteOs6rpcx1GSJYLqSy1C5s1voVztiu0hkRbqMbmwkwdRubjk121vbxWdvFb28SQQRKEjijUKqKBgAAcAAdqUXyw5X2iv8AwFWb/wC3tG/TqEvenzecn97vb0XT/hyWiiikAUUUUAeVfGT/AJKL8Cf+xzuf/Ue1mvVa8q+Mn/JRfgT/ANjnc/8AqPazXqtABRRRQAUUUUAFFFFAEV1I8NtLJFE08ioWWJSAXIHCgkgDPucV8m/EjWP2hPgv4j0Hx1qfjjQvFvhbVNbstKvfANnoC232KO6mSFWtbve0s8iFgT5m1SNx2jgD6xu7uDT7Wa6upo7e2hRpJZpWCoigZLMTwAAM5NfHL/8ABQb9nvxt8RLOG78cG+l0rUDBomjWmkX0xvb05iWfesJjbO4rEN20b97HJXY6f8WNtXdad1fVW89l17W1CX8OV9FZ6+dtNfLf87n0T8W7XWToN/qFv49l+H9nYxCaK8tLe0m81wD8s4uYpFMZO0BY9jnHDjOBxes/GHxhovwj+Fy6pp9vpHxK8bXNjpLWzxMYrK4kjMtzKYyc/u4o5WCE/eCqT1NT/GbxH8CviFrE3wz+J0vh6+1qO2W9g0TXoQLnEisA9oXGXkwrj9wS4wRXl8Pwy8VeGfgz8DNd197/AFO88AeIf7QuhdI8l4ukyfaLdGlUZYyRQTQs4wSPLfuKIW+1s5R+67T16efkr6WCT7b8svvteOnX/gpdT1fQ/iJf/DX4nX3gLxZ4guvEkB8PSeJLDXNQgt4rlo4Zdl1DILeKKI7N8LKVRThiDkjJ4mH4zeLdJ+D+gfHPVdYnbw7qklpcXPhP7JAttZ6ZdXCpHMsgj88zxxyxu5aQxttYCNcgiXUPDemftIfG658TaBqVtq3gyw8E33h+PW7CUTWt1dX0i71ilU7ZBFHCNxUkBpAM5BA4TUIx42/ZJ8O/ANJYT8Rxb6b4d1XQ13efYwwTxrPdyJ95YPKgd0lOEfKBSSwBunqo83xXWnlzzT/8lUNezv1CVrv+Xq+3uxenzctO6t0sfaisGUEHIPIpaZDEsEMcS/dRQo+gGKfWYle2oUUUUDCiiigAooooA8q+Mn/JRfgT/wBjnc/+o9rNeq15V8ZP+Si/An/sc7n/ANR7Wa9VoAKKKKACiiigAooooAKKKKACiiigAooooAKKKoa5JqUOk3D6RDa3GogfukvZWihzkZLMqseBk4A5xjIzkJvlV2NauxforzD9mv4oat8Zvg3oni7W7Oz0/U76W6SW208uYY/KuZYlCl/mPCDJOMnJwOg9Pq5RcXZkp3VwoooqRhRRRQAUUUUAMliSeN45EWSNwVZGGQwPUEdxXmlh+y/8GtLv7e+svhJ4Fs723kWaG5t/DdkkkUinKurCLIYEAgjkEV6dRQtHdbhurMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyr9pb/knWkf9jn4T/8AUh06vVa8q/aW/wCSdaR/2OfhP/1IdOr1WgAooooAKKKKACiiigAooooA8S+PHjjxd4H+IXwmi0jWLW20LxD4mh0e/sTYB5pI2gnlYiZmO0ZiUYCA8n5vS38eviNe+EvEPgDw8mvN4N0zxTqE2nz+Jkhhke1lEJeCCPz1eFJJWBCtIjj5Cu0lgR59+2L8SvCPhP4gfAq01zxToujXVr4yg1GeDUNRhgeK1+y3aee6uwKx7yF3n5cnGc10H7VGuaXNJ4H0DxlZWcvwf165uE8T6teoGtYFSHfapLJ0gjeTB87IAKKNy7qS/h3/ALz/ACjpf77efToXJWml/cv87z1t6W7eq3LEPxi1b4X+AvizrXie8m8V6N4ILfYNakgign1Pbbo7xP5SrE0izExF40RcnbtDI1I3jTxh8K9S+Heo+MPEMmv2fjO/g0i/sfscENvpF5NAzxG1MaLIYjIhjImeRiXUhlwVPlmm/Cq/8d/s8/F/4WeDtdbxd4AWwiXwPq88oljyUMgskuAf9IiieOILLk8SbSSUNdd4213TP2jpfhH4e8O3CXl3pPiGx1/xFbKGEujLaRNJ5NyvWGVpWiQRyYYgswBCkjZJc6XnC/8Ah+07d7Xvvay1fXKXwNrtP70vd/Hba+ummmunxE8Z/ETR/H/jfwtrsmm6V4S1C/sNL0NLWCSDWms12zm6eSNpVDTLIieS8e0KGbfnaPafh542sfiT4D8PeK9M3f2frVhBqEAbqElQOAfcZx+FfNvg/V7P4D/D/wCJ3w41KWP/AISu61bWb3w3o+T9p1uK8Zp4fsydZdrSmN9udmwlto5r3b4C/D2X4T/BXwP4OuJFludE0e2sp5F6NIkYDke27NRG3Jfyhb1afN+NrrptoVP47LvP7k1y/hez6+Z3tFFFSAV5V4c/5Om+If8A2Jnhn/0u16vVa8q8Of8AJ03xD/7Ezwz/AOl2vUAeq0UUUAFFFFABRRRQAUUUUAFFFFAHiP7SHjbxh4B1L4c3Oga1a2Ol6t4s0zRr+0fT1llmhmkbzMSsxC5CqOEyMtzkgr6h4u07VNW0822n65J4bhZHM+qWqQvcw8fKYhNHJEDnks6MMLjac5X5/wD23fiF4W8Jj4TWmueJdH0a6XxzpOoGDUL+KBxbRyN5k+12B8tcjc/QZ5Neo/F74n/CjQtF0zSPiVq+gReHvFCslsPECI+mXqqFfa8sgMPIKsodhuxlc4OFH3qTtvztL/wGGn33/EH/ABkunKn/AOTTu/ut+BzXgX4ra14R+D3j3xV431AeINH8Lz3sun+II4Y4ZNY0+GJXWcpEBHuL+ZHujVUfYGVQDiskfELxl8OtH+H/AI18Xa9JqOn+Lr+w07U9D+ywR2ujPeLiE2zpGszBZWjR/OeTduLLs+7XH+F/2djqHwh+PvgPwmZNP8AeJGmi8J2cxYQWzyWqicwBjkW7XGSuMLwxX5SCZ/F2sWX7QHgL4Y/D/SZkfxLZ6zo974l0tSTcaHHZlZ5hdJ1hLPEI03437wV3DmtoWc43/wCnd/R/G/8AN9Olrky0i7f9PPvVnD9bLrtrY7WDxt4w+Kmo/ETU/CniF9B03wbqM2k6fZR2cE0Wr3cEIef7S0iM4i8xxGFhaNgY2JY5AHp3wk+Iln8W/hj4Y8Z2ETW9rrmnw3qwOctEXUFkPurZX8K8K8Da5pn7Or/Fvwrr1wltqWreINQ1/wAOWJyZ9aju4ll8u1TrNIsokRkTLKArEAMCfVf2ZPhtefCH4A+BfCGo7RqWmaZGl2qNuVZ2y8qg9wHZh+FRD+Hd9ofe4vm/G1108rlT0nZd5/cmuV/d9+vY9OoooqQCiiigAryr4N/8lF+O3/Y523/qPaNXqteVfBv/AJKL8dv+xztv/Ue0agD1WiiigAooooAKKKKAPKvDn/J03xD/AOxM8M/+l2vV6rXlXhz/AJOm+If/AGJnhn/0u16vVaACiiigAooooAKKKKACiiigDzHT/jNcXfx7n+Glz4XutO2aJJrcWrXF3EyzxrcLAAsaFiMklssQQNvGSQvp1eAT/wDJ+Fn/ANk7l/8ATile7alJcR6ddPaoHulicxKehfB2j88UnLloRqPe0vwnJfkkFr1pQW3u/jGL/Ns831j4yajqni7U/C/gDw0vi7VdJZY9Uvry/wD7P0uxlO0+RJcCOV2m2Nv2RxPgY3lNwzy3xY+Nfxg8L+MptI+HvwFm+I+lW0EZudYfxVaaRGtwwLNFGk6EyBVKEuvGWI6qa+f/AAno+qeF/wBhKz+Kfh/xH4g0v4i6THd61cxQ6lObW71E3bm6tbmy3eTKXk3x/MhkUkbWBAr7G8c+KL/SfhlNqEMX2XXby3htrSB8nZeXBWKJT7CSRc+wNXODirLVp29X5eXbr38yMk5eT28rPr5/8HtpX+B/j/Xvid8N9P8AEXiXwovgvVrmWeOTRl1JNQ8kRyvGD56Iqvu2bgVBGCME13lZnhnQbbwr4d0vRrJdtpp9tHaxA9dqKFGffivI/FXxY+M2k/FldA0X4D/2/wCCDdW8R8Yf8JhZW2IXCebN9jZPM/d7n+XOW2cdRTlaVTlj1+78dvmyY35OZ/1/n8j2+iiioKCiiigDyr4yf8lF+BP/AGOdz/6j2s16rXlXxk/5KL8Cf+xzuf8A1HtZr1WgAooooAKKKKACiiigAoqK6keG2lkiiaeRULLEpALkDhQSQBn3OK+TfiRrH7QnwX8R6D461PxxoXi3wtqmt2WlXvgGz0Bbb7FHdTJCrWt3vaWeRCwJ8zapG47RwA4+9NQ7tL5vRfe/u62B6Rcu1392r/r7j63or5b/AG1fjprnwzXw/ouk+Jdb+Gdle7rrUPiDbeDm16x05FIVIJQ2I0MhLEt8xUR/d+bcOjuviF4h+Hvwj+HOmr46t/iT4w8Zapb6XYeLW0+C3t51m3zPcrBB8myO3RyqgncVXLHJpRvNXXdL5vT5a97d9tQl7rs+zfolr+Xa59A0V4tofxEv/hr8Tr7wF4s8QXXiSA+HpPElhrmoQW8Vy0cMuy6hkFvFFEdm+FlKopwxByRk8TD8ZvFuk/B/QPjnqusTt4d1SS0uLnwn9kgW2s9MurhUjmWQR+eZ445Y3ctIY22sBGuQRUY81mtnbX1bS/FNfJ9Ael09/wDgJ/k1966n0/RSKwZQQcg8ilqQCiiigAooooAKKKKAPKvjJ/yUX4E/9jnc/wDqPazXqteVfGT/AJKL8Cf+xzuf/Ue1mvVaACiiigAooooAKKKKACiiigAooooAKKKKAPEfA/8Aw0f/AMLSk/4TH/hVv/CuPOuNn9h/2l/a/lfN5GfN/c7vub+33sdq9sk/1bfQ06s/X/D2leLNGu9I1vTLPWNJvE8q5sNQgSeCZP7rxuCrD2IqZaw5V2D7TZ4l+wr/AMmx+F/+vnUf/S+4r32ua8EfDPwf8M7O5tfB/hTQ/ClrcuJZ4ND06GzSVwMBmWJVDHHGTXS1rOXNK6JirBRRRUFBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeVftLf8k60j/sc/Cf/AKkOnV6rXlX7S3/JOtI/7HPwn/6kOnV6rQAUUUUAFFFFABRRRQAUUUUAFFeJfHjxx4u8D/EL4TRaRrFrbaF4h8TQ6Pf2JsA80kbQTysRMzHaMxKMBAeT83pd+KHxA1Sb4teD/hdoeqTeHb3XtPvtVutbtoIpp7e3t/LQJAsyvGJGeZTudHUKjDaSQQK8lp3a+5cz/DUb912fZP720vxVj2CivFvhp8U9W0/xZ8R/Avie4n8R6r4Lgtr+HU7a1X7XqdlcRO8ZeCFQpnDRSIRGqq2FKqudo8a/Zh+LfjH41fGW+udV+M2o6U1mJLy9+DmreCINKvbGJwVjX7TIWmljRiuZFwWIGdgbbVRXNLlXa/8AXX8NOtiZe6m33t/XTt959nUV86p8RPGfxE0fx/438La7JpuleEtQv7DS9DS1gkg1prNds5unkjaVQ0yyInkvHtChm352j2n4eeNrH4k+A/D3ivTN39n61YQahAG6hJUDgH3GcfhSSbjzej/8CV199n+o5e6+V+a+cXZ/df8AyOhooopAFeVeHP8Ak6b4h/8AYmeGf/S7Xq9Vryrw5/ydN8Q/+xM8M/8Apdr1AHqtFFFABRRRQAUUUUAFFFFABRRRQAUVwPxI+NGh/C3VvDenavZ6vNNr+pW2lWs1nYPJAs87lYxJMcIo+ViRuyAvTLKD0XirxOfDdmGt9Kvtf1GRXa30vTPKE8+0ZbBmkjjUdBud1XLKM5IBOnN02+en+aDry9d/lr/kzcori/hx8V9H+JWhalqFtBe6NPpN1JY6rpusRrDc6fcRqrPHLtZk4VlYMjMhDAhiOax/Cvx70XxVqmlQpperabpGuHboOvX8cKWWsHY0mINsrSqSiMy+dHHvAym4c07O9v612+/p36B0b7fpv93XsemUV5x4q+OWk+Gda1Wwi0jWNdi0RFl12+0mGKSDSEZDIDNvkV3OwbikKyOFZSVAYE+gWN9b6lZwXdpNHc2txGssU0TBkkRhlWBHUEEGlurg9HYnooooAKKKKACvKvg3/wAlF+O3/Y523/qPaNXqteVfBv8A5KL8dv8Asc7b/wBR7RqAPVaKKKACiiigAooooA8q8Of8nTfEP/sTPDP/AKXa9XqteVeHP+TpviH/ANiZ4Z/9Lter1WgAooooAKKKKACiiigAooooA86/4UD4O/4WgPiGY9cPiwIYhdnxJqXkiIncYfs/2jyfK3AN5WzZnnbnmultvAehWfjm+8Yw2OzxHe2MWm3F750h328Tu8abC2wYaRzkKCc8k4Fb9eZfDb4zXHj74keO/CF34XuvD1z4WWxZpLu7ima4FyjupCxFlXCoP4jyT2ALOP8AKun9P8wfWT62v+n5fkX5PgP4Hk8Uy6+dGcXctyL2W0W+uBp8t0GDC5eyEn2dpwwU+cYy+VB3cCuw1TQ7LWpbCS8h85rG4F3b/OwCyhWUMQDhsBzgNkZweoBFLxt4gufCvhHVtWstKuNdvrS3eS20u1IWW7mx+7hUnhSzYXceBnJ4FeBeEP2ivjlfePvC+h+MP2cV8F6TrV6bRtYbx1ZX3kYieVm8mGIs2Fjb0GcZIzSjq1BdPu/y6fkEtE5vz/4Pn/mfTNFeQax8bdduNW8VDwl4Ss/EOj+ErhrXW7m81n7Fc+asCTvHaw+RIsrBJF/1skKkkAMRkj0nwn4msfGvhbR/EGmM76dqtnDfWzSLtYxyIHXI7HDDimtVzLbT8dvv6dxNpPl66/hv93Xsa1FFFIYUUUUAeVfGT/kovwJ/7HO5/wDUe1mvVa8q+Mn/ACUX4E/9jnc/+o9rNeq0AFFFFABRRRQAUUUUAQ3d3Bp9rNdXU0dvbQo0ks0rBURQMlmJ4AAGcmvjl/8AgoN+z342+IlnDd+ODfS6VqBg0TRrTSL6Y3t6cxLPvWExtncViG7aN+9jkrs+zKKI6STe39f1t5g/haW/9f1ucJ4i+MXgHSfE7eDNf8QabY6/dWgmTRNRYJLeROGysKN/rzhWBSPcR3HIz8/XXwSvvhr8NfhRqsVpKLDwN4zudc/syOJmex0i6lukEYQEkmCK5jYgZwI2A6V9eUU4txs1vdP7ndf167XB6pxezT9dU0/z/LsfMuoeG9M/aQ+N1z4m0DUrbVvBlh4JvvD8et2Eomtbq6vpF3rFKp2yCKOEbipIDSAZyCBwmoRjxt+yT4d+AaSwn4ji303w7quhru8+xhgnjWe7kT7yweVA7pKcI+UCklgD9q0U4vlSittPwlKX5yfy9AbbfN16eWiX/tqfqMhiWCGOJfuooUfQDFPooqRJJKyCiiigYUUUUAFFFFAHlXxk/wCSi/An/sc7n/1HtZr1WvKvjJ/yUX4E/wDY53P/AKj2s16rQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADZGEaMxBIUZwoyfwFfL/AIu+Onxu+Gni/Rdf8VeCPCy/CjWNVtdJS306+uJNf083MyxQzXAZRC3zOu6OPcV3ffOMn6ir558VftAfB7xf42trDV/iZ4Ot7DwxqPnNpk+tWv2m81KLIRRCX3lYmOQAu5pQuPufM4fxI9dVp5X1/DReYS+CX5+dtPx38l6n0NRSK25QR0PNLSAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPKv2lv8AknWkf9jn4T/9SHTq9Vryr9pb/knWkf8AY5+E/wD1IdOr1WgAooooAKKKKACiiigAooooA+XP2xfiV4R8J/ED4FWmueKdF0a6tfGUGozwahqMMDxWv2W7Tz3V2BWPeQu8/Lk4zmu2/aCsfh5eX3hPWNe8X3XhPxjp5nuPDd94fnjfV5lKL58VtatHKLtWXbuj8mQfdOAcGvbaKFpG3m3+CX6FNpyT8rfi3+p4H8JfDknw3j+Inxb8etdabe660c0q3q+ddWOmWsZWBZhCCPMO6SV1jXapk2gfLmp9TtvC/wAcviZ8LvHPgbVtM1z/AIR66uprnxBpMq3ETWcltLE1oZkbaS0rRNsOSvlEkDv7rRVc2qfbb7rf18+5HR+d7/P+tO2nY+TPB+r2fwH+H/xO+HGpSx/8JXdatrN74b0fJ+063FeM08P2ZOsu1pTG+3OzYS20c17t8Bfh7L8J/gr4H8HXEiy3OiaPbWU8i9GkSMByPbdmu9opJtRt3UV/4Cml+bv+g5e9Lm85P/wJpv8ALT9QooopAFeVeHP+TpviH/2Jnhn/ANLter1WvKvDn/J03xD/AOxM8M/+l2vUAeq0UUUAFFFFABRRRQAUUUUAFFFFAHgH7X3/AB5fCX/somi/+jHr2vxRa6zeaBeweH9Qs9K1l48W15qFk15BE2fvNCssRfjPAdecdeh4T4zfApPjRP4fe58aeJPDUOiX0OqW1voa2Gw3cTFopnNxazMSuT8oIU55U1qeOvhhe+M20Ga08feLPCd/pO7/AEvQp7Vftm5VB+0QzW8sEnKgj92NpJ24BIoj/DcH1k38nGK/9tB/xFJdIpfNOT/9uX4nzHcat40tf2af2l/COsafaL8RNCgvZb3WtGSRIda+02YlS6VSSUk8rCGMEhfLAHGBXZ/H/wD5ID8Gv+Ef2/bP+El8L/2X5Of+e0WduO3k+Zn/AGc19C+HfA+leGrPUYYYmupdTma41C6vCJJbyRlCFpDjB+VVUKAFCqFAAAFcp4W+A2i+F9U0uf8AtXWNW0zRWL6FouozRPZ6MSjJ+42xrI+EZlUzPIUBITaOKuMuWUW+jpv/AMA3Xz6dFrotiZLmi0v7/wD5Pb8ra63fd7nm/wCzXu/4R748f25s+3/8JvrX27fn/VeVH5Oc9vs/lY9sV0f7En9of8Mm/C3+0932n+xIdm7OfJ58nrz/AKvZXUeKvgbpPifXNTv01jWtEt9ajEWu6bpM8cVvq6hPLXzi0bSI2zCl4HidlChmIUAegWNjb6bZwWdpDHbWtvGsUUMShUjRRhVAHQAAClF8sOXygv8AwBNfjfTsOWsm11cn/wCBO9vl/kT0UUVIwooooAK8q+Df/JRfjt/2Odt/6j2jV6rXlXwb/wCSi/Hb/sc7b/1HtGoA9VooooAKKKKACiiigDyrw5/ydN8Q/wDsTPDP/pdr1eq15V4c/wCTpviH/wBiZ4Z/9Lter1WgAooooAKKKKACiiigAooooAK8A+EX/J2nx8/69/D/AP6TTV7/AF514P8AgD4O8C+OtV8YaRHri+INUAF9cXniTUryO4ABCh4Zrh4zsBIT5fkBwuBRHSV32f6ClrGy8j0WuEtv+Kk+MF3N96z8NaeLVcHK/a7kiSQEf3khjhwfSc1t+HvAeheFdd8Razpdj9l1LxDcx3epzedI/wBolSJYlbazELhEUYUAcZ681o6Xodjosl89nB5L31w13ctuZjJKVVSxJJ/hRQB0AUAULdPy/H/LfX007N7WX9f1/mfIXjTwprfxC+I3xU8VfCS9/s6bRL6PR/FfhXUJdlj4vkito3kUsPmtHEciRideX2kONgyfqP4W+MNO+IHw38MeJdItWsdL1XTYLu2tWUKYY3jBVMDgbQccccVj+IPgL4J8TeKLjxDd6bd2+q3QVb19N1W8sYtQCgKou4oJUjuQFG0CZXGOOnFd3Z2cGn2kFrawR21rAixRQwoFSNAMBVA4AAGABTi7U+V76fgnf5N6pfZ2QS96fN6/pb5rv169LTUUUUgCiiigDyr4yf8AJRfgT/2Odz/6j2s16rXlXxk/5KL8Cf8Asc7n/wBR7Wa9VoAKKKKACiiigAooooAiupHhtpZIomnkVCyxKQC5A4UEkAZ9zivk34kax+0J8F/Eeg+OtT8caF4t8LaprdlpV74Bs9AW2+xR3UyQq1rd72lnkQsCfM2qRuO0cAfWN3dwafazXV1NHb20KNJLNKwVEUDJZieAABnJr45f/goN+z342+IlnDd+ODfS6VqBg0TRrTSL6Y3t6cxLPvWExtncViG7aN+9jkrsdP8Aixtq7rTur6q3nsuva2oS/hyvorPXztpr5b/nc9g+O3x8h8AeINM8IabrOg6Brd9atqF7rniW4WLT9FsVcJ9olDOgkd5CI44967juJOFIL/HnjrV/hH+z/q/ibTtW174q6nJH5theaXpMF/K3mkBHjgs441eCMEvyclVIaQ5zXI6pe6V8H/2rvFfjTx5fWmieFvFHhqwtNP1vV3WKztZraSYTWsk7nZEzidGVSw34YDJU1X+AWv6D+z78PfE2qeLtWt/B/gbXfGmoTeGv7SV7a2tLOVsxhmcBYI5HSWRN5VcSIBgsBUqPNB3e6ev/AG9bl8nbbro31RTfLNNdLaf9u8zfmk9H026p3b+yF481bxJ4P8UeMdd+Pj/F3SbMNFJZy+E7bQZtGlh3NMs8SfvN5AGA2BgEjOch0Pxm8W6T8H9A+Oeq6xO3h3VJLS4ufCf2SBbaz0y6uFSOZZBH55njjljdy0hjbawEa5BHT2nwt0rxz8RPiN4m0IwRaB4u8MQ6Nc3tqP3WpXH78C4VgcOEilRfMXht2Mnbx5FqEY8bfsk+HfgGksJ+I4t9N8O6roa7vPsYYJ41nu5E+8sHlQO6SnCPlApJYA7RfNLVWd4WXzkpfLSLvuk97kWS6+7rd/JNW++Sts2j7UVgygg5B5FLTIYlghjiX7qKFH0AxT6yBXtqFFFFAwooooAKKKKAPKvjJ/yUX4E/9jnc/wDqPazXqteVfGT/AJKL8Cf+xzuf/Ue1mvVaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAZLEk8bxyIskbgqyMMhgeoI7ivNLD9l/4NaXf299ZfCTwLZ3tvIs0Nzb+G7JJIpFOVdWEWQwIBBHIIr06ihaO63DdWYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHlX7S3/JOtI/7HPwn/6kOnV6rXlX7S3/ACTrSP8Asc/Cf/qQ6dXqtABRRRQAUUUUAFFFFABRRRQB82/tAaZ8fobfXPGvgr4iaD4S0fw/bz3UHhO+0GO7XVI4lLFrm8aTdFv2sVESjAI3HOcacnxs13x1Y/CDQNLjm8I+I/H2lPrN9MYUkn0m0jt0eUxrIrIZTJNEi+YrKMklWxtPFfHj9uL4EaL4x1L4a+L/AB7bafaWo2a5Hb2N3eeec82QaCJ1XoRLk5AOwDLMU3PE+vaLffEb4QfHezla18Af2RqGmXWo3kTW6WtpdLHLbXcgbHlQkwAFnA2iVS23nDp2cVfWLe/yl1/vStp5O2jHUupf3knp810/uq+vmr6mrN+0FL8KdK+Lem+LLqbxBqHw806DVYr5444p9UtJ4WaEusaLGJTLHJGSiqpwpCjOKnbxp4w+FepfDvUfGHiGTX7PxnfwaRf2P2OCG30i8mgZ4jamNFkMRkQxkTPIxLqQy4KnzXx18Hrv9oq3/aD8SaA0dzY+J/D9hofhu6DEQ6g1oslx56NnDRNNKqK4+VghIJHJ6XxtrumftHS/CPw94duEvLvSfENjr/iK2UMJdGW0iaTyblesMrStEgjkwxBZgCFJFx1cb73jfyjfV+ttX2ZM/hfL2nb1UU0v/ArpLr8tNdPiJ4z+Imj+P/G/hbXZNN0rwlqF/YaXoaWsEkGtNZrtnN08kbSqGmWRE8l49oUM2/O0e0/DzxtY/EnwH4e8V6Zu/s/WrCDUIA3UJKgcA+4zj8K+bfB+r2fwH+H/AMTvhxqUsf8Awld1q2s3vhvR8n7TrcV4zTw/Zk6y7WlMb7c7NhLbRzXu3wF+Hsvwn+CvgfwdcSLLc6Jo9tZTyL0aRIwHI9t2amNuS/lC3q0+b8bXXTbQc/jsu8/uTXL+F7Pr5ne0UUVIBXlXhz/k6b4h/wDYmeGf/S7Xq9Vryrw5/wAnTfEP/sTPDP8A6Xa9QB6rRRRQAUUUUAFFFFABRRRQAUUUUAFFc54/8f6P8MvC934h19r6PSbQbp5dP025v3jXBJdo7eORwgAJLbcKOSRXF+F/2o/hx4svdFtbbV9R05tb2/2VNr2g6hpMGolhuVbea7gijmZl5CoxJHIFC952QP3Vdnq9FFFABRRRQAUVieK/GGmeC9ON5qRu3XBK2+nWE99cyY5OyCBHlfA67VOKj8D+PNB+JPhy313w3qMep6XMzIJVRkZHRirxujgPG6sCrI4DKQQQDRve3QDfooooAK8q+Df/ACUX47f9jnbf+o9o1eq15V8G/wDkovx2/wCxztv/AFHtGoA9VooooAKKKKACiiigDyrw5/ydN8Q/+xM8M/8Apdr1eq15V4c/5Om+If8A2Jnhn/0u16vVaACiiigAooooAKKKKACiiigDzHT/AIzXF38e5/hpc+F7rTtmiSa3Fq1xdxMs8a3CwALGhYjJJbLEEDbxkkL6XNMtvC8rnCIpY8Z4AzXgc/8AyfhZ/wDZO5f/AE4pXv8AQtaUJdXzfhOSX4JCelWcei5fxhF/m2fJ+sftSfHzSma9P7Lskfh17qOGDU73x5YwSPHJKI4ne38ppEZtyfu8FgTjk16/r3xc1m68Y6t4X8EeG7LxRq+gw28+tC+1c2ENsJlZo4YnEEpknKru2MI0wykyLnFa3jT/AIqDx54S8PD5re3kk1y9GMqVgwsCH0JmkSQf9cDXnOveE9Z+BXxS8efFHTtQ8Pv4N8SW9tc+ILfXLuW0lsJraIxrcQOkUom3ptXyWEfzAEPzildKKv56/ctfnfZb26bVrd28tP8ALrtZ77ee/q/wx+I+k/FjwVYeJdG81LW5MkclvcKFmtpo3aOWGQAkB0dWU4JGV4JHNdVXiv7IfgnVvBfwahk12GWz1XXtUv8AxDNYzLta0F5cvOkJXJ2lUddwycMWGai8VfFj4zaT8WV0DRfgP/b/AIIN1bxHxh/wmFlbYhcJ5s32Nk8z93uf5c5bZx1Fayj76hs39yfVX8n3IjrFyTul+K6P5rXQ9vooorMoKKKKAPKvjJ/yUX4E/wDY53P/AKj2s16rXlXxk/5KL8Cf+xzuf/Ue1mvVaACiiigAooooAKKKKACiorqR4baWSKJp5FQssSkAuQOFBJAGfc4r5N+JGsftCfBfxHoPjrU/HGheLfC2qa3ZaVe+AbPQFtvsUd1MkKta3e9pZ5ELAnzNqkbjtHADj701Du0vm9F97+7rYHpFy7Xf3av+vuPreivDPiB461TV/jtb/DZfGN38ObaTQ11ew1HT4LR7nVZRK6TQo13DLEFhRY2ZVQufNB3KF5yT8dPFdv8AC3watxFap4w8WeJX8OaVfNbkQzW4nm26j5WTw1rCZgudpLL/AAmiKckmurt+PL+f9bjl7rafTV/dzfl/lvY+iaK8W0P4iX/w1+J194C8WeILrxJAfD0niSw1zUILeK5aOGXZdQyC3iiiOzfCylUU4Yg5IyeJh+M3i3Sfg/oHxz1XWJ28O6pJaXFz4T+yQLbWemXVwqRzLII/PM8ccsbuWkMbbWAjXIIcY81mtnbX1bS/FNfJ9BPS6e//AAE/ya+9dT6fopFYMoIOQeRS1IBRRRQAUUUUAFFFFAHlXxk/5KL8Cf8Asc7n/wBR7Wa9Vryr4yf8lF+BP/Y53P8A6j2s16rQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHlX7S3/JOtI/7HPwn/wCpDp1eq15V+0t/yTrSP+xz8J/+pDp1eq0AFFFFABRRRQAUUUUAFFFFABRXz78dPDnx61ebUtf8A/EXQ/Aul6LG81toV7oMd9/a+xdzG5uWfMCMQQBEm4LyTk4Xsfhz488RfFj9nnw34wgjh8K+INZ0aHUHjubU3CW7sgZsJvUkHkrk9CCQelTf3JVH0tf53t+T8+6Hb3lHvf8AC1/zXl2PUaK8k/Zj+ImsfEL9nDwb4y8SzHUNZ1DTPtl5Ja2wUyNubISJB6DAUDJ46mvBv2f/AIy+MPjZ8froXvxi1XwktrJJezfBzXfAkGm3qWgLJGFu5iZZFyFdmXnkjCZGNeVqq6XVX/D8fw9Sb/u/af1/l+J9qUV4ZD4u8V/Fvxt8QLPwr4lm8L6b4KvI9Mh8iygnGp34t1mlW4MyMfIUSwptiMb5Vz5gGBXd/BL4mw/GP4VeG/GENsbJtUtQ89oTkwTqSksee+2RXX8KlK65vR/J6p/NDejt/V1uv68zuKKKKQBXlXhz/k6b4h/9iZ4Z/wDS7Xq9Vryrw5/ydN8Q/wDsTPDP/pdr1AHqtFFFABRRRQAUUUUAFFFFABRRRQBw3x2/5Il8QP8AsX7/AP8ASd6+WU8L+Of2kP2Xfhd8PLLwBqnhTTvsmiXdz4u1nUbAQwwW3kyeZaR21xLM0rhPlEiRgBjuIPFfV3xc8H614/8Ah5rfhzQtZsdAutVtpLOS+1DTnvkSGRCkm2JZ4Tvw3DF8A9VPSovgz4I1n4a/DbQvC2t61Y6/No9rFYwXthpr2CtBGipHujeebL4XlgwBzwop0vdlOT7wa9YuT/C6/EVT3lBLtNP/ALe5V+j/AAPAf2nvi542+Gtn8Qdb0PxpMbvwtZR6jp/hvQtOt7q3MAjQyHWJZ4SYizeZsWGaN2TlQ5Bx3Xirx94m8WfFDwZ4LsdeuvAdhrfhqbXP7ZsLa2mnuLpHhAtYmuY5YgFR3dxsLlcYK4Jqr42/ZUvfFlt8YNJt/Gzad4c+JEfm3do2lrNc2d39nSAvHMZQDCVijzEY92QcSLmvI/2oPBseu614f8J+IPjfovw0s9H0aGGaTxt4V0+90TV5HbINvHfnyhLH5Iz87uoZR3YlRdlFPXb73GV/udn5+V2lUlr7um/5xt96uvLvszp/DP7SfxEPwq0jUtVt7XxFr3iHxdP4X0iLwzpKWsjxQSXAe5U3d75MpkjtmdWLRopbo4GD6P8AAPWPizJ4t8SaZ440PX08KJBDPo+teKH0ZdSeUlhNBKmmTNEVHyMjhEONwbJwTx2j/s7+Jvih8H7vwZ44+Ji+KBp97a6l4Y8b+HtEh0a4sZ4sspiiiLRMifKA6YDK7L1Ga9V+Cvwx8YeA9PeTx78Srz4na+VMMWoT6VbabFbw5B2JDAOSdq7ndmJ2jGBxWitFyv8A0rL7ne7f5vYzl7yVv6fM391rJdfJbnX+NDrtroV3eeFdK0rVfEscRS0h1e7e0gOWG4NMkUrKOAcBOSoBK/eHkv7IXiUaz4V8X2Gp6JJ4d8b6d4jux4osGlEsf9oS7ZjJC4A3QvG8ZTPIUAHJBJ9B8feG/Hera3o194P8bWHhu1tVkS+0zVdBGpW96GK7Wys8EkbphsFX2necqcDGj4H8B2ngldXnSZ73VdZvW1DUr+VVVriYoqDgcKqxxxoq9lQZJOSYhZXb6q34p/c9X627Fy1SXZ3/AAa+9f5nT0UUUgCvKvg3/wAlF+O3/Y523/qPaNXqteVfBv8A5KL8dv8Asc7b/wBR7RqAPVaKKKACiiigAooooA8q8Of8nTfEP/sTPDP/AKXa9XqteVeHP+TpviH/ANiZ4Z/9Lter1WgAooooAKKKKACiiigAooooA86/4UD4O/4WgPiGY9cPiwIYhdnxJqXkiIncYfs/2jyfK3AN5WzZnnbnmultvAehWfjm+8Yw2OzxHe2MWm3F750h328Tu8abC2wYaRzkKCc8k4Fb9cl4N+LXhD4ha5rmkeG9etdZv9E8n+0I7TcyweaGMeXxtO4KT8pPGD0Iy47JR6fh/VwfVvra/n2/LT0N+HQrG31y71iODGpXUEVtNOXY7o42dkUAnAAMrngDO7nOBWFf/C3w1q3i6PxLqNlNqepxFHgW/vZ7i1tnQYWSG2dzDDJ/toise5NdPdXUNlby3FxKkFvEhkklkYKqKBksSeAAO9cV4R+Nvg3xzrv9j6Tqc7ag8TXFvHe6fc2a3sKkBprV5o0W5jG5cyQl1G5eeRSWr03QPbXqd1RXjvjr9sH4NfDP4iW3gbxN8QNL0nxROVX7DL5jCEkAqJpVUxwkgggSMucjHWvYEdZEV0YMrDIZTkEetC1XMtgej5XuOooooAKKKKAPKvjJ/wAlF+BP/Y53P/qPazXqteVfGT/kovwJ/wCxzuf/AFHtZr1WgAooooAKKKKACiiigCG7u4NPtZrq6mjt7aFGklmlYKiKBksxPAAAzk18cv8A8FBv2e/G3xEs4bvxwb6XStQMGiaNaaRfTG9vTmJZ96wmNs7isQ3bRv3scldn2ZRRHSSb2/r+tvMH8LS3/r+tz5Q/aV/4Qrxx8Uo/B3xs+w+HPhquiJf6HrepXK2KNq5ldZNt6WAimijVCke4b/MckOFG3Om0Pxfqnw9+F/jDxBc3niN/h940lnOrTWZjudS0bE1qL1oV53COVZCQPmWMuBhhX2BRTi+RK26d/mnf/wC1329FYl72j7W+Tjyu3r8Xrr3PmXUPDemftIfG658TaBqVtq3gyw8E33h+PW7CUTWt1dX0i71ilU7ZBFHCNxUkBpAM5BA4TUIx42/ZJ8O/ANJYT8Rxb6b4d1XQ13efYwwTxrPdyJ95YPKgd0lOEfKBSSwB+1aKcXypRW2n4SlL85P5egNtvm69PLRL/wBtT9RkMSwQxxL91FCj6AYp9FFSJJJWQUUUUDCiiigAooooA8q+Mn/JRfgT/wBjnc/+o9rNeq15V8ZP+Si/An/sc7n/ANR7Wa9VoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyr9pb/knWkf9jn4T/8AUh06vVa8q/aW/wCSdaR/2OfhP/1IdOr1WgAooooAKKKKACiiigAooooA+Vf2hP22vgn4N8XX3wz8XePYdG2xAa39ls7u6fy262itbxOEdh98kgqrYHzNlPY9K+L3gnWPgpH46tNVtdF8DTWRe01LVcafb+RkxxPiXb5aN8u0MFJBXgZxXo9FRKPNTcHu+v8AwPy1/MpStNSWy/rf/gdux80fsP8AxE8NR/sZ+D9Ri1uzvrXQNJK6p/Z8n2p7Nk3O6SRxbmDhSDsxuwRxyK39efwh+0H4s+GHivwLq+l+I5/DurtfNr+kzLcJbWpt5Umt2lRsBpC8amInPVtvy5HvFFbznz1HU87/AD3+7y7aEJWjy+TT9GrHzT4L1vSP2c/HvxfsPE97FpyeJNcbxJoKyBt+qedaxrJb268madZYJB5KZfDIduCK7v8AZR+HGofCn4BeFPD+sQ/ZtYWKW9vrcHPkz3EzzvHnP8JlK/8AAa9boqE7R5fKK+UVZf8AB9By95382/m/6f3hRRRSAK8q8Of8nTfEP/sTPDP/AKXa9XqteVeHP+TpviH/ANiZ4Z/9LteoA9VooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8q+Df8AyUX47f8AY523/qPaNXqteVfBv/kovx2/7HO2/wDUe0agD1WiiigAooooAKKKKAPKvDn/ACdN8Q/+xM8M/wDpdr1eq15V4c/5Om+If/YmeGf/AEu16vVaACiiigAooooAKKKKACiiigArwD4Rf8nafHz/AK9/D/8A6TTV7/Xjfw4+DXjDwd8ZvGnjnVfGOh6vaeKEt0uNMs/Ds1pJCLdGSDZM17KPuud+Y/mPI2dKcfi17P8AQUvh+78zQ/am8D6/8Sv2efHnhnwu3/E+1HTJIrWLeE89uCYdxIC+YAUyTgbua8d+JfjyT4ja1+z3b6LoGuaB4nt/GEMk9lrmlz2MlrBDZzfbVBdVEqCNtvmRb4mJX5uRX0RHoHjC1l8XTReLbS5fUJVk0OG+0cPBpCiJVKOI5Y3uVLhn5dD820EAVQ8G/CsaJ4lm8V6/q03ijxhNbfY/7RmiEMFpASGaG1gBIhRmUM2Wd2IXc7BVAdN8sk3srS+a1t+j6dn3c9YuPlJf+BKzf6rz37rmv2gfAWk+IPgx4m8BafpNnc6h4sjuLS1tZow4a6myWunzziIt5rPnI2DHO0H0rwf4dTwf4S0XQoria7j0yyhsluLhi0kgjQIGYnqTjJr578Z/s8/HvXviFrHiXQf2kbfwrbXh8u20yDwDZ3a2duDlYlknndj2LHjc3OAAAPoXwlo954f8MaXpuo6rPruoWtukdzqlwoSS7lA+eUqOF3Nk7RwucDgClD4G9m7ael7eWn6+QS+JLdK+vra/nrZfd5mvRRRSAKKKKAPKvjJ/yUX4E/8AY53P/qPazXqteVfGT/kovwJ/7HO5/wDUe1mvVaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyr4yf8AJRfgT/2Odz/6j2s16rXlXxk/5KL8Cf8Asc7n/wBR7Wa9VoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyr9pb/AJJ1pH/Y5+E//Uh06vVa8q/aW/5J1pH/AGOfhP8A9SHTq9VoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAryrw5/ydN8Q/+xM8M/8Apdr1eq15V4c/5Om+If8A2Jnhn/0u16gD1WiiigAooooAKKKKACiiigAooooAKKKKAM5vEWlJrcejNqdmusSRNOmnm4QXDRrt3OI87io3Lk4wNw9a0CQoJJwBXzjrmh6bpf7efgm6s9PtbS6vPBOsPczQQqjzsLuzwXYDLEbm6+p9a9I+Klxc+KLPU/ClhJNb232CSfV76FirRQlTtgRh0klwckcqgY8FkNTOXJRjV6tSf3Skv/bblxjzVHD0/FJ/rY7jR/EGl+ItJi1TStStNT0yUMY7yznWWFwpIYh1JBwQQeeoNc54N+M/w/8AiNqlzpnhTx14a8T6jbIZZ7PRtXt7uaJAQpZkjdioyQMkdSK+c/2W/Beu/ET/AIJy+DfDXhvxHH4S1XU9Fkto9WksReCBWnkD4iLoCSu5ck8Zzg4xVz9m+C7+CviXxp4I8S/DrwT4c8XWekHWLPxB4F0aPT7bxBYo7L88aqCssblQyZIHmgjg5OlRKlUnGW0b/O12/uSv33MYN1KcJrd2+V7L8W7evqfSv/CeeGf+EuHhX/hItJ/4SgwfaRon26L7b5P/AD08ndv2/wC1jFbtfEwvLiH/AIJv/wDCwlkx4tOn/wDCbnUsfvTqRn+0l85z/wBM+v3Pl6cV9maLftqmj2F60Zia5t45jGwwVLKDj8M1UoODcZbxdn/X3r5X62T5lKzWz2+X/Dr8ul3dooorMoK8q+Df/JRfjt/2Odt/6j2jV6rXlXwb/wCSi/Hb/sc7b/1HtGoA9VooooAKKKKACiiigDyrw5/ydN8Q/wDsTPDP/pdr1eq15V4o+Cer698VNU8ZaV8SPEHg37fo1hpElloVnpz+Z9lnvZRJI95bXGc/bSAqKmNrEl9wCH/Cm/F3/RdviB/4A+Hv/lVQB6rRXlX/AApvxd/0Xb4gf+APh7/5VUf8Kb8Xf9F2+IH/AIA+Hv8A5VUAeq0V5V/wpvxd/wBF2+IH/gD4e/8AlVR/wpvxd/0Xb4gf+APh7/5VUAeq0V5V/wAKb8Xf9F2+IH/gD4e/+VVH/Cm/F3/RdviB/wCAPh7/AOVVAHqtFeVf8Kb8Xf8ARdviB/4A+Hv/AJVUf8Kb8Xf9F2+IH/gD4e/+VVAHqtFeVf8ACm/F3/RdviB/4A+Hv/lVR/wpvxd/0Xb4gf8AgD4e/wDlVQB6rRXlX/Cm/F3/AEXb4gf+APh7/wCVVH/Cm/F3/RdviB/4A+Hv/lVQB6rRXlX/AApvxd/0Xb4gf+APh7/5VUf8Kb8Xf9F2+IH/AIA+Hv8A5VUAeq0V5V/wpvxd/wBF2+IH/gD4e/8AlVR/wpvxd/0Xb4gf+APh7/5VUAeq0V5V/wAKb8Xf9F2+IH/gD4e/+VVH/Cm/F3/RdviB/wCAPh7/AOVVAB8ZP+Si/An/ALHO5/8AUe1mvVa8K8Tfs2+KPEmteE9Ql+OvjgvoGpvqUXnaboTMGayubX92U05ArbbpuXWRdu4bAxWSPoP+FN+Lv+i7fED/AMAfD3/yqoA9Voryr/hTfi7/AKLt8QP/AAB8Pf8Ayqo/4U34u/6Lt8QP/AHw9/8AKqgD1WivKv8AhTfi7/ou3xA/8AfD3/yqo/4U34u/6Lt8QP8AwB8Pf/KqgD1WivKv+FN+Lv8Aou3xA/8AAHw9/wDKqj/hTfi7/ou3xA/8AfD3/wAqqAPVaK8q/wCFN+Lv+i7fED/wB8Pf/Kqj/hTfi7/ou3xA/wDAHw9/8qqAPVaK8q/4U34u/wCi7fED/wAAfD3/AMqqP+FN+Lv+i7fED/wB8Pf/ACqoA9Voryr/AIU34u/6Lt8QP/AHw9/8qqP+FN+Lv+i7fED/AMAfD3/yqoA9Voryr/hTfi7/AKLt8QP/AAB8Pf8Ayqo/4U34u/6Lt8QP/AHw9/8AKqgD1WivKv8AhTfi7/ou3xA/8AfD3/yqo/4U34u/6Lt8QP8AwB8Pf/KqgD1WivKv+FN+Lv8Aou3xA/8AAHw9/wDKqj/hTfi7/ou3xA/8AfD3/wAqqAPVaK8q/wCFN+Lv+i7fED/wB8Pf/Kqj/hTfi7/ou3xA/wDAHw9/8qqAD4yf8lF+BP8A2Odz/wCo9rNeq14V4m/Zt8UeJNa8J6hL8dfHBfQNTfUovO03QmYM1lc2v7sppyBW23Tcusi7dw2BiskfQf8ACm/F3/RdviB/4A+Hv/lVQB6rRXlX/Cm/F3/RdviB/wCAPh7/AOVVH/Cm/F3/AEXb4gf+APh7/wCVVAHqtFeVf8Kb8Xf9F2+IH/gD4e/+VVH/AApvxd/0Xb4gf+APh7/5VUAeq0V5V/wpvxd/0Xb4gf8AgD4e/wDlVR/wpvxd/wBF2+IH/gD4e/8AlVQB6rRXlX/Cm/F3/RdviB/4A+Hv/lVR/wAKb8Xf9F2+IH/gD4e/+VVAHqtFeVf8Kb8Xf9F2+IH/AIA+Hv8A5VUf8Kb8Xf8ARdviB/4A+Hv/AJVUAeq0V5V/wpvxd/0Xb4gf+APh7/5VUf8ACm/F3/RdviB/4A+Hv/lVQB6rRXlX/Cm/F3/RdviB/wCAPh7/AOVVH/Cm/F3/AEXb4gf+APh7/wCVVAHqtFeVf8Kb8Xf9F2+IH/gD4e/+VVH/AApvxd/0Xb4gf+APh7/5VUAeq0V5V/wpvxd/0Xb4gf8AgD4e/wDlVR/wpvxd/wBF2+IH/gD4e/8AlVQB6rRXj+pfBfx5Lboun/H7xxa3HnQs0lzpPh+ZTEJFMqBV01CGaMOqtkhWZWKuFKNb/wCFN+Lv+i7fED/wB8Pf/KqgD1WivKv+FN+Lv+i7fED/AMAfD3/yqo/4U34u/wCi7fED/wAAfD3/AMqqAPVaK8q/4U34u/6Lt8QP/AHw9/8AKqj/AIU34u/6Lt8QP/AHw9/8qqAPVaK8q/4U34u/6Lt8QP8AwB8Pf/Kqj/hTfi7/AKLt8QP/AAB8Pf8AyqoA9Voryr/hTfi7/ou3xA/8AfD3/wAqqP8AhTfi7/ou3xA/8AfD3/yqoA9Voryr/hTfi7/ou3xA/wDAHw9/8qqP+FN+Lv8Aou3xA/8AAHw9/wDKqgD1WivKv+FN+Lv+i7fED/wB8Pf/ACqo/wCFN+Lv+i7fED/wB8Pf/KqgD1WivKv+FN+Lv+i7fED/AMAfD3/yqo/4U34u/wCi7fED/wAAfD3/AMqqAPVaK8q/4U34u/6Lt8QP/AHw9/8AKqj/AIU34u/6Lt8QP/AHw9/8qqAPVaK8q/4U34u/6Lt8QP8AwB8Pf/Kqj/hTfi7/AKLt8QP/AAB8Pf8AyqoA9Voryr/hTfi7/ou3xA/8AfD3/wAqqP8AhTfi7/ou3xA/8AfD3/yqoAP2lv8AknWkf9jn4T/9SHTq9Vrwrxx+zb4o8a6LbafP8dfHBSHU9O1IfadN0J13Wt7DdLgR6dGd26EbSWKhtpZJFDRt0H/Cm/F3/RdviB/4A+Hv/lVQB6rRXlX/AApvxd/0Xb4gf+APh7/5VUf8Kb8Xf9F2+IH/AIA+Hv8A5VUAeq0V5V/wpvxd/wBF2+IH/gD4e/8AlVR/wpvxd/0Xb4gf+APh7/5VUAeq0V5V/wAKb8Xf9F2+IH/gD4e/+VVH/Cm/F3/RdviB/wCAPh7/AOVVAHqtFeVf8Kb8Xf8ARdviB/4A+Hv/AJVUf8Kb8Xf9F2+IH/gD4e/+VVAHqtFeVf8ACm/F3/RdviB/4A+Hv/lVR/wpvxd/0Xb4gf8AgD4e/wDlVQB6rRXlX/Cm/F3/AEXb4gf+APh7/wCVVH/Cm/F3/RdviB/4A+Hv/lVQB6rRXlX/AApvxd/0Xb4gf+APh7/5VUf8Kb8Xf9F2+IH/AIA+Hv8A5VUAeq0V5V/wpvxd/wBF2+IH/gD4e/8AlVR/wpvxd/0Xb4gf+APh7/5VUAeq15V4c/5Om+If/YmeGf8A0u16j/hTfi7/AKLt8QP/AAB8Pf8Ayqrn7L9m3xRZ+PtZ8Tr8dfHH2jUtMsdNcrpuhCbbbS3ci7mOnFCubttoWNWB37nkBRYwD3WivKv+FN+Lv+i7fED/AMAfD3/yqo/4U34u/wCi7fED/wAAfD3/AMqqAPVaK8q/4U34u/6Lt8QP/AHw9/8AKqj/AIU34u/6Lt8QP/AHw9/8qqAPVaK8q/4U34u/6Lt8QP8AwB8Pf/Kqj/hTfi7/AKLt8QP/AAB8Pf8AyqoA9Voryr/hTfi7/ou3xA/8AfD3/wAqqP8AhTfi7/ou3xA/8AfD3/yqoA9Voryr/hTfi7/ou3xA/wDAHw9/8qqP+FN+Lv8Aou3xA/8AAHw9/wDKqgD1WivKv+FN+Lv+i7fED/wB8Pf/ACqo/wCFN+Lv+i7fED/wB8Pf/KqgDnvEHw9+I2oftS+HfHtrpXhdvCmk6TdaITNrtyl9LFcS28jz+SLIoGQwkCPzSGyDvXpXXePv2d/hp8RLjUtT1z4deENb8QXcBjOqarodtcXDME2oWleMsdoAA54A4ql/wpvxd/0Xb4gf+APh7/5VUf8ACm/F3/RdviB/4A+Hv/lVSklKmqb2V/xbb/FtlKTU3Ndbfhp+iOH/AGf/AIC+K/2av2c/Dnhjwpo/gmfx1bsjazI7S2tpqfztuZrmOAyeYEKhXeJ/u4xjketeH/B1zeeIj4r8SW1jH4gk04aatrYyGeC0hLB5UWZ40aTe4XLFEGEQbQQSed/4U34u/wCi7fED/wAAfD3/AMqqP+FN+Lv+i7fED/wB8Pf/ACqq5Sc5OUt3+qt+RnGKjFRWy/zv+Zxy/s769/wgp+EjSaQPhUtyJFuxPKdRNn9p8/8As82/l+WF/wCWfn+bnZx5Wfmr6ERVjVVUBVUYAHQCvLP+FN+Lv+i7fED/AMAfD3/yqo/4U34u/wCi7fED/wAAfD3/AMqqV3a39f1/w+7ZXW/9f1/WyR6rRXlX/Cm/F3/RdviB/wCAPh7/AOVVH/Cm/F3/AEXb4gf+APh7/wCVVID1WvKvg3/yUX47f9jnbf8AqPaNR/wpvxd/0Xb4gf8AgD4e/wDlVWr8JPhZefDGXxjLf+K9Q8YXfiLWl1d7/VLa3huExY2loI3+zxxxNgWgIZY04YAgkF2APQKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//Z" /></p><p>&nbsp;</p><p><strong>Table : Standard and reduced dose calculations according to body surface area for a starting dose</strong> of Capecitabine SPC <strong>of 1000 mg/m2</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>Dose level 1250 mg/m</strong>2 <strong>(twice daily)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Full dose 1000 mg/m2</strong></p></td><td style="vertical-align:top"><p><strong>Number of 150 mg tablets per administration (each administration to be given morning</strong></p><p><strong>and evening)</strong></p></td><td style="vertical-align:top"><p><strong>Reduced </strong><strong>dose (75%) 750mg/m2</strong></p></td><td style="vertical-align:top"><p><strong>Reduced dose (50%) 500</strong></p><p><strong>mg/m2</strong></p></td></tr><tr><td style="vertical-align:top"><p>Body Surface</p></td><td style="vertical-align:top"><p>Dose per administrat ion (mg)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>150 mg</p></td><td style="vertical-align:top"><p>Dose per admini</p></td><td style="vertical-align:top"><p>Dose per administrat ion (mg)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:84px"><p>&le; 1.26</p><p>1.27 -</p><p>1.38</p><p>1.39 -</p><p>1.52</p><p>1.53 -</p><p>1.66</p><p>1.67 -</p><p>1.78</p></td><td style="vertical-align:top; width:165.188px"><p>1150</p><p>1300</p><p>1450</p><p>1600</p><p>1750</p><p>1800</p><p>2000</p><p>2150</p><p>2300</p></td><td style="vertical-align:top; width:404.375px"><p>&nbsp;</p><p style="text-align:center">1</p><p style="text-align:center">2</p><p style="text-align:center">3</p><p style="text-align:center">4</p><p style="text-align:center">5</p><p style="text-align:center">2</p><p style="text-align:center">- 1</p><p style="text-align:center">2</p></td><td style="vertical-align:top; width:168px"><p>800</p><p>1000</p><p>1100</p><p>1200</p><p>1300</p><p>1400</p><p>1500</p><p>1600</p><p>1750</p></td><td style="vertical-align:top; width:135px"><p>600</p><p>600</p><p>750</p><p>800</p><p>800</p><p>900</p><p>1000</p><p>1050</p><p>1100</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Duration of Treatment</u></p><p>For metastatic disease, Capecitabine SPC is intended for long-term administration unless clinically inappropriate. In the adjuvant setting, treatment duration is recommended for 24 weeks.</p><p><u>Dosage Adjustment During Treatment</u></p><p><em>General</em></p><p>Toxicity due to Capecitabine SPC administration may be managed by symptomatic treatment and/or modification of the Capecitabine SPC dose (treatment interruption or dose reduction). Once dose has been reduced, it should not be increased at a later time.</p><p>Dosage modifications are not recommended for Grade 1 events. Therapy with Capecitabine SPC should be interrupted if a Grade 2 or 3 adverse experience occurs. Once the adverse event has resolved or decreased in intensity to Grade 1, Capecitabine SPC therapy may be restarted at full dose or as adjusted according to Table. If a Grade 4 experience occurs, therapy should be discontinued or interrupted until resolved or decreased to Grade 1, and therapy can then be restarted at 50% of the original dose. Patients taking Capecitabine SPC should be informed of the need to interrupt treatment immediately if moderate or severe toxicity occurs. Doses of Capecitabine SPC omitted for toxicity are not replace</p><p><strong><em>Haematology</em></strong><em>: </em>Patients with baseline neutrophil counts of &lt; 1.5 x 109/L and/or thrombocyte counts of &lt; 100 x 109/L should not be treated with Capecitabine SPC. If unscheduled laboratory assessments during a treatment cycle show Grade 3 or 4 haematologic toxicity, treatment with Capecitabine SPC should be interrupted.</p><p>The following table shows the recommended dose modifications following toxicity related to Capecitabine SPC.</p><p><strong>Table: </strong>Capecitabine SPC <strong>dose reduction schedule</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Toxicity Grades</strong>#</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>During a Course of Therapy</strong></p></td><td style="vertical-align:top"><p><strong>Dose Adjustment for Next Cycle</strong></p><p><strong>(% of starting dose)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 1</strong></p></td><td style="vertical-align:top"><p>Maintain dose level</p></td><td style="vertical-align:top"><p>Maintain dose level</p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 2 </strong>1st appearance 2nd appearance 3rd appearance 4th appearance</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Interrupt until resolved to Grade 0-1 Interrupt until resolved to Grade 0-1 Interrupt until resolved to Grade 0-1 Discontinue treatment permanently</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>100%</p><p>75%</p><p>50%</p><p>Not applicable</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:288px"><p><strong>Grade 3</strong></p><p>1st appearance 2nd appearance 3rd appearance</p></td><td style="vertical-align:top; width:542px"><p>Interrupt until resolved to Grade 0-1 Interrupt until resolved to Grade 0-1 Discontinue treatment permanently</p></td><td style="vertical-align:top; width:155px"><p>75%</p><p>50%</p><p>Not applicable</p></td></tr><tr><td style="vertical-align:top; width:288px"><p><strong>Grade 4</strong></p><p>1st appearance 2nd appearance</p></td><td style="vertical-align:top; width:542px"><p>Discontinue permanently or</p><p>If physician deems it to be in the patient&rsquo;s best interest to continue, interrupt until resolved to Grade 0-1</p><p>Discontinue permanently</p></td><td style="vertical-align:top; width:155px"><p>50%</p><p><strong>&nbsp;</strong></p><p>Not applicable</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p># According to the National Cancer Institute of Canada Clinical Trial Group (NCIC CTG) Common Toxicity Criteria (version 1) or the Common Terminology Criteria for Adverse Events (CTCAE) of the Cancer Therapy Evaluation Program, US National Cancer Institute (version 3.0). For hand-foot syndrome and hyperbilirubinaemia see <strong>PRECAUTIONS.</strong></p><p>&nbsp;</p><p>General combination therapy</p><p>Dose modifications for toxicity when Capecitabine SPC is used in combination with other therapies</p><p>should be made according to the table above for Capecitabine SPC, and according to the appropriate product information for the other agent(s).</p><p>&nbsp;</p><p>At the beginning of a treatment cycle, if a treatment delay is indicated for either Capecitabine SPC or the other agent(s), then administration of all agents should be delayed until the requirements for restarting all medicines are met.</p><p>During a treatment cycle for those toxicities considered by the treating physician not to be related to Capecitabine SPC [for example, neurotoxicity, ototoxicity, neurosensory toxicity, fluid retention (pleural effusion, pericardial effusion or ascites), bleeding, gastrointestinal perforations, proteinuria, hypertension], then Capecitabine SPC should be continued and the dose of the other agent adjusted according to the appropriate product information.</p><p>If the other agent(s) have to be discontinued permanently, Capecitabine SPC treatment can be resumed when the requirements for restarting Capecitabine SPC are met.</p><p>This advice is applicable to all indications and to all special populations.</p><p><u>Dosage Adjustments in Special Populations</u></p><p><em>Hepatic Impairment due to liver metastases: </em>Patients with mild to moderate hepatic impairment due to liver metastases, should be carefully monitored when Capecitabine SPC is administered. No starting dose reduction is necessary. Patients with severe hepatic impairment have not been studied.</p><p><em>Renal Impairment: </em>In metastatic colorectal and breast cancer clinical trials, patients with renal impairment had a greater incidence of Grade 3 or 4 adverse reactions than other patients, the incidence increasing with the degree of renal impairment from 35% in patients with normal renal function to 55% in patients with moderate renal impairment (creatinine clearance 30-50 mL/min). Based on the pharmacokinetic data, a dose reduction to 75% is recommended in moderate renal impairment for both monotherapy and combination use. No initial dose reduction is recommended in patients with mild renal impairment (creatinine clearance 51-80 mL/min). Further dose reductions should be made if adverse reactions occur. Capecitabine SPC is contraindicated in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min). Capecitabine SPC is contraindicated in patients with creatinine clearance below 30 mL/min (see CONTRAINDICATIONS).</p><p><em>Elderly: </em>For Capecitabine SPC monotherapy, no adjustment of the starting dose is needed. However, severe Grade 3 or 4 treatment-related adverse reactions were more frequent in patients over 80 years of age compared to younger patients. When Capecitabine SPC was used in combination with other agents, elderly patients (&ge; 65 years of age) experienced more Grade 3 and Grade 4 adverse drug reactions (ADRs), and ADRs that led to discontinuation, compared to younger patients. Careful moving of elderly patients is advisable. For treatment with Capecitabine SPC in combination with docetaxel, an increased incidence of Grade 3 or 4 treatment- related adverse reactions and treatment-related serious adverse reactions were observed in patients 60 years of age or more. For patients 60 years of age or more treated with the combination of Capecitabine SPC plus docetaxel, a starting dose reduction of Capecitabine SPC to 75% (950 mg/m2 twice daily) is recommended. For dosage calculations, see Tables.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capecitabine SPC tablets are contraindicated in patients who have:
•	A known hypersensitivity to Capecitabine SPC or to any of the excipients contained in the tablets
•	A history of severe and unexpected reactions to fluoropyrimidine therapy or with known hypersensitivity to fluorouracil
•	Severe renal impairment (creatinine clearance below 30 mL/min)
•	Known dihydropyrimidine dehydrogenase (DPD) deficiency
•	Treatment with sorivudine or its chemically related analogues, such as brivudine
•	If contraindications exist to any of the agents in combination regimen, that agent should not be used.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dose limiting toxicities</p><p><strong><em><u>Dose limiting toxicities</u> </em></strong>include diarrhoea, abdominal pain, nausea, stomatitis and hand-foot syndrome (hand- foot skin reaction, palmar-plantar erythrodysesthesia). Most adverse reactions are reversible and do not require permanent discontinuation of therapy, although doses may need to be withheld or reduced.</p><p><strong><em><u>Diarrhoea</u></em></strong><em><u>.</u> </em>Patients with severe diarrhoea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated. Standard antidiarrhoeal treatments (e.g. loperamide) may be used. NCIC CTC grade 2 diarrhoea is defined as an increase of 4 to 6 stools/day or nocturnal stools, grade 3 diarrhoea as an increase of 7 to 9 stools/day or incontinence and malabsorption. Grade 4 diarrhoea is an increase of &ge;10 stools/day or grossly bloody diarrhoea or the need for parenteral support. Dose reduction should be applied as necessary (see section 4.2).</p><p><strong><em><u>Dehydration. </u></em></strong>Dehydration should be prevented or corrected at the onset. Patients with anorexia, asthenia, nausea, vomiting or diarrhoea may rapidly become dehydrated. Dehydration may cause acute renal failure, especially in patients with pre-existing compromised renal function or when capecitabine is given concomitantly with known nephrotoxicmedicinal products. Acute renal failure secondary to dehydration might be potentially fatal. If grade 2 (or higher) dehydration occurs, capecitabine treatment should be immediately interrupted and the dehydration corrected. Treatment should not be restarted until the patient is rehydrated and any precipitating causes have been corrected or controlled. Dose modifications applied should be applied for the precipitating adverse event as necessary (see section 4.2).</p><p>&nbsp;</p><p><strong><em><u>Hand-foot syndrome </u></em></strong>(also known as hand-foot skin reaction or palmar-plantar erythrodysesthesia or chemotherapy induced acral erythema). Grade 1 hand-foot syndrome is defined as numbness, dysesthesia/paresthesia, tingling, painless swelling or erythema of the hands and/or feet and/or discomfort which does not disrupt the patient&#39;s normal activities.</p><p>Grade 2 hand-foot syndrome is painful erythema and swelling of the hands and/or feet and/or discomfort affecting the patient&#39;s activities of daily living.Grade 3 hand-foot syndrome is moist desquamation, ulceration, blistering and severe pain of the hands and/or feet and/or severe discomfort that causes the patient to be unable to work or perform activities of daily living. Persistent or severe hand-foot syndrome (Grade 2 and above) can eventually lead to loss of fingerprints which could impact patient identification. If grade 2 or 3 hand-foot syndrome occurs, administration of capecitabine should be interrupted until the event resolves or decreases in intensity to grade 1.</p><p>Following grade 3 hand-foot syndrome, subsequent doses of capecitabine should be decreased. When capecitabine and cisplatin are used in combination, the use of vitamin B6 (pyridoxine) is not advised for symptomatic or secondary prophylactic treatment of hand&ndash;foot syndrome, because of published reports that it may decrease the efficacy of cisplatin. There is some evidence that dexpanthenol is effective for hand-foot syndrome prophylaxis in patients treated with Xeloda.</p><p><strong><em><u>Cardiotoxicity. </u></em></strong>Cardiotoxicity has been associated with fluoropyrimidine therapy, including myocardial infarction, angina, dysrhythmias, cardiogenic shock, sudden death and electrocardiographic changes (including very rare cases of QT prolongation). These adverse reactions may be more common in patients with a prior history of coronary artery disease. Cardiac arrhythmias (including ventricular fibrillation, torsade de pointes, and bradycardia), angina pectoris, myocardial infarction, heart failure and cardiomyopathy have been reported in patients receiving capecitabine. Caution must be exercised in patients with history of significant cardiac disease, arrhythmias and angina pectoris (see section 4.8).</p><p><strong><em><u>Hypo- or hypercalcaemia.</u> </em></strong>Hypo- or hypercalcaemia has been reported during capecitabine treatment. Caution must be exercised in patients with pre-existing hypo- or hypercalcaemia (see section4.8).</p><p><strong><em><u>Central or peripheral nervous system disease.</u> </em></strong>Caution must be exercised in patients with central or peripheral nervous system disease, e.g. brain metastasis or neuropathy (see section 4.8).</p><p><strong><em><u>Diabetes mellitus or electrolyte disturbances.</u> </em></strong>Caution must be exercised in patients with diabetes mellitus or electrolyte disturbances, as these may be aggravated during capecitabinetreatment.</p><p><strong><em><u>Coumarin-derivative anticoagulation. </u></em></strong>In a interaction study with single-dose warfarin administration, there was a significant increase in the mean AUC (+57%) of S-warfarin. These results suggest an interaction, probably due to an inhibition of the cytochrome P450 2C9 isoenzyme system by capecitabine. Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy should have their anticoagulant response (INR or prothrombin time) monitored closely and the anticoagulant dose adjusted accordingly (see section 4.5).</p><p>Brivudine. Brivudine must not be administered concomitantly with capecitabine. Fatal cases have been reported following this drug interaction. There must be at least a 4-week waiting period between end of treatment with brivudine and start of capecitabine therapy. Treatment with brivudine can be started 24 hours after the last dose of capecitabine (see section 4.3 and 4.5). In the event of accidental administration of brivudine to patients being treated with capecitabine, effective measures should be taken to reduce the toxicity of capecitabine.</p><p>Immediate admission to hospital is recommended. All measures should be initiated to prevent systemic infections and dehydration.</p><p><strong><em><u>Hepatic impairment. </u></em></strong>In the absence of safety and efficacy data in patients with hepatic impairment, Capecitabine use should be carefully monitored in patients with mild to moderate liver dysfunction, regardless of the presence or absence of liver metastasis. Administration of capecitabine should be interrupted iPf atgrea8tment- related elevations in bilirubin of &gt;3.0 x ULN or treatment-related elevations in hepatic aminotransferases (ALT, AST) of &gt;2.5 x ULN occur. Treatment with capecitabine monotherapy may be resumed when bilirubin decreases to &le;3.0 x ULN or hepatic aminotransferases decrease to &le; 2.5 x ULN.</p><p><strong><em><u>Renal impairment. </u></em></strong>The incidence of grade 3 or 4 adverse reactions in patients with moderate renal impairment (creatinine clearance 30-50 ml/min) is increased compared to the overall population (see sections 4.2 and 4.3).</p><p><strong><em><u>Dihydropyrimidine dehydrogenase (DPD) deficiency: </u></em></strong>Rarely, unexpected, severe toxicity (e.g. stomatitis, diarrhoea, mucosal inflammation, neutropenia and neurotoxicity) associated with 5-FU has been attributed to a deficiency of DPD activity.</p><p>Patients with low or absent DPD activity, an enzyme involved in fluorouracil degradation, are at increased risk for severe, life-threatening, or fatal adverse reactions caused by fluorouracil. Although DPD deficiency cannot be precisely defined, it is known that patients with certain homozygous or certain compound heterozygous mutations in the DPYD gene locus, which can cause complete or near complete absence of DPD enzymatic activity (as determined from laboratory assays), have the highest risk of life-threatening or fatal toxicity and should not be treated with Xeloda (see section 4.3). No dose has been proven safe for patients with complete absence of DPD activity.</p><p>For patients with partial DPD deficiency (such as those with heterozygous mutations in the DPYD gene) and where the benefits of Xeloda are considered to outweigh the risks (taking into account the suitability of an alternative non-fluoropyrimidine chemotherapeutic regimen), these patients must be treated with extreme caution and frequent monitoring with dose adjusment according to toxicity. There is insufficient data to recommend a specific dose in patients with partial DPD activity as measured by specific test.</p><p>In patients with unrecognised DPD deficiency treated with capecitabine, life-threatening toxicities manifesting as acute overdose may occur (see section 4.9). In the event of grade 2-4 acute toxicity, treatment must be discontinued immediately. Permanent discontinuation should be considered based on clinical assessment of the onset, duration and severity of the observed toxicities.</p><p><strong><em><u>Ophthalmologic complications:</u> </em></strong>Patients should be carefully monitored for ophthalmological complications such as keratitis and corneal disorders, especially if they have a prior history of eye disorders. Treatment of eye disorders should be initiated as clinically appropriate.</p><p><strong><em><u>Severe skin reactions:</u> </em></strong>Xeloda can induce severe skin reactions such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. Xeloda should be permanently discontinued in patients who experience a severe skin reaction during treatment.</p><p>As this medicinal product contains anhydrous lactose as an excipient, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Textbox_x0020_2" o:spid="_x0000_s1027" type="#_x0000_t202" style='position:absolute;
  margin-left:54.1pt;margin-top:7.65pt;width:481.5pt;height:149.15pt;z-index:-15728640;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#dadada" strokeweight=".48pt">
  <v:path arrowok="t"/>
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='margin-top:1.05pt;margin-right:
     0in;margin-bottom:0in;margin-left:3.8pt;margin-bottom:.0001pt;text-align:
     center'><b style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:
     normal'><span style='font-size:12.5pt;mso-bidi-font-size:11.0pt;
     font-family:"Traditional Arabic",serif;mso-hansi-font-family:"Times New Roman";
     mso-bidi-font-family:"Times New Roman";color:black;mso-font-width:85%'>Warfarin</span></i></b><b
     style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
     style='font-size:12.5pt;mso-bidi-font-size:11.0pt;font-family:"Traditional Arabic",serif;
     mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
     color:black;letter-spacing:1.6pt'> </span></i></b><b style='mso-bidi-font-weight:
     normal'><i style='mso-bidi-font-style:normal'><span style='font-size:12.5pt;
     mso-bidi-font-size:11.0pt;font-family:"Traditional Arabic",serif;
     mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
     color:black;mso-font-width:85%'>Drug</span></i></b><b style='mso-bidi-font-weight:
     normal'><i style='mso-bidi-font-style:normal'><span style='font-size:12.5pt;
     mso-bidi-font-size:11.0pt;font-family:"Traditional Arabic",serif;
     mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
     color:black;letter-spacing:1.8pt'> </span></i></b><b style='mso-bidi-font-weight:
     normal'><i style='mso-bidi-font-style:normal'><span style='font-size:12.5pt;
     mso-bidi-font-size:11.0pt;font-family:"Traditional Arabic",serif;
     mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
     color:black;letter-spacing:-.1pt;mso-font-width:85%'>Interaction</span></i></b><b
     style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
     style='font-size:12.5pt;mso-bidi-font-size:11.0pt;font-family:"Traditional Arabic",serif;
     mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
     color:black'><o:p></o:p></span></i></b></p>
     <p class=MsoBodyText align=center style='margin-top:5.25pt;margin-right:
     5.5pt;margin-bottom:0in;margin-left:41.4pt;margin-bottom:.0001pt;
     text-align:center;line-height:150%'><span style='font-family:"Traditional Arabic",serif;
     mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
     color:black'>Capecitabine<span style='letter-spacing:-.3pt'> </span>Warfarin<span
     style='letter-spacing:-.25pt'> </span>Interaction:<span style='letter-spacing:
     -.2pt'> </span>Patients<span style='letter-spacing:-.25pt'> </span>receiving<span
     style='letter-spacing:-.15pt'> </span>concomitant<span style='letter-spacing:
     -.4pt'> </span>capecitabine<span style='letter-spacing:-.3pt'> </span>and<span
     style='letter-spacing:-.25pt'> </span>oral<span style='letter-spacing:
     -.3pt'> </span>coumarin- derivative anticoagulant therapy should have
     their anticoagulant response (INR or prothrombin time) monitored
     frequently in order to adjust the anticoagulant dose accordingly.<o:p></o:p></span></p>
     <p class=MsoBodyText align=center style='margin-top:0in;margin-right:5.5pt;
     margin-bottom:0in;margin-left:41.55pt;margin-bottom:.0001pt;text-align:
     center;line-height:150%'><span style='font-family:"Traditional Arabic",serif;
     mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
     color:black'>A<span style='letter-spacing:-.25pt'> </span>clinically<span
     style='letter-spacing:-.1pt'> </span>important<span style='letter-spacing:
     -.35pt'> </span>Capecitabine<span style='letter-spacing:-.25pt'> </span>-Warfarin<span
     style='letter-spacing:-.2pt'> </span>drug<span style='letter-spacing:-.1pt'>
     </span>interaction<span style='letter-spacing:-.2pt'> </span>was<span
     style='letter-spacing:-.2pt'> </span>demonstrated<span style='letter-spacing:
     -.2pt'> </span>in<span style='letter-spacing:-.2pt'> </span>a<span
     style='letter-spacing:-.05pt'> </span>clinical pharmacology trial.<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><v:shape id="Textbox_x0020_3" o:spid="_x0000_s1026" type="#_x0000_t202"
  style='position:absolute;margin-left:68.25pt;margin-top:170.9pt;width:481.5pt;
  height:74.45pt;z-index:-15728128;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#dadada" strokeweight=".48pt">
  <v:path arrowok="t"/>
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-left:4.45pt;line-height:150%'><span
     style='font-family:"Traditional Arabic",serif;mso-hansi-font-family:"Times New Roman";
     mso-bidi-font-family:"Times New Roman";color:black'>Altered coagulation
     parameters and/or bleeding, including death, have been reported in
     patients taking Capecitabine<span style='letter-spacing:-.25pt'> </span>concomitantly<span
     style='letter-spacing:-.1pt'> </span>with<span style='letter-spacing:-.2pt'>
     </span>coumarin-derivative<span style='letter-spacing:-.25pt'> </span>anticoagulants<span
     style='letter-spacing:-.2pt'> </span>such<span style='letter-spacing:-.2pt'>
     </span>as<span style='letter-spacing:-.2pt'> </span>warfarin<span
     style='letter-spacing:-.2pt'> </span>and<span style='letter-spacing:-.2pt'>
     </span>phenprocoumon.<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img alt="" width="861" height="462" src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAeAB4AAD/2wBDAAMCAgMCAgMDAwMEAwMEBQgFBQQEBQoHBwYIDAoMDAsKCwsNDhIQDQ4RDgsLEBYQERMUFRUVDA8XGBYUGBIUFRT/2wBDAQMEBAUEBQkFBQkUDQsNFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBT/wAARCAHOA10DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD9U6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPj3wR4Ij8dw+JtY1jxN44kvX8W+IrYC08b6zaQxxQ6zeQwxpDDdJGipHGihVUDCiuj/wCFM6R/0MfxA/8ADha//wDJtHwZ/wCRc8R/9jn4p/8AT/f13lAHB/8ACmdI/wChj+IH/hwtf/8Ak2j/AIUzpH/Qx/ED/wAOFr//AMm13lFAHB/8KZ0j/oY/iB/4cLX/AP5No/4UzpH/AEMfxA/8OFr/AP8AJtd5RQBwf/CmdI/6GP4gf+HC1/8A+TaP+FM6R/0MfxA/8OFr/wD8m13lFAHB/wDCmdI/6GP4gf8Ahwtf/wDk2j/hTOkf9DH8QP8Aw4Wv/wDybXeUUAcH/wAKZ0j/AKGP4gf+HC1//wCTaP8AhTOkf9DH8QP/AA4Wv/8AybXeUUAcH/wpnSP+hj+IH/hwtf8A/k2j/hTOkf8AQx/ED/w4Wv8A/wAm13lFAHB/8KZ0j/oY/iB/4cLX/wD5No/4UzpH/Qx/ED/w4Wv/APybXeUUAcH/AMKZ0j/oY/iB/wCHC1//AOTaP+FM6R/0MfxA/wDDha//APJtd5RQBwf/AApnSP8AoY/iB/4cLX//AJNo/wCFM6R/0MfxA/8ADha//wDJtd5RQBwf/CmdI/6GP4gf+HC1/wD+TaP+FM6R/wBDH8QP/Dha/wD/ACbXeUUAcH/wpnSP+hj+IH/hwtf/APk2j/hTOkf9DH8QP/Dha/8A/Jtd5RQBwf8AwpnSP+hj+IH/AIcLX/8A5No/4UzpH/Qx/ED/AMOFr/8A8m13lFAHB/8ACmdI/wChj+IH/hwtf/8Ak2j/AIUzpH/Qx/ED/wAOFr//AMm13lFAHB/8KZ0j/oY/iB/4cLX/AP5No/4UzpH/AEMfxA/8OFr/AP8AJtd5RQBwf/CmdI/6GP4gf+HC1/8A+TaP+FM6R/0MfxA/8OFr/wD8m13lFAHB/wDCmdI/6GP4gf8Ahwtf/wDk2j/hTOkf9DH8QP8Aw4Wv/wDybXeUUAcH/wAKZ0j/AKGP4gf+HC1//wCTaP8AhTOkf9DH8QP/AA4Wv/8AybXeUUAcH/wpnSP+hj+IH/hwtf8A/k2j/hTOkf8AQx/ED/w4Wv8A/wAm13lIyllIDFSRjcMZHvzQBwn/AApnSP8AoY/iB/4cLX//AJNo/wCFM6R/0MfxA/8ADha//wDJtfFHjT4//F/wx8Ov2gr6D4k6lLrHw+8U2un2DT6Vph3WMtw0KGULagMzBgSw28ouAASD734Tf4jeJrfQLJPiR4mtr/xFMNZjFxY6QZ9J0NFAUzYsAhuJ3dAFIG3ccBvs8u8A9c/4UzpH/Qx/ED/w4Wv/APybR/wpnSP+hj+IH/hwtf8A/k2qdn8fvAa+MLDwcPEct5rdxdPpcNwbGc2txeRRl5YRdrELYzKFO6NXBDfLtDfLWNqP7Xnwi0zxvP4Qk8ZwXHiSHUYdJbT7G0ubpjdS52RKYo2ViCpVtpIRhtfa3FAHS/8ACmdI/wChj+IH/hwtf/8Ak2j/AIUzpH/Qx/ED/wAOFr//AMm14HafGDRv2gtU+Kt1rnifxR4D+H/hYpp+m6ppr3+hyR3CDbdTyz7EVpvMlijS1k3EbcmElq9m8L/Hb4eQeCdcu18S3Ntpvg2OK11ibxJb3VpeWp8tTGZ1uo0lZ3BXDFSXY4GWOKANb/hTOkf9DH8QP/Dha/8A/JtH/CmdI/6GP4gf+HC1/wD+Ta841z9s74N694B8UXWn/EtNKhtbKKOTV4dOumezku0YW7Ihi/eSjl/LUFgI3LABWIm0H47fDb4A6PoPw98X/E+41bxVZaQL64utbE899cqVaQs5CtiRudkBYyFdgAbIJAPQf+FM6R/0MfxA/wDDha//APJtH/CmdI/6GP4gf+HC1/8A+Ta2fh38RPD3xX8G6d4q8K6iNV0DUBIba8EMkXmbJGjb5ZFVhh0YcgdK82/bM+IOpfC/9nTxV4i0bWbvRNZt0ijsp7JIXkeaSVY1TEsbjB35OAGwpwwPNAHYf8KZ0j/oY/iB/wCHC1//AOTaP+FM6R/0MfxA/wDDha//APJtfO/xc8IeL/2f/wBmS2+IWi/ELxTZ+PNA0m0bVV1rV59VsdTmke3WdZLe7aVY23btjQhCNxGcHj1fUP2vPhv4J8O+Erjx14ktfDGta5ocWtHTGimmkgRoVkYOERinJKqHwXYbV3NxQB2P/CmdI/6GP4gf+HC1/wD+TaP+FM6R/wBDH8QP/Dha/wD/ACbWN/w1F8Nf+Jnt165kbS9Ci8S3qx6Reu1vp8gRkmcCHI+WRWKffC5YqArEap+PXgX/AIV9ovjUa08nh/WpI4dLeOxuHub6R3KpHBaiPz5HJBO1YydqlsbQTQBJ/wAKZ0j/AKGP4gf+HC1//wCTaP8AhTOkf9DH8QP/AA4Wv/8AybUHw5/aC8A/FrWrvSPCuvf2nqtnC093ZtZ3EEtqFmaErMssamJ96MPLfD4+bG0g11vi7VLfQ/CmtaleX0umWlnZTXE19CqF7dEjZmkUOrKSoBI3AjjkEcUAcz/wpnSP+hj+IH/hwtf/APk2j/hTOkf9DH8QP/Dha/8A/JtfP/7Pv7SH/CI/Bfwl48+OfxPkhvPGk80WlabfWVtHFFGkrKjj7NbK/wB0KzyufLUSJnaSM+z6X+1F8M9c8M+MvEGmeIn1HSvB7mPWpbXTrp2tSCQTsEW51G1iWQMoCkkgAmgDZ/4UzpH/AEMfxA/8OFr/AP8AJtH/AApnSP8AoY/iB/4cLX//AJNrm/Av7S3h7xD8MdO8Y63Bqfh2PUrnybPT7zR7xbq581ma2S3h8stdO0Oxj9nEi8OQSqki5qf7Unws0XwRo/i6/wDGFrZ6Fq901lZTTQzLLLMjmN08gp5qlGGG3KNvG7AIoA2P+FM6R/0MfxA/8OFr/wD8m0f8KZ0j/oY/iB/4cLX/AP5Nrn7f9q/4W3nha18RWfiSbUNLujceS1jpV7cTOlvnz5hDHCZPJQjDTbfLBwN2SK6u++L3hGw8H6P4nbWFuNI1pIn0s2dvLc3F/wCYu9Fgt41aWVtuWKohYKrEgBSQAVP+FM6R/wBDH8QP/Dha/wD/ACbR/wAKZ0j/AKGP4gf+HC1//wCTa4Lxh+2N4F034e6T4i8Nz6h4nl16/k0jR4LLR7yQy3quEaORPKDoV3b9hAd1VvLVyKlm8YeH/i38evCmnaB8Rdb07UPC9jNq2q+D7WzuLVbqOZYlhN6ZFXYU3Z+zyAv+8U7U2kkA7j/hTOkf9DH8QP8Aw4Wv/wDybR/wpnSP+hj+IH/hwtf/APk2qek/tFfD3XPFOk+H7LXmkvtYMq6XO1hcpZakYhmT7LdtGIJ8D/nnI3tXN+IP20vgr4Xv/EVlqPjyzju/D8yW+oww21xM0TsxXC+XG3mAN8rFNwRiAxUkAgHYf8KZ0j/oY/iB/wCHC1//AOTaP+FM6R/0MfxA/wDDha//APJtdrp99BqljbXlrIJra4jWaKQAgMjAFTz6gip6AOD/AOFM6R/0MfxA/wDDha//APJtH/CmdI/6GP4gf+HC1/8A+Ta7yigDg/8AhTOkf9DH8QP/AA4Wv/8AybR/wpnSP+hj+IH/AIcLX/8A5NrvKKAOD/4UzpH/AEMfxA/8OFr/AP8AJtH/AApnSP8AoY/iB/4cLX//AJNrvKKAOD/4UzpH/Qx/ED/w4Wv/APybR/wpnSP+hj+IH/hwtf8A/k2u8ooA4P8A4UzpH/Qx/ED/AMOFr/8A8m0f8KZ0j/oY/iB/4cLX/wD5NrvKKAOD/wCFM6R/0MfxA/8ADha//wDJtH/CmdI/6GP4gf8Ahwtf/wDk2u8ooA4P/hTOkf8AQx/ED/w4Wv8A/wAm0f8ACmdI/wChj+IH/hwtf/8Ak2u8ooA4P/hTOkf9DH8QP/Dha/8A/JtH/CmdI/6GP4gf+HC1/wD+Ta7yigDg/wDhTOkf9DH8QP8Aw4Wv/wDybR/wpnSP+hj+IH/hwtf/APk2u8ooA4P/AIUzpH/Qx/ED/wAOFr//AMm0f8KZ0j/oY/iB/wCHC1//AOTa7yigDg/+FM6R/wBDH8QP/Dha/wD/ACbR/wAKZ0j/AKGP4gf+HC1//wCTa7yigDg/+FM6R/0MfxA/8OFr/wD8m0f8KZ0j/oY/iB/4cLX/AP5NrvKKAOD/AOFM6R/0MfxA/wDDha//APJtH/CmdI/6GP4gf+HC1/8A+Ta7yigDg/8AhTOkf9DH8QP/AA4Wv/8AybR/wpnSP+hj+IH/AIcLX/8A5NrvKKAOD/4UzpH/AEMfxA/8OFr/AP8AJtH/AApnSP8AoY/iB/4cLX//AJNrvKKAOD/4UzpH/Qx/ED/w4Wv/APybR/wpnSP+hj+IH/hwtf8A/k2u8ooA4P8A4UzpH/Qx/ED/AMOFr/8A8m0f8KZ0j/oY/iB/4cLX/wD5NrvKKAOI+GOhN4L/AGkvD2mWOveKLzTdR8Ja1c3NnrfibUdUhaWG80lYpAl1PIEZVnmG5QDiQivpqvnjw/8A8nTeDP8AsTPEX/pdolfQ9ABRRRQAUUUUAFFFFAHzB8Gf+Rc8R/8AY5+Kf/T/AH9d5XB/Bn/kXPEf/Y5+Kf8A0/39d5QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB+evxj/Z5+IPiTxt+1R/ZmnX1r4U1iz0/UYFtrZ3m1u6gtxLHb24x86iVnLlQTuRUH3mx9PfB3wt4o+FfwD/tfWrJ/EHxEXQI5bmwtxhne3tiLexjGTjaBtODhpZJXGN+B7ZRQB8B/CPRfFWsfGr4ZeJPFXgrxhZaJ4d0DUdeukTw99h0zTr64Z91va2MSq7FGMoH7uS6ld1c+ZFskHefs7XknhfwP8Vvid4j8C+Ij421fxHd6tFpdz4UvPt6ptZLGCJRDucBS43qSE85t7Lkk/YFFAHwh4FsvFfhH9mf4V+GrTwd4jn1PWvEjXfirULrwq1xfaZN5puDJHb3MJjEjP5SJcujRJtYkggFeYXRvGei/sq/FG3PgjxzH41+JPie5UC80i51C6i04yxxs03liRlVIRIq+ZtZy5Kb1ANfotRQB8iftC+GNPvvDvwh+GHhfwdrknhvUNX0e41u6sfDV2IIdKgPyx3DLCPLkZguUf5owCXVQQTzXiPxN4gl+JP7QPxEsvBfjObVf+Edt/C3g6NfC+oCS5V0dpZVBhGEFwFc5x8q+pFfcFFAHmf7M/g2H4f/AAA8A6DDb3Fq1ppEBniurd7eUTuu+bdG4DIfMZztYZGea8U/bL1S+8Z+PPhf4Mg8NeLdQ8M6b4ktta8Sajpnhy+u7VYYVDRxB4oWE27e2Qm7aQM8jA+t6KAPnD4veDvEH7WDaP4TbRtR8M/ChbuLUNZ1LVVNpe6ysZJS0htW/fQpvCl3nWJvlUoCOWxPD+jwfEj9tPXNS1rwjq8fhjw94Y/sDQn1bw1cxafcSSMTdyRySQhAAjNAMkB1dtu5Tk/VVFAHwJ8Qrf4jjU/2mpdN+F3i7U/EfjK9tvDWlapBBGtktgIxbq4ZpA+wo0jl0RkUld7JyRL8cPH3hf4M/FL4EaHql1dfDg+CfDsl1Y6prelSarpzvLbratayWtrIGeZApbzo5tqMMYcOGX72rx5fgLq+k+PPFWu+HfiJq+hWXiuZbvV7f7HbXVykyRpHG1pPKjCFQiKhSSOYbchPLOGAA79lPS/BFl8HLG+8Ba3ceJ9I1a8utQudeu4Whn1C8eZluJnjZEKnehUDaMKi9ep5X9uvxNrtn8A/EHhnwr4b8QeJfEXiOD7BFDoukXN4sULMoneR40ZU/dllAYgktwCA2Pb/AAb4N0b4f+GdP8PeH7FdO0ewQx29urs+0EliSzEszFiWLMSSSSSSc1tUAfGusWdtN8VfgF4dsvDXi5fAHw/0iXU7i8PhXUvLa5SyUWsZzBuMqhWYgAtvbZ/rPlrz7U9C8ba1+yb8YNag8HeLoPFnj/xk76hpZ0SYala6c00e1Y4GUGVRANuVJX94w3AqSP0LooA+KfjNoPiO8/aA+Dd/c/DXxzfeCLHw/PaWdh4Xu2gvdLvpCY8TXFvcxxwfuRCpYzhCC4ywU1N4w+HtjafEz4F/Dmy8B65p/gjRdXn8Qa15enahq9hFfyKWto2vXjYODLK5kctsTcdxABx9oUUAfB37Vkfj7xLrHxW8PeG/h74itre20ux0bRZvDeiKiazDdP5l29xehN/kRPJ/x7wyDc0jNKrJ5uzsofDusfDL9p/wHeXnhDxJe+BNE+H66P4ei0zTmvfsWoF41eKYwl44ZGjXYZHcR/dzJtDMPr+igD5R+Kmn67H+0Z8Ent/h1rL+F9Jt9S1qe20GzjktLfU7hX3G5lBWNChaSUsCzO7nYsjNg+e654d8c/FDwv8AtUeK/D/hrxFpninXhaaTotrrGlXNhLcaTCqpIYBKi7jLGJzsHzBigIBYA/eFFAHyRa+DZ/iFr3wV15PD+ueHfAfwu0lrq5hvtHuob6e9FvFHHaQWhjE7iIIGLrGUfO1Cx3bfGbzSfEniX9n/AMRaVeeC/HNt4h+KPxCa81+M+Gr4S6XpguYnyxEONixrHjG7O+QDOxgP0dooAjtreKzt4reBFihiQIiL0VQMAD8KkoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm/D/APydN4M/7EzxF/6XaJX0PXzx4f8A+TpvBn/YmeIv/S7RK+h6ACiiigAooooAKKKKAPmD4M/8i54j/wCxz8U/+n+/rvK4P4M/8i54j/7HPxT/AOn+/rvKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm/D//ACdN4M/7EzxF/wCl2iV9D188eH/+TpvBn/YmeIv/AEu0SvoegAooooAKKKKACiiigD5g+DP/ACLniP8A7HPxT/6f7+u8rg/gz/yLniP/ALHPxT/6f7+u8oAKKKKACiiigAooooAK85+OfxEv/h/4d0WHRlg/t3xFrdn4f0+a6QvDby3DHMzqCNwRFkfbkbioGRmvRq4T4zfCqH4u+EItLGoyaLq1hfW+raTq8UfmtY3sD74pdhIDj7yspIyrsAQcEAGRq/wTvF0m+utB8e+LdP8AGUkDiHXLvV5LqEzFeGewkDWQUnGVjt0wM7Nh5rc1/wCMnhbwt4ktdC1O7vI9QnuLazL22l3dxaQ3Fw6pDDLdRxGGJ3Z0wsjq2JEOAHUnE/tT40yaf9mPhnwJDetF5f8AaS+JL10STGPOFsbAEgH5vK84Z+75n8VcN8aPhD8UPH2vx/YdS0vUdD02/wBJ1LS4L/W57Ab7WeGaZbiG3tGWVpWjfDu7InybIVYFyAdlq37T3gjQdc8T6Zfx+JIW8Nn/AImV1F4X1K4t4BsLlzJFAwVAo3b2wrL8ylhk10Pir4zeFPB8lul3dX9+09oL8f2HpF5quy2Ods0n2WKTy422ttZ8Btj7SdrY8r01fG2o/GD4w6boGleH3t746bBd3+papMjWbvp6KWjgW2YXAUEttaSHdjGVzuE2vfs3f2L4t0bU9C8I+D/Hel2Wg2Wipp/jV/LmsWsywt7i3uBa3HLJIyuuxeY42DdRQB6bq3xo8J6Va6VOl1f6xHqlmmoWo8P6ReaqzWzgGOZltYpCiP8Aws4AbDYztOMv/hZXh5viBdkX/icXtl4bfU5dFfSLqO3a23RyeckbwB5bj5wmyMsyncjIH4qhe+EPiB4b+IU/i3QYvDniS41jRbPTdXs9SvZ9KSK4tXmZJrdkguWMb/aZgY35XapDtk4fJ4J8a3HxusvEVzDoM2gL4dk0S5vIr2eK6aR2SVpktTCyhfMTaENwSFbduJG0gB4K/aU8L+L/AId6N4say8QWEepxxPFp58P6hNcuzx+ZiFEgLXCKvWWEPGP72CK5fx98TtJh8efB3xrpepeIbvw9rS3sb2+kwajcLdQ/ZHeMvp8SsSyuc7jFvXHJAHFfRfhj8W/D3wf8G+C7SbQYotBSHTbtdP165spNUsorcxhvtYsnktmdthKRLvXZlbgZxVbwp8GfiR4L8K/CmC1tfC+p6r4JnvYpYp9ZuoYb2CaB40kEv2SR0ky+ShVxhfvsTkAHaeKPjT4M13whDeLr3iHSIU12z06V9P0y6hu7a9W4haO1ukeAm3SVmijPnBFdJsBsOCdTW/2hvBfh/wARaxoV1Jr0uq6QqSX1vY+GNTu/IjcMUkLQ2zL5bbHw4O07GweDXD+OPgv4y1zwj4hm0618Pv4r8UeItK1zUoLnVJ4rO0Sxe0aOGGVbVnlLLZKpdo05lZsYUIdhvBPxDj8c/ErXINM8NCLxFolnY6era3cB0uIBKP3oFn8qH7TIdyliPKX5fnJQA7TVvjF4W0fS9DvzdX2ow61ai+0+PRtJu9Rnnt9qN53k28UkixgSR5dlABdQTlgK1NK16w+JXgmLU/DmtzwWWqW5NrqlnEomhzkbgk8bBXUggpJGcMpDLkEV4Vcfs667ceHfhrJqfhTwL4w1Dw7oX/CP6j4f8RXDz2EqRhBBdW9w1m7JKPLOVMGCJ3Xd8gZvoPw1DqFvoVlHqsdjDfqn7yHTQwt4efljQtgsFXC7sLu27tiZ2gA+YNZ8QfEmx+Hnxcto/iZrS+Nfh9ez33mT2mkxRX2mtElxb7i1ntUGBZV3jGJhIWyqhF7PwvN4r8UfDb4eC1+KGuT614qeHVJNUt7bSpGt7P7P5k0aj7EI2jBKIHKb/MkQkhcpXS+Pfgzf+Jvi74f8UabqFvY6RJbCy8S2bhvN1CGCdLmyCEDHyyrIrhuGimdcc0nwV+DOpfC/XPEIvNRtr3QIriaLwtZQoQ2mWM8zXM0LEgcmVwgAJAjtoehyKAOkuPi54Y0fxVZ+Frq/1CXVZZ0sVuP7KuntWuSm8RPdJD9nSUqN2wuDyOBkVl/8NE+C5NT1nTbdtfvtQ0aaS31C2s/DGpzvbSJGJMPstyFDIQUY8SA/IWrg/iV8Kvin4u+JVprUNzo2oaPo2uWuq6PaXWv3VnEsEcarJBJbRWjKZGcu/nSyTbdoVEjDtXS+DfBvj7wz4l+K17NpXhuW18SX7alpnl63cb962tvaxxTg2eI1ZbfezqXKltoV8biAcb8Jfit4SvPBPhv4ma/eeNP+Ei1uza6ubBItdubZSYo3maDT0VojbRCaNBcJEY8lf3hdiT6hrnx/8E+H7zQrS5vdSmuddsBqelRWGh31419BwSYfJhfe6qwdoxl1Q7mULzXlNj8H/i9D8HfBXgMzaBZWGk6U2jalFpniO7tjehIYEt7gXCWQmUArOzW8Zj3YjBnKl0Ov4T+GHxJ8P6h8G5ZtL8Kyw+DtCl0TUSmvXO6QSC3iMsINj82I7VX2sVy0hTIC72AOqt/jL4Q0Sb4h+IbrWPEpsND+zvq1tfaNeCPTFCMN0MH2cSmMqpkeQBkwd24KDjf8KfGzwp4z8RW+h6dNqkWpXNpLfW0ep6HfWCXUEbRrI8MlxCiSgGaL7jHhwenNebeNPhT8RPEafHG2ttP8MR2/jjSf7L0yaXW7kPFiBrYSTqLMhf3cjyYVn+ZAmcMZF6KHwX48uPil8PNfutP8PQaRoeh3enX6Q6zcPN51wbYs0Sm0VZFT7KoG5kLeax+XbhgCH9o7VvE2j3nw3Tw74u1Lwwms+J7fRL0WFtZTeZDNFK5b/SLeXa6mEbSMDDNkNxjf1n9oDwd4d8R6r4eupdfuNY0mOOW9t7Hwxqd2Y45A2yXdDbMpRtj/ADqSuVIzkYrN+Pngfxj42uvAcnhSy0O6XQNfh124/tjVJrMyGKORFiTy7ab73msSxxt2Dht3y15PBfj2z+KHxG8R2WneHZbLXdCsdO04TazcRyie2NyQZVFoQiMbt+VZiPKXg7zsAL2rftGeGNN8T+CdKt7bWNWtvFmlSaxY6jpej3l3CbceTsb91Ex+bz1J4HljBfbvTdrX3x08Hab4k/sW5vr6Of7cmm/bf7HvTp32p2CrCb0Q/Zw+9hHt8zIf5Dhhtrz3wn8IfHvhXT/gzPDD4ck1TwZoFx4av7eTU7hoHhkWzRbmKQWwZ3AswxhZEBMhXzBt3GfwR8D9W+Hvj/Ub7TvC3gW9hudZu9Rt/F90jJrdrbXUzTzWxjW3PmkPLNGr/aUARkyh2FXAOy079oTwPqmpapZQX2pCXSpZ4dRkn0K/hgsXij81xPM8Aji+TBUuwD5GzdkVpaD8Y/CniLT9dvYby8sIdDVX1Fda0u702S3VlLKzR3MUbFSAcEAg4ri/C3gr4l+HrX4sC2j8N6ZqHiG+utV0K/i1Ka68m4e2ihhWeJrVAqgwq5YF8bsbGAy3FaP+z38Qbu3+I0Or3umWs3iqzsZ4tSk1y51aeHULSTevmJJawoYZWJZliESRgmOOILggA9H8WftIeHfDPw/8S+KV0jxTPDodt9okt7vwxqVg0pJwqqZ7dARnG5hkIPmbAq1H8TPD3iTx94OtYb/xVpuoXkN3La6bd6JeafbXiBWDmf7Rbp80fl5VNyv86ttKsDVDxx4Q8f8AxY+E3jTw1rlr4b8O3+qaa9pYDT9QuL+IzFSQ8sjwQlEJ2jaqMQMncfu1Fq3hn4j+IPiN8PPEV3o/he2ttFN2dQhh1y5d0E48oiHNmBLtRVfLeXuZimFC72ANu7/aD8EWN99nnvtSitvta2P9rHQ7/wDsvzmlEIX7d5H2bHmkR7vMxu+XOeKi1r9orwT4f13WtHupdel1HRQG1GGy8Mapdi2RgSsjtFbMojYK5V87W2PgnaccOvwT8a/8K3u/hNKugz+BZpJIE8QNqE41JLF5vN8s2f2cxmUKTEJPPA6SbePLrZ1DwH4/Xxd8V9SsbDw61v4m0y3s9KabWLhJFkiR4w0yi0IQETO3yM5BRR/EWUA9Ss/GGh3yaI0OrWZbW4ftGmRvMqSXkYQSFokOGYBGDHA4B5xXln7WnijXPAfwwi8SaJ4vu/CD2ep2FvczwxWbxNBcXkMMjSG5hkC7Ed2BBUA8tuAxXW/DvRfEfhfwh4D0PU9G0mSXTbAWV/dWupPKLbyohHE8O+3Qy+YFG7Ij2bj98DNZH7R/gPxT8SvAdrofha30eS4/tSxv5pNYv5bVEW2uorgKvlwSlixi287du7POMEA4X4f/ABali+LWoWlh8Sm+Jvw6tPDkmpapr0osJYtLvFnCxRLPYwRRszx+aTE25/kVhgHDdx4l/aT8LaH8OvF3iy2ttbvV8NIv2vTZtEvbO7EjqGjBinhV1Rsg+Zt2gZJPFdh4ij8W6l8OtQj0ptN0XxpPp7rbN57XFpbXRQ7SJGhBZQ3RjF2yUP3T4NZ/s9fEHUPDPxb0vVJ9Jim8baXGsN5Pr93qcsV7HGUAlL2sQ8pyS58oRrHnYkO0A0Aepx/Ezw94k8feDrWG/wDFWm6heQ3ctrpt3ol5p9teIFYOZ/tFunzR+XlU3K/zq20qwNX7f46eDrnxHa6Kt7qC3N3dSWNrdSaNepY3NwiuzRRXjQi3kbEcmAshJKEDJ4rnNW8M/EfxB8Rvh54iu9H8L21topuzqEMOuXLugnHlEQ5swJdqKr5by9zMUwoXe2T8Hvgjqvwn15YbXwr4ES3ieWEeMbZGTWrqyL7kgmiFuuXACIZPtDA+WrbP4QAdDp/7T3w+1TyWhvNcW3k1BdKa7uPDGqQ20F21wLcQTTPbCOF/OIQiRlwSM4zT5v2i/DFj448X+HdQttY0+Lwxai6vdVl0e8azVRBJPKzTLCY0RY4wQzOPMJKoDgbvPpPhD8UJPhLqnhwad4TTVb7xo3iVtuv3Xkrbtqo1Ixb/ALDu37lEP3MYJf8A2K7iTwH4wsfiB421S20/w1quieKNNgWa21O7mDJcRW0sQgaMQMskDs0e6QsCF3jy24oA9D8K+LLLxlpZ1Cwg1K3gEhi2arpV1p02QASfKuY43xz97bg84PBrltB+PngrxJqmoWFjfaj5umyTw6hNdaJfW1vYPCm+QXE8kKxwYT5h5jLuBBGcjMHwJ8A6x8OfDN/pmprb2Nk14ZNM0Wz1SbUoNLtRFGot4p5oonKb1dghTCBwq/Koxy2i/B/xRrnhf4u+FfFUGj6dpHjS4v5re+0jUprueEXMCw4eKS2iUFQgfIdsk4xgZIB23hv44+D/ABTqEtjb3moaddR2T6j5eu6Pe6VvtkKiSZDdQxh0Xem5lyF3LnGRUuh/GTwzr4vpIjrNhaWNpJfz6hrHh/UNOs1gTG5xcXEEcTDB3fKxJUFhkAkeeaB8D9a1D4eeLfB+p+GvAvgODxDo02najqXgqNml1C4liMZuGiNvAIgu6RvLLTE+Zjeu0l+huvB/jz4lfDvX/CHjaHw7oFvqGjSab9u0C9mvpJJ3QL54SSCBYVXBby8ybt4G5dnzgFtvj34N1ix1e2W78Radc2+nPfPFN4a1K2vfs25Y2nt4ZbYPMEZ0yY0cLuUtgGpPCfxe8KQJ4B8Npqutahf+INIhu9Jur/TLqRr+EQBzLLcrD5Il2gM4LKQWGQNy55rwV8OvF3hfwdrunWngT4b+Fry805opI/DVxLBDqd4yhfOlZbNPIRR5hC7Z2PmAb12EuQ/B3xXcfBD4faN9p0nRPH/gz7C2n6hbTy3VoGgT7PISTHE5Wa2aVWTaMGXGW2gkA2NS+L/hXxJdeExFqXivSXuNfNnaquhX1lHeXEasr207T26qIvnZuSu5oWCEtGy0uqftPfD7RpdeS7u9dQaBM8GrSp4X1SSKxZEDkzSLbFUXYyuHJ2lTuBI5pnxP+HviW9tfh5ZeD7HR7qz8O6tDqVy2sanLauyxRtGqr5dtLvZ/NdmY7cFRw24leN8SfCD4j6x4U+PGkW1p4Yhk8fXEn9mzPrNziGKSyismMwFnwwSESbV3AlymQF3sAeqeMfjN4W8C3z2epzapcXEdqt7MukaJfamLeBiwWSU20MgiVvLkwXIzsbGcGt3wf4v03x54dtNc0g3babdrvge9sZ7OR17N5c6I4U9QSuCCCMgg188eKvC/jrxb8V9Vt/D8Wj2ky+HNOsfElnY+JWtRKC1yy200kmmTs67JJNksK20gWR9x/wBXs9k+Hd5bfED4P2kMelv4Zt5rSfSTYwzLMtr5TPbN5Mo4kizGTHJgb0KMVXO0AE3hv4y+GPFl8INMfV5oGiadNTl0G/h02WJRu82O9kgW3eMr8yushVwQVJBBqno/x88Ga1rGl6dDdapbSarL5Gn3WoaDf2dneybGkVYbqaBIZCyIzLtc7wCVzWJ4M8DeOJPh+ngDxbB4ej0CDRW0VtW0i9mkur6PyfIV/s7QIlsxX5yBJMAflHHzDN0z4Z+PNc0rwX4Y8Vx+Ho9F8L31lejWtMv55bvUWsyDBm1e3Vbcuyo7kTS42sg3bt6gG1dftQfD6zfVRNea4kek3LWmo3H/AAi+qGCylUKSs8v2bZEMOrZcgbWDZwQa6fxZ8VvD3g3VF029/ta91Dylne20XQ77VHhjYsEaUWsMnlBir7d+N2x8Z2nHkWvfCH4j6t4A+MWgRWXheKfxlq73djKdbudscEkMUMgl/wBCyrhbdCAu4EysCRsBfsF8MfEXw/451XxJotj4avx4jsrIajY6hqtxCNNuoUZGMEiWrG5iIbgOsJymeN5CgHTeIPjH4a8NahHY3A1q8vWgS5e20jw9qGoyQI+dhmW3gkMJbDYWTaTtPHBrM1D9orwHp9v4bnGpX+oQ+JLb7XpD6Tot9fi9TaWIj8iF8uqhmaP76qrMVABNZ914P8c+D/iJr3iXwrbaB4ig8R29r/aFnrGpT6Ybe5t08sSQtHb3O5HQqCjBSpjB3NuwuBo/wV8U+D9W+FMWlDRtT0zw1c395qt1dXstrNJLe+b5xggWCRdqtM7KrSLnAUkfeoA6KP8Aae+H8iSyfadejgguRZ3NxN4V1WOG0mLKvl3EjWwWBsshIkKkB1Y8MCbGqfEvw9oPjzxhNLqPiS4vND0GK6v9ETTpzbJCjyss9upiHnSSbnQtEzr+4AO0rz59q3wj+Jep/Dn4jaGNN8KR6h4n8RDVbc/27cmKGE+UWDt9hzvBt0AAXB8xjkbAG6dvh/448QfFLXdb1ax8P6Zo2seFIdAkey1ae6uIJlM0jOI2tY1dN9wyD51JWMNgFtigGr4f/aM8L6x4F0XxJcWuv2R1KJHTTl8O6lNdZ8pJHZIlt/MlhQOoNwiGLLKN2WAN3VP2hPBGkw+GZXvdUu08TWK6jo/9m6Df3pvYGQSAxiGByWCEOU++F+YqBzXB/wDCu/i7N8NfBvhdptAsINNtBpuq22la/d2xu4o4Io4pVu1tPNT5lkdooxEx+QefjcGi+H3wj+IfhW3+CVpe2Phl4PBGnyabqM1vrVwzTK0CwCSFTZjJ2pv2sV5O3dxuIB1/ib9pTwroPgmy8T2tvrOq2Vxr1v4fe3g0a8W6t7iSdInEtu0PmoUDEhSgLnai5Z1B9BXxZpa+Fm8RXM8mm6QlsbuWbU7eSzaGIDcWkjmVXjwAch1BHpXh3/CnviFqXgvxDbX1v4btdbl8aWni7T44dWuJ7eUQ3kNx9nlkNojRfLAqh1STJbO0YxXp/wAQPBesfEr4S6noF1dWmi69qFqp8223XNtbXAYSKuWCGWMMoUkqhcAnamdoAG2Xxq8M3mnahfNF4g0+2sURpG1TwxqdiZC7hEjhWe3QzSM7KqxxhnZmUBSSBWVrH7SHgvR/BN54qdtbl02z1OPR7mFdAvUuoLpwhVJYJIlkjBEkZ3OFU70AJZlBNXj+L+veCdXhgi8L+FvEhWFLGSw1Oa9Rj5qmZjLNZgRExh1QGCYBmVjuAKnxDxV8OPGXww+CvxJTVbbS7j+2vFeja1YlfEF3fy+a11psLQTzT24faGtwRKN2Q+BGgUKQD6D0P44eDtdbXFGoXelS6LYjU9Qh1/S7vSpILQ+Z/pGy6ijZoh5UgLqCoKkEinaD8bfCHiC81C0W9vtIubCybUriPxDpF5pBW1U4ecfa4ot0an7zLkLkbsZGeT174Qa98VrPxPdeLRpvhfV9R0GXw/Yrod3JqUdsjv5puHklhg3t5ixYi2AARN87eZhMnSfgfrep/C/xX4NuPC/gP4ZQ61pUlrJN4Jjadbi8ZAouHja3twiJg/uz5pcSY8xNn7wA67U/jV4X1fwj4guCfGOkWNtYtJcagPCWrW00Eb4TzYfMtPnZd4b5VbaFLkbVYilD8e9A0TxT4M8IG28R6nJrWgDVoNTTSLq7JjD28aGUwQsAzecWd+EjwNxXzEzPqtn8UvFXw/8AEml6povhCx1O80x7K2hs9aupoZ5ZV2PK8rWitCqKWIQRyliQC6YycPQ/hr480XXvhrrsdv4dN9ovhy48M6ratqVw0UUck1owuYH+zAzMFtMmJ1iBL7fMGN1AHaWXxU8I+ONeufB9te6n9uurW5KSLY31lFcRRlY5ntb3y0SQqZU+eGQkbgQe9ea/s9fHXRIfhz4R0jxBqHiA6rc3MmmpqmtaZqLW9xcNcSLDH9vmi8qRmACqfMO5gFyWIBTw38KfilH8adB8aeIrnRtVjsBqFnM/9vXJza3EkbRmC0FosMJjWILtyzybvnnbYtSeEfg142m8CaF4A8U2nh238N6XqkOpvqml6rPcXV15F8LyGLyHtY1i3MqKziVjgMAPmBUA6ax+NXgvwzp/j3xJfeIPED6Vp+tLb6mdU0u62aVN9mgHlxxCASR2+zy5C7ApulZ9+GrqPCvxi8MeMNZudJspNVstSt7U3z22taHfaWxgDBTIv2qGPeoYgErnGRmvI/Efwd+JOteHfjJp0en+FY38aapDfWLtrlziGNYLaAiX/QuG22of5dwzIVz8u5uv1b4e+MPFnxSbVNWsNEtfDV54Vm0C7+yaxPLdRST7ZJWjja1VXUOoQEupK/OQD8lAHT+F/jd4R8YeILXRtOutQS+vIJLmyOoaNe2UF7Em3c1vNPCkc4AdW/ds2VO4ZXJqb4hfGTwp8Lgx8Q3l7Csds15O1jpV3fLawKSDNcG3icQR8Nh5NoOx8E7GxxvwK+FeufDFo7O58J+AtEVYBDfa/wCG43S91spkRyTQ/Z4xCxzvbMs/JYD724Z/7THwp+IXxe0vVPD+galp8HhnUNEns2t7jVp9PZL1w4WaTybd3ni2lF8rzI05cuso2qoB3Hib45eE/CXiyXwzfNrc2ux263ZstN8OajfM0JOPNUwW7hkBIUspIViFOCQKst8XtAuvCeka7o4vPECayCNLsLC3K3d4wzuURzeX5e3B3NKUVP4itcnp/hP4g2/xUt/Fc2j+GRbx+Fv7Ia3TXbhn+1BzKME2QHllwE3/AHgpLbCRsPL+D/g/8R/COifDzUY4vDdz4n8Lf2nZ3Gnvq9wLK/tLwrIzi4+yF4pVliiIHlOCoYbstkAHS/s0a3ca1b/EbzZNb8i18W3Fvb2uv3E01zZp9ltXaHMruQqyPJgKxTnKEqQT0nir48eDvBl5qdvqNxq0o0tS2oXWm6BqF/a2eEEjCae3geONlQq7KzAqrAkAEGs/4J+D/GPhPUvHM/iq30ONde1k61bto99NOYy8EMTQOskEf3PJXEgP7zcTsj+7WU3gDx54T1TxrYeGIPD2q+HvFN7JqQutY1Ce2udMmniWOdRClvIlygKCVQZISd7IcYDkA6XX/j14M8OeILfRLm81K61S5shqNrBpeiX1/wDarclR5sLW8LrKo3rnYW2hgTgVatPi54U17xUfCcF5fnUpzcQxyDTbyG2naIETLDeeWIXZMMCI5CVKsOCpxxPhv4S+JvAfxG8CS6LbaRfeEPDnhNfCrXF7qcsV8UD2584QrbMjEC2UbTIu7eTlcc4LfCv4r3Hxk0TxlqU+h6zFo+qX3kJN4huoYzp04kjiSO0Sz8qKSJGBJYyySMzKZ1RUUAHdfs5TXLeAdTt7i/vtRFj4m16wgm1K8lu5xBDqlzFEjSyszvtRFUFmJwo5rdj+L3hy48UNoNsNavrxbn7G1zY6Bf3FiswOGRryOA24KNlXzJhGVlbBUgZfwL8J+KPBvhrWLLxTaaRa3V1rmparF/Y+oS3ibLu7lutjNJBCQUMxTgHdt3cZ2jP+G/hHx98PZpPDaxeHr3wmuq3l7DrUl7ONQ8ie4kuTE9oIBGXDStH5onAIAkKE5QgGjqf7QngfR76WC6vtSS2huxYy6smhX76XHN5ohKtfLAbZQsv7tmMmEYMrEFSBrXnxa8NWN14qtpJ9Qe58LxwTapBDpN3LJHHMGMbxqkRMykI/MQcDa2cYNeXXHwV8ar8O/EXwqi/sK48D6tJfRJ4gl1CZdStrS7leV4/sn2do5JI/NeNX89QQEYqCCp2vFHw58c2fj7xfqXhOLw7PpfijRLLS5JtYvbiKbT5YPtK+YsMcLi4UrcKdpliOVI3DOaAOi1b9oPwTo3/COebd6rcnxHYrqOkDT9A1C8N7Cyb/AN2IYGy4T5zH99V+YqBzVCD9pzwBcLvF1r0cC3S2M1zN4W1WKC1uDIIxFPI1sEgbcygiQqQGUnhgTzPhT4X/ABB0aX4JpdWHhoweC9MfTtTeHWbhmkzCtuHgU2Y3/JGsmGKfMxTOFDtlan8I/ibqHwy8baF/ZnhOPVPEHihdaj/4n10YYoDNHMys/wBh3Fw0CKAFwQ7NkbQrAHrmsfGLwroXiyHw5eXd6NSluobLzIdKu5rSO4lCmKGS6SIwxyMHQhHcNh0OMMuc7/hoDwa/iLWdBhk1281fRpXh1C0s/DWp3D2zKm8FvLtz8rrkxt92XH7svXmvxM+Ffxc8e+LLDVGk0Gax0rVtL1jTNNbxHd21tCYDBJcW8kcdl++LypLtuJS4VRHshiYuT23gvwv478N/Eb4la3caT4dk07xBNHeaf5WtTmbzIbWK3ijmU2YCK4i3M6s5TOAr9aAINC+OXgnwj4E8IXFzrviTWLLXJJ7bS9QvNGvbu7vpEaQlHENvlZCEcrGyq7KhwpKtjuvA3xI0L4jQ6m+iTXhk0y6Fne22o6dc2FxbymJJQrw3EccgzHLGwO3BDcE814r4f+D/AMStL8J/CfSptP8ACpm8I+I5tWvHj125KywNDcxKI82Qy/8ApspIbAHkoMnzCY+v8KfC7xFe+JvibJ4ujt7LR/E2q29/ZSeG/EV9BdxpDbQW6o7xxwPGSLcOdkhBMhUggbmAPYaK5nwf8O9K8DSXT6bd67ctchVf+2PEF/qYG3ONgup5AnU5K4zxnOBXTUAc34f/AOTpvBn/AGJniL/0u0Svoevnjw//AMnTeDP+xM8Rf+l2iV9D0AFFFFABRRRQAUUUUAfMHwZ/5FzxH/2Ofin/ANP9/XeVwfwZ/wCRc8R/9jn4p/8AT/f13lABRRRQAUUUUAFFFFABRRRQAUUUUAc3ovwz8IeGvEl/4h0jwpomla/qHmfbNVstOhhurnzHDyeZKqhn3OAxyTkgE810lFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHJeLvhD4E+IGpR6h4o8FeHfEmoRxC3S61fSoLqVIwzMEDyISFBZjjOMsT3rqba3is7eK3t4kggiQRxxRqFVFAwFAHAAHapKKACiiigAooooAKKKKACiiigAooooAKKKKACsPxd4E8NfEDT4rHxR4d0rxJZQyieO21eyiuo0kAKhwsikBsMwyOcE+tblFAFfT9PtdJ0+2sbG2hsrK1iWCC2t4xHHFGoCqiKOFUAAADgAVYoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb8P8A/J03gz/sTPEX/pdolfQ9fPHh/wD5Om8Gf9iZ4i/9LtEr6HoAKKKKACiiigAooooA+YPgz/yLniP/ALHPxT/6f7+u8rg/gz/yLniP/sc/FP8A6f7+u8oAKKKKACiiigAooooAKKKKACiivDv2ofjNbeAfh34kj0bxTcaF4r0+2FzDNa2a3EUcnBjhuJJIZIYjLnCo5R3/AIMmgD3GiuX8WfFTwV4Bvbaz8T+L9B8OXdyu+C31bU4LWSVc4yqyMCwzxkd6i1f4u+BfD+szaRqnjXw7purQzQ28thearBFPHLKu6JGjZwwZ1+ZQRlhyM0AdbRXmeifGjwVpvh+71vV/il4VvtFudUmhsdUN7bWtqowHW1WXzCkzop5YHJ5yAQa6a6+KHg2x1DWbC58W6Hb3+iwfadTtZdShWWxhwp8ydS2Y1wync2B8w9aAOmorzzxF+0J8OfDPhCw8U3PjHRZ/D19qMOlwalaX8Mtu88kgTHmBtuEBLuc/KiOx4FNtfi14U1DxTc3Vp8SvDdzotnopvrvT4LqB/IjLIwvZLgSfJFsdQAwAIbcDxQB6LRXJW/xe8CXcOhyweNfDs0WvSvb6S8eqwMuoyI4R0tyH/esrMqkJkgkDqalsfip4K1TxXL4XsvF+g3fiWFnSTRoNTge8RkBLgwht4KgHII4xzQB1FFY3irxp4f8AAmljUvEuu6b4e04yCIXmq3kdrDvIJC75CBk4PGc8GsjV/jJ4A8P2unXWqeOfDem22o232yymvNXt4kuoOP3sTM4DpyPmXI5HNAHYUV574i/aB+HfhvwKvjGbxho134be9i09NRsb+GeF7iRwgjDq20kZ3Nz8qqzHAUkS6H8RtA8Y+P7K28PfEDQdYtv7Hmun0HTZYbmaUGWEJeeajkrGoLIBtwxlzn5cUAd7RXKaZ8WvA+teKZvDOneMvD9/4khkkil0e11SCS8R48+YrQq5cFdp3AjIwc9Kj0f4xeAfEXiQ+HtK8ceG9T1/fJH/AGVZ6tby3W5AS6+UrlsqFbIxxg56UAdfRXOWfxI8Jah4suPC1r4p0W58TW4Jm0WHUIXvYwACS0IbeMAg8juKxdS+P/wv0XVrnS9Q+JHhGw1O2la3ns7nXbWOaKRThkZGkBVgeCCM5oA72iuVuPix4Is9JbVLjxl4fg0xb46Y17JqkCwi7Gc25cvt80YPyZ3cdK5vTfEepaV8cvF+mal4gln8NweHrHWIre9S3jisGea6jl2yLGrbNturHzGfB3YIHAAPTqK4y3+NXw9u/Dd14ig8eeGZvD9rMtvcarHrFu1rDKcYjeUPtVjuGFJzyPWpND+MXgLxNLqMWj+N/DmrSabC9zepY6tbzG1iTh5JQrnYo7s2AKAOvorjfhf8YPCHxk0H+1vCOu2Ws26hTLHb3CPNb7s7RKisWjLBSQrAHHbrXKeIPjn4U8V2vxA8MeF/G9rY+MvD0VxE8dpPbPdxzQwiV2jilDh1QnY5KEBg68MpwAeu0V5f8EvjZ4b+JHhHwxDF4r0vWfEtzpFvc3cdtPGWlmESG42hPlLI7fOqf6suoYLuXPT2/wAVPBV14vPhSHxhoM3ikO0Z0OPU4GvQyoXZfIDb8hQWIxwAT0oA6miuK0343fDrWmK6f4+8L37C0kvyLbWbaQi2jLCSb5XP7tdjbn6Dacng1Fc/Hb4c2vg+48VHx14fn8OQXH2N9TtdSing+0bQ3khkY5k2kHYMtgg4oA7qiuHsfjp8NtU0jU9Vs/iD4Vu9L0sRm/voNatngtBI2yPzXD7U3N8q7iMngVp2/wATPB93eaJaQeK9DmutciM+lQR6jCz6hGASXgUNmVQATlMjigDpaKwPE/xC8LeCbrTrbxF4l0fQLjUnaOxh1S/itnumBUFYg7AuQXQELn7y+oryvQ/jdpXg34rfEnw7408eWkcFjd2s+m2+qyW0D2ttLbrJJ/q0Q+Qjtt82XOPlDOSeQD3Oiuc8XfEnwj8P7e0n8UeKdF8Nw3hItpNX1CG1WYgAkIZGG7AI6eop8PxC8K3EGiTReJdHlh1ximkyJfxFdQYDJEB3fvTjn5M0AdBRXj3xy+JUUnwR+I+s+A/G1vDrvhWyup5J9GltLx7a5gjd/InSRJVXJXDKVDcHBBrsPiN4+0HwnY/YdU1+40K8voZPKudPtjc3FpGAA92y+VKscMRZd08yeShZN5G4AgHY0V53+zz4q1Xx58B/AniDW7w3es6pottdXd0I0jLyvGCzbVUKOTnAGPauN+Bvx00i7tdR8N+KvHllqniqy8T6poifbZLaG5cRX80NpHKsKJGs0kaDYu1TJtcop2tgA92ornLj4keErPxdD4Vn8U6LD4omAMWiSahCt64KlgVgLbz8oJ4HQE1nr8a/h42l6lqa+PPDLabpsy299eDWLfybWViQqSvvwjEggBiCSDQB2dFclq/xe8CeH9WsNK1Txr4d03U7+OOWzsrzVYIprlJDtjaNGcM4YghSAckcVZ+I3xC0P4U+CdX8V+JLxbHR9MgM00hI3N2VEBI3OzEKq9ywHegDpKK8K8Y/HTQ9L+IXw61mx+Iulv4D1pdQs7nybqzmsJ54ow0eyYKXMu87diyYOANuevqdv8RvC1z4Tl8UL4i0xfDsIbztUlu0jt4SrbXWR2ICMrfKytgqwIIB4oA6KivN/EPxe8I6x4Ph1LQPid4Z0+G41GCzt9Wju7e9hmmWRJJbRFEgDyyRBkCqS48wMASADt3fxe8Cafrkmi3XjXw7bazHdRWT6dNqsC3C3EufKhMZfcHfB2rjJxwDQB1tFY3irxp4f8CaWNS8S67pvh7TjIIheareR2sO8gkLvkIGTg8ZzwayNX+MngDw/a6ddap458N6bbajbfbLKa81e3iS6g4/exMzgOnI+Zcjkc0AdhRXnfiL9oT4c+GfBVv4un8Y6Nc+HLjUIdLi1Kyv4ZoHuJHChBIrbcqCXbn5UR2PCmrOg/ETQfGHj6C20Dx9oWs239kPcvoWmyw3MzBpItl2ZUclY9rbQu3DeZkHigDu6K5TSPi14H8QeJpvDml+MvD+peIYWkSXSbPVIJbuNoyRIrRK5cFSDkEcY5qPR/jF4B8ReJD4e0rxx4b1PX98kf8AZVnq1vLdbkBLr5SuWyoVsjHGDnpQB19Fc5Y/Ejwlqniq58MWXinRbvxLahjPo0GoQveRAYyXhDb1xkZyO4rFvvj/APC/TNXuNKvPiR4RtNUt52tZrGfXbVJ45lba0bIZNwcMCCpGQRigDvaK5Wf4seCLXSY9Um8Y+H4tMkvjpiXsmqQLC12M5tw5faZflb5M7uDxxXNaP4k1PS/jp450nVPEEtx4btfD2ma1DDfJbxx6e0s9/HNtkSNGMe21jb96zkHdyBwAD0+iuMt/jV8Pbvw3deIoPHnhmbw/azLb3Gqx6xbtawynGI3lD7VY7hhSc8j1p+jfGTwB4jbU10nxz4b1RtMge6v1s9Xt5jaQp9+SXa52IvdmwB3oA7CiuO+F/wAXvCPxl8Oxa14R1yz1i0ZEaSO3nR5rYsMqsyAkxORztbB9RUkPxd8C3OvLocPjXw7LrTXctgumpqsBuTcx48yERh93mJkbkxkZGRQB1tFclpHxe8CeINWv9K0vxr4d1LU7COSW8srPVYJZrZIztkaRFcsgUkBiQME81l337Q3ww0/w/FrsvxB8NPo0t4unpfQarDNCbg7Mx7kYjKiRHb+4h3ttUFgAeg0Vzfhv4leEPGWk3uqaB4q0TXNMsci6vdN1GG4ht8LuPmOjFVwvPJHHNVPDfxi8BeMvt39geN/DmufYYTc3f9m6tb3H2eIdZJNjnao/vHAoA6+iuH0j46/DbxBrFrpOl/ELwrqWq3RUW9jZ61bSzzEjcAiK5ZsjkYHStjSviJ4V13XtS0PTfE2j6hrWmhjfaba38UtzahTtbzY1YsmCQDuAwTQB0FFcx4P+KXgv4hTXMPhXxdoPiaW1VXnj0fU4btolJIBYRsdoJBxn0qTxB4xXSvEeieH7K2XUNZ1Nmm8hpfLWCzjKCe5dtp4XeiKoGXeRB8q73QA6OivDfAfj/wCIniq4+LNvdar4Yik8K6lJpenyQ6FcgM628Nx5swN6dw2zFNilOV3budtWPgr8cNY8S3sHhL4gWNjoPju4shqlg9gr/wBn6xZsAwltt7Fg8YZVkhZiykbgSrAgA9qor5z8ZfFD4o+Dvgt8Q/GD6x4QvdS8L3VwIoV8O3UcM8VuGDqw/tBiGdjGQwOFCsCr7gV3v+Fg/EHwb8Tvh5oHiO98O+JtO8XfbIiNF0a40+5sDDbiYTHzLu4EkWfkbhMGRDk/dIB7dRRXH6h8ZPAOkeKB4avvHHhuy8RmWO3GkXGr28d35km3y08kvv3NuXAxk7hjrQB2FFclffF7wLpeuSaNe+NfDtnrEdxFZvp8+qwJcJPKCYojGX3B3AJVcZbHANS+Ovij4Q+GMNjN4s8SaZ4djvpfJtm1G5WHzW4zjJ6LkFm6KDliBzQB1FFcbbfGf4fXnh2bxBb+OvDU+gw3AtJdUj1e3a1jmIBETSh9ochl+UnPI9adL8ZPAEOg3GuSeOfDcei294dPm1JtXtxbRXQAYwNJv2iTBB2E7sHpQB2FFefeIvj98PfDPgRPGVx4u0e68NSXkVhHqVlfQzQyTvIECK6ttJGSzc/KquxwFJHFar8dNH0D42aI8/j+zuPA2veGbm8sLaOS2mguLyO5t40+yPGnmzyMry/u1d8kfKvFAHu1FcpffFrwNpel6ZqV54z8P2mnapFJPYXk+qQJDdxxrukeJy+HVV5YqSAOTVXVPjd8OtD03TNR1Lx94X0/T9UjaWwurrWbaKK7RSAzROzgOASASpOM0AdrRXI6x8YPAfh210y51bxt4d0y31S2+2WE15q1vCl3BtDebEWcB02kHcuRgg5rLT9or4USCAr8TvBrCdtkW3X7Q+YwIGF/ecnkcD1FAHoVFeI6v8YdP+G/7Qmt6J4w8f2Ok+Hbrw/Z6np9lrlxZ2kcM7TzxSiF9qO67YUYh2faWY5AwB297480fUPFvgyy03xzosTapHJfQ6TG8VxPrNq0DtHJAQ+VjUjzPMUMrBMZGaAO3orgbb9oH4XXl9a2Vv8AEnwjPeXbiK3t49dtWkmctsCookyxLArgd+Otd9QAUUUUAc34f/5Om8Gf9iZ4i/8AS7RK+h6+ePD/APydN4M/7EzxF/6XaJX0PQAUUUUAFFFFABRRRQB8wfBn/kXPEf8A2Ofin/0/39d5XB/Bn/kXPEf/AGOfin/0/wB/XeUAFFFFABRRRQAUUUUAFFFFABXy94+8I/EWP4Z/FbwFYeB77xHc+INR1G80zXYNRsYrR4LlxMscvmzrMske54VAjKny4/nVSSn1DRQB84+JPAOr6h8SNW8Qap4A8UeI9J8RWdnIun2HiaOzWykSMRy2eoWwvY4LiE8Mdv2hTvmXaQfm6bSdC1zT/wBpR9ZbwJcw6G3ha00KLWrWeyNrbOks08iKpmWfyvnijGIRlkBKhQGr2iigD5/8J/DfWvHXgD4p+G/EnhvUvCDa7rVzqem3V7PZzMjSFXt5k8iaXbJDLEj/ADY5243c43Lyz+IFv8IH1h/DGm6v8SL2exurnSZPKuoLV0khUmESTQo5iVWmVfOiBk3EMpNeyUUAfKOkfD34it8PfEVtfeGdcvdVg8eaZ4stf7WvdLFzqdrHdWs0kYNvKsKTqtu4ZWEceWXaz8tXpWnr4p1L9obSPEF14G1bTdEk8NSadLfzXdg6W0zypcKkipcGQkBPLYojKJD8pZP3leyUUAeTfCP4b6z4J1jVdKvUiXwlo19cS+GFSQMfJuSJWRkH3fILSwx558tjzXGfBP4W6l4LvtH0rXfA2tajqGjyyKniXUvEv23SCFLBbu2tJLl2huXRsHbbRkGSYeZtY7/oyigDzT40N4viXQX8I6HNqMrTyxXmoafHZPqFjC0Z5tvtkscSszBQXbzAAv8Aqnz8vkvgDwT450XSP2fNP1TwDqrzeELieHVrj7bpzx24azltlnX/AEkM6ZmD/Ku/YjfIG2qfqWigD5j1DwR438QeB/inbf8ACE6hYX994007xJp1rdXlgPt9vBcWDskbR3DKsm2xc/vSgzKnzfeK9Ze2njDxF8dPDuunwXrGi6W3hTUdJm1J7uwk+wXFzPayxF0S5LsUW2YN5YYB2UKWXLj3CigDxX4XWHjBfhfpfw51fwde+F5dP0L+x7jxEl9ayWbtHB5ImtFjmadizASASpEQpOW3AK2Bpng/xj4o8I/DfwTq3gq58PXPhDUdLup/EX2uzk0+RbBlDG0Ecxn/AH6oUAkhjxHM4bBG1vomigD5mtNF+Jtx8b/C2r33gy/s/Deja1qcH2TSn0uHT1tbjzUivRm4NxNIxfzZiwi4ZQluzh2bmfA2qa3pNj4c1HxT4d8RRfDnwzrNzqGnXlnbWU4hkaS4t1lnuY79prm2UXMhVo7OMlRG7FkVi/1/XnGh/s9+CPDk9mbG01ZLOzlWa20mbX9Qm0yFlbcm2yedrcBGAZFEeEZVKgFQQAeR+P8Awd8QV8J/GDwjpPgK91lvEetPqenatHqVjDZyQPFallIeYSrKGjkQK0YQlQfMAOR0fiRPHF98QfGeuad8Mry5W88IWljYJrVxp0ltLexS3E/lyRrdliAbhF/hVmjcb1XbIfoCigD5A1bwP8Utc+Hvx10++8H+INT1XxpYRrpr3t1o8J8w2y27xskV1siVWBZRukPlKu6R5MrXrcdv4jvv2gvCOvDwNq2neHoPC15ps13LPp+20nuJrSZY3RLlnIQWpQmNXXc67SVyw9kooA8s/Zs0fxD4S+FejeFvEXh+fRbvQbdLDzpbmCaO9KlsyxeU7ERkbceZsfk5QYyeZbw/4u8Pa18arWDwffavaeJ5m1HTr+0vLNY5M6bbWvkbZJkcS+ZEx+ZVj25O/OFPvNFAHzzoeg+MbS++Aay+BdXjj8Oae1trE/2vTytmzWotcMBdZdQyiQ+WH+XbgFsqIfhR8L9S8I69b6brfgXWdWu7HU55ofEd74l+06KY2laRLuOykuXaG62uQdtsv7wv+8CuXP0ZRQB87eBdJ8a6D8OPiVDD8MpLbxBe+Ib7XdPtdak0+eC/NxdmSJiIrshpIkWMlZHiBKIqyDG5fPvE2i+NNC+E/wAcrzxboGt/8Ty/0/VbW61OXTS9wFjsrdoDHazFEYNAQARt2bN0jtuY/ZVc18QPh3ofxQ8OtofiKK8uNLaVZnhs9RubIuy52hngkRmUHnaTjIBxkAgA4/w/4dvvHHxO/wCEz1nwpe+FYLfQrjQG07WJLSaa/WaeKUs4tppo/LQRFVDPkmaXKqAC9f4B+EdW8M2t/peqOtzp3hmWTQNAuVlL+bYKwkUk55ZV8m3bOTus2PG4ivT7PRbex0SLSo5LtrWKAWyyTXk0twVC7cmdmMjPj+MsWzznPNM8PeH7HwrotrpWmxPFZWy7UEkrzOckks8jku7sSWZ2JZiSSSSTQB5b8ePDviW+1bw/q/gvSdbPizT0mWy1jTLu0SzQOU322owXEyebbSFUYmNZJEMZZNrYD814l8O+MLhv2glg8CapeL4kso7XRx9r09Vv2+xi0JG65GxQxLnzAp2A4BbCH6IooA8F0fS/Gfg7xVoHjBfBusa5BceE7XQL3Q7e8sFv9PuLeWSQS/vLlYGSQSkMUmLAxx8Nk7Myb4X+KdC8DaLqVn4dkvNRi8dv4ul8MWdzbrNbW00k2YEeSRYTKqyiRwHCFzIFdhh2+jaKAPlbxp4b+Ifibw18e4E+GurRXPjXTYrfSIV1LTWOTZC3xMTcgIyt8zBSy4+6znivQLe48aeGviZrniSHwFqmtaf4n0zT1ihjvbCO40meDzg0FzvuApj/AHocNAZcEy8HjPtNFAHmP7M2g634T+A/grw/4i0W40HWdH02HT7m1uJoJSWjQKXVoZJFKnGRyDjqBXkVx4T8ezfBPVtJX4ca2NZu/iC2vx2f27TPMjszra6l5m77Zs3eUDHtD58w4+589fVdFAHzJ480n4na18TtIvLXwTqMXhvRfE0GrR2ulPpUMV7AbcpLNNJJc+dJch5DhQsMYRXBaYhCfQZfhvrFj8ZtQu7COL/hCvESW+p6uN4VotRtCqR7VGCfPX7PuPIxZMDjzBn1qigD5x1/4W6na/E7xrcah4E1jx3pfiC7hvrKS28SfZtKGbaK3e21KykuUSSNWgDb1guCY5MbCUCH0/4/+D9S+IPwR8deGtGjjl1bVdGurS1jkcIryvGwVSx4GTgZPHPNd/RQB4tq8ni3xR8UPhfrz+ANY02wsDqH283F7p7PZCaIRIZQlyd3Klv3XmfIVP3iyLwknw78a+IvA/iQTeDdY0u6j8bv4lg0h9Zt7SbUbR2IaOG4tblvKmAJkBZ4wJAnzdWH1JRQB83eNvButXHwd1HT/DXwu1+DU7/WNNnkh1LWrO71W4W3uop3muria8cOoSHy483EjDKrtRBx1ng/T/EEf7R3i3xBe+BtUstI1fRNLsLXWZ57BlhaA3csyMqXLSgMbiJRtQgtGScKFY+y0UAeafGhvF8S6C/hHQ5tRlaeWK81DT47J9QsYWjPNt9sljiVmYKC7eYAF/1T5+XyXwB4J8c6LpH7Pmn6p4B1V5vCFxPDq1x9t0547cNZy2yzr/pIZ0zMH+Vd+xG+QNtU/UtFAHzBqHgfxxr3hX4ir/whGo2N7ceO9M8UWFpc3lgGv7WCeyZ0jaO4ZVk22THEpjH7xPmPzbes1Cx8ZeJPjZpmsL4O1jQtPn8JX2ktq0l3YOLC5nlhmjLqlyZCUEJVvLVgHIClly49zooA8b+Gdn4sm+GenfD7VfBt54RbT9BGjy64l7aSWe6OAQLJZrFM0zAkB1EqREL1O4YPNaZ4P8Y+KPCPw38E6t4KufD1z4Q1HS7qfxF9rs5NPkWwZQxtBHMZ/wB+qFAJIY8RzOGwRtb6JooA+Z9J0b4m3Hxv8L6zqXg2/sfDmkahqlr9k019LhsIba4ZlhukAuDPMx+/MzeX95NluW3seY+HWqa1pem+D9R8WeHPEMPw/wDDOqSXekXlpbWc6wSSGe0jlmuY795rq3C3T7XjtI8qUkbKAk/XzKsilWAZWGCpGQRXnXh/9n3wV4ZuLBrC11YWlhIktppdz4g1C402BkYNFsspJ2t1EbBWjAjxGyIybSqkAHkXjfwh8QY/B/xR8I6X4AvtXbWvEL6vY6rHqVjFazW7vbylQHnEolBSRQrRqhKg+YAc10XiCHxxefEXx9run/DS7uUvvCFhYaautT6dJbT3tvNeTGOSNbssRm7jAztVmicb0G1z9A0UAfIGreB/ilrnw9+Oun33g/xBqeq+NLCNdNe9utHhPmG2W3eNkiutkSqwLKN0h8pV3SPJla9bjt/Ed9+0F4R14eBtW07w9B4WvNNmu5Z9P22k9xNaTLG6Jcs5CC1KExq67nXaSuWHslFAHlX7M+i+IfCPwf8ADfhXxH4fn0O+8PWEGmNJLcwTJeNGm1pYvKd8RHAxv2PycouATj+DPDOvN8VPjE954U1LQLLxPJCLHxIZrJleOGzjtl4juGmB3iSRAyAAE5KMdte20UAfNnwp+GV5o3hu30fX/hXq02pWGkTWFzeap4oF/p0oEDQsmmJJcyvbrOMDb5VsFjYhj8io2B4qtfFnhj4YaXFrGleIbywsvHmgtoGk65cWM+sfZ1ubc+S88dw0Mn70OI3llD4x5jcbz9ZVyfxC+F/h/wCKFpYW3iGPUJYbG5W8txYatd2BSZCGSQm3ljLMrAFSc7SMjBoA8o8YfCvxH8TrPx94htdJl8H6xrmm6XY22katNAXnewu5rndcvbSTR7ZRKIRguVQEtndsXejs/Efj74meE/Fl74G1Xwinhi0v/MXUrqxkuL9riNEW3h+z3Mq7MoXYytGNyQ4ByxT2KGFbeGOJSxVFCgu5dsAY5Ykkn3JzT6APljR/CvjnSfg34C0UfDXWRqOl+Lzq17ZxXml7kt1vZLrzAxuwhL+btwG3blfOBtLa+q/C3xhr118TvDOh2ereFvCviPTtWUprl3bXNidSnkGy5s/KmeeKKbdNJNFIqrmTKqGL5+kKKAPHfgp4dnsdTF7ffDrXPC+orYeVcal4m8SDWZldmjLW1nIbm4cW5ZCzZMIJSE+WxJ8vVKtY/tKeZc58vUfCYjsWYcB4LtmuFB9SLi2OO4TPavTaztY0Cz1ySwkuUPn2Nyt1bTRna8TjIOD2DKWRh3V2HegDw34c2HjHw7dfGm6vvh5rkY17WJNU0uNbzTGa6ja1t7YIMXeEfMTP85Ubcc7vlro5fhWvxb+DPhzSvEmlan4M8R6TDC9jdCeBr7SryFAi3EUkEkiEHB43fMrYYDJA9gooA+XfFfgH4n3X7KvjvwpqugJ4m8eeIrnULf8A4kU1tBbsJS3l3R+0TIEjIVcqCXBfhMA42I/g1qngyHSfH/wq8Lx+C/EsFqLXVfAd5JbwWer2iOzeSfs7yQW9wGZ5IpozjdKwl4dtv0VRQBjeFddvfEWlm6v/AA7qXhifzCn2HVZLV5iABh8200yYOf72eDkDjPgWofD3xl/wqfxr8JJvCN1qo1y61X7J4vW6s/sKJe3MtwlxOjTrcCWFp+QkT5aJSGOcj6WooA8Y8N6Dr+l/tMeINYufCWpTaJd+HtO0e38TST2TR77d7qaUsvn+eFczRL/q+XQkgKAxk/aZvJdO0nwDdQaZc6zPD4x02RLCzaJZpmBkIVDK6Rg/7zqPevY65H4gfCvw98UF0xdfTUnGmz/arX+z9YvNPMc3GJM20se5lx8pbJXJxjJyAeMfE74d+J/GXgP4u6zYeDNQt9b8aaXZ6Rb+GprmxFx+485ftM7i4MALCfbhZWPlwx9yUXtPF+m+JZPEXw78daR4S1CWLRba+sr3wj9os4r2OO5WEJJGTP8AZi8ZgA2+cBslfDZGxvYFUIoUZwBjkkn8zS0AfN3ij4X+KvEnhH4ia7aeG5tN1TxDr+iaxbeF5rq2Fzs0+4tHlaR0la3E8q274AkK7Vh3OCWVOpX/AISu8+PGh+KZfAesW2kx+FLyymkN5p7GG4knhnjhYC5yX2wFSVDIHdRvK7nHtFFAHyjY+EPG9v8AC34d6fd/DDWru+0LxrPrl1p/2zSmZLcT3E8ToWvNhINyiqNwIaFjhRsLenX9r4p8B/F7xB4qsvCWpeMdJ8SaXYW/kaVc2Ud1p01q0+UcXM8StG4uNwKOdrLJlfmDH2CigD5mtfhZ4p8H2nwb0+Hwtc6zBo/ivUNf1H+z7i0W30uC5W+EcCiaZGbyjexj92rDELkc7VNDxl4L8da54D/aN021+H2r/bvGN2Royve6aPtCNp8FpvJ+1fIqvbs5DYO2RMAtuVfqiigDw+8vPF2j/GhvGUHw18Q6rpmpeFbOwe3s7zS1uLO5jurmRo5RJeIp+WVfmjZ19657R/hn4o+H9/8ABnTrXwxea1Z6Hqup6lql1pt1aC2sBerdgQoJpo5HSFroDKx8xx5A3YSvpGigD5Z1Hwp45k+EPj/Sbf4b6x/a2t+M21SC2+2aXue1e8jnMxY3e3Kxw7MFt25kAG3cy/UNpM9xawyyQSWskiK7QTFS8ZIyVYqSuR0OCRxwTUtFABRRRQBzfh//AJOm8Gf9iZ4i/wDS7RK+h6+ePD//ACdN4M/7EzxF/wCl2iV9D0AFFFFABRRRQAUUUUAfMHwZ/wCRc8R/9jn4p/8AT/f13lcH8Gf+Rc8R/wDY5+Kf/T/f13lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzfh/8A5Om8Gf8AYmeIv/S7RK+h6+ePD/8AydN4M/7EzxF/6XaJX0PQAUUUUAFFFFABRRRQB8wfBn/kXPEf/Y5+Kf8A0/39d5XB/Bn/AJFzxH/2Ofin/wBP9/XeUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWd4i8Q6d4T0HUNa1i8j0/StPge6urqY4SKNFLMx+gBrRry39qPwfP49/Z5+IOh2mkjW7+50e4NnZeUJWe4VC0RRT/GHVSuOdwGOcUAd5qlxqsOuaKlp/Zw0uZ5UvjdSutwcRloxAoG1juBLbiMKCRmtavmObTfBdj8V/g9qfhP4cahoFgkt/byT2fgi7s1ggmikiRZttsPIQzu2RLsAyZCNjBz5ZcfDLwWvwZ8T3dp8J76PXv+E4MmmMngO9S9hsDqqTp5I+y+ZFCLVX4UBRkpwzbSAfd9UtZ1GTSdLubyOxutSeFN/2WzCGaT1ChmUE45xnnHGTgV8wT+EV0H4jfFbQ/hX4XvPBM2seBbe10u60zw3caXp7ashv3DeeIUhEirPbjzC2RnaCWQqN/wDZm8A+DPDeuSal4f8ADnirStWn08JdjWPDMWhQ2Kko32ZvItbWO7fcDiQC42+W2JFEn7wA+gdG1iy8Q6TZappt1He6feQpcW9zC25JY2AKsD6EEVcryz9nBZk8A6opDLp48Ta6NODDGLX+07ny9v8Asddv+xtxxivma++GHgtPhB44urP4UXseu/8ACYk6Q0fgS8W9hs2vUlT7OPsvmRQiGOU/JhVLbThnAYA+7KK+WR4StdB+KXxF0X4YeFrrwRLrPgWOz06+07wxc6bp41Ufa5EdphAsIdFmh+YnIPyfeUqE8J+DPDeoeIPhxL4I+HF54G8Y6ZfR3HiC/bwxNpQS1W3kS6hlu2iWO83yMihY5JdzESD5UZwAfU9YUmqX+n+ItTbUZ9JtfDUOnxXEMrTst0kitL9oeUMNghCeRtYHIIk3cbcfHFx8O/COn/C/xrqVh8K76LxLH4236NcQ+BrwXtvbG+SWOS3xbeZHCsUcrZTCgnH3pAreia94d07xT8X/AItWmm+Db82/ibwLa25muPDVzbWl/qCteuRJNLCsbShJbUZds5AXOYyFAPpXSdUtdc0qy1Kxl8+yvIUuIJdpXfG6hlOCARkEcEZq3XyVpfhHQYPh18MJE+Gd0vgGykZfFfhs+EpUknvXsoo0vJNO8kSXOyVdhcRuckOAVTeuV49+HWnTfCf4uv4f8Eala+DdXk05/D3h618OXUM0d/Guy4uoLEQiW2ziNd/lplonccOHYA+yqo65r2meF9JudU1nUbTSdMtV3z3t9OsMMS5xl3YhVGSOSe9fMfxc+FvhnUI/Abad4Y1TSvhfcLfzX9joPg6K5mg1F1gNveXGm3FlM7MY4riIyGAyKZVyQrMa2bWxsvhzffC69tPC/iWf4bafa6lDHZto9zeXdlqEjxvbXr2UMbywq0aXaIBEghFwE2RBggAPTfgn461bx3o/iGXWLjTLyfTdcutNhu9JgeGC4hj2FJArSy8kN1DkHtTdY8SeKfFPjLWNB8G6voeinQVgGoTazpE2omaWZDIiIsd1b+WFQKSSX3GTGE2Zfmv2YWjt7Hx5axeHdU8NQSeJ7zULa11HR5tPR7ecq0ckYdFVt21iVUlkyA4VjivJPE3gfwbJ4g/aKB+GN1PfanZMum3KeBbuQXUv2ZVlMMwtSrlrra+VY7mHmDIG4AH2NRXyN4o+F+h3XwY8Avo/hLVtM8OPfwN4tt9O8LB9VuHFtJCtzcWV3ayPe7bhlLGSGViGMy5ZFcatx4I0Dw/4A8Gwab4N1/W/hlb+IZptc0jUNAfzb1ZLWSNLr+yEhU+SlyyEwrbxgMnnrEQFkYA+pKK+LLjwXofiHwN+0Xp/gvwK1nYrJp19p2gx6GbKVpIrOKTdDZsiukjFGKqUV2Y5AywJ7+O8TxR+0FqWt+FvC+vaHcaz4OutOj8SXvhi7sEmv1kRohM8sKupREG1pgqnAVCx4AB9KUV8mfAX4Z+CdD87UNU8I+LJfETaPcWuu2ureEo7eCONk/0qF5beziGqrIyAAF7tn+VwMlmPL/DnwT4f8F+CPgBqVp8NtT0zxhb6ug1nUoPBl6l/BClrcRS/aJVt94jLywoN52kHIyqEqAfSPxd+JF3oPwn+IHiLwdqGlz6v4Rtbq4nS/tZLmDzbe3+0PbsEljIYoVG4MdpbkEgrXolnM1xZwSsAGkjVjjpkjNfHviLwXo3hHwj+0dp9r8N9Qi8YawmsQ6dqGk+E55mu7e7s4hDHFcwwkOrzMdyKx2Mrs4XBNd3448F2mn+KPCvxN8L+EoLjUvEFk3hnWUvNL+z3EkV0iLb3FxFMiyfu5YokcOAfKkfIOxQAD6NrI8K3Gq3Wio+t/wBnf2l506SDSpXkgCrK6oAzgHcEChhjh9wHArP0TwP4a8B+AR4b07RbW38NWlo8T6bbWKsksZUmQGGNP3jPliwCkuWPBJr5L0/wroWrfCP4U6Tqvw71m4j0nxve+bY3Pgu+P2XT5Lm6kIMZtvlgdJrXIxsYDac+WwUA+26K8M+AulaR4X+KHxV0fQPCl14V0L7davZQx+H7jTbCYx26RTyQs0SQvmQEZQ/MF3DKkMaHxK8O6GfjRqOpfEnwTJ438JXWjWkOhSDw1Nr0enXEcs5u0MEUMrQtKJLdvM2AOIgpb5FUAH0FXL/ETxdbeE/D7sdd0fQtWvM22lNrJBjnuipKRLH5kbSscH5EcMe1fLWtfDe00nQ/gxaeKvBmp6xp1h4m1adLWHw/dapJp2gyR3otbScwwuVQCWyQwNwQu0qVjbb6HrVpYeCPGHjzRNW8DX+o6HqOjW2n+GodG8OS31mLMwGOXT/3MTR2485dxEpjjIkQk4Q7QD134Q+Lrz4gfCbwV4o1COCHUNb0Sy1K4jtVZYkkmgSRwgYkhQWOASTjHJrra+Jf+EH/AOEm+HfwWg8YaR4tg8Mad4Qt9Knt7bwcupzafqkMcSSCaxurG4cK4RlWdIcfu8Bwsnzdb4k+HPgaX4nfByzuvhzq974ctdCvdNePUfDl3qEccLSQCwhu3EciCNSs0ixTNiDIZliIGAD6d8QeINO8K6Le6vq13HY6bZxGae4lPyoo/UnsAOSSAOTWhXkv7TngmPxV+z34s0Wz0BNZaGxElrpcNqszExFWCxRY5cKp2qoyTgKMkCvP/EXhnwfHr/hG+vfhnLffCD+zLy1tdBj8GzTpp2om4WQXD6WsBlj81FlAlMOVIIJTzRvAPpqivKf2dfC8vhbw54kjt9Pm0Xwze69c33h7SJ7drZrKxkSL5BAwVoFaYXEoiKqUEoBVfujxfXlf/hpfwt4htPh3eaQdN8VXVvqesw+F9QvNQvYJLK6gjuJb8RbPsxdo1WFDKsaiIl4QojAB7V8dvi0/w70q2TRdZ0FPEi3dhLNoupfvri4sJryO1eSONJo3TDSgiUh1yhUqScjv7O41NvEmpwXH9njS44Ld7QQysbrexkEplUjaqfKgQgnOJM4wK+UPGbzr8J9c8Nax4G8Ran48h8YJq11eWnhm7vI7lU1ZJEvYrpIWR8WWxFRWMiIvlBAEwNfxt4BsPGGuftL6Tonh62muvEHgTS7mKz+wiJ7m+dNVMMjxsoPneYsRyw3hkXoVGAD6trP17xBp3hfTW1DVbyOxs1lihM0pwPMlkWKNfcs7ooHcsBXzlpusWGvfHj4deIrDwR4os1Xwxqek6lrFx4WvLKRpz9ieG3lkeJXG0RzbZHxFlyEctvA8+i+FVn/wobxR4X0/wH/bnh7R9Z0PUbC8n8ESaXqd9Cl9GbmOe0eCM3M8Nqrq08UeJkmKhS28EA+3WZY1LMQqqMlicACvMfG3xQu7ez+HOueFb3TNQ8O+I9YtbKWSa2kkae3uFJSWCQSIEIC5+ZHBDDpjno9G0PQNV+Go0nS/DkOneG7uxlt4tDuNMFnH5DhgY3tXVdisCcxuoOGwyg5FfKXh3wX4esfgB8J/DFx8MNShuINZ0hfFNl/whdyyXM0MJW5kuFW3PnKCV/fEMj7vlZiG2gH2lY6ha6papc2dzDd27EhZoHDocEg4I44II+oqevlfVNEv5rj496F4N8O6zpIuhYy2cFvos1hBfCGKOK8S2lliWB2kRPKBDENwRlfmrsf2afAvg7wlNq914V0nxJazXkMQvLvWvDUfh9PlJKQ/ZorW0jkdS8h80QufmKmXG1QAe70V8l/tYWs2seLGh0/4ezanq+njTL628RHw5e6vcuEuw8sNlJHGYrQoiGRmMm+Q5QQsWVqm1Twb4F8SfGr4ra3rvwyuNas7jw5pd1aTX/gi7mS4ukF0ZzHutvnn2zWikD95wR/yzcKAfT114g06y1yw0ee8jj1S/immtbUn55Y4tnmsB6KZI8n/AG19ag0G41ae81tdT/s7yYr7ZYCwld3Fv5MTDz9wG2Xe0hwuRsMZzkmvlPw/4L0vUI/2c9c8V/D2/wBfGmeEJtC1E3/hae4ubfUUWxECzRyQ+ZGBJHd7JpAsa7mbeA+42NP0qWz8K/F/TfD/AIM1m30OTx3aardaNF4eubFdS0Yx2CXq28bwotxv8i6DQpkyqGGD5q7gD67or5v8UeFfDl98L78/Db4byaPokesadc67pMHhhtHk1qxinV7q3FrJHFJPiHd8jJtlBMal9zLWba+G9C0nxD4m8TfDr4ealpXhGHwhfW2saHp+hXXh+TWrwOj2scUDQxSPIsf2oeaiEjzgqlj8oAPqKiviHQ4W0Twb8coU8LXHg7R9S0i01G0g0LwTfafp6RoGS5jKTRx+dt3KkhZYnmjV3WELxWz4B+Hfw+8WeJPFDzfD7w14Q8Uax4dl03SPDMfhm5soZAizedcRT3thaeZI4uY0dY4/kSNSzMGAQA+xG3bTtIDY4JGRn6Vwnwb8Wa54s8O6q/iKTT59U03Wb7S3n0y1ktoZVgmaNXEbyyspIGSN5rwXwbqVrfeKP2fdSHgTxRaaloml/wBk6vqt34SvIJLNmsDGlvJI8IcxiVm+dd0KnJLjIy2fWLbU/Aep2t98PNW163v/ABrqM4TxH4R1We0tIZmnlivJbAW/mXYAxtj2qAzANJC2DQB9cVn694g07wvpcupardx2NjGyI00p43O6oi+5Z2VQBySwFfGmi+EdP17wX+z3pXir4fapf3Wi65eWOqwXXg27aO1tTbXKBHHksq25kltP4mjO3OWETlbms/D/AEvVPh78avD+lfDq8h0W28Y6Zq2maJ/witxbwPaxJp6XMtpE8KpIW8i8ysWWYFvlIkXcAfZ9eU+Pvi4+h/EzwV4d0PWdAvmvNbXSNe0hv31/ZiWxubqCXKTDyci2PEkbbw+QRt56fRbG0/4VibbwTpS+FoGspl0qyfTjp62zEN5bG3KqYgWIbayg88gHIr50t9StZLH4Bwp4A8U2GteF9bV9bmbwreubJ5bC7jumNwISJxLdOjvNGzq5xI7ZIJAPrqivjnxB8ObDUvB/jXQ9a+H93ffG66v9SfSPF0fh2eRnme4kl026TVlhMcCRI1uu1pUMYhKbQAoPct4Wk0f9pl9V0rSW1XWtVjWDVNS1PwtIBprLp+1bqx1XyfL8tikUb2pc/OzsoU7wwB9G0V8m/szfDLRPDvibQtQ1XQfFqfEm3hlh1ae+8PRWVrBcBHS4nbUYrWEX8crjK757lmMschXcjOneftSW8OqW2haVP4Fj8XG8ivBFe3+iXWtWOmyhYtjNZwoQ0zk7Y5JGiWNRMfNUEpIAe7UV8keG7W3v/Bvwbb4i+BtZ8R+ErLwcum3mm3/ha7v2stajW2VnnsPIaTJWKZUn8sqoLgMBNlur8YaF4Zh8ReETr/w0uL74WLok8dhokPhZ9Qh06+MyMrSadBFI0TPFna5jBT94jbC5UgH0ZRXzd4v8LeG7fxl4cu/Evw2k1P4Xf8I+LXTNEj8LNqcekXwnZyWsYIpGiMkLIA4jwvlFWKFsNxPij4e2Vj8MvDkOpeDNWu9BHj/+09G0q30C7vLjTNFacM6GGGJpLaN1Dt5LBSEkEZUEGMAH1d4s8Saf4X0d7i/1vTNAM7C1tbzVpFWD7Q+REpBdN5LY+QMC3QEda4f4W+PfFPjv4f8AgbXrldDjlv7mZNZ/1sAMaC4RfsqFn+cypCSHcjZ5nJOMchNb6P8ADL4og3Hgq9bwFc+Gorbw9BoPhi4u4NOmM8zX0DW1vCxtzOs1sxLqofySCcoRXl/gXT7fS9K/Z6km8CeIdO1vw9r19b3znwle+bp1q9veoI2lSAqITJcW3KsYz94EiNioB9oUV8Pa58N/Ca/D74wX1p8LbxvE3/CTu2hXK+CLz7XFG/lGOS0b7NvWMPHO5MfyqxLHmUb9X47Wej+PPiJ4s06/8G/8JCutaDZRW2r6z4Q1K+u/D8M0Uyie0jgsZ2J3Fm8mV7VhLE4zySoB9Hp4s123+OH/AAjFxLp82gXWhSapbLHaSJdQyRzQxMrymUrIreYSMRoRgDJ613tfNfhnT/APiT4k+GdB0Lw2dW+Hlz4PuLCJ4PDkzaLKZJ4bgI0qwC2DMI5GYEjEgKnDkLWh8DvhPZadqEPh/WvC+ntb/DO6uNP8PajNaRSGWOcpcRTRuQWSSOFokcgjfIzseQDQB9CUVn6Hr1p4is5Lqy+0eTHPNbN9ptZbdt8UjRvhZFUkblOGAww5BIINaFABRRRQAUUUUAFFFFABRRRQBzfh/wD5Om8Gf9iZ4i/9LtEr6Hr548P/APJ03gz/ALEzxF/6XaJX0PQAUUUUAFFFFABRRRQB8wfBn/kXPEf/AGOfin/0/wB/XeVwfwZ/5FzxH/2Ofin/ANP9/XeUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFUtZsZtU0u5tILyXT5Jl8v7VAB5kYPDFM8BsZwSDg4ODjFXaKAKWiaLY+G9HsdJ0y1jstOsYUt7a3iGFjjRQqqPYACrtFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHC+B/hX/AMIT4v8AE3iJvFOua7c+IHje5t9SWzEKNGoSMx+TbxsNqALyxyBk5PNd1RRQAUUUUAFY154aF/4o0/WJtRvDHYxSLDpgMYtvNYbfPPyeYZAhdAN+zDsdu7DDZooAr6lqFvpOn3V9dyeVa2sTTSybSdqKCzHA5OAD0rnY/ij4Ymg0OZNTzHrcrQ6e32eX986uIyPu/L8xA+bHX0rqqK6KcqKX7yLb8mlpZ/3X1s/S6trdBysnxR8MQwa5M+p4j0SVYdQb7PL+5dnMYH3fm+YEfLnp6VYt/iDoF1rGk6XFf7r7VbVb2zi8mQebCVZg2duBwjHBIPHSuiorRywtnaEv/Al2/wAHe79NN1do43/hcPhD/hHv7c/tf/iV/avsX2j7NN/rtm/bt2bvu85xj3rQuPiDoFrrGraXLf7b7SrVr28i8mQ+VCFVi2duDw6nAJPPSuioqnPCX0py6/aXlb7HrfvdbW1NTlY/ij4Ymg0OZNTzHrcrQ6e32eX986uIyPu/L8xA+bHX0ok+KPhiGDXJn1PEeiSrDqDfZ5f3Ls5jA+783zAj5c9PSuqoo58J/wA+5f8AgS2v/g/l09dbW90NTnbf4g6BdaxpOlxX+6+1W1W9s4vJkHmwlWYNnbgcIxwSDx0rP/4XD4Q/4R7+3P7X/wCJX9q+xfaPs03+u2b9u3Zu+7znGPeuyooU8JfWnLp9ped/selu1nvfQ1M6x8QafqOsalpdvceZfab5X2qLYw8vzF3JyRg5AzwTjvWjRRXJLlb91WWnnrbXouu3ZaXe4ylremf21ot/p32u6sPtdvJb/a7GTy54d6ld8b4O11zkHHBANYPgf4fR+DJtQvJ9Z1LxJrOoCJLnV9WW3FxJFEGEUREEUSbU3yEfJnLsSTmuroqACiiigAooooAKKKKACiiigAooooAKKKKAOf8AHvgu1+IPhW80K7u73T4rhopFu9PlEc8MkcqyxuhYMuQ6KcMrKQCGBBIOT4a+Gc2ka3Dq2teLtd8ZXlqjpZHWls40s94xIyJa28CszABdzhio3BSod93bUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV53q/whurnxVrGu6L4+8UeFZdXaKS8tNNFhNA8kcSxK6i6tJmQ7EUEIwUkZxkkn0SigDM8P+HbLwtoNrpGmI8FnbJsj3SGSQkkkuzuSXcsSxZiSxJJySai8J+G18K6Mlj9vvNWnMjzT6hqBQ3FzI7Fmd9iIuecAKqqqhVUAAAbFFABRRRQAUUUUAFFFFABRRRQAUUUUAc34f8A+TpvBn/YmeIv/S7RK+h6+ePD/wDydN4M/wCxM8Rf+l2iV9D0AFFFFABRRRQAUUUUAfMHwZ/5FzxH/wBjn4p/9P8Af13lcH8Gf+Rc8R/9jn4p/wDT/f13lABRRRQAUUUUAFFFFABRRRQAUUUUAFFZHi7xJb+D/Cusa7dKXt9NtJbt0XO5wiFtowCSTjAABJJGAawvg78SV+LHw/0/xE2nNo17I81rfaVJMJXsbqGV4Z4GYAbisiMM4GRg4waAO0oorjNa8c6jovxQ8N+GW0m1l0nWrW5lTUxfMJ4poQGaM2/lbShVkw/m5ySNnAJAOzorL8N6lqOq6dJPqmkSaJcrdXES2slxHMWhSZ0il3ISB5kapJt6rv2nkVPrl5d6fot/dafYNqt/BbyS29gsqxG5kVSViDt8qliAu5uBnJoAu0VDZTS3FnBLPbtazyRq0kDMGMbEZKkjg4PGRxxU1ABRXk/if4weIdB134g6TB4X0y7ufDWiWuv2bSa1JGl9bSyXKOshFqxgkUWkpAAlDZQFlySvo/hzV/8AhIPD2l6p5XkfbrWK58rdu2b0Dbc4GcZxnAoA0aKKy/Depajq2lC41TSH0O88+eP7HJPHOwjSV0jk3ISv7xFSTbnK79p5BoA1KKKKACiiigAoqKa7gt5II5Zo4pLh/LhV2AMjhWYqoPU7VZsDspPapaACiiolu4HupLVZo2uY0WR4Qw3qjFgrEdQCUcA99p9DQBLRXK+PPiJY+BRpls1pdaxrerTtb6ZounBDc3jqpdyu9lRERAWZ3ZVAwM7mRWw7bx94z0XUtPg8W+B7W1s9QuY7SLUPDWtf2jDau7bQboTwWrorMyqpjWXknds43AHo1FFFABRRRQAUVi2eu3SzeIH1fTv7F03TpsW+oXF1E0d3biCOR5zg5iCu0qEPg4i3dG42qACiuH0X4hX998XvEfgm90i3tYtN0uz1e11CC+aZrmGeWeLbJEYl8ple2fgM4IKnIOQOl1DUdQtda0m1ttJkvLG6Mou79Z40WzCplCUJ3Pvb5flBx1PFAGnRRRQAUUVleKNauvD+iz31loWoeI7iMrjT9La3WeQE4JUzyxJwOTlwcDjJ4oA1aK8E1j9r7SND+Hfhvxxc+BvFa+Gtd2rDeNJpcYt5GaQLHPvvl8tiIyeeAWVSQ52Dt5Pi5fwnwtFJ8PPFUd5rzyqLNpNNEtiqYJkuB9swF2nd8hcjhSA5VSAeiUUVS1zWrLw3ot/q2pXC2mnWFvJdXNwwJEcSKWdjjnAUE8elAF2iuQ8E6/4v1+ZrnW/Dmk6Jo80Ims5LbWpLu7O7BVZovsyRxttPOyWQBhgFh81dfQAUVmaFqOoait+dQ0mTSTDeSwQB545ftEKn5JxsJ2hxztb5hjmtOgAoqK7adLWZrWOOa5CMYo5pDGjPjgMwVioJxkhTj0PSuU+Efjyb4mfD/TfEdzpsekXF088clnFcm4SNop5ITtkKIWBMeclV69KAOwooooAKKKzNF1LUNQm1Rb/SJNKS2vGgtXeeOX7XCEQicBCdgLM67W+b5M9xQBp0UVFaXcGoWsN1azR3NtMiyRTQsGSRCMhlI4IIIIIoAlooooAKKKg+3QtJcRROs9xAoZ7eN1LjIJUEE8ZwcZxQBPRWb4Z1DUNV8O6Xe6tpbaHqlxbRy3emNOk5tJWUF4vMT5X2tldy8HGa0qACiiigAooooAKKK5D4u+Nr74a/DHxP4ssNLt9Zm0PT5tSexubxrVZYoUMkgEgjkw2xW2jbgnAJUHcADr6Kr6bef2hp9rdbPL8+JZdmc7dwBxn8asUAFFFFABRRRQAUVEt3A91JarNG1zGiyPCGG9UYsFYjqASjgHvtPoaloAKKiuLuC1MQmmjhMriOPzGC73OcKM9TwePapaACiuf+IHiK+8I+Cdc1zTrC31S7020ku1s7q6a2jlCLuYGRY5Cp2g4+Q5OBxnIt+E9d/wCEo8K6NrPkfZv7RsobzyN+/wAvzI1fbuwM4zjOBnHSgDVorL8L6lqOseHdOvdX0h9A1OeBZLnS5J452tZCPmjMkZKvg/xKcGtSgAooooAKK4r4o+PdQ+HtpoF7a6RbarZX2t6fpF20181vJbrd3UVsksaiJxKVaUEqWTgH5s8V0VjqOoXGuapaXGkyWmn2whNrqDTxut4WUlwEB3JsIA+YDOeOlAGnRRWX4b1LUdW0oXGqaQ+h3nnzx/Y5J452EaSukcm5CV/eIqSbc5XftPINAGpRRXGa/wCOdR0L4l+F/Dh0m1m0nXIrjbqX25lnhmhjaQoYPK2lCoHz+aDkkbeMkA7OiiigAooooA5vw/8A8nTeDP8AsTPEX/pdolfQ9fPHh/8A5Om8Gf8AYmeIv/S7RK+h6ACiiigAooooAKKKKAPmD4M/8i54j/7HPxT/AOn+/rvK4P4M/wDIueI/+xz8U/8Ap/v67ygAooooAKKKKACiiigAooooAKKKKAPH/jV4q0DXfEXhr4ZSeM7Tw5rusXcd66RXNqL1YYGEsXlRzq6szzpCoVo2DoJsA7TXCfCHxVoXwk/aM8a/DG78eQa9c+IFh8Q2zahdWiXa6g37q6tnjgSNFkZVt5VRUUsGdsH5jX03RQB4t8dvE2n6T428G6d4u1y58K/D++t783Wrw6vNpMf9oJ5BtYZLyKWNow0ZvGClwHZAOcCuZ1Txl8PtN+I/wi0qy8YwtYT2mrvbSanr8s13PDMNiSpPcSmaRJHSQRShiGCjy2Kha+j6KAPhyy+Inhi8+C/hct8Tri3ij+JF3pst/b+MZ45pNPfU5xslnE++RTa+WQ7sWVCrqynDV1HiDxd4W8N237QXhqD4iX0FroWkW11aC68a3Ul5Z3gjkDbJ3uDOn782sZTftLuEI+cqfruigD5ek+IXhPVrnwTbeLvGraD4DuPCVvd6ZrFn4lm0i0vL9ZPLuYmvIJ497ogixEXOd0h2koSvM/tMfFHQvCOnwWGgeItdtdb0/Q7PVLBtS8XXemxratM48xYTJ9o1CdhGS4nV41jjYtLGflk+x6KAPlXx18XvAk3xE+L1zH418OvbzfDbTkimXVYCjs02plQp34JIubYgDr58X99c3n1GLwvY/DT4l6LquseI/DWqabF4f1DTtN1y5lsftE0McVpcRRLIYkf7RGLYlF+9dbj8yk19OVha1oN9rGu6RMdRhi0Szc3E2n/ZS0lzOB+6JlL4EaE79uzcXSM7wFKsAUvC3hK28E+AYtHvdVv7uKC1IvNS1DVbmWZmK/vZPPmlaRBncR8/yDpjFfI9l8RPDF78CfAjSfE+4tfL+IF5pk97b+Mp4ZpbF9WuCyTTLOGkBtTEwdyWVHV1Zchq+4qKAPjjXJvB2n+IPjbpzfEnXILfwppNvcWMTfELUg1ndNFKku9vte5j5wt02SFgrMqgAuQy6t4p8D+JPHXwa8SeKviG+n6Lqvgq/E2qw+MrjTLaa7ilsFKrLDcRqJNxnDhCCxTD58sBfsavOde+G/iDVPjR4e8b2viLTbXTtJ065006VNpEks00dxJC8rC4FyoVs28e390QMtkNkbQDx241bUdA8H+Dl8UeJdZg+GFx4j1KK48SS6xcW1wunt5p0x7i/R1mSFn2qJi678wB2IfDc58QPE0GjfCX403/AId8f6pN4FtbWxuPDXiFfFNzOy6mVkW4ht75pmeZAVtj5Zd18x5Fx1UfZdFAHyl8TtB+H1j4h+EOvT+M9Xl8H3mo6ju8RnxrqBheWSyfYI7pbnCb2hIVI2UE71VfmYHM1j4yaJY/tJeE0sPFF9aQr4outH1v+2/FkiI5+w3SxQjSw/kxQ+YsSpLIscsjxqQJd5lb7AooA+HdS8V+GNN+G/xK8Tw/FDV31XRPFzafpUjePL1ooYzPGYojGbkxyqVE7fvVbKq/O1Pl9T0FfCa/te+JNQudeuo7/WtC0S80KCHXrpYdUwb8SmK3SXy7mNEEbldrJHuaTC7nY/R9FAHhHxlkufAnxy+HvxGv4ZJfBtjp+oaLqt5GjONKM5ikjupAAdsOYNjyHAQMCxxyO0sf2hPhvrmqWGl6D430DxNq99cJb2+m6Hqlvd3L55Z/LRydiIGdm7KjH2PodFAHyD4T+L+hap+0lotlp3ii+XTNRfV9Kv49W8XySzT3iyIsS/2eshhstxV/IA8uZwJP3S7STifC8aJ/wh9rZ+FPH2qTfFO18ZXoGgDxfdXTm3XXZhN9psXuGUxm13u8jx7jnfuLEE/atyszW8q27pFOUIjeRC6q2OCVBBIz2yM+orgvgn8Otb+FvhO40PV9esNfVr+8v4ZrHS3sShubmW5lVg1xNuxJMwUgrhQAcnLEA8Mm1CTWPjdrcXin4rS+EdVsddC2Xhm3uL+G/u7VWVrU2sAvPs1xHIoUP/oUxJ85SQQCnVaV4m8J658SvENn458WarpHjOz19rXS/DsPiS+08z2g2G1eGxgnRblHU7mfy3yTIrHCYX6KooA+KfHereH/ABJ4O/aT0W18U3Gs2+j63Y3iRQ+Ibi5ntbdLeye4O8TGRYUmN1lc7EZXGF2YB+0n8UfCvhfwHPaeCvF+tXmp2vh2bVdFvJPHV3BbMomuA0sUgmafU5i8bYjfzYkjhX5oVb959rUUAfKvjTxJ8MNV/aWvdR8U+PbXRNJvfA+kzaZfW3i+bR4L1Te6iSySwXESzAAoRy2M5GM5qDw54nm8M+L/ANn628Z+Lbq08TXy31rJY6zq8kE11bGOdNPe4s3cL9pcPGhdo/NMhKE7htr6xooA+F18ZeFdH+FHiHxbB8UtWm1LTPHv9l6bcTePryWFbX+1kEcTRvcmOZDaiRyZVcmMMxO1cjsviVrA8QfGbxBaeIfiwvgDTIxZSaBDBe31tNqNjJbxsZLEw3sVvcT/AGj7QuHt7k8RAoylVP1tRQBk61c6xb+HXm0GztdW1YInk2+rXb2MUuSNxkkSGRkO3ccCI5IAwucjM8H6j41vbi4XxT4f0HRoFQGF9H12fUGds8hlks4Aox3Bb6CupooA+RPFHgHUNU1rx98ArEvYWmv3h8YaTqxtw8Wm2sjvNKE3Kybk1GJBs4YJd7lxsyPVf2ffGl78Y7VfG2qadPpd5Y2a6A9ncx7GivkIbUinqnnrHEPe1Y9CK9mooA+QdB+Mmg3X7SWiW1j4pvIdNvL3VtI1JdZ8XyPJLdISsSf2cshhs1LoVhyI5pNr/uuN7cnHfeDfFX7JPxk1m6+I+pa7e6fB4hsYfO8cXk0cMJubpdOiZBc7ZPNCRBDKGaZX2ZdG2191UUAfDPxq+K3hHw18O7a08FeNNUv9VsfD0ep6fdf8J9cx2ijzphI0RWZ5tRn3xOrQuHiiSDBaDOJPT18QeD/G/wC1Zc6XH8R7qexvfDmn6nZaPpfjGeG3ubwvOweKKGcZzbJE5jT926v5joxIavpeigD4e1j4jeFoPgn4yNh8T54jpvxGs7a01KHxlO1yLWW8t4yr3BuC8sZtVuiBIzLtidx/q8r7F8Ldf8PaH+0h4t8F6H4wutWs18N6ZeDTdT8TXGrSJdGe8MpjFzNI6nyTbFgpxhoiRyCff6KAPBPir4m8JQ/GUaJ8VL3StN8FtoMN7ov9vXSW9hcXwuJVuiWkZUeaNDZsgOWTezpg5I8L8M+OPB8Pw6+BtnJ8RLjw3Zv4m1fTNVjj8UT6dILYJeytFdAzKyvvazy8gEqGZMMrOCfu+igD5q1zXvD3w1+L3jbwx4j8X6tpWiap4T0uTSbS+8SXzXFxcJJeRSiyZpjMZ2CWwZYT5jsVJDM+T59/wubTG+DfwD1LxJ4vvtV03UPD839pw6f4s/si9vL6KK1UyvfPd2yM0TtKjwvOHZptwRzExT7Wrg/HvgfxNrninQte8N+JrDSJ9Mt7mD7FrOkvqNo7SmP9+qR3EDLMqxsgfew2TSDA3EkAxP2adLtrP4Zw3sPiqTxhJqF1czvqA8RT61EqmeTyoEmkmkGYoykTbCAWjYnJOa+e9e+Inhu1+E/xgisPiXPby6T46thYXsPi+Y3UMUi2abfOM5d4yBdgI5ZP3T8fu/l+rvh/4Fk8IDWb2/u7XUNe1u7F7qV3Y2X2OCSVYkiXZDvcqAkafed2JyS2MAdbQB8sXFx4aX4leOvh94f8YanrEOoeBhcrpM3i681K4a5czMpg824eVGaExsRGRlHjJGGBPI2uvaTb/AX4WJ4a+IMmj+ErzyIdf8RXes6je21hefYYzHBLPHewyWsW/KlEmiRJDGrD5irfatFAHyD441rwx4Z8G/CSOf4yajNpt14nmtrnXk8T3NlBeWT280lykczzs01usnkoszyzPDv2pMrdK/7QHxF0L4d+J7HS9J8UazZaroN/oTyzat42uYIorF72Ay7LYylr8GNpDLLcgoqO370lBEPsaigD5vvvGHg7Xfid4tsvH/jHUdD1CC8th4Z0uw8T3ul/2lp0lrC0UlrBazp9teS4NyuVV3LARgfKorJtLPwRoXxu+Ni+IvFGo6DqM7wX0MMniu+sQbU6bF5lyEW4VRGkiuglxiMqEVlwq19TUUAfHfgn4g2Gt/DH4EzeK/GFzZeALvwzIura/Z+IZtPC63HHb+XFd30EqOh2/bBseRQ0gG7Lqgqt488Tw6H8I/FV5F8QNVt/B0PjfR4fCfiOTxRcJLc20slmL6NLwzbruFA1/gyM4AjkOSIlK/ZtFAHgHwt1/wAPaH+0h4t8F6H4wutWs18N6ZeDTdT8TXGrSJdGe8MpjFzNI6nyTbFgpxhoiRyCb/xusJ/B3jbw341W68RXeh3ryeHtZ0nT9YvI4s3aCK0nihSVUSUT+XCGQBs3W/O5FI9wooA+dfhX4X1U+Ip/h/4j1TxJd3XhLU5NZ/tddc1EC/tbgb7SJ5DNulRXaeLy3Zh/oILKRLk+feDfjLoeo/Haxj0zxlqFlo+q6Nrlvcyav4re9uJL1JbUxudP3tBZyACZooowshQyBoo9oB+y6KAPDP2UfEEeoeHdf0ldZg8VS6TepE3iXTvElzrdlqYaNSsiPPNK1vIAP3lsGKoSGDMHBryX4/eIfBeseE/jvZ+P72zg8fadZ6jB4asr66Md1FZmwDQvp6Bg2yUlxM8Y/ebXjmLRxhV+zaKAPj74heKbTxP400eHU/i1p/gHwdP4cs7nRdQk1S8s7TUvmkW7NvdWuoWsbTxnyAVl84ANEVQAyb97ULjwlqvx8i0TWfiN4ggsk8GRaldWdx4tvdHm8+MqfPmgimgMEn2cGR0CRryzsmRkfUdFAHxH4P8AiD4a8P8AgX4O+L7j4n3p1XU/EjWN9Nqfja5mtp7WMTpIrwS3BhIRTbbm2ZBdGJ3Pk9f4u8RaBdah8SrPxz451nwn48try6j8PafZ+KLzTZJrUxA2MlnZRzJHdszZH+rkLyhkbONg+raKAPlVr6x1340eGtG8feNdQ0TVZvAianrWi2Pi+60uJNQjMRkk8uC4TZtjFwxC4UqGdg2wMvGt8ULG8+DPw+8Tj4ixauulz6tDNoMnjK5sbzW0S4UxpHdwzq0t3FF5GyGbeJFuCGALK6/blFAHy2bfwVpPx++K0niLxJqXh7UrvTrW/treXxRfaeHtzYzCefy1uFXZHsf95jETKNpRsVzngfxv4Ssf2X/A/inWfHfiHXb/AFxbDT9Vul8cTW8Q1D7I0hhubppwtgiHDSNEY5WKIrCZnMcn2PRQB8MWviTRPHHwg+D2r+LPFc0cGhfEDUrDWNQh8V3if2bDjVEgE955scgO0WqpNLtcrIAMCZg3UeMtSTVPi1r1h4h+K9x4AsrP7D/wj9kb3UoL3UdPe1iZJLMC9SK6uDcfaUYS21y5YIrKwKKfr+igD5N+LnibwZqGofFvS/iZf2lr4isLU/8ACI2eoXJguHs5NPUpNYRgh2ne5+1xu8I8w7VjPygLXs3w91rw5rn7O/h+/uNdt4/Dn/CPwrdatZ6obaOFEhCysLqJ1MRQq4LK6lSp5BFemUUAfEnhTxxoPirwb+zRBffEa8hm1m6ubDVjY+Lri0lvG+xXDlJjFOpaU3JtxvP7zfIqhgXwfa/2Z/Fmk6tqfxR0LS/FL+I7XRfE7Q2cd1rb6pcW9qbK14MksjybDcC6A3MeVcD7vHuFFAHyL8SvjJomi/tBaNDa+J7ywn0/xPBYa22qeLXt4Ft3tWO1NLR/L+zhnRTcTpGfMMYVpd4I9t/aD8QT+G/A9ncm6u9O0WXVrO31vUbKR4pLPT3lAnl81CGiXGFaVSGjVmcFSu4em0UAfLXxM8YfDDw78M9IuNC8dxajpUvjTw/IdQ1TxVcanAxh1O1km8q4up5FxHGrO4jbCAEtjrWN448f+GrO4/aYsrT4gvDcWeg2+o2nk+K5hPZ3SpOSIHE++FRcvAhiQqmZVjK4fafr6igD5U8P+KPB3hz4nfDKytfiPe3UPifwxqFzqS6h41ubuO4+W28qVFluGWJy32jY0Ow/JLt4Q7cTwL8TtJufgv4Miu/Gtw/glvGWs6d4h8Q23iCXzrS3+1X8lgtxfpN50CSMLPEpkBYNEpbZKd32NRQB80fEDxr8O/D/AIJ8PW2k+KdY1TSNVv7hdPvZPHd7Z2V1Oka7mk1Z5mnaJc7Vjt3lDOWAicoxTnPhT8ZNC8RWf7M39r+NNLvvEk2mSw3a3WqRvdyXLWfk4kDPvMrSqUOfmL5HWvrqigAooooAKKKKAOb8P/8AJ03gz/sTPEX/AKXaJX0PXzx4f/5Om8Gf9iZ4i/8AS7RK+h6ACiiigAooooAKKKKAPmD4M/8AIueI/wDsc/FP/p/v67yuD+DP/IueI/8Asc/FP/p/v67ygAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5vw//AMnTeDP+xM8Rf+l2iV9D188eH/8Ak6bwZ/2JniL/ANLtEr6HoAKKKKACiiigAooooA+YPgz/AMi54j/7HPxT/wCn+/rvK4P4M/8AIueI/wDsc/FP/p/v67ygAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorxj4zW/iG++K3ww0zSPG2t+FbLUp76O6i0lLRg5itJJFb9/BICc8YYMmOQocK4AO7+IPxEtvhzFoc17pmoX9tqurWmj+fYiEray3MyQxPKHkRtm91B2B2Gc7cV1lfKvj+48T6t4A1HQdY8RXmotpfxO0HTNL8ULb20d1LCb2wk37ViEDSQyyyxZ8rYWhwykhgeutfFGp+B/EHxS8P6n431L+yNG0rSb+31rULSO9u7aa7e6ScRpHEPMdnhVo49jKryqiR+WEioA98or5Mm+KHjtfhL8ZriDxRr1lq/hLWYE0y+1ux0w3vkvZ2khiuI4IfJKF5pGwFWUKyqxRlIHc+ONL8beH/ABv8ONBtfir4j8nxDqF7b307afpJdUjspZ18r/QsKQ8QA3BvlZgcnBAB71RXyjrHiH4g6L4J+KWvr8T9fuLjwXrbadZ28un6V5V3EsVrLm422QYsTcOpMbRjaqYAYFm6L43/ABR1rwr460/+wfFGsy/Ztf0TTNQ0ix02zGmW0N1dQK63VxPG0rzyRysVW2cFFMTNGozI4B9GUV4vaaxqvj3xh49kl+IOqeCLDwlqiac2nafDp4jMItYLj7RcPd2srjzDO+GRlTYi4G4MxzJ9W8UePtS+Kbw/ETVPAU3hO+ksbewsbPT5IEhFnFPFdTi5tpZGDtI5yropVNoAKs7AHqK/ECH/AIWYPBUuk6jb3cmmSarb6jJ5JtLiOOSKORV2ymQOrTp9+NQecE4rqq+evDPjLWfEnjb4feK73R/I1+++GV9qcukxhlxcPNp0hhAOWHzHbg8joeazdJ8YeMY/h78MfiLaeP8AUvEcniS/0mK88NTWVgti63jLHcRQmK3W4jMBkeQb5nKi3IkLfMaAPpeivmLVPEXxC8ZeKNW07QPGXinTNYj8T/YltNK0eym0SLS47pEmkF9LYyoJxAJC0bTs6zgr5eBsrZv9S8Y+EPiBrfga/wDiDrV/c+JtPt7jwjqNxZ6cs1vLHLsvU+S0WORo1khlIZWzFvwFKFyAfQlFef8AxettQ034EeLorfXtRi1Oz8P3JXWY/JS7eSOBj5p2xiNXYrzsRQNx2heMeSQp4t0az+CWiaR8UdcMHiCd7K+kks9LleKIaRLdIqYtAFZDChQtnh8uJBgUAfQ9vr63Hia90X7Dfxva2kF39uktmFpL5jyr5ccvRpE8rLL2EkZ5zxkfFL4hQfCrwHq/iu80nUdYsNKga6u4NL8nzkhRSzyATSxqQqgkgNuPYE15hN4l1rwP8SvH2l6v4/v7jRtL8GWGrxahq1lbSGymea8illEVtDF5pItY2CEE7iQowQleeeJfG2u+Ifgj+0nousajr2pW+j6DIbKTxNbWVvfeXNp7yZeO1jjCBuHCyIsqh8OqkYAB9e0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc34f/AOTpvBn/AGJniL/0u0Svoevnjw//AMnTeDP+xM8Rf+l2iV9D0AFFFFABRRRQAUUUUAfMHwZ/5FzxH/2Ofin/ANP9/XeVwfwZ/wCRc8R/9jn4p/8AT/f13lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXjfxs+FOqfE7x14Enl8MeFfE/hTRZ5p7+z8R3T5lMsbRfJB9llRigIcFmGWGPl+9XslFAHK6t8KfBOveHdP0DU/B2gajoOnkGz0u70uCW1tsAqPLiZSqYBI+UDgmo7r4P+A77VNW1K48E+HbjUdWiaDUbuXSbdpr2NipZJnKZkUlFJDEg7R6CuuooA4RfgJ8Mls7izX4c+ExaXCxpNANDtfLlWM5jDL5eCFPQHp2q83wi8CyS6HI3grw60mg7f7Jc6VATp21g6/Zzs/dYYBhsxgjPWutooA4dvgX8NmsL6xPw98Kmyv50uru2Oi23l3Ey7tski7MO43vhjkje3qaS++BHw01Tb9s+HnhS7220dkvn6JbPi3j2+XEMp9xdq4XoNowOK7migDmNQ+FvgzV/EGna7feEdBvdb01Y0stSuNMhkubVY2LRiKQruQKSSNpGCcijxJ8LfBnjLWbTV9f8I6DrmrWaqttf6lpkNxPCqsWUJI6llAYlhg8Ek109FAHOzfDnwnc+LofFc3hfRpfFEK7Y9bfT4TeoNpTCzld4G0leD0JFRaX8LfBmieKLnxLp3hHQbDxHctI0+sWumQx3crOcuWmVQ7FjycnnvXT0UAfMmqfs2alrOoeJxf/AA++G1/qOt6ld3I8ctNLDqtqsrnyZo4Es8rLDH5YGy6Qu8e8uruzV7fZ+G9Qm8XWtzqMdpLpejWwi0u4adpryaZ0CyyzZjURkKNo2s27zHJ28CusooAbJGk0bRyIrxsCrKwyCD1BFcPJ8BvhnJZ2Fm/w68Jvaae7yWdu2h2pjtmcgu0a7MIWKqSRjJA9K7qigDk7z4SeBtQ1rUtYuvBfh651fUoXtr6/m0qB57qJlCPHLIU3OpUBSrEggAdKzF/Z9+Fq2r2y/DXwgLd4xC0I0G12GMP5gQjy8bd/zY6buetd/RQBh6X4H8O6Jeafd6doen6fcadYtplm9pbJF9ntWZGMCBQAse6NDtHA2ityiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm/D/APydN4M/7EzxF/6XaJX0PXzx4f8A+TpvBn/YmeIv/S7RK+h6ACiiigAooooAKKKKAPmD4M/8i54j/wCxz8U/+n+/rvKoR/styafeaq+j/FXxxodlqGp32qnT7SLRpIYJbu5luZlRptOkk2+ZM5AZ2IBAzxUn/DNer/8ARa/iB/4C6B/8q6ALdFVP+Ga9X/6LX8QP/AXQP/lXR/wzXq//AEWv4gf+Augf/KugC3RVT/hmvV/+i1/ED/wF0D/5V0f8M16v/wBFr+IH/gLoH/yroAt0VU/4Zr1f/otfxA/8BdA/+VdH/DNer/8ARa/iB/4C6B/8q6ALdFVP+Ga9X/6LX8QP/AXQP/lXR/wzXq//AEWv4gf+Augf/KugC3RVT/hmvV/+i1/ED/wF0D/5V0f8M16v/wBFr+IH/gLoH/yroAt0VU/4Zr1f/otfxA/8BdA/+VdH/DNer/8ARa/iB/4C6B/8q6ALdFVP+Ga9X/6LX8QP/AXQP/lXR/wzXq//AEWv4gf+Augf/KugC3RVT/hmvV/+i1/ED/wF0D/5V0f8M16v/wBFr+IH/gLoH/yroAt0VU/4Zr1f/otfxA/8BdA/+VdH/DNer/8ARa/iB/4C6B/8q6ALdFVP+Ga9X/6LX8QP/AXQP/lXR/wzXq//AEWv4gf+Augf/KugC3RVT/hmvV/+i1/ED/wF0D/5V0f8M16v/wBFr+IH/gLoH/yroAt0VU/4Zr1f/otfxA/8BdA/+VdH/DNer/8ARa/iB/4C6B/8q6ALdFVP+Ga9X/6LX8QP/AXQP/lXR/wzXq//AEWv4gf+Augf/KugC3RVT/hmvV/+i1/ED/wF0D/5V0f8M16v/wBFr+IH/gLoH/yroAt0VU/4Zr1f/otfxA/8BdA/+VdH/DNer/8ARa/iB/4C6B/8q6ALdFVP+Ga9X/6LX8QP/AXQP/lXR/wzXq//AEWv4gf+Augf/KugC3RVT/hmvV/+i1/ED/wF0D/5V0f8M16v/wBFr+IH/gLoH/yroAt0VU/4Zr1f/otfxA/8BdA/+VdH/DNer/8ARa/iB/4C6B/8q6ALdFVP+Ga9X/6LX8QP/AXQP/lXR/wzXq//AEWv4gf+Augf/KugC3RVT/hmvV/+i1/ED/wF0D/5V0f8M16v/wBFr+IH/gLoH/yroAt0VU/4Zr1f/otfxA/8BdA/+VdH/DNer/8ARa/iB/4C6B/8q6ALdFVP+Ga9X/6LX8QP/AXQP/lXR/wzXq//AEWv4gf+Augf/KugC3RVT/hmvV/+i1/ED/wF0D/5V0f8M16v/wBFr+IH/gLoH/yroAt0VU/4Zr1f/otfxA/8BdA/+VdH/DNer/8ARa/iB/4C6B/8q6ALdFVP+Ga9X/6LX8QP/AXQP/lXR/wzXq//AEWv4gf+Augf/KugC3RVT/hmvV/+i1/ED/wF0D/5V0f8M16v/wBFr+IH/gLoH/yroAt0VU/4Zr1f/otfxA/8BdA/+VdH/DNer/8ARa/iB/4C6B/8q6ALdFVP+Ga9X/6LX8QP/AXQP/lXR/wzXq//AEWv4gf+Augf/KugC3RVT/hmvV/+i1/ED/wF0D/5V0f8M16v/wBFr+IH/gLoH/yroAt0VU/4Zr1f/otfxA/8BdA/+VdH/DNer/8ARa/iB/4C6B/8q6ALdFVP+Ga9X/6LX8QP/AXQP/lXR/wzXq//AEWv4gf+Augf/KugC3RVT/hmvV/+i1/ED/wF0D/5V0f8M16v/wBFr+IH/gLoH/yroAt0VU/4Zr1f/otfxA/8BdA/+VdH/DNer/8ARa/iB/4C6B/8q6ALdFVP+Ga9X/6LX8QP/AXQP/lXR/wzXq//AEWv4gf+Augf/KugC3RVT/hmvV/+i1/ED/wF0D/5V0f8M16v/wBFr+IH/gLoH/yroAt0VU/4Zr1f/otfxA/8BdA/+VdH/DNer/8ARa/iB/4C6B/8q6ALdFVP+Ga9X/6LX8QP/AXQP/lXR/wzXq//AEWv4gf+Augf/KugC3RVT/hmvV/+i1/ED/wF0D/5V0f8M16v/wBFr+IH/gLoH/yroAt0VU/4Zr1f/otfxA/8BdA/+VdH/DNer/8ARa/iB/4C6B/8q6ALdFVP+Ga9X/6LX8QP/AXQP/lXR/wzXq//AEWv4gf+Augf/KugC3RVT/hmvV/+i1/ED/wF0D/5V0f8M16v/wBFr+IH/gLoH/yroAt0VU/4Zr1f/otfxA/8BdA/+VdH/DNer/8ARa/iB/4C6B/8q6ALdFVP+Ga9X/6LX8QP/AXQP/lXR/wzXq//AEWv4gf+Augf/KugC3RXE+Pv2c/ifaQ6bP4I+LviDVZVnYX1hr76PYrJCUbDRXEWjTbHV9mQ0LBlLDKkAnX8L/s0+Ml8O6cPEfxv8YS695Km9bS7LREtfNI+YRB9MLbQeAWOTjOBnAAN+iqn/DNer/8ARa/iB/4C6B/8q6P+Ga9X/wCi1/ED/wABdA/+VdAFuiqn/DNer/8ARa/iB/4C6B/8q6P+Ga9X/wCi1/ED/wABdA/+VdAFuiqn/DNer/8ARa/iB/4C6B/8q6P+Ga9X/wCi1/ED/wABdA/+VdAFuiqn/DNer/8ARa/iB/4C6B/8q6P+Ga9X/wCi1/ED/wABdA/+VdAFuiqn/DNer/8ARa/iB/4C6B/8q6P+Ga9X/wCi1/ED/wABdA/+VdAGN4f/AOTpvBn/AGJniL/0u0SvoevKPAPwAXwX4+t/F19478UeL9SttMutKtotbTTo4YYriW2llYC1s4CWLWkPLEgAHjnNer0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXx74I8ER+O4fE2sax4m8cSXr+LfEVsBaeN9ZtIY4odZvIYY0hhukjRUjjRQqqBhRX2FXzB8Gf+Rc8R/wDY5+Kf/T/f0Ac9428M+CPhxptnf+JPGnj3S7O7vYNOhmk8f+IWDXEz7I0O28OMn+I4A6kgc0vjfwn4P+Heirq2u+KPiTb6eZkgaa28aeJroRs3ClxDdOUTPBdgFBIyRkVz37Qng3XPjPqV14T0fR9I1jTbHSbhLs6vq0tisF5dxtHBNEY7WfdLDEsxwduBcoQTWXqfjq8+IH7HN/f6sNniKzgGla1F3j1C2uVguQR2zJGzD2YUAeq/8KZ0j/oY/iB/4cLX/wD5No/4UzpH/Qx/ED/w4Wv/APybXFWvijxta/Hr4kebr1hP4Q0HSdNvf7G/sqRrgo8d4xWKUXIVJC0eWdo23DYuF25MXwj8dfGD4hGDU9Q0rRtH8OahppurW6uLBPkeWMPbvE0Oozm6jGfmEkdozKQw2nKAA7r/AIUzpH/Qx/ED/wAOFr//AMm0f8KZ0j/oY/iB/wCHC1//AOTa8q0b41/Ef/hSOm+O9RXw7fahr0tpp2maPpemyx+VczXS26yPLNeKsobllhPkjeyxmYDMtbsPxK+JfhvwW934v03SNN1bVNZsNG0Z5bQQeS9zMsJkureK9uUKoW3qEuQZeEPkn56ANew8K+DtS8a6r4Th8VfEga9plvDd3NvN428SxJ5MuQkkcrXQjlUlWUmNmwyspwQQOh/4UzpH/Qx/ED/w4Wv/APybXD+AtF1bQf2nPEVrq3iG48TP/wAIfp7Q3l5aww3AQ3t5lX8lUjbDbsFUX5doO4gu3XeLvFniO/8AiFD4M8KX+j6PqEel/wBsXN7rOny36NG0xiSOOGO4gOcq5LlyBhRtO7IALX/CmdI/6GP4gf8Ahwtf/wDk2j/hTOkf9DH8QP8Aw4Wv/wDybWFqnizxvdePLPwHpWr+H7HXbbQ49Z1DV77Q557a53zPCEgt1vEaPBjLEtK+AyDnJI5+H4zeJpPBt4dQ1fwz4d1/TPEF1oNxey6bdX0eoyRDfGLKwimWaWSRCD5aysyFHAEnUAHe/wDCmdI/6GP4gf8Ahwtf/wDk2j/hTOkf9DH8QP8Aw4Wv/wDybXl3/DQ+uXnw3+FmvXWr+GfA8XinTZLvUPEXiCykfTLa5RIytsEN1CUaXdMyb5SQIGGGJyLnhz4pfEqHS/h5qXiKTw80XibxNNo8lrb6JcWkgtAl00FwjPeSYMi2ySDKn5ZgMZXJAOk8deFfB/w28N3Gva/4o+JNtpNuR59xbeNPE135S/33WG6dlQY5cjaO5FdD/wAKZ0j/AKGP4gf+HC1//wCTa8o+K3jLX9d+Ff7ROg65Jptwvh63e3s59PtJLctDNYx3CiRXlky6+btLAqG252rnA6D42fGjW/hv4o06Gw1fw9JbtqGlWs2g/wBm3V7qDwXV7FBJcSTxypHZLiRxGZY3V3jwGLPsAB2rfBvRo1LN4k8fqqjJY/EPXgAP/A2s7wx8PfCvjLw5pmvaL4u8e3+kanbR3dpcp8QfEAEsTqGVsG8BGQRwQCOhANc94avviRrfxm+KFja+LNEh0jTJLSGys73Qp5zD5loJEIZbyMcO+X+XL4wCgwFzPBnxq8X+PPCvwjs7CfR9J8T+M/D82v3Go6hp0t1ZxrCLffDHAk8TFi10hBMnyrGchiwIAPR/+FM6R/0MfxA/8OFr/wD8m0f8KZ0j/oY/iB/4cLX/AP5NrzDxR8Z/iH4b8K+NIN/hqbxP4U8QaZp0t5/ZtwLHULW9NuE2xfad8Eq/aVzmSQfu+B842d34H8VeMIPitrHg3xVqOhawINFtdXt7vRtKn08r5k88TI6SXM4YfuQQQy9SCOhoA1P+FM6R/wBDH8QP/Dha/wD/ACbR/wAKZ0j/AKGP4gf+HC1//wCTa5j4leIviDb/ABt8G+GfC+v6FpWlavpGpXkiapokt6yy20lquSUuoiwIuRgArtKsSX3ALmL8XfFS+CJn1TV/C/h3XrHXrzRJb6TTLq+i1FoSxjWysI5lmllkTBMayuylHAD9gDuv+FM6R/0MfxA/8OFr/wD8m0f8KZ0j/oY/iB/4cLX/AP5NrzHS/jR8QPF3h34KX2jS+G7Cfx1bSJfC/wBLuZVtpks5LgyxBblDszER5THJz/rBir/jD4yeJvBXxD8MaDca94Y1VrrU9P0rUNM0zRruW5j89VBuZZxcGOxDuWMUMyuXVDtkkIbaAd//AMKZ0j/oY/iB/wCHC1//AOTaP+FM6R/0MfxA/wDDha//APJteU+LPir8VdJs/jZqFlq3g5bT4eCaeGGfw9dySX0Y02K+WNmF+ojYCXyy4DBiN21fu11uh/ELxrpHxO0XQvEt5oWraXrPh6/1uEaRpM9pcWrW8loBGWkupVlytyRkLHygPfFAHU/8KZ0j/oY/iB/4cLX/AP5No/4UzpH/AEMfxA/8OFr/AP8AJteffBv4j/Fv4oNpmt3OjaRpXhDVrA30FxcWSAxLLFvtzFJFqMzXOCUDiSC13KWYFCPLPNeCfit8SdD+AnhPWb29sPF/iPxTfpY6Z5OlGN4JG+0SyGYS3yJNkQlUUPbqCVGcUAezf8KZ0j/oY/iB/wCHC1//AOTaP+FM6R/0MfxA/wDDha//APJtec+I/iN8YPCPwwtdd1Wx8N2OszeItP06OzvLGRGltbm5htv3scN7OkEivKzhknuFZAuVRiVXW1rx74+8C/EHwvpPijU9Di8NagsUUniC18NXP2e5vXuHQWZP25vsTMhgEckglSR2cZUhUYA7D/hTOkf9DH8QP/Dha/8A/JtH/CmdI/6GP4gf+HC1/wD+Tat/FTxPeeE/DCXllrOieH5HuEhN/rsMtzGuQ21IraN43uJnYLGsSyKSXJG8qI38g0/44ePfE3wz+HWvaRP4ftNQ1/xLd+Hb06jod2qDy7i6hSdIDcpJEQLUs0MhZiX27kIJoA9U/wCFM6R/0MfxA/8ADha//wDJtc/D4U8HXHji48IL4p+JC6/DZDUGt5PG3iVI2g3Ku9JmuhG+GZQQrEgnkCsO4+NHinwbp/j208RTaJq2q6Hqmk6XZ32nafNZW27UGgjjeaJ7iU7Y3nDNiQblGBtNP8M6JrWh/tQwxax4jl8SGTwdcSRzXFnFBJETfQ7k/dBVKA42gruA+87nmgDrrP4W+HtQuL+C38T/ABAklsZhb3C/8LA8QDZIY0lA5vOfkkQ5GRzjqCKt/wDCmdI/6GP4gf8Ahwtf/wDk2uTufGGs6ND4M0bQJtPtNZ8c6hqF9DqerWkl1DBCEkulVoUliaR/K8uMDzFACs3O3aeb8Z/Gf4h+B/DPxWtriXw1f+JPBdlZaxb6hHpdxFZXtrcLL+5aD7UzxSq9vKN4lYbWjO3qKAPTpPg5o8UbO3iL4gkKCTt+IOvsePQC9yfoKwfA/hPwd8RtC/tjQfFXxGuLIXE1o/2rxv4ltJY5oZGjljeKa6R0ZXVlIZRyDXoPhO38R2+nyjxPqGl6hfNMXjbSbGS0iiiIXEZEk0pdgd37zKAgj5Fxz80+FPFHjv4b/Dn4geMNLv8AQdQ8PaX4116aTQJtJm+2XEX9szLMqXYutokILFP3BGcKQ2dwAPVfDfhTwf4s1XXdN07xR8SjfaHc/ZL6G68aeJrYxuQSpXzbpfMRgMq6bkYYIJBroP8AhTOkf9DH8QP/AA4Wv/8AybXnXiTx5dfDbxB8Z9dsbMX9+t3oVnawtgr51ykNtGzAugKq0yswLpkKRuXqJZPil8U/Bvw38R+IfF/h+wS5jnsrHSIFtY7Sc3Fxcpb7poUv7qIxK00bbvtSMwWQFYwFcgHoH/CmdI/6GP4gf+HC1/8A+Ta5+Pwr4Ok8dP4O/wCEq+JCeIFsTqQt5PG3iVI3tw6ozpMboRvhpEBVWLDcMgVi2/xQ+JXg/wAA+IPEPjrRtNsxHcWVlpitaraTCa4uEt988MV7eJ5KtNG24ThiFkBRcKzUrfw/4q0n9pO1gl8Wx6zqM/gjUXs7zUtLTbaym9s8gxwPF5kIO3ahIkABDSuSCADs/C/w/wDCnjTw7p2vaJ4v8eahpGowLc2t1H8QvEAWWNhlWAN4CPxGa1P+FM6R/wBDH8QP/Dha/wD/ACbXlmj/ABi+IviXwr8E7zTb3w3Z3vjpp4b5r7SZ50t5Fs7i6DxBLqP5AINmxiSQQS+QSdNvjN4w0XwJ8QLnU30S61bwv4nt9Cl1i102aKxgtZY7GSS+mt2uGfZAl47uBMBthLblGSAD0D/hTOkf9DH8QP8Aw4Wv/wDybR/wpnSP+hj+IH/hwtf/APk2uZ+C/jjxj468Ta7Ld+JPCnifwZZJFHZax4b0eaCLUJmXMnlzm+nRliI2sFByzY3KVZa9bvluZLK4Wzligu2jYQyzxGWNHx8rMgZSwBxkBlJHGR1oA828N/D/AMKeMNIj1TRvF/jy/wBPkkliS4j+IXiDaWjkaKQc3nZ0YfhWp/wpnSP+hj+IH/hwtf8A/k2vLbX4v/EXUPhv8PtUs77w2msa74nvPD1/Jd6RO8A23N1HHNEi3SlQq23KMzltwG9cFjsyfGbxR4P0/wCIFt4km0TV9U0DUtK06zvNNsZrG3d78wRxGWKSeYgJJOCxEnKj+E0AbPjjwn4P+HOgvrWveKPiTb6ZG6xyT23jTxNd+XnozrDdOVTjl2AUcZIzXQf8KZ0j/oY/iB/4cLX/AP5NriPjRp/jGx+A/wAQf+Er13Q9aVtO/wBHGj6JNp5jO75t5ku7jfn5cY24weueOgk8ceK7z4pfEHwnaXOj28Ol6Hp2q6TdTadLK0TztdJIlwouF84brXcNhiwHwc4yQDX/AOFM6R/0MfxA/wDDha//APJtcXp0fw61LQZdZTxt8RLewi1aPQ5GvvGvia1kS9eZIUhMct0rgmSVBnbjnOcAkQeEvi5r3xS8O/CzS476LwxrnjHwu3iS+1Owt1fyEjW1Dw2qTb1Ds92pDSCQKkbAqxYMvGeH/FHi34c+CvEd9Zarpt3cn4nLpmpS3OmtuuYrm9tbZmi2zBYnAl3ZIdSRwq54APbv+FM6R/0MfxA/8OFr/wD8m0f8KZ0j/oY/iB/4cLX/AP5NrhNc8dfE6bxv8SNN0rWfCOn6Z4Ws7e/ga+0C6uZZ0milkETlL6MKU8n74B3b/uLt+av4j+PGrQWfgWebxD4W+Hlnrvh6PWJNY8UWT3NnNcOIj9khIu7cLIA5bBZmZeg+VjQB6H/wpnSP+hj+IH/hwtf/APk2ue8ZeF/BvgCDTZ9c8VfEe1g1C+g02CaLxt4lnT7RM4jiV2jumEYZ2VQz7VywGckV0vwW1bxh4g+G+jav45is7TX9RgS7ksbPTpbH7GropEMkcs0rb1OcklTyAUUg14Z8Stc174kfDHw345HiHyNDv/F2iRxeG1s4mhS3TWrdEdpceb9q3oCzbvKClo/J3DzqAPb/APhTOkf9DH8QP/Dha/8A/JtH/CmdI/6GP4gf+HC1/wD+Ta4C6+KHxT8UfEfWdN8GaBp7+HtH1VdMnuNStY2jZkSOSbzLgX6Swkq/yhbOcAGNiW3MqWfFHxo1rw/8aPDvhuLV/D+oadqWtDSrrSLLTbqe7sFa0lmR570TCGKViiMIHiDFGJUsFLUAbPjfwb4R+HXhXUfEeveKPiRb6Pp0Rnup7bxt4lumijH3nMcN077VHLNjCgEnABNbFt8IdEvLeKeLxJ8QHilQOjf8LC18ZUjIPN7Ximv6p441z4I/tJ3HiLxHpuq6Ta2niKwt7SDSpYJ4jHZ7Y9spuXQRhARsEeSxLF8kg+ieCvE3jHwz8QvBnhbxDq+l67Y+IPD95qCPZaY9k1pNatZoEQGaTMbR3OSGLNvViGCsEQA6z/hTOkf9DH8QP/Dha/8A/Jtc94Z8K+DvGGpa/p+meKviQ97oV59g1CG58beJbZopdocY826XerKysrplWDAgkEGvXa+Xtd1Txl4V8YftF+KfDWtaVZQaCLfUv7PvtLe4N3NDo0EgR5ROu2JlGCFQOG2tvwCjAHsv/CmdI/6GP4gf+HC1/wD+TaP+FM6R/wBDH8QP/Dha/wD/ACbXn3xo+PGseA7XTdS0vVNAhWW1s7xvD82m3Oo6jPDNMEeVjDKgtIVztE0iuhchSVOFbU8W/Efxp4R+JWs6FeXugppmoaFLfeF3XSJ2mlvUlSNraVjdBJWHmQ7VXyzJ5pwV8s7gDrf+FM6R/wBDH8QP/Dha/wD/ACbVHW/hjoHh/SbvUrvxD8SHtrWMyyLaeOfEdzLtHJ2xRXbO59lUn2rivGPxL+Ktj4ug8GeHNN07WNf0/SLbUtWv7fSI3t5WuZZ44/Khn1W2aKNPssm5g8xJdflXHzez2ranJ4RjbWorSHWDZZvI7CRpLdZtnziNmVWKbs4JUHGMigDhvCvgDwr428M6V4g0XxZ8QL3SNUto7y0uP+E/8Qx+bDIoZG2teBhkEHBAPqK1f+FM6R/0MfxA/wDDha//APJteJfAjxR478A/BX4F3N1f6DrfhnWoNK0g6dbaTNa3trFNbHy5fPN1IsrIwTePKQMu4jZtwet8B/FH4p/ETxgt5pugafb+BP7VurVp7y1jXNvBcSQOVuUv3kM+6Mt5bWSqGDR+ZgCVgD0D/hTOkf8AQx/ED/w4Wv8A/wAm0f8ACmdI/wChj+IH/hwtf/8Ak2vP/AfxR+KfxE8YLeaboGn2/gT+1bq1ae8tY1zbwXEkDlblL95DPujLeW1kqhg0fmYAlbHuvi18U9P8K+M/E0+q+DnsPC+vSaS9iugXYkvY0miQuJftxELES4A2SAFc5w21QD1j/hTOkf8AQx/ED/w4Wv8A/wAm0f8ACmdI/wChj+IH/hwtf/8Ak2tf4l6tqnh/4feItV0SWzg1SwsZruBr+3e4gzGpchkSSNiCFI4cYJB5xg+Qat8WPiXo/gPwZe+Toer+JfGk0C6dZaXpbBLFTZy3UqN9ov4lun2xFVPmW46tgkBCAekf8KZ0j/oY/iB/4cLX/wD5No/4UzpH/Qx/ED/w4Wv/APybXm/ijxl8ZNL8H+Dpby58O+HNd1bxPBpkiy6S05NrLgo0kKXjrE4KyBkSeUMu0rLGSQtnWPjR4w+Htr4+sfEyaNrGp6J/Yzafqml2M1nayLqVwbVPOheeVgYZUZ32yfNGVxtJoA7/AP4UzpH/AEMfxA/8OFr/AP8AJtH/AApnSP8AoY/iB/4cLX//AJNrnB4p+Ifhn4g6L4W13VfDOrjxFYXzWGoabolxafYbq3VGBmhe8l86Jg/O14yCoGfmyvmur/Ej4teIv2b7bxx/wkXhnQ7rUrnToorfTdFuWeFZNQit3Jla85Dht20ICoZkDsQJaAPbf+FM6R/0MfxA/wDDha//APJtQ3fwi0WytZriTxD8RGjhRpGWHx94hkcgDJ2ot4WY+gAJPQCuG8c/En4paT4utfBnhywsdf16z0mHVNT1C10aMwSieeeKIRwT6tbmIL9nbcfNmJ3rwvfoD4k8WeLPGEXgeTVrfwjrum6DZ61q15o8SXSzTTyzRLFbm4THkhraQuWj3FZECsjAtQBJ4N8F+EfiB4bs9f0LxX8RLrS7vf5UsvjrxHbuSjsjBo5LtXUhlYYZQeKn0P4feFPEjaiumeLvHl2dOvHsLrZ8Qtf/AHU6BS0ZzedQGXp61U/ZTWZPgToC3MkctwLjUBJJEhRGb7dcZKqSxUE9iTj1PWuO1b4wfETSPhr4x1ZL3w3da7oHjGHQi0mkzpaT20klrDhYxdF433XIfcXkHykbfmBUA9Q/4UzpH/Qx/ED/AMOFr/8A8m0f8KZ0j/oY/iB/4cLX/wD5NrL8D+KvGEHxW1jwb4q1HQtYEGi2ur293o2lT6eV8yeeJkdJLmcMP3IIIZepBHQ1n/E7xD4/tvjJ4J8OeFde0PSdM1jTtQuJl1TRZb1hLbmHklLmIlSJ1AUbSpViWcMFUA6T/hTOkf8AQx/ED/w4Wv8A/wAm0f8ACmdI/wChj+IH/hwtf/8Ak2uEX4ueLIfB96urax4X8P69p3iC60STUH0u7vItSMY8yEWWnxziaSV42GY1mdlaOQAP25yz+JnxD+JEPwI1LRdd0fw7J4m066vdQtrjR57m3edLbP3BdRP5Y3ttQvwdpJYqMAHpWl/D/wAKa1qus6ZZeL/Hlxf6PPHbX8C/ELxAGgkeJJkU5vO8ciNxkc+oNan/AApnSP8AoY/iB/4cLX//AJNrz/WfjV4q8JWvxYa+TT9Yu/Dur6bpOkpY2Zt4z9uFv5TzLJOd5Rrxd58yNWWLjy8kil4h+JXxl8HfBfx/4v1zTdB0y90OxN9p8V/phjeby1ZpUlgt9RuECsNoSQXO4HfuiwFLgHpv/CmdI/6GP4gf+HC1/wD+TaP+FM6R/wBDH8QP/Dha/wD/ACbXPaX4q+IGnfFe38G65q3hm/8A7T8O3+r2lzp+i3FsbOaCe1iVZA93J5yH7Vk7TEf3fbdx5j4S+J3xY0T9nXwb4yvtX03W4L7yrjU9Ui8L3N9Pptoyvvmlt475XuAJDHuaEL5aBj5TKCUAPb/+FM6R/wBDH8QP/Dha/wD/ACbR/wAKZ0j/AKGP4gf+HC1//wCTas+O/EF/H8INc1zw7qtmNQTRpb6y1IW/n27MIS6yLHv+ZT1A3EcjO4dfLU8e+OPBfwZ8JX+qeM/C39q31glxFcXGg3t3dXYFtEyW0VlHdmW5mOZZJJ1k+VUH7nBZ0AOovPC/g7T/ABxp3hG48U/EiLXNQtZLy1jPjXxN5E0aHD4uPtXlb14JTfuAZTjDAm7r3w/8KeF4bOXVfF/jyyjvLyGwtzJ8QvEB8yeVwkcYxedWYgV498Q/jNdx6f8AAz4jTaczXGpeF77Urj7K3lw2JntLR2nkYrKyQRF9zMI5SiqWKMFNek+K/E3jbwP4Z8FaiPFWj+If7Y8R6bZX86aVshktrqeGJRZlJv3Y2ksWkMxYyMVKLtVQDrP+FM6R/wBDH8QP/Dha/wD/ACbR/wAKZ0j/AKGP4gf+HC1//wCTa858SfEX4owax8WRpus+D7TTvBcQu7dbzw/dzy3MbWn2lY3Zb5ArKPlLhTuzkIuMGx46+OGs6XqHh6BfEPhfwHaaloMWqRX/AInsZLqLULlzhrO323dviRBsYrl2YTLgDacgHff8KZ0j/oY/iB/4cLX/AP5No/4UzpH/AEMfxA/8OFr/AP8AJtW/hDqXi3WvhzoWp+N4rO18SX9pFd3VjZWMlotmzxqxgZJJpWLISVLbhnH3V6V2NAHB/wDCmdI/6GP4gf8Ahwtf/wDk2j/hTOkf9DH8QP8Aw4Wv/wDybXeUUAcH/wAKZ0j/AKGP4gf+HC1//wCTaP8AhTOkf9DH8QP/AA4Wv/8AybXeUUAcH/wpnSP+hj+IH/hwtf8A/k2pfhjoTeC/2kvD2mWOveKLzTdR8Ja1c3NnrfibUdUhaWG80lYpAl1PIEZVnmG5QDiQiu3rm/D/APydN4M/7EzxF/6XaJQB9D0UUUAFFFFABRRRQAV8wfBn/kXPEf8A2Ofin/0/39fT9fMHwZ/5FzxH/wBjn4p/9P8Af0AXvDPws0Dwjqmvajpp1ZbvXJDNftda5fXKySFVXeqSzMsbBVRQyBSFRVGAoA5SH9ln4eW+i6xpKWuvjT9YuxfahCfFerH7Tcd5HJusljxuOfm2puztXHrNFAHH23wl8M2niyz8Sx216NatrOGx+0Nql0wuIoRIIjcIZdlw6ebIVkmDuCxIbPNZ3hv4C+C/CEjnSLHULKHZMlvaLrN61tY+buDm0gaYx2jYd1DQKhVWYKQCRXoNFAHn+lfAfwTo/wAPNQ8DR6ZdXXhW+UrLp+o6pd3gQHGPKeaV3hwQGXy2Xaw3LhuakX4H+D38M6voN1Y3uq2OreWLuXVtWvL67cRtvhC3M0rzII3y6BHAR2Z12sxJ7yigDgvC/wAD/CXg7xX/AMJNpsWrtrptvscl7fa/qF480ILMqS+dO4lCl227wduflxWh40+Ffhzx7qFjqGqwX0OpWMckNvqGk6pdabdJG5UvH51tLG5QlFJQsVyoOMgV1tFAHFa98G/CfiK30eOexurKTSImgsbvSdTutOuoYmADR+fbypIUbapZSxDFVJBIBqDUPgb4O1DSNI05rG+tYdKkmmtZ9P1e8tLnzJsmd5LiKVZZWlJLSGRmLsSzbjzXeUUAfOnjb4H2fhPVfA9p4a8F+KNV8KaLaajGieFvFk1nqFrJM1ttgDzX0GLQiJmKJIcPFFhVXdu6jwj8IB4m8I3uneMIPECaS2qpqWjabq2vTTarpOxFAzfQztLvMnmsMTybVcLvx8i+x0UAeVyfsw/DyTT9fsTp2rLa6/5f9rRx+ItST7cyIEDykXGXdlADsfmf+MtUuufs2eA/EjyPqNnrNw0i2wlP/CSaknnPb7PImk23A3zJ5aYmbMnyg7q9PooA4i6+DPha68QXet+Rqdvqt3aLZXFzaa1e27SqsZjV2EcygzKjMonx5oB4eqNr+z74HsfB+i+GbbT7+30zRJDJpckWtXy3dgShQiC6E3nxKUYptVwu0lcY4r0WigDz/U/gR4M1jwY3ha7stQk0mS9TUZyutXqXVzcIQUlnulmE0zKVTHmO2PLjx/q0xoaX8J/Dmj+O7jxjbJqZ8Q3FpHYS3E+s3s0bwRg7EMLzGLClnYfLnc7t952J7CigDwr4veBdU8cfHbwBcP4a8TXHhnS9O1G2u9Z0PXV0zypbqS02ZaK8huGRBbSFwFI+ZMBznb32sfBfwnrelaLp81nfW0OjmRrObT9WvLO4UyA+aXnhlSSQyEkuXZt7Es2Sc129FAHl9r+zX4CsbXw7bWlnrNnb+HZJJdJjtvEmpxLZlxtYIFuBhduVC/dCsygAMQZvEv7OvgXxZrd9q2oWWqi8vLyLUZfsev6haRC6jSNEuEihnVI5gsSL5iKrEA5PJz6VRQB5ve/s8+CNRt/GMFxa6xLD4vffrcZ8RaiBd/KFxxcfIpQLGVTaDGoQjYAtXbf4JeFLXxRoPiFE1htX0Oz+wWM8niDUHVIPl3IyNOUkDFELGQMXKIWyVGO7ooA4Xwr8EfB3gvWU1LR9PurVoZZri2sm1S7lsbSSUuZHt7R5TBAx8yQZiRSBI6jAZga0H7P/AIEt/DWo+H00eY6PfXC3TWr6ldOLeRJDKjWxMpNrskZmUQFApJKgV6HRQB5zqn7P3gvWvDa6HfW+sXVkL2LUWmk8Q6ibuSeIgxPJc+f5z7CFKKzkKVUqAVBGpqPwj8Oavqmk396uq3M2mRW8UMcmt3xhkEDl4Wni87y7h1c7t8yuxOCSSBXZUUAc544+H2ifESxsbXW4rtlsboXtrNYahcWNxBMI3j3pNBIkinZLIpw3Icg9a5K3/Zr8A2mm6fp9vZaxb2Wn6pJrNpbw+I9SRILt2LPIgFxxlmdtv3cyOcZds+oUUAefP8BfBU83jB7nTry+XxcGGsw32rXlxDc5AAKxySlIioChDGFKBVC7QoAoxfs8eFtM1ObW9Kl1q38UfYJ9Pg1m/wBf1G/lSORCAkgmuG82NWO9Y3JVXJZdrEtXp9FAHN+LPh34f8baDaaPq1iz2dnLFcWjWtxLaz2ksYwkkE8LLJEwUsu5GBKsyn5WIOJe/AnwbqXgvVPC13ZahdaTqrh9QabWr17u8IwAJbozefIoAC7WkI2gLjHFd/RQBR0PRbfw7pNtp1rJdy29uuxHvrya7mIzn55pmaRzz1Zia4rS/gH4L0fX59WtrLUvNn1KTWJLKbXL6bT2vHlMzT/YnmNvvEp8xT5fyOqsuGVSPQ6KAOBb4F+DJrzxZcXWn3mo/wDCVRtFq9vqWrXl3b3Kt2EMsrRx7RwuxV2AALtHFSWPwT8H2mgaxos+n3Wsafq9v9kvV13U7rU5JIcHEQkuZZHVBkkKrAAksADzXdUUAcJafBDwdb+HdZ0O40+71jTtYt/sd6uuapd6lJJBggRCW5lkdEGSQqsAGJYYPNZtr+zn4Ks9aXWY18RNrK2k1iNSl8V6rJdfZ5RhojK1yXKA/Mq5wj/Ou1vmr02igDzPS/2cfAujW/hSCztNYhh8LXDXWjx/8JHqRFq7LtbANx8ylSybGyu13XG12B5b4mfAfTtL8G62vhXQdb1q61nW7HVNUtYfE92t47R3EbNcWj3FyqRXChFIIeMFY1GTtRa91ooA8A0D4c+JtTi8TR6VF438FaZqGiT6d9i8UeLWvrlr1mXyLu2nS5vGtvKUyglXG8umYz5atXuFvpZXQotNubq4uiLYW8l15rRzSfLtL71IZWPXcpBBOQav0UAeX2n7NfgOx0fS9LgttcSx0vUn1ezj/wCEm1MmG6c5aQMbnJySxwSRl5DjLsTo/wDCiPBUlx4vluNNu78eLc/2zDf6rd3MNzkAAiKSVkjKhVVTGFKBVC7QoA7+igDzm8/Z+8G6l4b1HQr2PXL6x1FozdvdeJdTluZlTdsia4a4MpiBdz5W/Zl2O3JJqbXPgR4N8SX9ne6jaalcXVtp8ektJ/bd8pvLSMsVhu9sw+1pl3yJ/M3b33Z3Nn0CigDzhf2e/A8XhXw74ehsdStbDw6zHSZbXXb+G8slZCjRx3STicRlW2+Xv2YCjHyrjOb9lz4dtpF1pa2GsxWF1qEerTQQ+JtTjV7xG3LcfLcj95vAkLdWdVc5ZQR6xRQB59cfAfwfd33iW8li1lrjxJapZaow8Q6iBPCuNqgCfCYAIym04ZxnDsD5t4y+Ef8AwjvjLQk0vwZ4017wxpugnTrSbwv4yls71HNwXMVzJPqFvJJGihfKxI+N8gIAWPH0VRQBxPwh0PWtA8ItBrc+oM0l3NPZ2erXovbuxtWbMVvNcZbzXUdWLyYzt8yQKHbC1j9mT4ea4139p0zU0guL3+0jZ2uv6hb20V35om+0QwRzrHDL5g3b41Vss3PzNn1OigDgdU+Bfg3WPEk+uXFhei/ukhjvVg1a8ht9QES7Y/tcCSiK6wmEJmV9ygKcqAKqap+zv4G1jxA2tXNlqgvzqH9qp9n1/UIIorvGDPHCk4jjdgSGZFBYMwOQxz6TRQB55rHwB8Ea4PFa3Wn3wh8Uoyavb22sXsENwH8vzMRxzKsZkESCQxhTIAQ+4Eg2rf4K+FrXxRoHiFI9WbV9Csv7OsJ5Nev5FS3ONyOjTlJd21CxkDFiiFiSq47migDl/ht4Y1Dwf4Sh03U9UutWvBcXNw095dvduiy3EkqQiZwGdY1cRqWAO1BwOgwtS/Z/8F6tH4yju7XVZY/GBB1tP7f1BVugAF2gCceWuwCMrHtBQBCNny16LRQB5drX7NHgDxDF5WoWOsXMTWcNjLG3iPUgtxFCWaHzgLgec8bOSskm51IUhgVXHY3vgHQtTHhw31kb+Tw9Mtxps95PJNLDKsTRB2kZi0jbXOS5bJwxywBHQUUAcf4y+Evhrx3rFlq2p299b6vZwPaxajo+q3emXPkuys0TS2ssbvGWRW2MSuRnGa6Sw0ey0vSYNLs7WO10+CEW8VvCNqJGBgKAOgxVyigDz/wJ8B/Bvw3k05tDs9SWPTYvJsLfUNbvr+CxXaUzBFcTSJC2wsm5FU7WZc4Ygy2/wR8HWviu58QwafdQ3l1ejUp7SPVLtdOluwFxcNYiX7M0u5EfeY93mKsmd4DV3dFAHCW/wR8HWviu58QwafdQ3l1ejUp7SPVLtdOluwFxcNYiX7M0u5EfeY93mKsmd4DVm3H7N/gW60HV9GltdafTdW1BdVvYf+El1PMtyCSH3faNw5wxUEKSqEglFI9NooAxda8H6b4g8I3Hhq/F5NpNxbfY5Qt/Ok7xYAIM6uJSSBgtv3Nk5Jya5+T4J+EbjwLZeEJ7K+udEsZ4rmz+0ateS3VpLGwaJ4bppTPEyEYUpINoyowCRXdUUAfP/wAbPhTLZ+FvC2h+FPCfiTxHar4jg1jVLjT9fCX5WJdpZ7y6vIp2lK7ERhISqxBcoqqK9T074W+GbPwnqPh2TTJNQ0rVFYahFrN1NqE13uUKRNNO7ySYUKo3McKqgYAAHW0UAcT4c+DfhnwtLeTWa6xPd3No1j9s1LXr++uYIGwXjgmnnd7cMVQnymTJjjJyUQirpfwG8F6P8PrzwRBYX0vhi6IZrG81i9uTGQysvlSSzM8O1lVh5bLhhuGDzXoFFAHA6t8C/CGsJpBnt9Uhu9KgktrXUrLXb+1v/KkYPIkl1FOs0oZlDESO2WG4880/XPgj4P16XSZnsb3TLnS7RrC0udD1a80uZbdirGFpLWWNnTcittckAjPUknu6KAOZ+Hvw38PfCvw+dD8MWcunaR573Edm13NPHAz4LLEJXbyo8jIjTagJJCgk55SX9mnwFcaPrGlS22uSWOr6hFql7G3ijVCZbqMkpLu+07lOdpO0gExxkgmNNvqNFAHH6X8J/Dmj+O7jxjbJqZ8Q3FpHYS3E+s3s0bwRg7EMLzGLClnYfLnc7t952J88+MngjVfG3xq+Hsh8M+Jbvw3plpfRXmsaFriaZ5Mly1uEy0d5DcMqCFmcKpBDJgOchfc6KAOG1b4K+EtY0nRtPmtL+3i0dpHtJ7DV7y0uQ0ufOZ7iKVZZWkJLSGRmMjEs25iTWfD+zt4Dt/DuiaFDpl9BpuiTyT6akWs3ySWu9CjxpKJt4hZSVMO7yyONtek0UAcBH8B/BSzeLpJ9Nu9QXxYrLrMGpard3cF0CAv+qllZEIUKqlFUqqqq4AAFe6/Z98FX/hXV/Dt7bavqGmatEsF79u8Q6jcXEsKnIh+0POZVi5OY1cIdzZB3HPo9FAHE2nwd8M2XjDSvFKDWJNc0yy/s62ubjX7+YfZ8AFJI3nKS5IVmMisWZVYksoIzLb9nfwRp+knTLG31rTLLzWkRNP8AEmpWpiU5zDG0dwrRw5YnyFIjB5C55r0migChHoOnQ6CuiJZQrpC2wsxZbB5QhCbPL2/3dvGPSuAj/Zv8BQ6bpNiljqyQ6WssVq48Q6j5qxSrEskLS/aN7wlbeFfKdimI1G3Ar06igDzXR/2d/BGgz+GJbG31qBvDNu1ppC/8JHqTJawt1jCtcFWXGFwwPyoi/dRQKFr+yz8O7Hwpp3hq2s9dttC066S8srKHxTqqJbSoQyNGRc5TawDAAgBvmAB5r1migDzvUPgD4M1Q+Ljc2+ryDxYixayo8QagouUXACgCcCMbVCYTblCUPykqfOPGXwqk0b4gWctp4L8ba74es9Ag0yzuvCnjOWzumZZ5nZLx5tQt5JFjDJ5RDPjzZt2fkC/RdFAHG/CXQ9a8P+C4LXXbq9nuTPNLBDqV0Lu6tLZpGMNvLOM+bIkZVWcs5yCPMkx5jdlRRQAUUUUAFFFFABXN+H/+TpvBn/YmeIv/AEu0Sukrm/D/APydN4M/7EzxF/6XaJQB9D0UUUAFFFFABRRRQAV8wfBn/kXPEf8A2Ofin/0/39fT9fMHwZ/5FzxH/wBjn4p/9P8Af0Ad5RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzfh//AJOm8Gf9iZ4i/wDS7RK6Sub8P/8AJ03gz/sTPEX/AKXaJQB9D0UUUAFFFFABRRRQAV8wfBn/AJFzxH/2Ofin/wBP9/X0/XzB8Gf+Rc8R/wDY5+Kf/T/f0AcH4Ps7D9oLx18SW8X20Ws+HfDOunw7p/hu9HmWWYreCWW5ngPyTyPJL8hkDCMRLsCsXZu40nwBo/wjl1XV/DtpqEGktZrGvhXSjI9qkisSptLXd5UDOXIYIqKxIdiPmY5upfB/VdF8faz4v8BeI7Xw1f69FEmsafqmlnUNPu5YgRHcrGk0Ekc+07GYSbGUDchYBg/UPh7498ReH/EFrq/xAtYNSvbE2VhdeH9Jn0+Ky3NmSVkN5I8jthVDLLGyAHYVZi1AGR4g/aTTQvAfjTXn8DeII9S8KXEdtf6HdTWKzoZIY5Y5C8VxJGYysqZKszjJwhxW3pvx0sV1y+0rxP4c1zwJdWukza2G142jxTWkLKs8iPa3E65j3oWViGw6kAjOPCPin8LD8A/gb8WLzUvFfhq3tPE6wSJbwaS2nRrfKI48oz3chkLrEXZWJkdzI5kOcD2zRfh4PiRYza34s8R6N4zi1LRbnSbG88OWTWdmLC7CGcpuubje0nlxfvA+MIoAGWLAFH4e/tTeFviJqGpwWtjf2VpptlJf3WpPc2F5bW8aYJE7WdzObZyu5lScRlhHIACUYDaj+Kmo61ouo3TfDPxcmlfYXuYrh7jTI/tkZAwIwL7zEZlYsPMEeADkq2BUOi/CvxPceFbzwr4x8Z2/iPw5Npcuk+XZ6P8AYbueJ4zEWuJjNIHcIesSRDcSSMYUP0LwF8QdN8MT6Pf+PNJ1IQ6b/Z9jP/wjrxsW2qvnXf8ApZ859q9IjAuWY4xtCgHIaT8bG8P6R8GNK8H+ANY1Xw/4l8Pre2sMF3bNPa20drE0cO65uU3OqyJudmOQON7E7e5PxVtb/wAbWvhDUvCWuWdtq7XVtZ6lqUNstnfGFCZUEfnGcAqGwXhVWAyCVIJ5XRPgJ4j8P+GfhfaWfjPT01nwNZPpMd+dDYw3Vm0KQ4MJucpMFijIk3su4MTGQdoz7H9m3xBafFzTPHc3jLS9QvtP1S7uY5r7Qppr17G4Lg2TXDXh2pGj4iESRxK25zC7O1AHMfAX4pW/wo+E8NpeeCNZ0/wfZ+JdWsF1+zFl/Z1usmt3MceIVuPPWNGdYyfJG3GQCnzV3d38XNG8F3nxe8QN4N8QpdeGUgutZVbm3kkvIEicrcW8bXPlrGIE34zHIwyDHvwDH4d+AOvafos/hTVvFumap4Fm1e51Z9Oh0OS3vn82+e9ED3JunQoJH2tiEFkBAKk5pvin4D+KvE3/AAtuL/hMtHtrXx7p/wDZoT/hHpWewj8swA7vtoEreQ8gztQbyr42qY2AOn8NfGyPWvFenaFqfhDxD4VfUtOuNTsbzWDZGC4hgaESf6i5laNsXEbYkVON3cYrC+Gv7U/hb4reL4dC0HT9RuFnWSSPUIrixuYlRVLK80UFzJPah1Hy/aIouSEOHIU3f+FR+Jrvx/4L8Q6h4o0e5tNA0a50i40+PQpYzd/aPJM0iyG7Pl5+zQhVKvgb8ltwK2/hj8M/Fnw7tdI0KXxrbap4P0WNrfT7P+x/Kv2gUMkENxdGZkkWNCozHDE7GJCWxvVwDovG3xCi8H3mm6dbaNqPiTXNRWWW20jSWt1neGLYJpd1xLFGEQyxA5fOZFABrH1T4vS6ZHolofBXiG58U6rFcXKeF4JdPN9BbwuqSTyOboW4QNJCBiYsfOXC8Ptl+IHw51XxB4q8P+KvDWvW+geI9HhurISahYNfWlxa3HltLFJCs0LZ3wQOrLIMFCCGB4z9e+FXiDUtQ8MeJbPxXa2/jrRoLq1fUrrSDLY3UFyytLC1qsyOqK0cRjIm3r5YDNJliwBm6l+0tpek+E9S1m58J+JVutJ1q30LVdFCWf27T7idohAzr9p8t45PtEG1onkyJRx8r7dbS/jpp/2rxRb+JtA1rwLJ4d0qPW7w66bSRTZuZx5qNaTzg7TbSZUkN93AOa53xT+z/rXiLwfrFpH4r0+38Ua9run65q2ryaLJJbSNZtA0EMFsLpTEg+yW4O6VyR5vdwUs+IPgNqPjTxn401DxD4ktLjQfFHhyLw3Np+n6XJbXVvFGZ2Ekdwbh13b7mZuYiMCMfwsXAOhj+L0lho+s614n8GeIfBehaVYyX8+paw9hIjIgBKLHbXU0pcjJClBnGPvEA1LH43OviPR9G17wL4n8JXGtebHpk2rNp7xXU8cZlNuGt7uXZI0auyiQKp2MN2eC3/hVfiPxh4L1rwt8RvFdl4k0nUtLfTHXRtHbTHcOu15pGe4n3SDAK7PLUFn3K+V2N034W+KdS1fw7eeM/Fum+Il8NyteaYtjosli7XZgktxPcsbqUSkRzSfKixDc5PYAAHOxftWW8nh9dcb4b+NI9I/tb+w3um/svEd79s+x+UVF8Wb9/hNyhl5zuwCRvx/GaLXrHxrpt94G8T2GqaDp8F3e6JPNYC5ntrnzlVoZIrxoukE2cyow28ckZ5L/AIZz8Yf8KxHhP/hOtD8//hKP+EnN9/wjM23f9v8A7Q8ny/t/Tz+N27/V/Ljd89dJefCPxfJ468deIbXxdokMfibSbbSktZvD00htVgM/luXF6vmH/Sptw2rn5MY2ncAYuk/G2XRrv4R+HfDHgLWNT0DxH4YOqW5gvLZpbWCJLUJGTcXCFyi3CF2YknKbfMJfZ29v8YEk8dWnhm58KeINON+Lr+ztSvEto7e9NuAZAief5y8HKmSJAwGQcEE8tovwJ8R6HZfDF7fxjp66v4L0ufQmuv7DbyryylFupxEbkmOYLaRYkLum4sTGQQoytJ/Zt8Rab8WNP8dS+M9L1DUbK+vJVnvNBmlvJrO4Zs2r3DXp2rGpAiWJI4kJdvKYucAGppP7UFrqem2uqyfD/wAX6focmsroE+qXQ04w2t2b0WW2RUvGkKichS0aOOcgnmm3XxCn+JXiX4m+Ata+H1zceHtHAtJNQvDZT2cu61W4Bljacud29dgWNsDBYqcquWP2c/GA+GieFf8AhOtDMy+Kv+EoN4fDM2xm+3/2h5Bj+352+fxuD58v5fvfPXWXPwn8T2fizxnrGieLNNsYPE8UL3FpfaI9z5d1HbJbB1dbmP8AdFEB8vG7cAfMxlSAc/8ABL4oR6N4T+DHgu58Pawr614UtJbPWh9m+wMYbGJ5IyfO80OARhfL55IyquV9P8D+NJvGvhVdb/4R3VNFWTcYLPUHtWmnQDKyI0E8kZV/4SXGevQgnynxB8OE0r4X/Db4c6j4shPjLTbqzXQtR0u3+x3DJabY5ZkhaWU/LaPIkjbtp83A2l0WvdrO0hsLWG2tolht4UWOONBhUUDAAHoAKAPG7r9qHTrHwlc6/c+C/E1vFZ663h6+s5JNNFxZ3IaNd0i/bNpQmQHcrMQimQgR4cv+NnxQsNO8B/EaDXvAXiXWPDWjWjR6lPY3dpAlzE0Ikk8txdpMoVGXd8qtz8oat3VPgbo+t+LvGGqX88lzpHinTUstQ0RlxC8wieB7rOf9Y1uY4enCxj14zfFHwR1TXv2fLz4bReLFOo6jp7WOo+ItR077RJcmRSJpfKSWMKzZO35iFAAw2KALOofFbU5Pjhc/DweCdQ1LSRpNvezarFLaGILPLJGWdJJ1byl8tgQqM5O75NoBfzH9nv4kD4b/AA50nSJfBl9YeFG8Xapodrq1vJaLbLNca3dR2yxQLLvEKsfKYsqFWMexJEZnj9V/4Vn4lX4i6f4xj8U6dFfPo8OkaxAujOYroRSyTK9vm5Jgy0rhgxlypABUjdXGRfs7+L4fhlpXhVPHOhm4sPFJ8Ti+bw1MUdvt51BYTEL4EAXDNlt/KbVwCC7AHsXjTxhZeB9Al1S9Sa4HmxW1vaWoUzXVxLIscMEYYqu95HRQWZVG7LMqgsOZuPi9LpHh641TXvBXiLw9L9qt7Gx068ksJbjUbiZwkUUPkXUiAliATK8aqDuJChmGn8TvAL/EXwmumxam+j6pbXdtqNhqUUXmC3u7eVZYnaMsPMjLIA0ZI3KzDcpIYYHiD4V+IfHXg+fT/FHiu1m1uG+tdS0rUNG0g2lvYXNtIJYJPIkmmaXLj51aXayfKoQ5YgCWvx1RdR1bStV8F+JPD+u2ekya1baVqDWDS6jbxttl+zvDdSRbkYxhlkkQjzUPQki1pvxt03VNQ+HkMWiawtp44sheabqDrbiGI/ZWufJmAm8xX8tCflRkyQN1M0j4W6rqHiSXxB411yw1zVl0u40a0/sbTJNOgt7ado3nJSS4nLSMYYvm3AAJgLySeO8M/s/+NdFuPhj9s+IWl31n4DKwWdtF4aaH7XbfZWtXEzfa2PneU3yyJtRSWLRPwFALU/7UsNrpOtarP8N/GkWlaJftpup3h/swrazq6Iy7Re75APMQ5jVx82OoIHU6D8Z11LW9Z0fVfB3iTw1qmmaWNYNnfR2t1Jc25Z0zCtncT7n3RkbOGJIwDmuM1D9nzxfqHgDxn4bfxvoiyeJNbOsPdr4bmxAGdXeIJ9u+Ylo4sNuGAHBDbgV2fEPwf8aa5461vxDb+O9P0g6j4bOgR/YdCkFzatsdluY5Wuyu5Z5C4Up9wBM7h5hALM37QUFjoPje/wBQ8FeJdOvvCFnDqOoaPM+nvdPbSB282Mx3bREBYpWIMithCACSAc3XPitZeIF8D3Or/D3xVZ2Gpa7ajSr+7uLS3jSZxmGaSOK7MwRkd8RvGTlSJETg1zWj/sr6/oul/ES0tPF3h+2PjbRk0u/eDw1cZWVRKhui737yTSPHPLvaV3dpNrl8Aoev8TfCTxp4i8K+B9NHjHQbfUPDmoQ6hLd/8I5M0V00PECrF9uBjAUkPl33HBGzoQCtrn7TCaHJ45/4tz4xvrfwW8g1m5tTpmyJFt1uRIge9VpFaF1cKoLjOGVW+WvZLa4jvLeKeJt8UqB0bBGVIyDzXiXiD4B+KNc0v4yWK+M9JtofiIxXd/wj8rNp8RtY7Nl/4/MSt9niQbsIPM3Nt2kIOwuPgb4O8UWemzeNvCHhPxdr1taR2kmp3WgwtvVAcBBMZXROSQpdsZPNAF3xr4yurbVE8M6Dotv4k1+4tTdS2V9d/ZLWG13FC80vlyEbyGVVWNyzA52qGYeIfBv4v+G/gf8As3aHdarp50mG58Qa7aWejLPZWhgxq16TGZJZ47aNY1G3JlC52qpYsoPqetfB++03xXpfiD4farpPg+4tNJ/sOTT7rRTd2ElosnmQqkMU9uY2jYybSG24kYFehHNeH/2d/Efhvwno1naeOrY+INB16+1nStYk0Q7Gju5ZpLm3u4BcATK32iT5o2hIKxkAbTuANFv2mtNbwr4a16Dwd4ovLfX9SbSbSK1js5GNxgmHEgufKkjmAOyeJ3iABLvGASJ7P4gRXfxRmSb4e+JrHxXD4aku4Yri9sibm3E8eYI0S8aHzPMbBaQp93hypzTvGfwr8ceL9M8MF/HGjx6zo+sjWXuJfDkj2rukbRxxRQreI8cYDszb5ZGZmOGVcKNdvh14hf42WfjdvEOmf2XDpL6S+kjSJBO6MyyFxcfadoPmop/1R+TK9TvABV8J/HSHxpo/g7UtM8H+Inh8ST3EPlytYpLpogkMcj3SG6yFBDZEYkZSu1grlVZ2mfG4alrF/pLeCvEunajHo82t2FvqC2cL6nbxsq4iX7QWictJGNtwsRXeNwUggaXgn4U2vgjxR4r1a1v5pINavHvYLEooj095QrXPl+vnSr5rZH3jXnPwz/Zn17wL8QLPxXf+MtM1y+OlT6Pql02hTJfapE7RusstzJeSN5yvEuMgxqnyRxRgDABX0j44j4gfDL4a+IvFfw616yh13VNIe3nhvrVbWK5mkiME/wC7u/NaHe4wrJk7fnjUGu4f47Rx6h46sH8GeI01DwmlvLNas1gHv452dYpLbN1hlYRuRvKE7SoG8FByUf7PHjGz+GPhDwba+PdHFv4XvbC4sLi48NSOWhsmR7dJFW9Xc5ZBvcEBhgKkZyx9D8QfCq2174leHvGJv5LW5061ks7y0hjHl6jH5iSwCQ5yPJmQyJju7A8E0Acd46/au8N/D/WrfRL7R9SuNee2hnn0eC+0tLyCSRQy2wilvEa4nwR8lsJsllAJLLn1bWPEC6V4dl1aLT9Q1IrErxWNnbk3U7NgJGEfbtYkgEyFVTkuyKGI4vWPhr4mtfHeq+I/CHiyy0NNaihTVLHU9Ha/R5Il2JPAyzwmKTy8Kd3mKdiHbwd3QePvCeqeLPAV9oOmeIrnQ9TuIo401hFYyrtZSxIieJhvCspMbxsA5KspAIAOKvf2kNP0vwV4m8RXvhDxLat4a1SPStW0nFlJeWzvFDKsuEumjdNtxF9x2bLEbeDi9D8cLg3Gu2F54B8SaPrWm6O+tQ6dqEunk30SsVKxyQ3UqK24AfOy/eB5rz+x/ZU1/SvBPjrw1p/i3w7p1p4q1C31N1tPC0kcdrKkcCyBEF9yrm3RvmO4FnLM5bI7+T4U+IdR+J8/ifU/E2mT6dc6B/YU+nWujSQzbTl3lSZrpwpMpJAMbYUBckguQDk9N+Mn/CbeDfhVrPir4e6/YSa5qGnyWlyl5apaw3UkKtHMRFdtI0LCSXYrISdn7xEypPoEnxWmuvEV1pmieDdf8SWlnd/YbvV9PksI7W3mG3zEInuo5W2BhuKRsOoBLAgcKvwF8bx+A/AfhtPHuit/wiN3Zz21xL4ZlImjtYljgVlF8MMcOXYNhsrtWPad3VaN8MPE3hXxPq8mheL7W08L6tqj6tc6bdaQbi8ilk2mZILnz1REdlLYeGQgu+D93aAQ+IPj5Bo669eWPgvxN4k0HQpJodR1rSBZNBC8I/0hRHJdJPIY8ENsibJUhdxGKteKvjlYeF49Ovk8O65rHhy7axVvEVilstlD9rlSOFj500ckgJljJMSSBQ3PIIGRffBTxDZyeK9O8N+MLPR/C3ii5uLu/srrRmury3luF23LWlwLhEjLcuvmxShXYnDLhBzfxM/ZXvvHN5aR6f4psNP0TToNOj0mw1LR5b86W9m6ujW5+1xxoX2BXfy/NZCyCUKQAAdX8QP2iLHwC/iuRfCXiHxDp3hWNX1rUdKewWKzYwJPsK3F1FIxEUkb5RGGHABJBA2NN+Lr6h4g1bQH8G+ILPX9P0eHWRps72Je4jleRFjjdLpo/MDxOp3uq8Z3EHNfPHja5024+M3jWXV/ij4H8OX1pNZWx0XxTbXVsL+VLKFixs49TgS7gLPlJJo5n3F4wxWKPPsll4L8Z+LtZ0T4hWWq2fgjW9U8PW+m6xpN7pb37RKJGmBhcywmORTLIP3kbjkbo/lIIBhav4g0L4m+Lv2dfH+naV9nm1PVbv7PcXtvGL2K3fRtRcwsylsDcqkqGK5UHnFd5p3xmW98aR+Gp/B/iPTLq7sL3UdMuL9LSOPUo7Z4UkES/aDJGx+0RELOkXBOduCK4zwz+z54s8M6P8K9Mi8b6PcW/gO6edHk8OSiS9Vrea22sRe4Q+VcSfMARvCtjAKGv4T/AGa/Evhj4maf42fxrpOp6vawX1pNdXegTPdXsFw8bgTTtekkxtEoRVCxIrOqRJuyADb8N/tL23iO10LUD4C8W6ZoWsakukwaxejT/JS5MzQbXRLtpgPNRk3CMqcAglSGNS1/aUubOb4nXOueB9YstC8G6nJZHU4bixMcirb20gDbroMrubjeGKiNYyu91YOFqWv7PfjCy+HvhXw1H440MyaDrx1xbt/DUxWciYzxxGMXwK4keTLBuRsGBtJbqrP4VeJNB8R+OL7Q/Fen2uneJbwaoLK+0Q3LQ3n2e3t2DuLhBJbtHb8xhUfLZEoAIIB3PhLxBL4o8P2mqS6TeaI1ypdbO+lt5ZVXJ2tut5ZYyGGGBVzwRnByK82sf2ltMv8A4Y6n4+j8KeIP+EcsnRRMsunySTqZDG7KiXZKeWw+dJdkgzjYWBA6v4PfDcfCnwWuhC4s5h9ruLvy9Ms2s7GDzZWfyra3aWUwxjd9zewyWI2ghRwN1+zbfa3o3xGh1bxHpsWq+MNPjs3vdD0RrKNJozIY7ueFriRZ59zruYGPcqBeBjAB6E/xQsrX4iah4RvdNv8AT5bXSm1ldVuDB9jnt1ZFcoVlMilWfB3ov3SQSME5/h/xsvxUtWsbz4ea0vhPVrRmXUdaXT3sb23dcqGgFy822RG+7JCpAOHCnIrn4fgv4p1fx8/iPxV4x0vV7e60O58P3ul6foL2UbW8rBt0Lm6keOTcBuLGQEDCqhyTs+B/AfjvwjocekXHjjTNUs9O082WlO+gMk25U2QyXjfaiJ9oClhEINxzyucAA8u/ZY+K1xovwc+C+hav4U1TSrDWtNt9K03V5Z7aSOe4SzknyyRysyRvHC2xiNxZWDpGApf3zxf4ouPC9jBLZ+HtW8TXc0nlx2OjpD5nQkszzyRRIoA6u4ycAZJAryXRP2ePFGh+EfhFoEPjXSZIPh/dLciSTw9Lm/2W8ttGCBeDyyIZ5MnLAvtbAAKHuPjH8N9V+JmkaXY6drlrpcFtd+feWWpWMt5ZalF5bp5FxFFcQNJHlwxRnMbbcOjjoAYo/aO0m6s/Az6f4e1rUr3xhHcyWGnxy2MM0f2coJkczXMcbOu/OyJ3YhJGAKoxHXfFL4hJ8LfBOpeKJ9D1XX7LTYmuLu30dYGnigRWZ5dsssYZVC8hSW54B5x5QP2Y9bHwb0z4bP4p8P3Oi2TTos1x4Yfzo42YNDJAUvF8i5hJlKzL8vzLiMbfm99a1jktDbTL9oiZPLdZgG3rjBDZ65HWgDzxfjhZH4gJ4Sfw9q0d3PosmvWd41xYG2u7dBFvEbC6Lbg0qpllVSQxDFBvOf4l/aCPhTwOviq++HnjBdPi0+TVdQRY7APp1suSHlJuwjsyqzCOFpHUAb1QsobPsv2ZrGz8F+GdB/4SC+eXQdQM1tqBUGU2JR7f7AdxP7s2jCAtnOV8wYfGI/2g/wBnfUfjt9qtG8UWtjolzpMmnHTdQ0uS+jgnYuReQqLmOMTDcoDSJIVCfuzGWYkA6XxJ8aP7C+ICeD7TwX4k8QapLYf2nBLpf2L7PNbh1R2DzXMe3azqCH2k5+XdzXlvg/WLH4i+JPHHiPxb8HL/AF/WtD1/7Fo8l5ZaZeXFt5aQbLaBzcMIXVy8xcskYL58zdwPRtP+F/i+3+J2h+LrjxXokyWejDRruxi0CaM3CGRZHeOQ3reUSyLgFXwMg7icjnT8BfHB0bxhpy/ELTbaPxBrQ1ovZaFdWzo2+LfA7x6gHaJkiVSEaNjlssVJQgGzfftIadp/g218QzeEvEux9fHhu50+JLOS6srw3At1EirclXUyMoHlNIfmBxRH49t9Q+LHheHVPAHiTRPE82iapNp8l9e2ZT7Oktt9og2293JG0jMLRgXAABGHBDqOR079l3xHofgP/hGNK8X+HNOtY/FNv4pt1t/CbxwW8kVwt19nSFL1QIvNjQKAQVjBUlmPmDvtc+GvirWPij4S8YL4n0eFdD0u60+SxOhysbh7kwNNIJPtY2DdbRbV2ttBcFmyCoBi+H/2mrbXrPR9SbwD4u03Q9T1VdFTVrwaf5MV0bk2ux0S8aXHnKU3KjL3BI5r1DxT4gl8N6S13Bo+o69cl1ji0/S40aaViegMjpGgAyS0jqox1yQD4zb/ALPPjG1+G+heF4/HOhmfSfEh8RJeP4ZmKSEXRu0iMYvwQBM75YPym1cAgs3pfxY8E6p8QPCZ0jSNf/4R64a5hmedopZI5o0bc0Mghmhk2P0IWVcjg5UspAOTvP2kLCz8G6f4g/4Q/wASz/addfw3LpsIsmurS+FybYRyf6V5ZDSgKGR3GCCcDJGnpvx2054fFX9u+H9b8I3Xhu3t7q8s9WFrLI8c5kEJiNtPMrlmidQu4HOBjkVwGl/sweJfD/gO28MaT4w8O2FtaeKI/E9qIvCjpDC63H2n7OsKXqgRCXAUAjCDbyfnro/EPwB1Pxd4g+I1xq3ii1/srxbYW1nDBY6U8N3p72rs9rKJ2uHWQozuxHlLuO3lQCGAOd06bVdQ/a48Kahrfg618M6jceEdX2XNveRXUlzbi608xxTuqqVmiLPujHmRL5o8uWTL7fQfiP8AGC88BeM/DHh2z8E614pn1xZ2il0uezjC+Uhd1AnnjywG0ncVXB4Yt8pytL+FHjmT4oeG/GmveONF1ObSbC70uSysvDclqk0E7QOzKxvJCku+3T5juXbwEU5Y8v8AtAeLItN+OHwi0zT/ABf4b8NeIZG1AxDXkFwpWWJY4x5C3EDkyOCiEPywIAY8UAZnxk8eaZ8Q/BHhvXYfCeoHxB4Z+IGlWMmi30VqNStbpbuEtFG/mmEGSOSMhhNsZZVywGcel2fx2sLSw8XyeJtIvPC934Xggu7+1uJYZ8wzhmgMbRuQzNsKFeAJFZQXXa7ZHiX4E6xq/h2zgsfE2m2WvSeJLXxRq2pXGjSTRXt1AYiipCtyhijAghjALudkYBYsS5dq/wAB9S8TeJ/iLd6x4mtm0fxdp9vYpbafpbwXlg1uzNbyrcNO6OymSRjmIbm2HgKVYAq+G/2qtD8WeF/Feu6b4a1u9tPDtmL2f7BdaXfRzoMmRY7i2vJIBJGo3tFJKjlWUqrZrc8N/HUeINa0fT5/A3ijRP7asZr/AEq41H7B5d6kaI5VRFdO0blZFIEqp3BIIIpNQ+Hnj7xH4D8RaDr3jrR7y71PTJNMhurPw21vDGJF2STSxG7dpJNuduySNAWJKtxjPHwr8R6T4g+H+v6h4z0NNO8GaVNaXcbaHJELlXVVlm803hEIEcUYAIcA+YxLBlCAFDwr+1Aut6Ppus6r8PvE/h7Qb/WG0ZNauJLGa1hlN69pF5ojuTMm6VVQnyiis3DsmJG3tI+PltqviLxNpjeEfEVha+GbuS11nV7z7EtnZBbdbhZSwuSzo8bqwEasy5G9UyK8r/Zn01/iv8OYoG8Y+Hdb8GWXiK9vX0fSbMteLNHqst1bie6F06lCyxy7RCm5CgyVJ3epeFfg9q2meIPiRJruvabrXh7xpcyXE+mW+ky2s0O63htQnnm5cMvkwgH92pLsWBUYSgBbL4+QteeHv7U8F+JvD2jeILqKz07XNRFk1rLLKjNAGWG6kmi8zbhfMjXDMqttYgVq2fxXl1jxBJY6J4N1/XdKhv302fxBZy2CWUM0chinyst0k5ETh1bbE3KMFDd+e0L4KeIY7XwxoniLxhZ674U8NXNvdadbQ6M1rfytbf8AHr9puPtDxybMKzeXDFudFPyjcraHhP4W+JvA+tXlto/i+0i8F3WrT6udLn0gy38TTymeeGO7M/liJ5mkPMDMFkZQwO11AKOtftHWGj6bqmur4P8AE2oeDNMuJoLvxVZrZNZRrDKYriYRtci5aOJ0kDMsJyI2Zdy4J6GT4uWzeKPFnh+00DV9Q1Hw/p1pqgW3a12ajBceaENuzTqMhoJVIl8vlcjIIJ5Gf4Aaumg+IfBlj4rtLb4ca7PeSXWky6S8moRRXbvJdQQ3guVRUZ5JSC0DsokIycAjX8SfCHXZfiBe+I/C3imz8Oxano1toeoW1xpBvJBFBJO8ctvJ56LFIBcyAeYkqZCkocEEApt+0jZXGn+AbvSvBfijXE8bWAv9JSyFijf6nzmil826QI6xAsSTs4wHLEKaZ/afhh0/VNRufh34wtNM0i/Gm6reStphSwn3opV1W9LOAJY2JiVxhsAkhgK/hH4AeKPCtr8JLT/hM9IurXwDA1rj/hH5Ue+iMJg+99sIibyeM4Yb/mxj5Kh1H9nzxfqXgXxv4fk8b6IsvijWxrEl0vhubbAPkLRBPt3zEmGLDbhgBxg7gVAO88QfFd9P8S32haH4R17xlfaekTX/APY0ljGlmZAWjR2urmHLMo3YTdgEZxkZ56b9pTS59P8ABF3ovhXxJ4jTxesy6elhHaROk8SO8tvMtxcReXIgilBz8oMZG7OAbU/wv8XaZ4qu/E3hrxbo2m6xrFlawa7HqGgS3dndXECFUuII1vIngJDMpVpJRtCd1LNSj+At7ot98M/7B8R21rp/g+8ub24j1HTGuZ9RkuVlW4bzEnjWJmE8zDCMA7KcFV2EA7X4dfESH4iWerSLo+paBe6TqD6Ze6dqwg86GZY45OsMskbApKhBVz1rrK8t8E/Dfxl4Hh8dTR+JtC1HUvEOq/2vbO+hzQxW0jLHHIki/a2MimOKMLtKEMGJ3ZwPUqACub8P/wDJ03gz/sTPEX/pdoldJXN+H/8Ak6bwZ/2JniL/ANLtEoA+h6KKKACiiigAooooAK+YPgz/AMi54j/7HPxT/wCn+/r6fr5g+DP/ACLniP8A7HPxT/6f7+gDvKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuM8YXvjHSdUa48P6bFrtncWnkLaSTxw/ZLkM22Zi2C8bBgGAYkeWNq5Jz2dFROPOrJ29Dqw1dYepzygprtK9vwaf3Ndtro83Nj8Q4pjoP9pieCeVpv+EsENusltFsz5It8YMnmcBtpXYecsOWRv8AEq+VJnjt9Ok0kQh7ZWhdNcYH98QxyYEKgbM4YMfm+Uc+l0Vh7D++/v8A6/re6PU/tZ9cPTv/AIOvV9tVpa1lvBRlqeZNefEq1ibWEsIb2S+jkiTw5JJBGNNfd+5kaYH94NuTKAx5I2ZxzKbH4hxTHQf7TE8E8rTf8JYIbdZLaLZnyRb4wZPM4DbSuw85Yc+kUUfV/wC+/v8Av+/8Olg/tbth6f8A4B/4Du/s+d+b/l5zs80jf4lXypM8dvp0mkiEPbK0LprjA/viGOTAhUDZnDBj83yjlrXnxKtYm1hLCG9kvo5Ik8OSSQRjTX3fuZGmB/eDbkygMeSNmcc+m0Uew/vy+/8Ar/L56h/ayv8A7tSt25Xt2ve+r1vfmWyaj7p5ubH4hxTHQf7TE8E8rTf8JYIbdZLaLZnyRb4wZPM4DbSuw85Ycsjf4lXypM8dvp0mkiEPbK0LprjA/viGOTAhUDZnDBj83yjn0uij2H99/f8A1/W90H9rPrh6d/8AB16vtqtLWst4KMtTzJrz4lWsTawlhDeyX0ckSeHJJIIxpr7v3MjTA/vBtyZQGPJGzOOZTY/EOKY6D/aYngnlab/hLBDbrJbRbM+SLfGDJ5nAbaV2HnLDn0iij6v/AH39/wB/3/h0sH9rdsPT/wDAP/Ad39nzvzf8vOdnmkb/ABKvlSZ47fTpNJEIe2VoXTXGB/fEMcmBCoGzOGDH5vlHLWvPiVaxNrCWEN7JfRyRJ4ckkgjGmvu/cyNMD+8G3JlAY8kbM459Noo9h/fl9/8AX+Xz1D+1lf8A3albtyvbte99Xre/Mtk1H3Tzc2PxDimOg/2mJ4J5Wm/4SwQ26yW0WzPki3xgyeZwG2ldh5yw5ZG/xKvlSZ47fTpNJEIe2VoXTXGB/fEMcmBCoGzOGDH5vlHPpdFHsP77+/8Ar+t7oP7WfXD07/4OvV9tVpa1lvBRlqcJoP8AwnLapY6rqIjSxvpJI7rQW8rOnR8+VIsq58x8ABxuIy/y42/N3dFFbQhyK12/U83FYn6zJS5Ixt0irLy9bbXertq29Qrm/D//ACdN4M/7EzxF/wCl2iV0lc34f/5Om8Gf9iZ4i/8AS7RK0OM+h6KKKACiiigAooooAK+YPgz/AMi54j/7HPxT/wCn+/r6fr5g+DP/ACLniP8A7HPxT/6f7+gDvKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACub8P/APJ03gz/ALEzxF/6XaJXSVzfh/8A5Om8Gf8AYmeIv/S7RKAPoeiiigAooooAKKKKACvmD4M/8i54j/7HPxT/AOn+/r6fr5g+DP8AyLniP/sc/FP/AKf7+gDvKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACub8P8A/J03gz/sTPEX/pdoldJXN+H/APk6bwZ/2JniL/0u0SgD6HooooAKKKKACiiigAr5g+DP/IueI/8Asc/FP/p/v6+n6+UfCtn8QvAY8RaU/wAIvFOsxyeJtd1CDUNN1DRRBcQXWq3V1C6ibUI5BmOZMhkUg5GOKAPS6K4//hJvH3/RD/G3/gw0D/5aUf8ACTePv+iH+Nv/AAYaB/8ALSgDsKK4/wD4Sbx9/wBEP8bf+DDQP/lpR/wk3j7/AKIf42/8GGgf/LSgDsKK4/8A4Sbx9/0Q/wAbf+DDQP8A5aUf8JN4+/6If42/8GGgf/LSgDsKK4//AISbx9/0Q/xt/wCDDQP/AJaUf8JN4+/6If42/wDBhoH/AMtKAOworj/+Em8ff9EP8bf+DDQP/lpR/wAJN4+/6If42/8ABhoH/wAtKAOworj/APhJvH3/AEQ/xt/4MNA/+WlH/CTePv8Aoh/jb/wYaB/8tKAOworj/wDhJvH3/RD/ABt/4MNA/wDlpR/wk3j7/oh/jb/wYaB/8tKAOworj/8AhJvH3/RD/G3/AIMNA/8AlpR/wk3j7/oh/jb/AMGGgf8Ay0oA7CiuP/4Sbx9/0Q/xt/4MNA/+WlH/AAk3j7/oh/jb/wAGGgf/AC0oA7CiuP8A+Em8ff8ARD/G3/gw0D/5aUf8JN4+/wCiH+Nv/BhoH/y0oA7CiuP/AOEm8ff9EP8AG3/gw0D/AOWlH/CTePv+iH+Nv/BhoH/y0oA7CiuP/wCEm8ff9EP8bf8Agw0D/wCWlH/CTePv+iH+Nv8AwYaB/wDLSgDsKK4//hJvH3/RD/G3/gw0D/5aUf8ACTePv+iH+Nv/AAYaB/8ALSgDsKK4/wD4Sbx9/wBEP8bf+DDQP/lpR/wk3j7/AKIf42/8GGgf/LSgDsKK4/8A4Sbx9/0Q/wAbf+DDQP8A5aUf8JN4+/6If42/8GGgf/LSgDsKK4//AISbx9/0Q/xt/wCDDQP/AJaUf8JN4+/6If42/wDBhoH/AMtKAOworj/+Em8ff9EP8bf+DDQP/lpR/wAJN4+/6If42/8ABhoH/wAtKAOworj/APhJvH3/AEQ/xt/4MNA/+WlH/CTePv8Aoh/jb/wYaB/8tKAOworj/wDhJvH3/RD/ABt/4MNA/wDlpR/wk3j7/oh/jb/wYaB/8tKAOworj/8AhJvH3/RD/G3/AIMNA/8AlpR/wk3j7/oh/jb/AMGGgf8Ay0oA7CiuP/4Sbx9/0Q/xt/4MNA/+WlH/AAk3j7/oh/jb/wAGGgf/AC0oA7CiuP8A+Em8ff8ARD/G3/gw0D/5aUf8JN4+/wCiH+Nv/BhoH/y0oA7CiuP/AOEm8ff9EP8AG3/gw0D/AOWlH/CTePv+iH+Nv/BhoH/y0oA7CiuP/wCEm8ff9EP8bf8Agw0D/wCWlH/CTePv+iH+Nv8AwYaB/wDLSgDsKK4//hJvH3/RD/G3/gw0D/5aUf8ACTePv+iH+Nv/AAYaB/8ALSgDsKK4/wD4Sbx9/wBEP8bf+DDQP/lpR/wk3j7/AKIf42/8GGgf/LSgDsKK4/8A4Sbx9/0Q/wAbf+DDQP8A5aUf8JN4+/6If42/8GGgf/LSgDsKK4//AISbx9/0Q/xt/wCDDQP/AJaUf8JN4+/6If42/wDBhoH/AMtKAOworj/+Em8ff9EP8bf+DDQP/lpR/wAJN4+/6If42/8ABhoH/wAtKAOworj/APhJvH3/AEQ/xt/4MNA/+WlH/CTePv8Aoh/jb/wYaB/8tKAOworj/wDhJvH3/RD/ABt/4MNA/wDlpR/wk3j7/oh/jb/wYaB/8tKAOworj/8AhJvH3/RD/G3/AIMNA/8AlpR/wk3j7/oh/jb/AMGGgf8Ay0oA7CiuP/4Sbx9/0Q/xt/4MNA/+WlH/AAk3j7/oh/jb/wAGGgf/AC0oA7CiuP8A+Em8ff8ARD/G3/gw0D/5aUf8JN4+/wCiH+Nv/BhoH/y0oA7CiuP/AOEm8ff9EP8AG3/gw0D/AOWlH/CTePv+iH+Nv/BhoH/y0oA7CiuP/wCEm8ff9EP8bf8Agw0D/wCWlH/CTePv+iH+Nv8AwYaB/wDLSgDsKK4//hJvH3/RD/G3/gw0D/5aUf8ACTePv+iH+Nv/AAYaB/8ALSgDsKK4/wD4Sbx9/wBEP8bf+DDQP/lpR/wk3j7/AKIf42/8GGgf/LSgDsKK4/8A4Sbx9/0Q/wAbf+DDQP8A5aUf8JN4+/6If42/8GGgf/LSgDsKK4//AISbx9/0Q/xt/wCDDQP/AJaUf8JN4+/6If42/wDBhoH/AMtKAOworj/+Em8ff9EP8bf+DDQP/lpR/wAJN4+/6If42/8ABhoH/wAtKAOworj/APhJvH3/AEQ/xt/4MNA/+WlH/CTePv8Aoh/jb/wYaB/8tKAOworj/wDhJvH3/RD/ABt/4MNA/wDlpR/wk3j7/oh/jb/wYaB/8tKAOworj/8AhJvH3/RD/G3/AIMNA/8AlpR/wk3j7/oh/jb/AMGGgf8Ay0oA7CiuP/4Sbx9/0Q/xt/4MNA/+WlH/AAk3j7/oh/jb/wAGGgf/AC0oA7CiuP8A+Em8ff8ARD/G3/gw0D/5aUf8JN4+/wCiH+Nv/BhoH/y0oA7CiuP/AOEm8ff9EP8AG3/gw0D/AOWlH/CTePv+iH+Nv/BhoH/y0oA7CiuP/wCEm8ff9EP8bf8Agw0D/wCWlH/CTePv+iH+Nv8AwYaB/wDLSgDsKK4//hJvH3/RD/G3/gw0D/5aUf8ACTePv+iH+Nv/AAYaB/8ALSgDsK5vw/8A8nTeDP8AsTPEX/pdolU/+Em8ff8ARD/G3/gw0D/5aVa+Guk+M9c+PuieJNX+Hut+D9F0zwzq2nvc6zeabL5s9zdaZJGiLa3c7fdtJiSwUDA5yaAPomiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Post marketing reports have shown clinically significant increases in prothrombin time (PT) and INR in patients who were stabilized on anticoagulants at the time Capecitabine was introduced.</p><p>These events occurred within several days and up to several months after initiating Capecitabine therapy and, in a few cases, within 1 month after stopping Capecitabine. These events occurred in patients with and without liver metastases. Age greater than 60 and a diagnosis of cancer independently predispose patients to an increased risk of coagulopathy.</p><p>In 251 patients with metastatic breast cancer who received combination of Capecitabine SPC and docetaxel, Grade 3 hyperbilirubinaemia occurred in 6.8% (n = 17) and Grade 4 hyperbilirubinaemia occurred in 2% (n = 5).</p><p>&nbsp;</p><p><u>Use in Children</u></p><p>The safety and effectiveness of Capecitabine SPC in persons &lt; 18 years of age has not been established.</p><p><u>Use in the Elderly</u></p><p>In 949 patients assessed for safety, patients were also assessed for the incidence of Grade 3 and 4 reactions in terms of age groups as illustrated in the table below.</p><p>&nbsp;</p><p>Table: Summary of the occurrence (%) of treatment related Grade 3 and 4 adverse reactions by age</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Age Group (years)</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Number of patients at risk</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Grade</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Diarrhea</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Nausea</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Vomiting</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Stomatitis</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Hand- Foot Syndrome</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>3</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Tot</p></td><td style="vertical-align:top"><p>949</p></td><td style="vertical-align:top"><p>40.7</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>13.2</p></td><td style="vertical-align:top"><p>3.7</p></td><td style="vertical-align:top"><p>3.6</p></td><td style="vertical-align:top"><p>4.1</p></td><td style="vertical-align:top"><p>15.9</p></td></tr><tr><td style="vertical-align:top"><p>&lt;&nbsp;</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>30.4</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>4.3</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>6.5</p></td><td style="vertical-align:top"><p>10.9</p></td></tr><tr><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>369</p></td><td style="vertical-align:top"><p>36.3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>13.0</p></td><td style="vertical-align:top"><p>5.1</p></td><td style="vertical-align:top"><p>3.8</p></td><td style="vertical-align:top"><p>3.8</p></td><td style="vertical-align:top"><p>13.6</p></td></tr><tr><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>295</p></td><td style="vertical-align:top"><p>41.7</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>14.6</p></td><td style="vertical-align:top"><p>2.7</p></td><td style="vertical-align:top"><p>3.1</p></td><td style="vertical-align:top"><p>3.7</p></td><td style="vertical-align:top"><p>14.6</p></td></tr><tr><td style="vertical-align:top"><p>70</p></td><td style="vertical-align:top"><p>218</p></td><td style="vertical-align:top"><p>46.8</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>11.9</p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>4.1</p></td><td style="vertical-align:top"><p>4.6</p></td><td style="vertical-align:top"><p>22.9</p></td></tr><tr><td style="vertical-align:top"><p>80 and over</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>61.9</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>28.6</p></td><td style="vertical-align:top"><p>14.3</p></td><td style="vertical-align:top"><p>9.5</p></td><td style="vertical-align:top"><p>4.8</p></td><td style="vertical-align:top"><p>14.3</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Among patients with colorectal cancer aged 60-79 years receiving Capecitabine SPC monotherapy in the metastatic setting, the incidence of Grade 3 and 4 toxicities was similar to that in the overall population. In patients aged 80 years or older, a larger percentage experienced reversible Grade 3 or 4 adverse reaction. When Capecitabine SPC was used in combination with other agents, elderly patients (&ge; 65 years of age) experienced more Grade 3 and 4 adverse reactions (ADRs) and ADRs that led to discontinuation than younger patients. An analysis of safety data in patients equal to or greater than 60 years of age treated with Capecitabine SPC in combination with docetaxel showed an increase in the incidence of treatment- related Grade 3 or 4 adverse reactions, treatment-related serious adverse reactions and early withdrawals from treatment due to adverse reactions compared to patients less than 60 years of age.</p><p>&nbsp;</p><p><u>Carcinogenicity, Mutagenicity and Impairment of Fertility</u></p><p>Carcinogenicity: In a two-year carcinogenicity study in mice, there was no evidence for a carcinogenicity potential of Capecitabine SPC at dietary doses up to 90 mg/kg/day (270 mg/m2/day). In terms of plasma AUC values, systemic exposure to Capecitabine SPC and 5&rsquo;-DFUR at the highest dose was at least 10 times lower than that in humans at the recommended dose.</p><p><em>Mutagenicity: </em>Capecitabine SPC was not mutagenic or clastogenic in the following models: in vitro Ames test (bacterial) and V79/HPRT (mammalian) gene mutation assays and in vivo mouse micronucleus test. However, consistent with the known chromosome-damaging potential of nucleoside analogs, Capecitabine SPC was clastogenic in vitro in human peripheral blood lymphocytes in the absence of S9 metabolic activation.</p><p><em>Impairment of Fertility: </em>Impairment of fertility was observed in female mice receiving Capecitabine SPC at 760 mg/kg/day (2292 mg/m2/day) - a disruption in the oestrous cycle occurred with a subsequent failure of mating. A reduction in live litter size, decreased foetal weight and foetal abnormalities were observed in mice dosed at 380 mg/kg/day (1174 mg/m2/day) before implantation. At the no effect dose of 190 mg/kg/day (587 mg/m2/day), plasma Cmax for 5&rsquo;- DFUR was similar to that observed in humans at the recommended dose, while the AUC value was 4-fold lower than that in humans. The effect of Capecitabine SPC on female fertility was reversible after a drug-free period.</p><p>In male mice, degenerative changes and a decrease in the number of spermatocytes and spermatids were noted at 760 mg/kg/day (2401 mg/m2/day). At the no-effect dose of 380 mg/kg/day (1201 mg/m2/day), plasma Cmax for 5&rsquo;-DFUR was slightly greater than that observed in humans at the recommended dose, while the AUC was about half that in humans.</p><p>&nbsp;</p><p><u>Use in Pregnancy &ndash; CATEGORY D</u></p><p>&nbsp;</p><p>Capecitabine SPC may cause foetal harm when administered to pregnant women. Women of child bearing potential should be advised to avoid becoming pregnant while receiving treatment with Capecitabine SPC. There are no adequate and well-controlled studies in pregnant women using Capecitabine SPC. If the medicine is used during pregnancy, or if the patient becomes pregnant while receiving this medicine, the patient should be advised of the potential hazard to the foetus.</p><p><em>Studies Conducted in Animals</em></p><p>Mice: Capecitabine SPC and/or its metabolites have been shown to cross the placenta in mice. Capecitabine SPC was shown to be teratogenic and embryolethal when administered orally to mice during organogenesis at a dose of 198 mg/kg/day (676 mg/m2/day). Teratogenic findings included cleft palate, anophthalmia, microphthalmia, oligodactyly, polydactyly, syndactyly, kinky tail and dilatation of cerebral ventricles. The non- teratogenic dose level in mice was 50 mg/kg/day (approximately 170 mg/m2/day). Systemic exposure to 5&rsquo;- DFUR at the 50 mg/kg/day dose level was not assessed in any studies; however, this dose level is estimated to be about 20 times lower than that in patients dosed at 2510 mg/m2/day, based on plasma AUC values.</p><p>Capecitabine SPC administered to mice dams for the period following organogenesis through to weaning at doses up to 400 mg/kg/day (1428 mg/m2/day) was not associated with any adverse effects on the dams or offspring. In separate studies, this dose produced 5&rsquo;-DFUR Cmax and AUC values about 1.4 and 0.43 times, respectively, of the corresponding values in patients administered 2510 mg/m2/day.</p><p><em>Monkeys: </em>Capecitabine SPC was embryolethal when administered to dams during organogenesis at a dose of 90 mg/kg/day equivalent to 1095 mg/m2/day. However, no teratogenic effects were observed in those fetuses that did survive at that dose level. The no-effect dose was 45 mg/kg/day (560 mg/m2/day), which produced a plasma 5&rsquo;- DFUR AUC value that was about one third of the corresponding value in patients at the recommended dose.</p><p><u>Use in Lactation</u></p><p>It is not known whether Capecitabine SPC and its metabolites are excreted in human milk. In a study of single oral administration of Capecitabine SPC in lactating mice, a significant amount of Capecitabine SPC metabolites was detected in the milk. No effects were observed on the offspring of lactating mice dosed orally with Capecitabine SPC at 400 mg/kg/day (1428 mg/m2/day). However, plasma AUC for 5&rsquo;-DFUR at this dose was lower than that in patients receiving the recommended dose of the medicine. Because many medicines are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, it is recommended that nursing be discontinued when receiving Capecitabine SPC therapy.</p><p><u>Interaction with Food</u></p><p>The effect of food on the pharmacokinetics of Capecitabine SPC was investigated in 11 cancer patients. The rate and extent of absorption of Capecitabine SPC is decreased when administered with food. The effect on AUC0-&infin; of the 3 main metabolites in plasma (5&rsquo;DFUR, 5-FU, FBAL) is minor. In all clinical trials, patients were instructed to administer Capecitabine SPC within 30 minutes after a meal. Since current safety and efficacy data are based upon administration with food, it is recommended that Capecitabine SPC be administered with food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.</p><p><u>Interaction with other medicinal products</u></p><p><strong><em>Brivudine: </em></strong>a clinically significant interaction between brivudine and fluoropyrimidines (e.g. capecitabine, 5- Fluorouracil, tegafur), resulting from the inhibition of dihydropyrimidine dehydrogenase by brivudine, has been described. This interaction, which leads to increased fluoropyrimidine toxicity, is potentially fatal. Therefore, brivudine must not be administered concomitantly with capecitabine (see section 4.3 and 4.4). There must be at least a 4-week waiting period between end of treatment with brivudine and start of capecitabine therapy. Treatment with brivudine can be started 24 hours after the last dose of capecitabine.</p><p><strong><em>Cytochrome P450 2C9 Substrates: </em></strong>Other than warfarin, no formal interaction studies with capecitabine and other medicines known to be metabolised by the cytochrome P450 2C9 isoenzyme have been conducted. Care should be exercised when capecitabine is co-administered with 2C9 substrates (e.g., phenytoin). See also interaction with coumarin-derivative anticoagulants below, and section 4.4.</p><p><strong><em>Coumarin-Derivative Anticoagulants: </em></strong>Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon. These reactions occurred within several days and up to several months after initiating capecitabine therapy and, in a few cases, within one month after stopping capecitabine. In a clinical pharmacokinetic interaction study, after a single 20 mg dose of warfarin, capecitabine treatment increased the AUC of S-warfarin by 57% with a 91% increase in INR value. Since metabolism of R-warfarin was not affected, these results indicate that capecitabine down-regulates isozyme 2C9, but has no effect on isozymes 1A2 and 3A4. Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR) and the anticoagulant dose adjusted accordingly.</p><p><strong><em>Phenytoin: </em></strong>Increased phenytoin plasma concentrations resulting in symptoms of phenytoin intoxication in single cases have been reported during concomitant use of capecitabine with phenytoin. Patients taking phenytoin concomitantly with capecitabine should be regularly monitored for increased phenytoin plasma concentrations.</p><p><strong><em>Folinic acid/folic acid: </em></strong>a combination study with capecitabine and folinic acid indicated that folinic acid has no major effect on the pharmacokinetics of capecitabine and its metabolites. However, folinic acid has an effect on the pharmacodynamics of capecitabine and its toxicity may be enhanced by folinic acid: the maximum tolerated dose (MTD) of capecitabine alone using the intermittent regimen is 3000 mg/m<sup>2</sup> per day whereas it is only 2000 mg/m<sup>2</sup> per day when capecitabine was combined with folinic acid (30 mg orally bid). The enhanced toxicity may be relevant when switching from 5- FU/LV to a capecitabine regimen. This may also be relevant with folic acid supplementation for folate deficiency due to the similarity between folinic acid and folic acid.</p><p><strong><em>Antacid</em></strong><em>: </em>The effect of an aluminium hydroxide and magnesium hydroxide containing antacid on the pharmacokinetics of Capecitabine was investigated. There was a small increase in plasma concentrations of capecitabine and one metabolite (5&rsquo;DFCR); there was no effect on the 3 major metabolites (5&rsquo;DFUR, 5-FU and FBAL).</p><p><strong><em>Allopurinol: </em></strong>interactions with allopurinol have been observed for 5-FU; with possible decreased efficacy of 5-FU. Concomitant use of allopurinol with capecitabine should be avoided.</p><p><strong><em>Interferon alpha: </em></strong>the MTD of capecitabine was 2000 mg/m<sup>2</sup> per day when combined with interferon alpha- 2a (3 MIU/m<sup>2</sup> per day) compared to 3000 mg/m<sup>2</sup> per day when capecitabine was used alone.</p><p><strong><em>Radiotherapy: </em></strong>the MTD of capecitabine alone using the intermittent regimen is 3000 mg/m<sup>2</sup> per day, whereas, when combined with radiotherapy for rectal cancer, the MTD of capecitabine is 2000 mg/m<sup>2</sup> per day using either a continuous schedule or given daily Monday through Friday during a 6-week course of radiotherapy.</p><p><strong><em>Oxaliplatin: </em></strong>No clinically significant differences in exposure to capecitabine or its metabolites, free platinum or total platinum occur when capecitabine and oxaliplatin were administered in combination, with or without bevacizumab.</p><p><strong><em>Bevacizumab: </em></strong>There was no clinically significant effect of bevacizumab on the pharmacokinetic parameters of capecitabine or its metabolites in the presence of oxaliplatin.</p><p><strong>Food interaction</strong></p><p>In all clinical trials, patients were instructed to administer capecitabine within 30 minutes after a meal. Since current safety and efficacy data are based upon administration with food, it is recommended that capecitabine be administered with food. Administration with food decreases the rate of capecitabine absorption (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Women of childbearing potential/ Contraception in males and females</u></strong></p><p><strong>&nbsp;</strong></p><p>Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with capecitabine. If the patient becomes pregnant while receiving capecitabine, the potential hazard to the foetus must be explained. An effective method of contraception should be used during treatment and for 6 months after the last dose of capecitabine.</p><p>Based on genetic toxicity findings, male patients with female partners of reproductive potential should use effective contraception during treatment and for 3 months following the last dose of capecitabine.</p><p><u>Pregnancy</u></p><p>There are no studies in pregnant women using capecitabine; however, it should be assumed that capecitabine may cause foetal harm if administered to pregnant women. In reproductive toxicity studies in animals, capecitabine administration caused embryolethality and teratogenicity. These findings are expected effects of fluoropyrimidine derivatives. Capecitabine is contraindicated during pregnancy.</p><p><u>Breastfeeding</u></p><p>It is not known whether capecitabine is excreted in human breast milk. No studies have been conducted to assess the impact of capecitabine on milk production or its presence in human breast milk. In lactating mice, considerable amounts of capecitabine and its metabolites were found in milk. As the potential for harm to the nursing infant is unknown, breastfeeding should be discontinued while receiving treatment with capecitabine and for 2 weeks after the final dose.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There is no data on Capecitabine and impact on fertility. The Capecitabine pivotal studies included females of childbearing potential and males only if they agreed to use an acceptable method of birth control to avoid pregnancy for the duration of the study and for a reasonable period thereafter. In animal studies effects on fertility were observed (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capecitabine has minor or moderate influence on the ability to drive and use machines. Capecitabine may cause dizziness, fatigue and nausea.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The overall safety profile of capecitabine is based on data from over 3000 patients treated with capecitabine as monotherapy or capecitabine in combination with different chemotherapy regimens in multiple indications. The safety profiles of capecitabine monotherapy for the metastatic breast cancer, metastatic colorectal cancer and adjuvant colon cancer populations are comparable. See section 5.1 for details of major studies, including study designs and major efficacy results.</p><p>The most commonly reported and/or clinically relevant treatment-related adverse drug reactions (ADRs) were gastrointestinal disorders (especially diarrhoea, nausea, vomiting, abdominal pain, stomatitis), hand-foot syndrome (palmar-plantar erythrodysesthesia), fatigue, asthenia, anorexia, cardiotoxicity, increased renal dysfunction on those with preexisting compromised renal function, and thrombosis/embolism.</p><p><u>Tabulated list of adverse reactions</u></p><p>ADRs considered by the investigator to be possibly, probably, or remotely related to the administration of capecitabine are listed in table 4 for capecitabine given as monotherapy and in table 5 for capecitabine given in combination with different chemotherapy regimens in multiple indications. The following headings are used to rank the ADRs by frequency: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000). Within each frequency grouping, ADRs are presented in order of decreasing seriousness.</p><p><u>Capecitabine Monotherapy:</u></p><p>Table 4 lists ADRs associated with the use of capecitabine monotherapy based on a pooled analysis of safety data from three major studies including over 1900 patients (studies M66001, SO14695, and SO14796). ADRs are added to the appropriate frequency grouping according to the overall incidence from the pooled analysis.</p><p>&nbsp;</p><p>Table 4 Summary of related ADRs reported in patients treated with capecitabine monotherapy</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:138px"><p><strong>Body System</strong></p></td><td style="vertical-align:top; width:119px"><p><strong>Very Common</strong></p><p><strong>All grades</strong></p></td><td style="vertical-align:top; width:164px"><p><strong>Common</strong></p><p><strong>All grades</strong></p></td><td style="vertical-align:top; width:305px"><p><strong>Uncommon<br />Severe and/or Life-threatening (grade 3-4) or considered medically relevant</strong></p></td><td style="vertical-align:top; width:261px"><p><strong>Rare/Very Rare<br />(Post-Marketing Experience)</strong></p></td></tr><tr><td style="vertical-align:top; width:138px"><p>Infections and infestations</p></td><td style="vertical-align:top; width:119px"><p>-</p></td><td style="vertical-align:top; width:164px"><p>Herpes viral infection, Nasopharyngitis, Lower respiratory tract infection</p></td><td style="vertical-align:top; width:305px"><p>Sepsis, Urinary tract infection, Cellulitis, Tonsillitis, Pharyngitis, Oral candidiasis, Influenza, Gastroenteritis, Fungal infection, Infection, Tooth abscess</p></td><td rowspan="1" style="vertical-align:top; width:261px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:138px"><p>Neoplasm benign,</p></td><td style="vertical-align:top; width:119px"><p>-</p></td><td style="vertical-align:top; width:164px"><p>-</p></td><td style="vertical-align:top; width:305px"><p>Lipoma</p></td><td style="vertical-align:top; width:261px"><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>malignant and unspecified</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Neutropenia, Anaemia</p></td><td style="vertical-align:top"><p>Febrile neutropenia, Pancytopenia, Granulocytopenia, Thrombocytopenia, Leukopenia, Haemolytic anaemia, International Normalised Ratio (INR)</p><p>increased/Prothrombin</p><p>time prolonged</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system</p><p>disorders</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>Dehydration, Weight decreased</p></td><td style="vertical-align:top"><p>Diabetes, Hypokalaemia, Appetite disorder, Malnutrition,</p><p>Hypertriglyceridaemia,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Insomnia, Depression</p></td><td style="vertical-align:top"><p>Confusional state, Panic attack, Depressed mood,</p><p>Libido decreased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Headache, Lethargy Dizziness, Parasthesia Dysgeusia</p></td><td style="vertical-align:top"><p>Aphasia, Memory impairment, Ataxia, Syncope, Balance disorder, Sensory disorder, Neuropathy</p><p>peripheral</p></td><td style="vertical-align:top"><p>Toxic leukoencephalopathy (very rare)</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Lacrimation increased, Conjunctivitis, Eye irritation</p></td><td style="vertical-align:top"><p>Visual acuity reduced, Diplopia</p></td><td style="vertical-align:top"><p>Lacrimal duct stenosis (rare), Corneal disorders(rare), keratitis (rare), punctate keratitis</p><p>(rare)</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Vertigo, Ear pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Angina unstable, Angina pectoris, Myocardial ischaemia/infarction, Atrial fibrillation, Arrhythmia, Tachycardia, Sinus tachycardia,</p><p>Palpitations</p></td><td style="vertical-align:top"><p>Ventricular fibrillation (rare), QT prolongation (rare), Torsade de pointes (rare), Bradycardia (rare), Vasospasm (rare)</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Thrombophlebitis</p></td><td style="vertical-align:top"><p>Deep vein thrombosis, Hypertension, Petechiae, Hypotension, Hot flush, Peripheral</p><p>coldness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal</p><p>disorders</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Dyspnoea, Epistaxis, Cough, Rhinorrhoea</p></td><td style="vertical-align:top"><p>Pulmonary embolism, Pneumothorax, Haemoptysis, Asthma,</p><p>Dyspnoea exertional</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Diarrhoea, Vomiting, Nausea, Stomatitis,</p><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Gastrointestinal haemorrhage, Constipation, Upper</p><p>abdominal pain,</p></td><td style="vertical-align:top"><p>Intestinal obstruction, Ascites, Enteritis, Gastritis, Dysphagia,</p><p>Abdominal pain lower,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:135px"><p>&nbsp;</p></td><td style="vertical-align:top; width:123px"><p>&nbsp;</p></td><td style="vertical-align:top; width:164px"><p>Dyspepsia, Flatulence, Dry mouth</p></td><td style="vertical-align:top; width:302px"><p>Oesophagitis, Abdominal discomfort, Gastrooesophageal reflux disease, Colitis,</p><p>Blood in stool</p></td><td style="vertical-align:top; width:261px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:135px"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top; width:123px"><p>-</p></td><td style="vertical-align:top; width:164px"><p>Hyperbilirubinemia, Liver function test</p><p>abnormalities</p></td><td style="vertical-align:top; width:302px"><p>Jaundice</p></td><td style="vertical-align:top; width:261px"><p>Hepatic failure (rare), Cholestatic</p><p>hepatitis (rare)</p></td></tr><tr><td style="vertical-align:top; width:135px"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:123px"><p>Palmar-plantar erythro- dysaesthesia syndrome**</p></td><td style="vertical-align:top; width:164px"><p>Rash, Alopecia, Erythema, Dry skin,</p><p>Pruritus, Skin</p><p>hyper-pigmentation, Rash macular, Skin desquamation, Dermatitis, Pigmentation disorder, Nail</p><p>disorder</p></td><td style="vertical-align:top; width:302px"><p>Blister, Skin ulcer, Rash, Urticaria, Photosensitivity reaction, Palmar erythema, Swelling face, Purpura, Radiation recall syndrome</p></td><td style="vertical-align:top; width:261px"><p>Cutaneous lupus erythematosus (rare), Severe skin reactions such as Stevens- Johnson Syndrome and toxic Epidermal Necrolysis (very rare) (see section 4.4.)</p></td></tr><tr><td style="vertical-align:top; width:135px"><p>Muskuloskeletal and connective tissue disorders</p></td><td style="vertical-align:top; width:123px"><p>-</p></td><td style="vertical-align:top; width:164px"><p>Pain in extremity, Back pain, Arthralgia</p></td><td style="vertical-align:top; width:302px"><p>Joint swelling, Bone pain, Facial pain, Musculoskeletal stiffness, Muscular</p><p>weakness</p></td><td style="vertical-align:top; width:261px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:135px"><p>Renal and urinary disorders</p></td><td style="vertical-align:top; width:123px"><p>-</p></td><td style="vertical-align:top; width:164px"><p>-</p></td><td style="vertical-align:top; width:302px"><p>Hydronephrosis, Urinary incontinence, Haematuria, Nocturia, Blood creatinine</p><p>increased</p></td><td style="vertical-align:top; width:261px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:135px"><p>Reproductive</p><p>system and breast disorders</p></td><td style="vertical-align:top; width:123px"><p>-</p></td><td style="vertical-align:top; width:164px"><p>-</p></td><td style="vertical-align:top; width:302px"><p>Vaginal haemorrhage</p></td><td style="vertical-align:top; width:261px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:135px"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:123px"><p>Fatigue, Asthenia</p></td><td style="vertical-align:top; width:164px"><p>Pyrexia, Oedema peripheral, Malaise, Chest pain</p></td><td style="vertical-align:top; width:302px"><p>Oedema, Chills, Influenza like illness,</p><p>Rigors, Body temperature increased</p></td><td style="vertical-align:top; width:261px"><p>&nbsp;</p></td></tr></tbody></table><p>** Based on the post-marketing experience, persistent or severe palmar-plantar erythrodysaesthesia syndrome can eventually lead to loss of fingerprints (see section 4.4).</p><p><u>Capecitabine in combination therapy:</u></p><p>Table 5 lists ADRs associated with the use of capecitabine in combination with different chemotherapy regimens in multiple indications based on safety data from over 3000 patients. ADRs are added to the appropriate frequency grouping (Very common or Common) according to the highest incidence seen in any of the major clinical trials and are only added when they were seen in addition to those seen with capecitabine monotherapy or seen at <strong>a higher frequency grouping </strong>compared to capecitabine monotherapy (see table 4). Uncommon ADRs reported for capecitabine in combination therapy are consistent with the ADRs reported for capecitabine monotherapy or reported for monotherapy with the combination medicinal product (in literature and/or respective summary of product characteristics).</p><p>Some of the ADRs are reactions commonly seen with the combination medicinal product (e.g. peripheral sensory neuropathy with docetaxel or oxaliplatin, hypertension seen with bevacizumab); however an exacerbation by capecitabine therapy cannot be excluded.</p><p>&nbsp;</p><p>Table 5 Summary of related ADRs reported in patients treated with capecitabine in combination treatment in addition to those seen with capecitabine monotherapy or seen at <strong>a higher frequency grouping </strong>compared to capecitabine monotherapy</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body System</strong></p></td><td style="vertical-align:top"><p><strong>Very common All grades</strong></p></td><td style="vertical-align:top"><p><strong>Common All grades</strong></p></td><td style="vertical-align:top"><p><strong>Rare/Very Rare (Post-</strong></p><p><strong>Marketing</strong></p><p><strong>Experience)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Herpes zoster, Urinary tract infection, Oral candidiasis, Upper respiratory tract infection , Rhinitis, Influenza, +Infection,</p><p>Oral herpes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system</p><p>disorders</p></td><td style="vertical-align:top"><p>+Neutropenia, +Leucopenia, +Anaemia, +Neutropenic fever, Thrombocytopenia</p></td><td style="vertical-align:top"><p>Bone marrow depression, +Febrile Neutropenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Appetite decreased</p></td><td style="vertical-align:top"><p>Hypokalaemia, Hyponatraemia, Hypomagnesaemia, Hypocalcaemia,</p><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Sleep disorder, Anxiety</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Paraesthesia, Dysaesthesia, Peripheral neuropathy, Peripheral sensory neuropathy, Dysgeusia, Headache</p></td><td style="vertical-align:top"><p>Neurotoxicity, Tremor, Neuralgia, Hypersensitivity reaction,</p><p>Hypoaesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Lacrimation increased</p></td><td style="vertical-align:top"><p>Visual disorders, Dry eye, Eye pain, Visual impairment, Vision</p><p>blurred</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth</p><p>disorders</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Tinnitus, Hypoacusis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Atrial fibrillation, Cardiac</p><p>ischaemia/infarction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Lower limb oedema, Hypertension, +Embolism and thrombosis</p></td><td style="vertical-align:top"><p>Flushing, Hypotension, Hypertensive crisis,</p><p>Hot flush, Phlebitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal system</p><p>disorders</p></td><td style="vertical-align:top"><p>Sore throat, Dysaesthesia pharynx</p></td><td style="vertical-align:top"><p>Hiccups, Pharyngolaryngeal pain, Dysphonia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Constipation, Dyspepsia</p></td><td style="vertical-align:top"><p>Upper gastrointestinal haemorrhage, Mouth ulceration, Gastritis, Abdominal distension,</p><p>Gastroesophageal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:179px"><p>&nbsp;</p></td><td style="vertical-align:top; width:326px"><p>&nbsp;</p></td><td style="vertical-align:top; width:370px"><p>reflux disease, Oral pain, Dysphagia, Rectal haemorrhage, Abdominal pain lower, Oral dysaesthesia, Paraesthesia oral, Hypoaesthesia oral,</p><p>Abdominal discomfort</p></td><td style="vertical-align:top; width:110px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:179px"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top; width:326px"><p>-</p></td><td style="vertical-align:top; width:370px"><p>Hepatic function abnormal</p></td><td style="vertical-align:top; width:110px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:179px"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:326px"><p>Alopecia, Nail disorder</p></td><td style="vertical-align:top; width:370px"><p>Hyperhidrosis, Rash erythematous, Urticaria, Night</p><p>sweats</p></td><td style="vertical-align:top; width:110px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:179px"><p>Musculoskeletal and connective</p><p>tissue disorders</p></td><td style="vertical-align:top; width:326px"><p>Myalgia, Arthralgia, Pain in extremity</p></td><td style="vertical-align:top; width:370px"><p>Pain in jaw , Muscle spasms, Trismus,</p><p>Muscular weakness</p></td><td style="vertical-align:top; width:110px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:179px"><p>Renal and urinary disorder</p></td><td style="vertical-align:top; width:326px"><p>-</p></td><td style="vertical-align:top; width:370px"><p>Haematuria, Proteinuria, Creatinine renal clearance decreased,</p><p>Dysuria</p></td><td style="vertical-align:top; width:110px"><p>Acute renal failure secondary to dehydration</p><p>(rare)</p></td></tr><tr><td style="vertical-align:top; width:179px"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:326px"><p>Pyrexia, Weakness, +Lethargy, Temperature intolerance</p></td><td style="vertical-align:top; width:370px"><p>Mucosal inflammation, Pain in limb, Pain, Chills, Chest pain,</p><p>Influenza-like illness, +Fever, Infusion related reaction, Injection</p><p>site reaction, Infusion</p><p>site pain, Injection site pain</p></td><td style="vertical-align:top; width:110px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:179px"><p>Injury, poisoning and</p><p>procedural complications</p></td><td style="vertical-align:top; width:326px"><p>-</p></td><td style="vertical-align:top; width:370px"><p>Contusion</p></td><td style="vertical-align:top; width:110px"><p>&nbsp;</p></td></tr></tbody></table><p>+ For each term, the frequency count was based on ADRs of all grades. For terms marked with a &ldquo;+&rdquo;, the frequency count was based on grade 3-4 ADRs. ADRs are added according to the highest incidence seen in any of the major combination trials.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><u>Hand-foot syndrome (see section 4.4):</u></p><p>For the capecitabine dose of 1250 mg/m<sup>2</sup> twice daily on days 1 to 14 every 3 weeks, a frequency of 53% to 60% of all-grades HFS was observed in capecitabine monotherapy trials (comprising studies in adjuvant therapy in colon cancer, treatment of metastatic colorectal cancer, and treatment of breast cancer) and a frequency of 63% was observed in the capecitabine/docetaxel arm for the treatment of metastatic breast cancer. For the capecitabine dose of 1000 mg/m<sup>2</sup> twice daily on days 1 to 14 every 3 weeks, a frequency of 22% to 30% of all-grade HFS was observed in capecitabine combination therapy.</p><p>&nbsp;</p><p>A meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabine monotherapy or capecitabine in combination with different chemotherapy regimens in multiple indications (colon, colorectal, gastric and breast cancer) showed that HFS (all grades) occurred in 2066 (43%) patients after a median time of 239 [95% CI 201, 288] days after starting treatment with capecitabine. In all studies combined, the following covariates were statistically significantly associated with an increased risk of developing HFS: increasing capecitabine starting dose (gram), decreasing cumulative capecitabine dose (0.1*kg), increasing relative dose intensity in the first six weeks, increasing duration of study treatment (weeks), increasing age (by 10 year increments), female gender, and good ECOG performance status at baseline (0 versus &ge;1).</p><p><u>Diarrhoea (see section 4.4):</u></p><p><strong>&nbsp;</strong></p><p>Capecitabine can induce the occurrence of diarrhoea, which has been observed in up to 50% of patients.</p><p>&nbsp;</p><p>The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabine showed that in all studies combined, the following covariates were statistically significantly associated with an increased risk of developing diarrhoea: increasing capecitabine starting dose (gram), increasing duration of study treatment (weeks), increasing age (by 10 year increments), and female gender. The following covariates were statistically significantly associated with a decreased risk of developing diarrhoea: increasing cumulative capecitabine dose (0.1*kg) and increasing relative dose intensity in the first six weeks.</p><p><u>Cardiotoxicity (see section 4.4):</u></p><p><strong>&nbsp;</strong></p><p>In addition to the ADRs described in tables 4 and 5, the following ADRs with an incidence of less than 0.1% were associated with the use of capecitabine monotherapy based on a pooled analysis from clinical safety data from 7 clinical trials including 949 patients (2 phase III and 5 phase II clinical trials in metastatic colorectal cancer and metastatic breast cancer): cardiomyopathy, cardiac failure, sudden death, and ventricular extrasystoles.</p><p><u>Encephalopathy:</u></p><p><strong>&nbsp;</strong></p><p>In addition to the ADRs described in tables 4 and 5 and based on the above pooled analysis from clinical safety data from 7 clinical trials, encephalopathy was also associated with the use of capecitabine monotherapy with an incidence of less than 0.1%.</p><p>&nbsp;</p><p><u>Exposure to crushed or cut capecitabine tablets:</u></p><p><strong>&nbsp;</strong></p><p>In the instance of exposure to crushed or cut capecitabine tablets, the following adverse drug reactions have been reported: eye irritation, eye swelling, skin rash, headache, paresthesia, diarrhoea, nausea, gastric irritation, and vomiting.</p><p><u>Special populations</u></p><p>&nbsp;</p><p><u>Elderly patients (see section 4.2):</u></p><p><strong>&nbsp;</strong></p><p>An analysis of safety data in patients &ge;60 years of age treated with capecitabine monotherapy and an analysis of patients treated with capecitabine plus docetaxel combination therapy showed an increase in the incidence of treatment-related grade 3 and 4 adverse reactions and treatment-related serious adverse reactions compared to patients &lt;60 years of age. Patients &ge;60 years of age treated with capecitabine plus docetaxel also had more early withdrawals from treatment due to adverse reactions compared to patients &lt;60 years of age.</p><p>The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabine showed that in all studies combined, increasing age (by 10 year increments) was statistically significantly associated with an increased risk of developing HFS and diarrhoea and with a decreased risk of developing neutropenia.</p><p><u>Gender:</u></p><p><strong>&nbsp;</strong></p><p>The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabine showed that in all studies combined, female gender was statistically significantly associated with an increased risk of developing HFS and diarrhoea and with a decreased risk of developing neutropenia.</p><p><u>Patients with renal impairment (see section 4.2, 4.4, and 5.2):</u></p><p><strong>&nbsp;</strong></p><p>An analysis of safety data in patients treated with capecitabine monotherapy (colorectal cancer) with baseline renal impairment showed an increase in the incidence of treatment-related grade 3 and 4 adverse reactions compared to patients with normal renal function (36% in patients without renal impairment n=268, vs. 41% in mild n=257 and 54% in moderate n=59, respectively) (see section 5.2). Patients with moderately impaired renal function show an increased rate of dose reduction (44%) vs. 33% and 32% in patients with no or mild renal impairment and an increase in early withdrawals from treatment (21% withdrawals during the first two cycles) vs. 5% and 8% in patients with no or mild renal impairment.</p><p><u>Reporting of suspected adverse reactions</u></p><p><strong>&nbsp;</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via submitting completed forms to: npc.drug@sfda.gov.sa.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The manifestations of acute overdose include nausea, vomiting, diarrhoea, mucositis, gastrointestinal irritation and bleeding, and bone marrow depression. Medical management of overdose should include customary therapeutic and supportive medical interventions aimed at correcting the presenting clinical manifestations and preventing their possible complications.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capecitabine SPC itself is non-cytotoxic; however, it is selectively activated to the cytotoxic moiety fluorouracil (5-FU), by thymidine phosphorylase in tumours.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><u>Bioactivation</u></p><p>Capecitabine SPC is a fluoropyrimidine carbamate derivative that was designed as an orally administered, tumour- activated and tumour-selective cytotoxic agent. Capecitabine SPC is non- cytotoxic in vitro.</p><p>Capecitabine SPC is absorbed unchanged from the gastrointestinal tract, metabolised primarily in the liver by the 60 kDa carboxylesterase to 5&rsquo;-deoxy-5-fluorocytidine (5&rsquo;-DFCR), which is then converted to 5&rsquo;-DFUR by cytidine deaminase, principally located in the liver and tumour tissue. Further metabolism of 5&rsquo;-DFUR to the pharmacologically active agent 5-FU occurs mainly at the site of the tumour by the tumour- associated angiogenic factor thymidine phosphorylase (dThdPase), which has levels considerably higher in tumour tissues compared to normal tissues. Several human tumours such as breast, gastric, colorectal, cervical and ovarian cancer have a higher level of thymidine phosphorylase than normal tissues. This minimises the exposure of healthy tissues to systemic 5-FU. Catabolism of 5-FU by dihydropyrimidine dehydrogenase (DPD) leads to formation of dihydro-5- fluorouracil (FUH2), followed by ring cleavage with dihydropyrimidinase (DHP) to 5- fluoro-ureido-propionic acid (FUPA) and finally to &alpha;-fluoro-&beta;- alanine (FBAL) by the enzyme &beta;-ureido- propionase (BUP).</p><p><em>Figure 1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metabolic Pathway of Capecitabine to5-FU</em></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="Image_x0020_4" o:spid="_x0000_s1026" type="#_x0000_t75"
  style='position:absolute;margin-left:168.25pt;margin-top:20.25pt;width:244.1pt;
  height:250.55pt;z-index:-15727104;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/O9B2F~1.ALH/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
   o:title=""/>
  <o:lock v:ext="edit" aspectratio="f"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p><img alt="" width="587" height="445" src="data:image/jpeg;base64,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" /></p><p><u>Mechanism of Action</u></p><p>Both normal and tumour cells metabolise 5-FU to 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5- fluorouridine triphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor N5-10 methylenetetrahydrofolate bind covalently to thymidylate</p><p>synthase (TS) to form a covalently bound ternary complex. This binding prevents formation of thymidylate from uracil, the necessary precursor of thymidine triphosphate that is required for DNA synthesis. A deficiency of thymidine triphosphate can inhibit cell division. The second mechanism results from the incorporation of FUTP into RNA in place of UTP, thereby preventing the correct nuclear processing of ribosomal RNA and messenger RNA. These effects are most marked on rapidly proliferating cells, such as tumour cells, which utilise 5-FU at a higher rate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacokinetics in Tumours and Adjacent Healthy Tissue</strong></p><p><strong>&nbsp;</strong></p><p>A pharmacokinetic study in 19 colorectal patients was conducted investigating the tumour selectivity of Capecitabine SPC comparing 5-FU concentrations in tumour, healthy tissue and plasma. Following oral administration of Capecitabine SPC (1250 mg/m2 twice daily, 5 to 7 days before surgery), concentrations of 5- FU were significantly greater in primary tumour than in adjacent healthy tissue (geometric mean ratio 2.5; 95% CI: [1.5 to 4.1]) and plasma (geometric mean ratio14).</p><p>Thymidine phosphorylase activity was four times greater in primary tumour tissue (colon) than in normal tissue.</p><p><u>Human Pharmacokinetics</u></p><p><strong>&nbsp;</strong></p><p>The pharmacokinetics of Capecitabine SPC and its metabolites have been evaluated in 11 studies in a total of 213 cancer patients at a dosage range of 502 to 3514 mg/m2/day. In the dose range of 250 to 1250 mg/m2 as a single dose, the pharmacokinetics of Capecitabine SPC and its metabolites were dose proportional, except for 5-FU. Area under the curve (AUC) of 5-FU was 30% higher on day 14, but did not increase subsequently (day 22). A summary of key data for a dose of 1255 mg/m2 twice daily is presented below:</p><p><em>Absorption: </em>After oral administration, Capecitabine SPC is rapidly and extensively absorbed, followed by extensive conversion to the metabolites 5&rsquo;-deoxy-5-fluorocytidine (5&rsquo;-DFCR) and 5&rsquo;-DFUR. Administration of food decreases the rate of Capecitabine SPC absorption but has only a minor effect on the AUC of 5&rsquo;-DFUR and the subsequent metabolite 5-FU. The absorption of Capecitabine SPC is confirmed since 95.5% of an orally administered dose is recovered in urine.</p><p>Distribution: In vitro human plasma studies have determined that Capecitabine SPC, 5&rsquo;-DFCR, 5&rsquo;- DFUR and 5- FU are 54%, 10%, 62% and 10% protein bound respectively, mainly to albumin</p><p>&nbsp;</p><p><em>Metabolism: </em>Capecitabine SPC is first metabolised by hepatic carboxylesterase to 5&rsquo;-DFCR, which is then converted to 5&rsquo;-DFUR by cytidine deaminase, principally located in the liver and tumour tissues. Formation of 5-FU occurs preferentially at the tumour site by the tumour-associated angiogenic factor dThdPase, thereby minimising the exposure of healthy body tissues to systemic 5-FU.</p><p>The plasma AUC of 5-FU is 6 to 22 times lower than that following an IV bolus of 5-FU (Dose of 600 mg/m2). The metabolites of Capecitabine SPC become cytotoxic only after conversion to 5-FU and anabolites of 5-FU. 5-FU is further catabolised to the inactive metabolites dihydro-5- fluorouracil (FUH2), 5-fluoro- ureidopropionic acid (FUPA) and &alpha;-fluoro-&beta;-alanine (FBAL) via dihydropyrimidine dehydrogenase (DPD), which is rate limiting.</p><p>&nbsp;</p><p><strong><em>Elimination</em></strong><em>: </em>After oral administration, Capecitabine SPC metabolites are primarily recovered in the urine. Most (95.5%) of administered Capecitabine SPC dose is recovered in urine. Faecal excretion is minimal (2.6%). The major metabolite excreted in urine is FBAL, which represents 57% of the administered dose. About 3% of the administered dose is excreted in the urine as unchanged drug.</p><p><em>Pharmacokinetic Parameters: </em>Table shows the time course of pharmacokinetic parameters for Capecitabine SPC and 5-FU in plasma at steady-state (day 14) following administration of the recommended dose (1250 mg/m2 twice daily) in 8 cancer patients. The peak of plasma concentrations of intact drug and 5-FU are reached within 1.5 and 2 hours, respectively (median times), and the concentrations decline with half-lives of 0.85 and</p><p>0.76 hours, respectively.</p><p>&nbsp;</p><p>Pharmacokinetic parameters estimated on Day 14 after administration of <em>Capecitabine SPC </em>(1250 mg/m2 twice daily) in 8 cancer patients</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Parameter</strong></p></td><td style="vertical-align:top"><p>Capecitabine SPC</p></td><td style="vertical-align:top"><p><strong>5-FU</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Cmax</strong></p></td><td style="vertical-align:top"><p>3.99</p></td><td style="vertical-align:top"><p>0.709</p></td></tr><tr><td style="vertical-align:top"><p><strong>tmax (h)</strong></p></td><td style="vertical-align:top"><p>1.50 (0.78 - 2.17)#</p></td><td style="vertical-align:top"><p>2.00 (1.28 - 4.08) #</p></td></tr><tr><td style="vertical-align:top"><p><strong>AUC0-t</strong></p></td><td style="vertical-align:top"><p>7.29</p></td><td style="vertical-align:top"><p>1.62</p></td></tr><tr><td style="vertical-align:top"><p><strong>AUC0-&infin;</strong></p></td><td style="vertical-align:top"><p>7.40</p></td><td style="vertical-align:top"><p>1.63</p></td></tr><tr><td style="vertical-align:top"><p><strong>T1/2 (h)</strong></p></td><td style="vertical-align:top"><p>0.85</p></td><td style="vertical-align:top"><p>0.76</p></td></tr></tbody></table><p># Median values (min-max) are reported for tmax</p><p><strong><em>Combination therapy: </em></strong>Phase I studies evaluating the effect of Capecitabine SPC on the pharmacokinetics of either docetaxel or paclitaxel and vice versa showed no effect by Capecitabine SPC on the pharmacokinetics of docetaxel or paclitaxel (Cmax and AUC) and no effect by docetaxel or paclitaxel on the pharmacokinetics of 5&rsquo;-DFUR.</p><p><u>Pharmacokinetics in Special Populations</u></p><p><strong>&nbsp;</strong></p><p>See also PRECAUTIONS and DOSAGE AND ADMINISTRATION for recommendations regarding the use of Capecitabine SPC in (i) the elderly; (ii) patients with hepatic impairment and (iii) patients with renal impairment.</p><p>A population pharmacokinetic analysis was carried out after Capecitabine SPC treatment of 505 patients with colorectal cancer dosed at 1250 mg/m2 twice daily. Gender, presence or absence of liver metastasis at baseline, Karnofsky Performance Status, total bilirubin, serum albumin, AST/ALT had no statistically significant effect on the pharmacokinetics of 5&rsquo;-DFUR, 5-FU and FBAL.</p><p><strong><em>Elderly</em></strong><em>: </em>A population pharmacokinetic analysis which included patients with a wide range of ages (27 to 86 years) and included 234 (46%) patients greater or equal to 65 years of age, found age has no influence on the pharmacokinetics of 5&#39;-DFUR and 5-FU. The AUC of FBAL increased with age (20% increase in age results in a 15% increase in the AUC of FBAL). This increase is likely due to a change in renal function.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>Race</em></strong><em>: </em>Based on the population pharmacokinetic analysis of 455 white patients (90.1%) 22 black patients (4.4%) and 28 patients of other race or ethnicity (5.5%), the pharmacokinetics of black patients were not different compared to white patients. For the other minority groups the numbers were too small to draw a conclusion. Limited available data suggest that there are no clinically significant differences in Capecitabine SPC pharmacokinetics between Caucasians and Oriental subjects.</p><p>&nbsp;</p><p><strong><em>Hepatic Impairment: </em></strong>Capecitabine SPC has been evaluated in patients with mild to moderate hepatic impairment due to liver metastases as defined by a composite score including bilirubin, AST/ALT and alkaline phosphatase. Cmax of Capecitabine SPC, 5&rsquo;-DFUR and 5-FU were increased by 49%, 33% and 28%, respectively. AUC0-&infin; of Capecitabine SPC 5&rsquo;-DFUR and 5-FU were increased by 48%, 20% and 15%, respectively. Conversely, Cmax and AUC of 5&rsquo;-DFCR decreased by 29% and 35%, respectively. Therefore, bioactivation of Capecitabine SPC is not affected.</p><p><strong><em>Renal Impairment: </em></strong>A pharmacokinetic study in cancer patients with mild to severe renal impairment showed that renal impairment significantly increased systemic 5&rsquo;-DFUR exposure. 5&rsquo;-DFUR is the direct precursor of 5-FU and is considered an indicator of tissue exposure to 5- FU. A 50% reduction in creatinine clearance increased 5&rsquo;-DFUR AUC by 35%, 95% CI: [12, 64], on the first day of Capecitabine SPC treatment. Exposure to another metabolite, FBAL increased 114%, 95% CI: [73, 165], when creatinine clearance was decreased by 50%. This was expected since most of the Capecitabine SPC dose is recovered as FBAL in urine. FBAL does not have anti- tumour activity.</p><p>&nbsp;</p><p>CLINICAL TRIALS<strong>&nbsp;</strong></p><p><u>Colon and Colorectal Cancer</u></p><p><strong>&nbsp;</strong></p><p>Monotherapy - adjuvant colon cancer</p><p>Data from an open-label, multicenter, randomised, phase III clinical trial investigated the efficacy and safety of Capecitabine SPC for the adjuvant treatment in patients who underwent surgery for Dukes&rsquo; stage C colon cancer (XACT: study M66001). In this trial, 1987 patients were randomised to treatment with Capecitabine SPC (1250 mg/m2 twice daily for 2 weeks followed by a 1 week rest period, given as 3 week cycles for 24 weeks) or 5- FU and leucovorin (Mayo regimen: 20 mg/m2 leucovorin intravenous (IV) followed by 425 mg/m2 IV bolus 5-FU, on days 1 to 5, every 28 days for 24 weeks).</p><p>The major efficacy parameters assessed were disease free survival (DFS, primary endpoint) and overall survival (OS). The median follow up at the time of the analysis was 6.9 years. Capecitabine SPC was shown to be at least equivalent to 5-FU/leucovorin in DFS and OS.</p><p>&nbsp;</p><p>Table Adjuvant colon cancer efficacy results monotherapy1</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Endpoint Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Number of patients (%) without an Event2</strong></p></td><td style="vertical-align:top; width:140px"><p><strong>Hazard</strong></p><p><strong>Ratio</strong></p></td><td style="vertical-align:top; width:111px"><p><strong>&nbsp;</strong></p><p><strong>p- value4</strong></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:132px"><p>&nbsp;</p></td><td style="vertical-align:top; width:130px"><p>Capecita bine SPC</p><p><strong><em>n </em>=</strong></p></td><td style="vertical-align:top; width:128px"><p><strong>5-</strong></p><p><strong>FU/leucovo rin</strong></p><p><strong><em>n </em>= 983</strong></p></td><td style="vertical-align:top; width:139px"><p><strong>3</strong></p><p><strong>[95% CI]</strong></p></td><td style="vertical-align:top; width:108px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:132px"><p><strong>&nbsp;</strong></p><p><strong>Disease Free Survival</strong></p></td><td style="vertical-align:top; width:130px"><p><strong>&nbsp;</strong></p><p>65.</p><p>3</p></td><td style="vertical-align:top; width:128px"><p><strong>&nbsp;</strong></p><p>61.3</p></td><td style="vertical-align:top; width:139px"><p>0.88</p><p>[0.77,</p><p>1 01]</p></td><td style="vertical-align:top; width:108px"><p>0.</p><p>06</p><p>8</p></td></tr><tr><td style="vertical-align:top; width:132px"><p><strong>&nbsp;</strong></p><p><strong>Overall Survival</strong></p></td><td style="vertical-align:top; width:130px"><p>80.</p><p>1</p></td><td style="vertical-align:top; width:128px"><p><strong>&nbsp;</strong></p><p>76.9</p></td><td style="vertical-align:top; width:139px"><p>0.86</p><p>[0.74,</p><p>1 01]</p></td><td style="vertical-align:top; width:108px"><p>0.</p><p>06</p><p>0</p></td></tr></tbody></table><p>1&nbsp; All-randomised population</p><p>2&nbsp; For disease free survival event = death, relapse or new occurrence of colon cancer (NOCC); for relapse free survival event = death related to treatment or to disease progression, relapse or NOCC; for overall survival event = death (all causes)</p><p>3&nbsp; Hazard Ratio Capecitabine SPC vs. 5-FU/leucovorin. Non-inferiority criterion: 95% CI upper bound&le;1.25</p><p>4&nbsp;&nbsp;&nbsp; Wald chi-square test</p><p>Study M66001 did not include patients with Dukes&rsquo; stage B disease. However, the findings of the study are considered to support the use of Capecitabine SPC as adjuvant therapy in patients with high-risk stage B disease, such as those with inadequately sampled nodes, T4 lesions, perforation or poorly differentiated histology.</p><p><em>Combination therapy - adjuvant colon cancer</em></p><p>Data from a multicentre, randomised, controlled phase III clinical trial in patients with stage III (Dukes&rsquo; C) colon cancer supports the use of Capecitabine SPC in combination with oxaliplatin (XELOX) for the adjuvant treatment of patients with colon cancer (NO16968). In this trial, 944 patients were randomised to 3 week cycles for 24 weeks with Capecitabine SPC (1000 mg/m2 twice daily for 2 weeks followed by a 7 day rest period) in combination with oxaliplatin (130 mg/m2 intravenous infusion over 2 hours on day 1 every 3 weeks); 942 patients were randomised to bolus 5-FU and leucovorin. In the primary analysis (ITT population), median observation time was 57 months for DFS and 59 months for OS. XELOX was shown to be significantly superior to 5-FU/LV (HR=0.80, 95% CI=[0.69; 0.93]; p=0.0045). The 3 year DFS rate was 71% for XELOX versus 67% for 5-FU/LV. The analysis for the secondary endpoint of relapse free survival (RFS) supports these results with a HR of 0.78 (95% CI=[0.67; 0.92]; p=0.0024) for XELOX vs. 5-FU/LV. XELOX showed a trend towards superior OS with a HR of 0.87 (95% CI=[0.72; 1.05]; p=0.1486). The 5 year OS rate was 78% for XELOX versus 74% for 5-FU/LV.</p><p><em>Monotherapy - metastatic colorectal cancer</em></p><p>A phase II open label, multicentre, randomised clinical trial was conducted to explore the efficacy and safety of three different treatment regimens in patients with advanced and/or metastatic colorectal cancer. These were continuous therapy with Capecitabine SPC (1331 mg/m2/day, n = 39) over 12 weeks; intermittent therapy with Capecitabine SPC (1250 mg/m2 twice daily, n = 34) 2 weeks treatment followed by a 1 week rest period, given as 3 week cycles over 12 weeks and intermittent therapy with Capecitabine SPC in combination with oral leucovorin (Capecitabine SPC 1657 mg/m2/day; leucovorin 60 mg/day, n = 35). The objective response rate was 22% in the continuous arm, 25% in the intermittent arm and 24% in the combinationarm.</p><p>&nbsp;</p><p>Data from two identically-designed, multicenter, randomised, controlled phase III clinical trials (SO14695; SO14796) conducted in 120 centres internationally, compared Capecitabine SPC with 5-FU in combination with leucovorin (Mayo regimen) as first-line chemotherapy in patients with advanced and/or metastatic colorectal cancer. In these trials, 603 patients were randomised to treatment with Capecitabine SPC at a daily dose of 1250 mg/m2 twice daily for 2 weeks followed by a 1 week rest period, given as 3 week cycles over 30 weeks. A total of 604 patients were randomised to treatment with 5-FU/leucovorin (20 mg/m2 leucovorin IV followed by 425 mg/m2&nbsp;IV bolus 5-FU, on days 1 to 5, every 28 days). The mean durationPoagfet2re6atment was 139 days for Capecitabine SPC treated patients and 140 days for 5-FU/leucovorin treated patients.</p><p>The major efficacy endpoints assessed were time to disease progression (primary endpoint), objective response rate and OS. The objective response rate included partial and complete responses. The results from the two phase III trials were similar; the pooled efficacy data from both trials are given in the tablebelow.</p><p>Table : Metastatic colorectal cancer pooled trials efficacy results monotherapy1</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Endpoint Parameter</strong></p></td><td style="vertical-align:top"><p>Capecitabi ne SPC</p><p><strong><em>n </em>= 603</strong></p></td><td style="vertical-align:top"><p><strong>5-</strong></p><p><strong>FU/leucovor in</strong></p></td><td style="vertical-align:top"><p><strong>Differenc e [95% CI]</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Time to Disease Progression</strong></p><p>median (range)</p></td><td style="vertical-align:top"><p>140 days</p><p>(131-161)</p></td><td style="vertical-align:top"><p>144 days</p><p>(134-164)</p></td><td style="vertical-align:top"><p>HR21.0</p><p>0 [0.89;</p><p>1 12]</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Response Rate</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>25.7%</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>16.7%</p></td><td style="vertical-align:top"><p>9%</p><p>[4.3 -</p><p>13.5%]</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall Survival</strong></p><p>median</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>392 days</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>391 days</p></td><td style="vertical-align:top"><p>HR 0.96</p><p>[0.85;</p><p>1 08]</p></td></tr></tbody></table><p>1&nbsp; All-randomised population, investigator assessment</p><p>2&nbsp; Hazard Ratio Capecitabine SPC /5-FU leucovorin. Non-inferiority criterion: 95% CI upper bound &le; 1.20</p><p>&nbsp;</p><p>Capecitabine SPC was equivalent to 5-FU/leucovorin in time to disease progression, equivalent in overall survival and superior in objective response rate.</p><p><em>Combination therapy - first-line treatment of metastatic colorectal cancer</em></p><p>Data from a multicenter, randomised, controlled phase III clinical study (NO16966) support the use of Capecitabine SPC in combination with oxaliplatin or in combination with oxaliplatin and bevacizumab (BV) for the first-line treatment of metastastic colorectal cancer. The study contained two parts: an initial 2-arm part in which patients were randomised to two different treatment groups, XELOX or FOLFOX-4, and a subsequent 2x2 factorial part with four different treatment groups, XELOX + placebo (P), FOLFOX-4 + P, XELOX+BV, and FOLFOX-4 + BV. The treatment regimens are summarised in the tablebelow.</p><p>Table : Treatment regimens in study NO16966</p><p><strong><em>&nbsp;</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:83px"><p>&nbsp;</p></td><td style="vertical-align:top; width:178px"><p><strong>Treatme</strong></p></td><td style="vertical-align:top; width:179px"><p><strong>Starting Dose</strong></p></td><td style="vertical-align:top; width:551px"><p><strong>Schedule</strong></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="6" style="vertical-align:top"><p>FOLFOX-4</p><p>or FOLFOX-4</p><p>+ BV</p></td><td rowspan="4" style="vertical-align:top"><p>Oxaliplati n Leucovorin 5- Fluorouracil</p></td><td style="vertical-align:top"><p>85 mg/m2&nbsp;&nbsp;&nbsp;&nbsp; IV 2 h</p><p>200 mg/m2&nbsp;&nbsp;&nbsp;&nbsp; IV 2 h</p><p>400 mg/m2 IV</p></td><td rowspan="4" style="vertical-align:top"><p>Oxaliplatin on Day 1, every 2 weeks Leucovorin on Day 1 and 2, every 2 weeks 5- fluorouracil IV bolus/infusion, each on Days 1 and 2 every 2 weeks</p></td></tr><tr><td style="vertical-align:top"><p>bolus, 600</p></td></tr><tr><td style="vertical-align:top"><p>mg/m2</p></td></tr><tr><td style="vertical-align:top"><p>IV 22 h</p></td></tr><tr><td style="vertical-align:top"><p>Placebo or</p></td><td rowspan="2" style="vertical-align:top"><p>5 mg/kg IV 30-90 min</p></td><td rowspan="2" style="vertical-align:top"><p>Day 1, prior to FOLFOX-4, every 2 weeks</p></td></tr><tr><td style="vertical-align:top"><p>Avastin</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>XELOX</p><p>Or</p><p>XELOX + BV</p></td><td style="vertical-align:top"><p>Oxaliplatin</p><p><strong><em>&nbsp;</em></strong></p><p>Capecitabine SPC</p></td><td style="vertical-align:top"><p>130 mg/m2 IV 2 h 1000 mg/m2 oral bd</p></td><td style="vertical-align:top"><p>Oxaliplatin on Day 1, every 3 weeks</p><p>Capecitabine SPC oral bd for 2 weeks (followed by 1 week off treatment)</p></td></tr><tr><td style="vertical-align:top"><p>Placebo or BV</p></td><td style="vertical-align:top"><p>7.5 mg/kg IV</p><p>30 - 90 min</p></td><td style="vertical-align:top"><p>Day 1, prior to XELOX, every 3 weeks</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>5-Fluorouracil: IV bolus injection immediately after leucovorin</p></td></tr></tbody></table><p><strong><em>&nbsp;</em></strong></p><p>Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4-containing arms in the overall comparison was demonstrated in terms of progression-free survival (PFS) in the eligible per-protocol</p><p>population (EPP), with progression determined by the study investigators who were not blinded to treatment allocation (see Table). The criterion set for concluding non- inferiority was that the upper limit of the 97.5% confidence interval for the hazard ratio for PFS was less than 1.23. The results for OS are similar to those reported for PFS. A comparison of XELOX plus BV versus FOLFOX-4 plus BV was a pre-specified exploratory analysis. In this treatment subgroup comparison, XELOX plus BV was similar compared to FOLFOX-4 plus BV in terms of PFS (hazard ratio 1.01 [97.5% CI 0.84, 1.22]). The median follow up at the time of the primary analyses in the intent-to-treat population was 1.5 years; data from analyses following an additional 1 year of follow up are included in Table.</p><p>&nbsp;</p><p><strong>Table: Key non-inferiority efficacy results for the primary analysis and 1 year follow-up data (EPP population, Study NO16966) </strong>PRIMARY ANALYSIS</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>XELOX/XELOX+P/ XELOX+BV (EPP</strong>#<strong>: <em>n </em>= 967)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>FOLFOX-4/FOLFOX-4+P/ FOLFOX- 4+BV</strong></p><p><strong>(EPP</strong>#<strong>: <em>n </em>= 937)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Population</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Median Time to Event (Days)</strong></p></td><td style="vertical-align:top"><p><strong>HR</strong></p><p><strong>(97.5% CI)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Parameter: Progression-free Survival</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>EPP (95% CI)</p></td><td style="vertical-align:top"><p>241</p><p>(229; 254)</p></td><td style="vertical-align:top"><p>259</p><p>(245; 268)</p></td><td style="vertical-align:top"><p>1.05</p><p>(0.94; 1.18)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Parameter: Overall Survival</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>EPP (95% CI)</p></td><td style="vertical-align:top"><p>577</p><p>(535; 615)</p></td><td style="vertical-align:top"><p>549</p><p>(528; 576)</p></td><td style="vertical-align:top"><p>0.97</p><p>(0.84; 1.14)</p></td></tr></tbody></table><p>&nbsp;</p><p>ADDITIONAL 1 YEAR OF FOLLOW UP</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Population</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Median Time to Event (Days)</strong></p></td><td style="vertical-align:top"><p>HR (97.5% CI)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Parameter: Progression-free Survival</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>EPP</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>242</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>259</p></td><td style="vertical-align:top"><p>1.02</p><p>(0.92; 1.14)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Parameter: Overall Survival</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>EPP</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>600</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>594</p></td><td style="vertical-align:top"><p>1.00</p><p>(0.88; 1.13)</p></td></tr></tbody></table><p># EPP=eligible patient population</p><p>Study NO16966 also demonstrated superiority of the bevacizumab-containing arms over placebo- containing arms.</p><p><em>Combination therapy - second- line treatment of metastatic colorectal cancer</em></p><p>Data from a multicenter, randomised, controlled phase III clinical study (NO16967) support the use of Capecitabine SPC in combination with oxaliplatin for the second-line treatment of metastastic colorectal cancer. In this trial, 627 patients with metastatic colorectal cancer who have received prior treatment with irinotecan in combination with a fluoropyrimidine regimen as first-line therapy were randomised to treatment with XELOX or FOLFOX-4. The treatment regimens used in study NO16967 are summarised in the table below.</p><p>&nbsp;</p><p>Table: Treatment regimens in Study NO16967</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:78px"><p>&nbsp;</p></td><td style="vertical-align:top; width:136px"><p><strong>Treatmen</strong></p></td><td style="vertical-align:top; width:222px"><p><strong>Starting Dose</strong></p></td><td style="vertical-align:top; width:544px"><p><strong>Schedule</strong></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>FOLFOX- 4</p></td><td style="vertical-align:top"><p>Oxaliplatin Leucovorin</p><p>5-Fluorouracil</p></td><td style="vertical-align:top"><p>85 mg/m2 IV 2 h</p><p><strong>&nbsp;</strong></p><p>200 mg/m2 IV 2 h</p><p><strong>&nbsp;</strong></p><p>400 mg/m2 IV bolus, 600 mg/ m2 IV 22 h</p></td><td style="vertical-align:top"><p>Oxaliplatin on Day 1, every 2 weeks Leucovorin on Day 1 and 2, every 2 weeks 5-fluorouracil IV bolus/infusion,</p><p>each on Days 1 and 2, every 2 weeks</p></td></tr><tr><td style="vertical-align:top"><p>XELOX</p></td><td style="vertical-align:top"><p>Oxaliplatin</p><p><strong>&nbsp;</strong></p><p>Capecitabine SPC</p></td><td style="vertical-align:top"><p>130 mg/m2 IV 2 h 1000 mg/m2 oral bd</p></td><td style="vertical-align:top"><p>Oxaliplatin on Day 1, every 3 weeks</p><p><strong>&nbsp;</strong></p><p>Capecitabine SPC oral bd for 2 weeks (followed by 1 week off treatment)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>5-Fluorouracil: IV bolus injection immediately after leucovorin</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>XELOX was demonstrated to be non-inferior to FOLFOX-4 in terms of PFS in the per-protocol population (see Table). The criterion set for concluding non-inferiority was the upper limit of the 95% confidence interval for the hazard ratio for PFS was less than 1.30. The results for overall survival were similar to those for PFS. The median follow up at the time of primary analyses in the intent-to-treat population was 2.1&nbsp; years; data from analyses following an additional 6 months of follow up are also included in Table.</p><p><strong>Table : Key non-inferiority efficacy results for the primary analysis and 6-month follow-up data of Study NO16967 (PPP population)</strong></p><p>PRIMARY ANALYSIS</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>XELOX (PPP</strong>#<strong>: <em>n </em>=</strong></p><p><strong>251)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>FOLFOX-4 (PPP</strong>#<strong>: <em>n </em>= 252)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Population</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Median Time to Event (Days)</strong></p></td><td style="vertical-align:top"><p><strong>HR (95% CI)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Parameter: Progression-free Survival</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>PPP (95% CI)</p></td><td style="vertical-align:top"><p>154</p><p>(140; 175)</p></td><td style="vertical-align:top"><p>168</p><p>(145; 182)</p></td><td style="vertical-align:top"><p>1.03</p><p>(0.87; 1.24)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Parameter: Overall Survival</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>PPP (95% CI)</p></td><td style="vertical-align:top"><p>388</p><p>(339; 432)</p></td><td style="vertical-align:top"><p>401</p><p>(371; 440)</p></td><td style="vertical-align:top"><p>1.07</p><p>(0.88; 1.31)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>ADDITIONAL 6 MONTHS OF FOLLOW UP</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Population</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Median Time to Event (Days)</strong></p></td><td style="vertical-align:top"><p><strong>HR (95% CI)</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Parameter: Progression- free Survival</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>PPP</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>154</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>166</p></td><td style="vertical-align:top"><p>1.04</p><p>(0.87; 1.24)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Parameter: Overall Survival</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>PPP</p></td><td style="vertical-align:top"><p>393</p></td><td style="vertical-align:top"><p>402</p></td><td style="vertical-align:top"><p>1.05</p><p>(0.88; 1.27)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p># PPP = per-protocol population</p><p>&nbsp;</p><p>A pooled analysis of the efficacy data from first-line (study NO16966; initial 2-arm part) and second line treatment (study NO 16967) further support the non-inferiority results of XELOX versus FOLFOX-4 as obtained in the individual studies: PFS in the per-protocol population (hazard ratio 1.00 [95% CI: 0.88; 1.14]) with a median PFS of 193 days (XELOX; 508 patients) versus 204 days (FOLFOX-4; 500 patients). The results also indicate that XELOX is comparable to FOLFOX-4 in terms of OS (hazard ratio 1.01 [95% CI: 0.87; 1.17]) with a median OS of 468 days (XELOX) versus 478 days(FOLFOX-4).</p><p>&nbsp;</p><p>Combination therapy - oesophagogastric cancer</p><p>&nbsp;</p><p>Two multicentre, randomised, controlled phase III clinical trials were conducted to evaluate the safety and efficacy of Capecitabine SPC in patients with previously untreated advanced or metastatic oesophagogastric.</p><p>Data from a multicentre, open-label, randomised, controlled phase III clinical trial (ML17032,) supports the use of Capecitabine SPC in this setting. In this trial, 160 patients with previously untreated advanced or metastatic gastric cancer were randomised to treatment with Capecitabine SPC (1000 mg/m2 twice daily for 2 weeks followed by a 1 week rest period) and cisplatin (80 mg/m2 as a 2 hour IV infusion every 3 weeks).</p><p>A total of 156 patients were randomised to treatment with 5- FU (800 mg/m2 per day, continuous infusion on days 1 to 5 every 3 weeks) and cisplatin (80 mg/m2&nbsp; as a 2 hour IV infusion on day 1, every 3 weeks).</p><p>Patients received treatment for at least 6 weeks (2 cycles) and were treated until disease progression or unacceptable toxicity.</p><p>The primary objective of the study was met, Capecitabine SPC in combination with cisplatin was at least equivalent to 5-FU in combination with cisplatin in terms of PFS in the per-protocol analysis. Duration of survival (overall survival) with the combination of Capecitabine SPC and cisplatin was also at least equivalent to that of 5-FU and cisplatin.</p><p>Table: Summary of results for key efficacy parameters (PPP, Study ML17032)</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Endpoint Parameter</strong></p></td><td style="vertical-align:top"><p>Capecitabine SPC</p><p><strong>/cisplatin n</strong></p></td><td style="vertical-align:top"><p><strong>5-FU/Cisplatin n = 137</strong></p></td><td style="vertical-align:top"><p><strong>Hazard Ratio [95% CI]</strong>#</p></td></tr><tr><td style="vertical-align:top"><p><strong>Progression-Free Survival</strong></p><p>median (months) [95% CI]</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>5.6 [4.9, 7.3]</p></td><td style="vertical-align:top"><p>5.0 [4.2,</p><p>6.3]</p></td><td style="vertical-align:top"><p>0.81 [0.63,</p><p>1.04]</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of Survival</strong></p><p>median (months) [95%</p></td><td style="vertical-align:top"><p>10.5 [9.3, 11.2]</p></td><td style="vertical-align:top"><p>9.3 [7.4,</p><p>10.6]</p></td><td style="vertical-align:top"><p>0.85 [0.64,</p><p>1.13]</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p># Unadjusted treatment effect in Cox proportional model</p><p>Data from a randomised multicenter, phase III study comparing Capecitabine SPC to 5-FU and oxaliplatin to cisplatin in patients with previously untreated locally advanced or metastatic oesophagogastric cancer supports the use of Capecitabine SPC for the first-line treatment of advanced oesophagogastric cancer (REAL- 2). In this trial, 1002 patients were randomised in a 2 x 2 factorial design to one of the following 4 arms:</p><p>Table : Treatment regimens in the REAL-2 Study</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Treatment</strong></p></td><td style="vertical-align:top"><p><strong>Starting Dose</strong></p></td><td style="vertical-align:top"><p><strong>Schedule</strong></p></td></tr><tr><td style="vertical-align:top"><p>Epirubicin</p><p>(E) Cisplatin (C) 5-Fluorouracil (F)</p></td><td style="vertical-align:top"><p>50 mg/m2 IV bolus</p><p>60 mg/m2 2 hour IV infusion</p><p>200 mg/m2 continuous infusion via a central line</p></td><td style="vertical-align:top"><p>Day 1, every 3 weeks</p><p>Day 1, every 3 weeks Daily</p></td></tr><tr><td style="vertical-align:top"><p>Epirubicin (E) Cisplatin (C) Capecitabine SPC (X)</p></td><td style="vertical-align:top"><p>50 mg/m2 IV bolus</p><p>60 mg/m2 2 hour IV nfusion 625 mg/m2 bd orally</p></td><td style="vertical-align:top"><p>Day 1, every 3 weeks</p><p>Day 1, every 3 weeks Twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Epirubicin (E) Oxaliplatin (O)</p><p>5-Fluorouracil (F)</p></td><td style="vertical-align:top"><p>50 mg/m2 IV bolus</p><p>130 mg/m2 2 hour IV infusion</p><p>200 mg/m2 continuous infusion via a central line</p></td><td style="vertical-align:top"><p>Day 1, every 3 weeks</p><p>Day 1, every 3 weeks Daily</p></td></tr><tr><td style="vertical-align:top"><p>Epirubicin (E) Oxaliplatin (O) Capecitabine SPC (X)</p></td><td style="vertical-align:top"><p>50 mg/m2 IV bolus 130 mg/m2 2 hour IV</p><p>infusion 625 mg/m2 bd orally</p></td><td style="vertical-align:top"><p>Day 1, every 3 weeks</p><p>Day 1, every 3 weeks Twice daily</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>The primary efficacy analyses in the per-protocol population demonstrated non-inferiority in OS for Capecitabine SPC versus 5-FU-based regimens (hazard ratio 0.86, 95% CI: 0.80 to 0.99) and for oxaliplatin versus cisplatin-based regimens (hazard ratio 0.92, 95% CI: 0.80 to 1.10). The median OS was 10.9 months in Capecitabine SPC -based regimens and 9.6 months in 5-FU-based regimens. The median OS was 10.0 months in cisplatin-based regimens and 10.4 months in oxaliplatin-based regimens.</p><p>&nbsp;</p><p><em>Colon, colorectal and advanced gastric cancer: meta-analysis</em></p><p>A meta-analysis of six clinical trials (studies SO14695, SO14796, M66001, NO16966, NO16967, ML17032) supports Capecitabine SPC replacing 5-FU in mono- and combination treatment in gastrointestinal cancer. The pooled analysis includes 3097 patients treated with Capecitabine SPC - containing regimens and 3074 patients treated with 5-FU-containing regimens. The hazard ratio for OS was 0.94 (95% CI: 0.89; 1.00, p=0.0489) indicating that Capecitabine SPC -containing regimens are comparable to 5-FU containing regimens.</p><p><em>Monotherapy - Breast cancer</em></p><p><em>&nbsp;</em></p><p>Two phase II open label, multicenter trials were conducted to evaluate the efficacy and safety of Capecitabine SPC in patients with locally advanced and/or metastatic breast cancer who had been previously treated with taxanes. Capecitabine SPC was administered at a dose of 1250 mg/m2 twice daily for 2 weeks treatment followed by a 1 week rest period, given as 3 week cycles.</p><p>In the first trial, 162 female outpatients were selected from an investigator&rsquo;s current practice or from referred patients. This heavily pre-treated patient population was refractory to previous paclitaxel therapy (77% resistant, 23% failed). Additionally, most patients were resistant (41%) or had failed (26%) previous anthracycline therapy and 82% had been exposed to 5-FU.</p><p>In the second trial, 74 patients were treated; all but three had received prior treatment with taxanes (paclitaxel and/or docetaxel). In addition, over 95% had previously been treated with an anthracycline- based chemotherapy.</p><p>Table : Breast cancer monotherapy efficacy results1</p><p><strong><em>&nbsp;</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>&nbsp;</em></strong></p><p><strong>Endpoint Parameter</strong></p></td><td style="vertical-align:top"><p>Capecitabine SPC</p><p><strong>with paclitaxel</strong></p><p><strong><em>n </em>= 162</strong></p></td><td style="vertical-align:top"><p>Capecitabine SPC <strong>with paclitaxel</strong></p><p><strong>/docetaxel</strong></p><p><strong><em>n </em>= 74</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Response Rate</strong></p><p>(95% CI)</p></td><td style="vertical-align:top"><p>20%</p><p>(13.6 - 27.8)</p></td><td style="vertical-align:top"><p>24.6%</p><p>(15.05 - 36.49)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of Response</strong></p><p>median (range)</p></td><td style="vertical-align:top"><p>241 days</p><p>(97 - 324)</p></td><td style="vertical-align:top"><p>253 days</p><p>(213 - 301)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Time to Disease Progression</strong></p><p>median (95% CI)</p></td><td style="vertical-align:top"><p>93 days</p><p>(84 - 106)</p></td><td style="vertical-align:top"><p>98 days</p><p>(71 - 130)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Survival</strong></p><p>median</p></td><td style="vertical-align:top"><p><strong><em>&nbsp;</em></strong></p><p>384 days</p></td><td style="vertical-align:top"><p><strong><em>&nbsp;</em></strong></p><p>373 days</p></td></tr></tbody></table><p>1 Intent to Treat population</p><p>&nbsp;</p><p>A prospectively defined clinical benefit response score (pain, analgesic consumption and Karnofsky Performance Status) was used to assess the effect of treatment on tumour-associated morbidity. The overall clinical benefit response was positive in 29 patients (20%) in the first trial and 8 patients (15%) in the second trial, 45 patients (31%) and 22 patients (41%), respectively, remained stable.</p><p>Of the 51 patients with baseline pain &ge; 20 mm on the visual analogue scale in the first trial, 24 patients (47%) had a positive response in pain intensity (greater than or equal to 50% decrease lasting for at least 4 weeks), similar analysis in the second trial showed 7/27 patients (26%) had a positive pain response.</p><p><em>Combination therapy - Breast cancer</em></p><p>The dose of Capecitabine SPC used in the phase III clinical trial in combination with Docetaxel Based on the results of a phase I trial, where a range of doses of docetaxel given every 3 weeks in combination with an intermittent regimen of Capecitabine SPC (2 weeks treatment followed by a 1 week rest period) were evaluated. The combination dose regimen was selected based on the tolerability profile of docetaxel 75 mg/m2 as a 1 hour intravenous infusion every 3 weeks in combination with 1250 mg/m2 twice daily for 2 weeks of Capecitabine SPC administered every 3 weeks for at least 6 weeks. The approved dose of 100 mg/m2 of docetaxel administered every 3 weeks was the control arm of the phase III study.</p><p>Capecitabine SPC in combination with docetaxel was assessed in an open label, multicenter, randomised trial. A total of 511 patients with locally advanced and/or metastatic breast cancer resistant to, or recurring after an anthracycline containing therapy, or relapsing during or recurring within two years of completing an anthracycline containing adjuvant therapy were enrolled. In this trial, 255 patients were randomised to receive Capecitabine SPC in combination with docetaxel and 256 patients received docetaxel alone.</p><p>&nbsp;</p><p>Capecitabine SPC in combination with docetaxel resulted in statistically significant improvements in time to disease progression, overall survival and objective response rate compared to monotherapy with docetaxel as shown in Table and Figures 2 and 3. Health related quality of life (HRQoL) was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC-QLQ; C30 version 2, including Breast Cancer Module BR23). HRQoL was similar in the two treatment groups.</p><p>Table : Breast cancer combination treatment efficacy results1</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint Parameter</strong></p></td><td style="vertical-align:top"><p>Capecitabine SPC <strong>/</strong></p><p><strong>docetaxel</strong></p><p><strong><em>n </em>= 255</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>docetaxel</strong></p><p><strong><em>n </em>= 256</strong></p></td><td style="vertical-align:top"><p><strong>Difference</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong><em>p</em>-value</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Time to Disease Progression</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>median [95% CI]</p></td><td style="vertical-align:top"><p>186 days</p><p>[165,198]</p></td><td style="vertical-align:top"><p>128 days</p><p>[105,136]</p></td><td style="vertical-align:top"><p>HR2 = 0.643</p><p>[0.563, 0.770]</p></td><td style="vertical-align:top"><p>0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Survival </strong>median [95% CI]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>442 days</p></td><td style="vertical-align:top"><p>352days</p></td><td style="vertical-align:top"><p>HR = 0.753</p></td><td style="vertical-align:top"><p>0.0126</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>[374, 492]</p></td><td style="vertical-align:top"><p>[298, 362]</p></td><td style="vertical-align:top"><p>[0.603, 0.940]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response Rate</strong></p><p>[95% CI]</p></td><td style="vertical-align:top"><p>41.6 %</p><p>[35.5, 47.9]</p></td><td style="vertical-align:top"><p>29.7%</p><p>[24.2, 35.7]</p></td><td style="vertical-align:top"><p>11.9%</p><p>[3.4, 20.0]</p></td><td style="vertical-align:top"><p>0.0058</p></td></tr></tbody></table><p>1.&nbsp;&nbsp; All-randomised population, Investigator assessment</p><p>2.&nbsp;&nbsp; Hazard Ratio</p><p>3.&nbsp;&nbsp; Figure 2.Kaplan-Meier Estimates for Time to Disease Progression Capecitabine SPC and Docetaxel vs. Docetaxel</p><p><br /><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><v:shape id="_x0000_i1025"
 type="#_x0000_t75" style='width:347.4pt;height:262.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p><img alt="" width="490" height="315" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p><strong>Figure 3. Kaplan-Meier Estimates of Survival Capecitabine SPC and Docetaxel vs. Docetaxel</strong></p><p>&nbsp;</p><p><img alt="" width="433" height="352" src="data:image/jpeg;base64,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" /></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In repeat-dose toxicity studies, daily oral administration of capecitabine to cynomolgus monkeys and mice produced toxic effects on the gastrointestinal, lymphoid and haemopoietic systems, typical for fluoropyrimidines. These toxicities were reversible. Skin toxicity, characterised by degenerative/regressive changes, was observed with capecitabine. Capecitabine was devoid of hepatic and CNS toxicities. Cardiovascular toxicity (e.g. PR- and QT-interval prolongation) was detectable in cynomolgus monkeys after intravenous administration (100 mg/kg) but not after repeated oral dosing (1379 mg/m<sup>2</sup>/day).</p><p>&nbsp;</p><p>A two-year mouse carcinogenicity study produced no evidence of carcinogenicity by capecitabine.</p><p>During standard fertility studies, impairment of fertility was observed in female mice receiving capecitabine; however, this effect was reversible after a drug-free period. In addition, during a 13-week study, atrophic and degenerative changes occurred in reproductive organs of male mice; however these effects were reversible after a drug-free period (see section 4.6).</p><p>In embryotoxicity and teratogenicity studies in mice, dose-related increases in foetal resorption and teratogenicity were observed. In monkeys, abortion and embryolethality were observed at high doses, but there was no evidence of teratogenicity.</p><p>&nbsp;</p><p>Capecitabine was not mutagenic in vitro to bacteria (Ames test) or mammalian cells (Chinese hamster V79/HPRT gene mutation assay). However, similar to other nucleoside analogues (ie, 5-FU), capecitabine was clastogenic in human lymphocytes (in vitro) and a positive trend occurred in mouse bone marrow micronucleus tests (in vivo).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lactose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; croscarmellose sodium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypromellose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; microcrystalline cellulose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capecitabine SPC tablets should be stored below 30&deg;C. Capecitabine SPC tablets should not be taken after the expiry date imprinted on the pack label.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The release of medicines into the environment should be minimised. Medicines should not be disposed of via wastewater and disposal through household waste should be avoided. Unused or expired medicine should be returned to a pharmacy for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDERS
Sudair Pharma Company (SPC)
King Fahad road, Building 911- The First Round Riyadh, Saudi Arabia Tel: +966-11-4668193
Fax: +966-11-4668195
Email: info@sudairpharma.com
Mailing: P.O. Box 19047 Riyadh, Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                09/2020, version: 01
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>